-- MySQL dump 10.13  Distrib 5.6.24, for Win64 (x86_64)
--
-- Host: 127.0.0.1    Database: uat
-- ------------------------------------------------------
-- Server version	5.6.24-log

/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8 */;
/*!40103 SET @OLD_TIME_ZONE=@@TIME_ZONE */;
/*!40103 SET TIME_ZONE='+00:00' */;
/*!40014 SET @OLD_UNIQUE_CHECKS=@@UNIQUE_CHECKS, UNIQUE_CHECKS=0 */;
/*!40014 SET @OLD_FOREIGN_KEY_CHECKS=@@FOREIGN_KEY_CHECKS, FOREIGN_KEY_CHECKS=0 */;
/*!40101 SET @OLD_SQL_MODE=@@SQL_MODE, SQL_MODE='NO_AUTO_VALUE_ON_ZERO' */;
/*!40111 SET @OLD_SQL_NOTES=@@SQL_NOTES, SQL_NOTES=0 */;

--
-- Table structure for table `categories`
--

DROP TABLE IF EXISTS `categories`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `categories` (
  `CategoryId` int(11) NOT NULL AUTO_INCREMENT,
  `CategoryName` varchar(100) NOT NULL,
  `ParentId` int(11) NOT NULL,
  `DeptList` varchar(255) DEFAULT 'All',
  `FilePath` varchar(255) NOT NULL,
  `Status` int(11) NOT NULL DEFAULT '1',
  `PAList` varchar(255) DEFAULT 'All',
  `ProductList` varchar(255) DEFAULT 'All',
  `CreatedUser` int(11) DEFAULT NULL,
  `CreatedTime` datetime DEFAULT NULL,
  `EditUser` int(11) DEFAULT NULL,
  `EditTime` datetime DEFAULT NULL,
  PRIMARY KEY (`CategoryId`)
) ENGINE=InnoDB AUTO_INCREMENT=614 DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `categories`
--

LOCK TABLES `categories` WRITE;
/*!40000 ALTER TABLE `categories` DISABLE KEYS */;
INSERT INTO `categories` VALUES (1,'总分类',0,',1,,3,,10,','d:/Data/file/',1,'All','All',1,'2015-06-06 15:51:10',1,'2015-06-06 15:51:10'),(2,'公司信息',1,',1,,3,,10,','0/2',1,'All','All',1,'2015-06-11 15:48:32',1,'2015-06-20 23:33:09'),(3,'TA/产品',1,',1,,3,,10,','d:/Data/file/1/',0,'All','All',1,'2015-06-11 15:49:07',1,'2015-06-11 15:49:07'),(4,'HR',2,',1,,3,,10,','d:/Data/file/1/2/',1,'All','All',1,'2015-06-11 15:51:12',1,'2015-06-11 15:51:12'),(5,'IT',2,',1,,3,,10,','d:/Data/file/1/2/',1,'All','All',1,'2015-06-11 15:51:12',1,'2015-06-11 15:51:12'),(6,'销售培训',2,',1,,3,,10,','d:/Data/file/1/2/',1,'All','All',1,'2015-06-11 15:51:12',1,'2015-06-11 15:51:12'),(7,'销售奖金',2,',1,,3,,10,','d:/Data/file/1/2/',1,'All','All',1,'2015-06-11 15:51:12',1,'2015-06-11 15:51:12'),(8,'销售绩效管理流程',2,',1,,3,,10,','d:/Data/file/1/2/',1,'All','All',1,'2015-06-11 15:51:12',1,'2015-06-11 15:51:12'),(9,'市场调研',2,',1,,3,,10,','d:/Data/file/1/2/',1,'All','All',1,'2015-06-11 15:51:12',1,'2015-06-11 15:51:12'),(10,'系统相关',2,',1,,3,,10,','d:/Data/file/1/2/',1,'All','All',1,'2015-06-11 15:51:12',1,'2015-06-11 15:51:12'),(11,'SOP',2,',1,,3,,10,','d:/Data/file/1/2/',1,'All','All',1,'2015-06-11 15:51:12',1,'2015-06-11 15:51:12'),(12,'医药代表晋升手册',4,',1,,3,,10,','d:/Data/file/1/2/4/',1,'All','All',1,'2015-06-11 15:53:07',1,'2015-06-11 15:53:07'),(13,'公司日讲义',4,',1,,3,,10,','d:/Data/file/1/2/4/',1,'All','All',1,'2015-06-11 15:53:07',1,'2015-06-11 15:53:07'),(14,'办公自动化管理',5,',1,,3,,10,','d:/Data/file/1/2/5/',1,'All','All',1,'2015-06-11 15:54:22',1,'2015-06-11 15:54:22'),(15,'密码管理',5,',1,,3,,10,','d:/Data/file/1/2/5/',1,'All','All',1,'2015-06-11 15:54:22',1,'2015-06-11 15:54:22'),(16,'OBL',6,',1,,3,,10,','d:/Data/file/1/2/6/',1,'All','All',1,'2015-06-11 15:56:27',1,'2015-06-11 15:56:27'),(17,'ITC',6,',1,,3,,10,','d:/Data/file/1/2/6/',1,'All','All',1,'2015-06-11 15:56:27',1,'2015-06-11 15:56:27'),(18,'ATC',6,',1,,3,,10,','d:/Data/file/1/2/6/',1,'All','All',1,'2015-06-11 15:56:27',1,'2015-06-11 15:56:27'),(19,'RDPAC',6,',1,,3,,10,','d:/Data/file/1/2/6/',1,'All','All',1,'2015-06-11 15:56:27',1,'2015-06-11 15:56:27'),(20,'考试管理规定',6,',1,,3,,10,','d:/Data/file/1/2/6/',1,'All','All',1,'2015-06-11 15:56:27',1,'2015-06-11 15:56:27'),(21,'奖金政策',7,',1,,3,,10,','d:/Data/file/1/2/7/',1,'All','All',1,'2015-06-11 15:57:22',1,'2015-06-11 15:57:22'),(22,'销售绩效内容路径参考手册',8,',1,,3,,10,','d:/Data/file/1/2/8/',1,'All','All',1,'2015-06-11 15:58:07',1,'2015-06-11 15:58:07'),(23,'iZOOM',10,',1,,3,,10,','d:/Data/file/1/2/10/',1,'All','All',1,'2015-06-11 15:59:40',1,'2015-06-11 15:59:40'),(24,'iSEARCH',10,',1,,3,,10,','d:/Data/file/1/2/10/',1,'All','All',1,'2015-06-11 15:59:40',1,'2015-06-11 15:59:40'),(25,'TSA',10,',1,,3,,10,','d:/Data/file/1/2/10/',1,'All','All',1,'2015-06-11 15:59:40',1,'2015-06-11 15:59:40'),(26,'市场部信息',3,',1,,3,,10,','d:/Data/file/1/3/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(27,'医学部信息',3,',1,,3,,10,','d:/Data/file/1/3/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(28,'文献解读',27,',1,,3,,10,','d:/Data/file/1/3/27/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(29,'幻灯片',27,',1,,3,,10,','d:/Data/file/1/3/27/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(30,'会议快讯',27,',1,,3,,10,','d:/Data/file/1/3/27/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(31,'指南',27,',1,,3,,10,','d:/Data/file/1/3/27/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(32,'疾病知识',27,',1,,3,,10,','d:/Data/file/1/3/27/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(33,'产品知识',27,',1,,3,,10,','d:/Data/file/1/3/27/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(34,'产品说明书',27,',1,,3,,10,','d:/Data/file/1/3/27/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(35,'问与答',27,',1,,3,,10,','d:/Data/file/1/3/27/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(36,'文献',26,',1,,3,,10,','d:/Data/file/1/3/26/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(37,'产品视频',26,',1,,3,,10,','d:/Data/file/1/3/26/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(38,'幻灯片',26,',1,,3,,10,','d:/Data/file/1/3/26/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(39,'DA',26,',1,,3,,10,','d:/Data/file/1/3/26/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(40,'必洛斯',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 16:51:08',1,'2015-06-20 16:51:08'),(41,'艾可拓',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 16:51:55',1,'2015-06-20 16:51:55'),(42,'倍欣',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 16:52:14',1,'2015-06-20 16:52:14'),(43,'尼欣那',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 16:53:00',1,'2015-06-20 16:53:00'),(44,'潘针',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 16:57:09',1,'2015-06-20 16:57:09'),(45,'潘片',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 16:57:24',1,'2015-06-20 16:57:24'),(46,'达克普隆',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 16:57:41',1,'2015-06-20 16:57:41'),(47,'普托平',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 16:58:03',1,'2015-06-20 16:58:03'),(48,'抑那通',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 16:58:16',1,'2015-06-20 16:58:16'),(49,'亚宁定',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 16:58:43',1,'2015-06-20 16:58:43'),(50,'开思亭',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 16:59:00',1,'2015-06-20 16:59:00'),(51,'爱宝疗',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 16:59:13',1,'2015-06-20 16:59:13'),(52,'内分泌',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 16:59:41',1,'2015-06-20 16:59:41'),(53,'心血管',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 17:00:01',1,'2015-06-20 17:00:01'),(54,'消化',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 17:01:11',1,'2015-06-20 17:01:11'),(55,'乳腺',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 17:02:15',1,'2015-06-20 17:02:15'),(56,'泌尿',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 17:02:31',1,'2015-06-20 17:02:31'),(57,'儿科',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 17:02:52',1,'2015-06-20 17:02:52'),(58,'妇科',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 17:03:09',1,'2015-06-20 17:03:09'),(59,'危重症',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 17:03:22',1,'2015-06-20 17:03:22'),(60,'抗过敏',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 17:09:01',1,'2015-06-20 17:09:01'),(61,'溃疡',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 17:09:22',1,'2015-06-20 17:09:22'),(62,'GERD',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 17:13:12',1,'2015-06-20 17:13:12'),(63,'UGIB',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 17:13:12',1,'2015-06-20 17:14:10'),(64,'SRMD',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 17:14:51',1,'2015-06-20 17:14:51'),(65,'ZES',1,',1,,3,,10,','d:/Data/file/1/',1,'All','All',1,'2015-06-20 17:15:29',1,'2015-06-20 17:15:29'),(66,'市场部信息',40,',1,,3,,10,','d:/Data/file/1/40/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(67,'医学部信息',40,',1,,3,,10,','d:/Data/file/1/40/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(68,'市场部信息',41,',1,,3,,10,','d:/Data/file/1/41/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(69,'医学部信息',41,',1,,3,,10,','d:/Data/file/1/41/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(70,'市场部信息',42,',1,,3,,10,','d:/Data/file/1/42/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(71,'医学部信息',42,',1,,3,,10,','d:/Data/file/1/42/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(72,'市场部信息',43,',1,,3,,10,','d:/Data/file/1/43/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(73,'医学部信息',43,',1,,3,,10,','d:/Data/file/1/43/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(74,'市场部信息',44,',1,,3,,10,','d:/Data/file/1/44/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(75,'医学部信息',44,',1,,3,,10,','d:/Data/file/1/44/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(76,'市场部信息',45,',1,,3,,10,','d:/Data/file/1/45/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(77,'医学部信息',45,',1,,3,,10,','d:/Data/file/1/45/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(78,'市场部信息',46,',1,,3,,10,','d:/Data/file/1/46/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(79,'医学部信息',46,',1,,3,,10,','d:/Data/file/1/46/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(80,'市场部信息',47,',1,,3,,10,','d:/Data/file/1/47/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(81,'医学部信息',47,',1,,3,,10,','d:/Data/file/1/47/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(82,'市场部信息',48,',1,,3,,10,','d:/Data/file/1/48/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(83,'医学部信息',48,',1,,3,,10,','d:/Data/file/1/48/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(84,'市场部信息',49,',1,,3,,10,','d:/Data/file/1/49/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(85,'医学部信息',49,',1,,3,,10,','d:/Data/file/1/49/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(86,'市场部信息',50,',1,,3,,10,','d:/Data/file/1/50/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(87,'医学部信息',50,',1,,3,,10,','d:/Data/file/1/50/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(88,'市场部信息',51,',1,,3,,10,','d:/Data/file/1/51/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(89,'医学部信息',51,',1,,3,,10,','d:/Data/file/1/51/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(97,'市场部信息',52,',1,,3,,10,','d:/Data/file/1/52/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(98,'医学部信息',52,',1,,3,,10,','d:/Data/file/1/52/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(99,'市场部信息',53,',1,,3,,10,','d:/Data/file/1/53/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(100,'医学部信息',53,',1,,3,,10,','d:/Data/file/1/53/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(101,'市场部信息',54,',1,,3,,10,','d:/Data/file/1/54/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(102,'医学部信息',54,',1,,3,,10,','d:/Data/file/1/54/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(103,'市场部信息',55,',1,,3,,10,','d:/Data/file/1/55/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(104,'医学部信息',55,',1,,3,,10,','d:/Data/file/1/55/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(105,'市场部信息',56,',1,,3,,10,','d:/Data/file/1/56/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(106,'医学部信息',56,',1,,3,,10,','d:/Data/file/1/56/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(107,'市场部信息',57,',1,,3,,10,','d:/Data/file/1/57/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(108,'医学部信息',57,',1,,3,,10,','d:/Data/file/1/57/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(109,'市场部信息',58,',1,,3,,10,','d:/Data/file/1/58/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(110,'医学部信息',58,',1,,3,,10,','d:/Data/file/1/58/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(111,'市场部信息',59,',1,,3,,10,','d:/Data/file/1/59/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(112,'医学部信息',59,',1,,3,,10,','d:/Data/file/1/59/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(113,'市场部信息',60,',1,,3,,10,','d:/Data/file/1/60/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(114,'医学部信息',60,',1,,3,,10,','d:/Data/file/1/60/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(115,'市场部信息',61,',1,,3,,10,','d:/Data/file/1/61/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(116,'医学部信息',61,',1,,3,,10,','d:/Data/file/1/61/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(117,'市场部信息',62,',1,,3,,10,','d:/Data/file/1/62/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(118,'医学部信息',62,',1,,3,,10,','d:/Data/file/1/62/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(119,'市场部信息',63,',1,,3,,10,','d:/Data/file/1/63/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(120,'医学部信息',63,',1,,3,,10,','d:/Data/file/1/63/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(121,'市场部信息',64,',1,,3,,10,','d:/Data/file/1/64/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(122,'医学部信息',64,',1,,3,,10,','d:/Data/file/1/64/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(123,'市场部信息',65,',1,,3,,10,','d:/Data/file/1/65/',1,'All','All',1,'2015-06-11 16:01:17',1,'2015-06-11 16:01:17'),(124,'医学部信息',65,',1,,3,,10,','d:/Data/file/1/65/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(255,'文献解读',67,',1,,3,,10,','d:/Data/file/1/40/67/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(256,'幻灯片',67,',1,,3,,10,','d:/Data/file/1/40/67/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(257,'会议快讯',67,',1,,3,,10,','d:/Data/file/1/40/67/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(258,'指南',67,',1,,3,,10,','d:/Data/file/1/40/67/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(259,'疾病知识',67,',1,,3,,10,','d:/Data/file/1/40/67/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(260,'产品知识',67,',1,,3,,10,','d:/Data/file/1/40/67/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(261,'产品说明书',67,',1,,3,,10,','d:/Data/file/1/40/67/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(262,'问与答',67,',1,,3,,10,','d:/Data/file/1/40/67/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(263,'文献解读',69,',1,,3,,10,','d:/Data/file/1/41/69/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(264,'幻灯片',69,',1,,3,,10,','d:/Data/file/1/41/69/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(265,'会议快讯',69,',1,,3,,10,','d:/Data/file/1/41/69/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(266,'指南',69,',1,,3,,10,','d:/Data/file/1/41/69/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(267,'疾病知识',69,',1,,3,,10,','d:/Data/file/1/41/69/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(268,'产品知识',69,',1,,3,,10,','d:/Data/file/1/41/69/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(269,'产品说明书',69,',1,,3,,10,','d:/Data/file/1/41/69/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(270,'问与答',69,',1,,3,,10,','d:/Data/file/1/41/69/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(271,'文献解读',71,',1,,3,,10,','d:/Data/file/1/42/71/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(272,'幻灯片',71,',1,,3,,10,','d:/Data/file/1/42/71/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(273,'会议快讯',71,',1,,3,,10,','d:/Data/file/1/42/71/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(274,'指南',71,',1,,3,,10,','d:/Data/file/1/42/71/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(275,'疾病知识',71,',1,,3,,10,','d:/Data/file/1/42/71/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(276,'产品知识',71,',1,,3,,10,','d:/Data/file/1/42/71/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(277,'产品说明书',71,',1,,3,,10,','d:/Data/file/1/42/71/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(278,'问与答',71,',1,,3,,10,','d:/Data/file/1/42/71/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(279,'文献解读',73,',1,,3,,10,','d:/Data/file/1/43/73/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(280,'幻灯片',73,',1,,3,,10,','d:/Data/file/1/43/73/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(281,'会议快讯',73,',1,,3,,10,','d:/Data/file/1/43/73/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(282,'指南',73,',1,,3,,10,','d:/Data/file/1/43/73/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(283,'疾病知识',73,',1,,3,,10,','d:/Data/file/1/43/73/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(284,'产品知识',73,',1,,3,,10,','d:/Data/file/1/43/73/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(285,'产品说明书',73,',1,,3,,10,','d:/Data/file/1/43/73/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(286,'问与答',73,',1,,3,,10,','d:/Data/file/1/43/73/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(287,'文献解读',75,',1,,3,,10,','d:/Data/file/1/44/75/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(288,'幻灯片',75,',1,,3,,10,','d:/Data/file/1/44/75/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(289,'会议快讯',75,',1,,3,,10,','d:/Data/file/1/44/75/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(290,'指南',75,',1,,3,,10,','d:/Data/file/1/44/75/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(291,'疾病知识',75,',1,,3,,10,','d:/Data/file/1/44/75/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(292,'产品知识',75,',1,,3,,10,','d:/Data/file/1/44/75/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(293,'产品说明书',75,',1,,3,,10,','d:/Data/file/1/44/75/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(294,'问与答',75,',1,,3,,10,','d:/Data/file/1/44/75/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(295,'文献解读',77,',1,,3,,10,','d:/Data/file/1/45/77/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(296,'幻灯片',77,',1,,3,,10,','d:/Data/file/1/45/77/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(297,'会议快讯',77,',1,,3,,10,','d:/Data/file/1/45/77/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(298,'指南',77,',1,,3,,10,','d:/Data/file/1/45/77/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(299,'疾病知识',77,',1,,3,,10,','d:/Data/file/1/45/77/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(300,'产品知识',77,',1,,3,,10,','d:/Data/file/1/45/77/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(301,'产品说明书',77,',1,,3,,10,','d:/Data/file/1/45/77/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(302,'问与答',77,',1,,3,,10,','d:/Data/file/1/45/77/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(303,'文献解读',79,',1,,3,,10,','d:/Data/file/1/46/79/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(304,'幻灯片',79,',1,,3,,10,','d:/Data/file/1/46/79/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(305,'会议快讯',79,',1,,3,,10,','d:/Data/file/1/46/79/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(306,'指南',79,',1,,3,,10,','d:/Data/file/1/46/79/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(307,'疾病知识',79,',1,,3,,10,','d:/Data/file/1/46/79/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(308,'产品知识',79,',1,,3,,10,','d:/Data/file/1/46/79/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(309,'产品说明书',79,',1,,3,,10,','d:/Data/file/1/46/79/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(310,'问与答',79,',1,,3,,10,','d:/Data/file/1/46/79/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(311,'文献解读',81,',1,,3,,10,','d:/Data/file/1/47/81/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(312,'幻灯片',81,',1,,3,,10,','d:/Data/file/1/47/81/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(313,'会议快讯',81,',1,,3,,10,','d:/Data/file/1/47/81/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(314,'指南',81,',1,,3,,10,','d:/Data/file/1/47/81/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(315,'疾病知识',81,',1,,3,,10,','d:/Data/file/1/47/81/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(316,'产品知识',81,',1,,3,,10,','d:/Data/file/1/47/81/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(317,'产品说明书',81,',1,,3,,10,','d:/Data/file/1/47/81/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(318,'问与答',81,',1,,3,,10,','d:/Data/file/1/47/81/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(319,'文献解读',83,',1,,3,,10,','d:/Data/file/1/48/83/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(320,'幻灯片',83,',1,,3,,10,','d:/Data/file/1/48/83/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(321,'会议快讯',83,',1,,3,,10,','d:/Data/file/1/48/83/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(322,'指南',83,',1,,3,,10,','d:/Data/file/1/48/83/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(323,'疾病知识',83,',1,,3,,10,','d:/Data/file/1/48/83/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(324,'产品知识',83,',1,,3,,10,','d:/Data/file/1/48/83/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(325,'产品说明书',83,',1,,3,,10,','d:/Data/file/1/48/83/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(326,'问与答',83,',1,,3,,10,','d:/Data/file/1/48/83/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(327,'文献解读',85,',1,,3,,10,','d:/Data/file/1/49/85/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(328,'幻灯片',85,',1,,3,,10,','d:/Data/file/1/49/85/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(329,'会议快讯',85,',1,,3,,10,','d:/Data/file/1/49/85/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(330,'指南',85,',1,,3,,10,','d:/Data/file/1/49/85/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(331,'疾病知识',85,',1,,3,,10,','d:/Data/file/1/49/85/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(332,'产品知识',85,',1,,3,,10,','d:/Data/file/1/49/85/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(333,'产品说明书',85,',1,,3,,10,','d:/Data/file/1/49/85/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(334,'问与答',85,',1,,3,,10,','d:/Data/file/1/49/85/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(335,'文献解读',87,',1,,3,,10,','d:/Data/file/1/50/87/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(336,'幻灯片',87,',1,,3,,10,','d:/Data/file/1/50/87/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(337,'会议快讯',87,',1,,3,,10,','d:/Data/file/1/50/87/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(338,'指南',87,',1,,3,,10,','d:/Data/file/1/50/87/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(339,'疾病知识',87,',1,,3,,10,','d:/Data/file/1/50/87/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(340,'产品知识',87,',1,,3,,10,','d:/Data/file/1/50/87/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(341,'产品说明书',87,',1,,3,,10,','d:/Data/file/1/50/87/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(342,'问与答',87,',1,,3,,10,','d:/Data/file/1/50/87/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(343,'文献解读',89,',1,,3,,10,','d:/Data/file/1/51/89/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(344,'幻灯片',89,',1,,3,,10,','d:/Data/file/1/51/89/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(345,'会议快讯',89,',1,,3,,10,','d:/Data/file/1/51/89/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(346,'指南',89,',1,,3,,10,','d:/Data/file/1/51/89/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(347,'疾病知识',89,',1,,3,,10,','d:/Data/file/1/51/89/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(348,'产品知识',89,',1,,3,,10,','d:/Data/file/1/51/89/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(349,'产品说明书',89,',1,,3,,10,','d:/Data/file/1/51/89/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(350,'问与答',89,',1,,3,,10,','d:/Data/file/1/51/89/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(351,'文献解读',98,',1,,3,,10,','d:/Data/file/1/52/98/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(352,'幻灯片',98,',1,,3,,10,','d:/Data/file/1/52/98/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(353,'会议快讯',98,',1,,3,,10,','d:/Data/file/1/52/98/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(354,'指南',98,',1,,3,,10,','d:/Data/file/1/52/98/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(355,'疾病知识',98,',1,,3,,10,','d:/Data/file/1/52/98/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(356,'产品知识',98,',1,,3,,10,','d:/Data/file/1/52/98/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(357,'产品说明书',98,',1,,3,,10,','d:/Data/file/1/52/98/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(358,'问与答',98,',1,,3,,10,','d:/Data/file/1/52/98/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(359,'文献解读',100,',1,,3,,10,','d:/Data/file/1/53/100/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(360,'幻灯片',100,',1,,3,,10,','d:/Data/file/1/53/100/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(361,'会议快讯',100,',1,,3,,10,','d:/Data/file/1/53/100/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(362,'指南',100,',1,,3,,10,','d:/Data/file/1/53/100/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(363,'疾病知识',100,',1,,3,,10,','d:/Data/file/1/53/100/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(364,'产品知识',100,',1,,3,,10,','d:/Data/file/1/53/100/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(365,'产品说明书',100,',1,,3,,10,','d:/Data/file/1/53/100/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(366,'问与答',100,',1,,3,,10,','d:/Data/file/1/53/100/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(367,'文献解读',102,',1,,3,,10,','d:/Data/file/1/54/102/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(368,'幻灯片',102,',1,,3,,10,','d:/Data/file/1/54/102/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(369,'会议快讯',102,',1,,3,,10,','d:/Data/file/1/54/102/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(370,'指南',102,',1,,3,,10,','d:/Data/file/1/54/102/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(371,'疾病知识',102,',1,,3,,10,','d:/Data/file/1/54/102/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(372,'产品知识',102,',1,,3,,10,','d:/Data/file/1/54/102/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(373,'产品说明书',102,',1,,3,,10,','d:/Data/file/1/54/102/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(374,'问与答',102,',1,,3,,10,','d:/Data/file/1/54/102/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(375,'文献解读',104,',1,,3,,10,','d:/Data/file/1/55/104/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(376,'幻灯片',104,',1,,3,,10,','d:/Data/file/1/55/104/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(377,'会议快讯',104,',1,,3,,10,','d:/Data/file/1/55/104/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(378,'指南',104,',1,,3,,10,','d:/Data/file/1/55/104/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(379,'疾病知识',104,',1,,3,,10,','d:/Data/file/1/55/104/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(380,'产品知识',104,',1,,3,,10,','d:/Data/file/1/55/104/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(381,'产品说明书',104,',1,,3,,10,','d:/Data/file/1/55/104/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(382,'问与答',104,',1,,3,,10,','d:/Data/file/1/55/104/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(383,'文献解读',106,',1,,3,,10,','d:/Data/file/1/56/106/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(384,'幻灯片',106,',1,,3,,10,','d:/Data/file/1/56/106/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(385,'会议快讯',106,',1,,3,,10,','d:/Data/file/1/56/106/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(386,'指南',106,',1,,3,,10,','d:/Data/file/1/56/106/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(387,'疾病知识',106,',1,,3,,10,','d:/Data/file/1/56/106/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(388,'产品知识',106,',1,,3,,10,','d:/Data/file/1/56/106/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(389,'产品说明书',106,',1,,3,,10,','d:/Data/file/1/56/106/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(390,'问与答',106,',1,,3,,10,','d:/Data/file/1/56/106/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(391,'文献解读',108,',1,,3,,10,','d:/Data/file/1/57/108/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(392,'幻灯片',108,',1,,3,,10,','d:/Data/file/1/57/108/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(393,'会议快讯',108,',1,,3,,10,','d:/Data/file/1/57/108/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(394,'指南',108,',1,,3,,10,','d:/Data/file/1/57/108/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(395,'疾病知识',108,',1,,3,,10,','d:/Data/file/1/57/108/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(396,'产品知识',108,',1,,3,,10,','d:/Data/file/1/57/108/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(397,'产品说明书',108,',1,,3,,10,','d:/Data/file/1/57/108/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(398,'问与答',108,',1,,3,,10,','d:/Data/file/1/57/108/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(399,'文献解读',110,',1,,3,,10,','d:/Data/file/1/58/110/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(400,'幻灯片',110,',1,,3,,10,','d:/Data/file/1/58/110/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(401,'会议快讯',110,',1,,3,,10,','d:/Data/file/1/58/110/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(402,'指南',110,',1,,3,,10,','d:/Data/file/1/58/110/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(403,'疾病知识',110,',1,,3,,10,','d:/Data/file/1/58/110/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(404,'产品知识',110,',1,,3,,10,','d:/Data/file/1/58/110/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(405,'产品说明书',110,',1,,3,,10,','d:/Data/file/1/58/110/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(406,'问与答',110,',1,,3,,10,','d:/Data/file/1/58/110/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(407,'文献解读',112,',1,,3,,10,','d:/Data/file/1/59/112/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(408,'幻灯片',112,',1,,3,,10,','d:/Data/file/1/59/112/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(409,'会议快讯',112,',1,,3,,10,','d:/Data/file/1/59/112/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(410,'指南',112,',1,,3,,10,','d:/Data/file/1/59/112/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(411,'疾病知识',112,',1,,3,,10,','d:/Data/file/1/59/112/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(412,'产品知识',112,',1,,3,,10,','d:/Data/file/1/59/112/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(413,'产品说明书',112,',1,,3,,10,','d:/Data/file/1/59/112/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(414,'问与答',112,',1,,3,,10,','d:/Data/file/1/59/112/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(415,'文献解读',114,',1,,3,,10,','d:/Data/file/1/60/114/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(416,'幻灯片',114,',1,,3,,10,','d:/Data/file/1/60/114/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(417,'会议快讯',114,',1,,3,,10,','d:/Data/file/1/60/114/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(418,'指南',114,',1,,3,,10,','d:/Data/file/1/60/114/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(419,'疾病知识',114,',1,,3,,10,','d:/Data/file/1/60/114/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(420,'产品知识',114,',1,,3,,10,','d:/Data/file/1/60/114/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(421,'产品说明书',114,',1,,3,,10,','d:/Data/file/1/60/114/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(422,'问与答',114,',1,,3,,10,','d:/Data/file/1/60/114/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(423,'文献解读',116,',1,,3,,10,','d:/Data/file/1/61/116/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(424,'幻灯片',116,',1,,3,,10,','d:/Data/file/1/61/116/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(425,'会议快讯',116,',1,,3,,10,','d:/Data/file/1/61/116/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(426,'指南',116,',1,,3,,10,','d:/Data/file/1/61/116/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(427,'疾病知识',116,',1,,3,,10,','d:/Data/file/1/61/116/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(428,'产品知识',116,',1,,3,,10,','d:/Data/file/1/61/116/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(429,'产品说明书',116,',1,,3,,10,','d:/Data/file/1/61/116/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(430,'问与答',116,',1,,3,,10,','d:/Data/file/1/61/116/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(431,'文献解读',118,',1,,3,,10,','d:/Data/file/1/62/118/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(432,'幻灯片',118,',1,,3,,10,','d:/Data/file/1/62/118/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(433,'会议快讯',118,',1,,3,,10,','d:/Data/file/1/62/118/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(434,'指南',118,',1,,3,,10,','d:/Data/file/1/62/118/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(435,'疾病知识',118,',1,,3,,10,','d:/Data/file/1/62/118/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(436,'产品知识',118,',1,,3,,10,','d:/Data/file/1/62/118/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(437,'产品说明书',118,',1,,3,,10,','d:/Data/file/1/62/118/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(438,'问与答',118,',1,,3,,10,','d:/Data/file/1/62/118/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(439,'文献解读',120,',1,,3,,10,','d:/Data/file/1/63/120/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(440,'幻灯片',120,',1,,3,,10,','d:/Data/file/1/63/120/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(441,'会议快讯',120,',1,,3,,10,','d:/Data/file/1/63/120/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(442,'指南',120,',1,,3,,10,','d:/Data/file/1/63/120/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(443,'疾病知识',120,',1,,3,,10,','d:/Data/file/1/63/120/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(444,'产品知识',120,',1,,3,,10,','d:/Data/file/1/63/120/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(445,'产品说明书',120,',1,,3,,10,','d:/Data/file/1/63/120/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(446,'问与答',120,',1,,3,,10,','d:/Data/file/1/63/120/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(447,'文献解读',122,',1,,3,,10,','d:/Data/file/1/64/122/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(448,'幻灯片',122,',1,,3,,10,','d:/Data/file/1/64/122/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(449,'会议快讯',122,',1,,3,,10,','d:/Data/file/1/64/122/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(450,'指南',122,',1,,3,,10,','d:/Data/file/1/64/122/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(451,'疾病知识',122,',1,,3,,10,','d:/Data/file/1/64/122/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(452,'产品知识',122,',1,,3,,10,','d:/Data/file/1/64/122/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(453,'产品说明书',122,',1,,3,,10,','d:/Data/file/1/64/122/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(454,'问与答',122,',1,,3,,10,','d:/Data/file/1/64/122/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(455,'文献解读',124,',1,,3,,10,','d:/Data/file/1/65/124/',1,'All','All',1,'2015-06-11 16:01:26',1,'2015-06-11 16:01:26'),(456,'幻灯片',124,',1,,3,,10,','d:/Data/file/1/65/124/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(457,'会议快讯',124,',1,,3,,10,','d:/Data/file/1/65/124/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(458,'指南',124,',1,,3,,10,','d:/Data/file/1/65/124/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(459,'疾病知识',124,',1,,3,,10,','d:/Data/file/1/65/124/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(460,'产品知识',124,',1,,3,,10,','d:/Data/file/1/65/124/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(461,'产品说明书',124,',1,,3,,10,','d:/Data/file/1/65/124/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(462,'问与答',124,',1,,3,,10,','d:/Data/file/1/65/124/',1,'All','All',1,'2015-06-11 16:06:45',1,'2015-06-11 16:06:45'),(510,'文献',66,',1,,3,,10,','d:/Data/file/1/40/66/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(511,'产品视频',66,',1,,3,,10,','d:/Data/file/1/40/66/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(512,'幻灯片',66,',1,,3,,10,','d:/Data/file/1/40/66/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(513,'DA',66,',1,,3,,10,','d:/Data/file/1/40/66/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(514,'文献',68,',1,,3,,10,','d:/Data/file/1/41/68/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(515,'产品视频',68,',1,,3,,10,','d:/Data/file/1/41/68/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(516,'幻灯片',68,',1,,3,,10,','d:/Data/file/1/41/68/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(517,'DA',68,',1,,3,,10,','d:/Data/file/1/41/68/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(518,'文献',70,',1,,3,,10,','d:/Data/file/1/42/70/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(519,'产品视频',70,',1,,3,,10,','d:/Data/file/1/42/70/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(520,'幻灯片',70,',1,,3,,10,','d:/Data/file/1/42/70/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(521,'DA',70,',1,,3,,10,','d:/Data/file/1/42/70/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(522,'文献',72,',1,,3,,10,','d:/Data/file/1/43/72/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(523,'产品视频',72,',1,,3,,10,','d:/Data/file/1/43/72/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(524,'幻灯片',72,',1,,3,,10,','d:/Data/file/1/43/72/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(525,'DA',72,',1,,3,,10,','d:/Data/file/1/43/72/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(526,'文献',74,',1,,3,,10,','d:/Data/file/1/44/74/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(527,'产品视频',74,',1,,3,,10,','d:/Data/file/1/44/74/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(528,'幻灯片',74,',1,,3,,10,','d:/Data/file/1/44/74/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(529,'DA',74,',1,,3,,10,','d:/Data/file/1/44/74/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(530,'文献',76,',1,,3,,10,','d:/Data/file/1/45/76/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(531,'产品视频',76,',1,,3,,10,','d:/Data/file/1/45/76/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(532,'幻灯片',76,',1,,3,,10,','d:/Data/file/1/45/76/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(533,'DA',76,',1,,3,,10,','d:/Data/file/1/45/76/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(534,'文献',78,',1,,3,,10,','d:/Data/file/1/46/78/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(535,'产品视频',78,',1,,3,,10,','d:/Data/file/1/46/78/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(536,'幻灯片',78,',1,,3,,10,','d:/Data/file/1/46/78/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(537,'DA',78,',1,,3,,10,','d:/Data/file/1/46/78/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(538,'文献',80,',1,,3,,10,','d:/Data/file/1/47/80/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(539,'产品视频',80,',1,,3,,10,','d:/Data/file/1/47/80/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(540,'幻灯片',80,',1,,3,,10,','d:/Data/file/1/47/80/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(541,'DA',80,',1,,3,,10,','d:/Data/file/1/47/80/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(542,'文献',82,',1,,3,,10,','d:/Data/file/1/48/82/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(543,'产品视频',82,',1,,3,,10,','d:/Data/file/1/48/82/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(544,'幻灯片',82,',1,,3,,10,','d:/Data/file/1/48/82/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(545,'DA',82,',1,,3,,10,','d:/Data/file/1/48/82/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(546,'文献',84,',1,,3,,10,','d:/Data/file/1/49/84/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(547,'产品视频',84,',1,,3,,10,','d:/Data/file/1/49/84/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(548,'幻灯片',84,',1,,3,,10,','d:/Data/file/1/49/84/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(549,'DA',84,',1,,3,,10,','d:/Data/file/1/49/84/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(550,'文献',86,',1,,3,,10,','d:/Data/file/1/50/86/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(551,'产品视频',86,',1,,3,,10,','d:/Data/file/1/50/86/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(552,'幻灯片',86,',1,,3,,10,','d:/Data/file/1/50/86/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(553,'DA',86,',1,,3,,10,','d:/Data/file/1/50/86/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(554,'文献',88,',1,,3,,10,','d:/Data/file/1/51/88/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(555,'产品视频',88,',1,,3,,10,','d:/Data/file/1/51/88/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(556,'幻灯片',88,',1,,3,,10,','d:/Data/file/1/51/88/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(557,'DA',88,',1,,3,,10,','d:/Data/file/1/51/88/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(558,'文献',97,',1,,3,,10,','d:/Data/file/1/52/97/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(559,'产品视频',97,',1,,3,,10,','d:/Data/file/1/52/97/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(560,'幻灯片',97,',1,,3,,10,','d:/Data/file/1/52/97/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(561,'DA',97,',1,,3,,10,','d:/Data/file/1/52/97/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(562,'文献',99,',1,,3,,10,','d:/Data/file/1/53/99/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(563,'产品视频',99,',1,,3,,10,','d:/Data/file/1/53/99/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(564,'幻灯片',99,',1,,3,,10,','d:/Data/file/1/53/99/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(565,'DA',99,',1,,3,,10,','d:/Data/file/1/53/99/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(566,'文献',101,',1,,3,,10,','d:/Data/file/1/54/101/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(567,'产品视频',101,',1,,3,,10,','d:/Data/file/1/54/101/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(568,'幻灯片',101,',1,,3,,10,','d:/Data/file/1/54/101/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(569,'DA',101,',1,,3,,10,','d:/Data/file/1/54/101/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(570,'文献',103,',1,,3,,10,','d:/Data/file/1/55/103/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(571,'产品视频',103,',1,,3,,10,','d:/Data/file/1/55/103/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(572,'幻灯片',103,',1,,3,,10,','d:/Data/file/1/55/103/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(573,'DA',103,',1,,3,,10,','d:/Data/file/1/55/103/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(574,'文献',105,',1,,3,,10,','d:/Data/file/1/56/105/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(575,'产品视频',105,',1,,3,,10,','d:/Data/file/1/56/105/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(576,'幻灯片',105,',1,,3,,10,','d:/Data/file/1/56/105/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(577,'DA',105,',1,,3,,10,','d:/Data/file/1/56/105/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(578,'文献',107,',1,,3,,10,','d:/Data/file/1/57/107/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(579,'产品视频',107,',1,,3,,10,','d:/Data/file/1/57/107/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(580,'幻灯片',107,',1,,3,,10,','d:/Data/file/1/57/107/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(581,'DA',107,',1,,3,,10,','d:/Data/file/1/57/107/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(582,'文献',109,',1,,3,,10,','d:/Data/file/1/58/109/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(583,'产品视频',109,',1,,3,,10,','d:/Data/file/1/58/109/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(584,'幻灯片',109,',1,,3,,10,','d:/Data/file/1/58/109/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(585,'DA',109,',1,,3,,10,','d:/Data/file/1/58/109/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(586,'文献',111,',1,,3,,10,','d:/Data/file/1/59/111/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(587,'产品视频',111,',1,,3,,10,','d:/Data/file/1/59/111/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(588,'幻灯片',111,',1,,3,,10,','d:/Data/file/1/59/111/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(589,'DA',111,',1,,3,,10,','d:/Data/file/1/59/111/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(590,'文献',113,',1,,3,,10,','d:/Data/file/1/60/113/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(591,'产品视频',113,',1,,3,,10,','d:/Data/file/1/60/113/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(592,'幻灯片',113,',1,,3,,10,','d:/Data/file/1/60/113/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(593,'DA',113,',1,,3,,10,','d:/Data/file/1/60/113/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(594,'文献',115,',1,,3,,10,','d:/Data/file/1/61/115/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(595,'产品视频',115,',1,,3,,10,','d:/Data/file/1/61/115/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(596,'幻灯片',115,',1,,3,,10,','d:/Data/file/1/61/115/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(597,'DA',115,',1,,3,,10,','d:/Data/file/1/61/115/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(598,'文献',117,',1,,3,,10,','d:/Data/file/1/62/117/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(599,'产品视频',117,',1,,3,,10,','d:/Data/file/1/62/117/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(600,'幻灯片',117,',1,,3,,10,','d:/Data/file/1/62/117/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(601,'DA',117,',1,,3,,10,','d:/Data/file/1/62/117/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(602,'文献',119,',1,,3,,10,','d:/Data/file/1/63/119/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(603,'产品视频',119,',1,,3,,10,','d:/Data/file/1/63/119/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(604,'幻灯片',119,',1,,3,,10,','d:/Data/file/1/63/119/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(605,'DA',119,',1,,3,,10,','d:/Data/file/1/63/119/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(606,'文献',121,',1,,3,,10,','d:/Data/file/1/64/121/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(607,'产品视频',121,',1,,3,,10,','d:/Data/file/1/64/121/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(608,'幻灯片',121,',1,,3,,10,','d:/Data/file/1/64/121/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(609,'DA',121,',1,,3,,10,','d:/Data/file/1/64/121/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(610,'文献',123,',1,,3,,10,','d:/Data/file/1/65/123/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(611,'产品视频',123,',1,,3,,10,','d:/Data/file/1/65/123/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(612,'幻灯片',123,',1,,3,,10,','d:/Data/file/1/65/123/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58'),(613,'DA',123,',1,,3,,10,','d:/Data/file/1/65/123/',1,'All','All',1,'2015-06-11 16:11:58',1,'2015-06-11 16:11:58');
/*!40000 ALTER TABLE `categories` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `categories_temp`
--

DROP TABLE IF EXISTS `categories_temp`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `categories_temp` (
  `CategoryId` int(11) NOT NULL DEFAULT '0',
  `CategoryName` varchar(100) NOT NULL,
  `ParentId` int(11) NOT NULL,
  `DeptList` varchar(255) DEFAULT 'All',
  `FilePath` varchar(255) NOT NULL,
  `Status` int(11) NOT NULL DEFAULT '1',
  `PAList` varchar(255) DEFAULT 'All',
  `ProductList` varchar(255) DEFAULT 'All',
  `CreatedUser` int(11) DEFAULT NULL,
  `CreatedTime` datetime DEFAULT NULL,
  `EditUser` int(11) DEFAULT NULL,
  `EditTime` datetime DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `categories_temp`
--

LOCK TABLES `categories_temp` WRITE;
/*!40000 ALTER TABLE `categories_temp` DISABLE KEYS */;
INSERT INTO `categories_temp` VALUES (1,'总分类',0,'All','d:/tmp/file',1,'All','All',1,'2015-05-20 14:56:32',1,'2015-05-20 14:56:36'),(2,'分类1',1,'All','d:/tmp/file/2',1,',PAL3,',',PL3,',1,'2015-05-20 15:14:10',1,'2015-05-20 15:14:10'),(3,'分类2',1,',1,,3,,10,','d:/tmp/file/3',1,',11,',',16,',1,'2015-06-16 19:51:17',1,'2015-06-16 19:51:17'),(4,'分类3',1,',1,,2,,19,,3,,10,','d:/tmp/file/4',1,',11,',',16,,17,',1,'2015-06-16 19:55:02',1,'2015-06-16 19:55:02'),(5,'公司信息',1,',1,,3,,10,','d:/tmp/file/5',1,'All','All',1,'2015-06-17 19:19:02',1,'2015-06-17 19:19:02'),(6,'HR',5,',1,,3,,10,','d:/tmp/file/5/6',1,'All','All',1,'2015-06-17 19:20:07',1,'2015-06-17 19:20:07'),(7,'IT',5,',1,,3,,10,','d:/tmp/file/5/7',1,'All','All',1,'2015-06-17 19:20:31',1,'2015-06-17 19:20:31'),(8,'培训',6,',1,,3,,10,','d:/tmp/file/5/6/8',1,'All','All',1,'2015-06-17 19:20:50',1,'2015-06-17 19:20:50');
/*!40000 ALTER TABLE `categories_temp` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `depts`
--

DROP TABLE IF EXISTS `depts`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `depts` (
  `DeptId` int(11) NOT NULL AUTO_INCREMENT,
  `DeptName` varchar(100) NOT NULL,
  `DeptCode` varchar(20) DEFAULT NULL,
  `ParentId` int(11) NOT NULL DEFAULT '0',
  `Status` int(11) NOT NULL DEFAULT '0',
  `PAList` varchar(255) NOT NULL DEFAULT 'All',
  `ProductList` varchar(255) NOT NULL DEFAULT 'All',
  `CreatedUser` int(11) DEFAULT NULL,
  `CreatedTime` datetime DEFAULT NULL,
  `EditUser` int(11) DEFAULT NULL,
  `EditTime` datetime DEFAULT NULL,
  `ParentCode` varchar(20) DEFAULT NULL,
  PRIMARY KEY (`DeptId`)
) ENGINE=InnoDB AUTO_INCREMENT=244 DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `depts`
--

LOCK TABLES `depts` WRITE;
/*!40000 ALTER TABLE `depts` DISABLE KEYS */;
INSERT INTO `depts` VALUES (1,'AMD-01','AMD-01',233,1,'All','All',NULL,NULL,NULL,NULL,'MD-01'),(2,'CBU-MM-01','CBU-MM-01',5,1,'All','All',NULL,NULL,NULL,NULL,'CNCBUD0001'),(3,'CBU-MM-02','CBU-MM-02',5,1,'All','All',NULL,NULL,NULL,NULL,'CNCBUD0001'),(4,'CBU-MM-03','CBU-MM-03',5,1,'All','All',NULL,NULL,NULL,'2015-06-20 15:40:07',''),(5,'CNCBUD0001','CNCBUD0001',227,1,'All','All',NULL,NULL,NULL,'2015-06-20 15:22:09','CNGBUD0001'),(6,'CNCDSM0001','CNCDSM0001',58,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0001'),(7,'CNCDSM0002','CNCDSM0002',58,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0001'),(8,'CNCDSM0003','CNCDSM0003',58,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0001'),(9,'CNCDSM0004','CNCDSM0004',58,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0001'),(10,'CNCDSM0005','CNCDSM0005',58,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0001'),(11,'CNCDSM0006','CNCDSM0006',58,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0001'),(12,'CNCDSM0007','CNCDSM0007',59,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0002'),(13,'CNCDSM0008','CNCDSM0008',59,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0002'),(14,'CNCDSM0009','CNCDSM0009',59,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0002'),(15,'CNCDSM0010','CNCDSM0010',59,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0002'),(16,'CNCDSM0011','CNCDSM0011',59,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0002'),(17,'CNCDSM0012','CNCDSM0012',59,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0002'),(18,'CNCDSM0013','CNCDSM0013',59,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0002'),(19,'CNCDSM0014','CNCDSM0014',59,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0002'),(20,'CNCDSM0015','CNCDSM0015',59,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0002'),(21,'CNCDSM0016','CNCDSM0016',59,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0002'),(22,'CNCDSM0017','CNCDSM0017',60,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0003'),(23,'CNCDSM0018','CNCDSM0018',60,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0003'),(24,'CNCDSM0019','CNCDSM0019',60,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0003'),(25,'CNCDSM0020','CNCDSM0020',60,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0003'),(26,'CNCDSM0021','CNCDSM0021',60,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0003'),(27,'CNCDSM0022','CNCDSM0022',60,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0003'),(28,'CNCDSM0023','CNCDSM0023',61,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0004'),(29,'CNCDSM0024','CNCDSM0024',61,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0004'),(30,'CNCDSM0025','CNCDSM0025',61,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0004'),(31,'CNCDSM0026','CNCDSM0026',61,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0004'),(32,'CNCDSM0027','CNCDSM0027',61,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0004'),(33,'CNCDSM0028','CNCDSM0028',61,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0004'),(34,'CNCDSM0029','CNCDSM0029',61,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0004'),(35,'CNCDSM0030','CNCDSM0030',61,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0004'),(36,'CNCDSM0031','CNCDSM0031',62,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0005'),(37,'CNCDSM0032','CNCDSM0032',62,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0005'),(38,'CNCDSM0033','CNCDSM0033',62,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0005'),(39,'CNCDSM0034','CNCDSM0034',62,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0005'),(40,'CNCDSM0035','CNCDSM0035',62,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0005'),(41,'CNCDSM0036','CNCDSM0036',62,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0005'),(42,'CNCDSM0037','CNCDSM0037',62,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0005'),(43,'CNCDSM0038','CNCDSM0038',62,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0005'),(44,'CNCDSM0039','CNCDSM0039',62,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0005'),(45,'CNCDSM0040','CNCDSM0040',63,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0006'),(46,'CNCDSM0041','CNCDSM0041',63,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0006'),(47,'CNCDSM0042','CNCDSM0042',63,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0006'),(48,'CNCDSM0043','CNCDSM0043',63,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0006'),(49,'CNCDSM0044','CNCDSM0044',63,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0006'),(50,'CNCDSM0045','CNCDSM0045',63,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0006'),(51,'CNCDSM0046','CNCDSM0046',63,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0006'),(52,'CNCDSM0047','CNCDSM0047',64,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0007'),(53,'CNCDSM0048','CNCDSM0048',64,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0007'),(54,'CNCDSM0049','CNCDSM0049',64,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0007'),(55,'CNCDSM0050','CNCDSM0050',64,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0007'),(56,'CNCDSM0051','CNCDSM0051',64,1,'All','All',NULL,NULL,NULL,NULL,'CNCRSM0007'),(57,'CNCNSD0001','CNCNSD0001',5,1,'All','All',NULL,NULL,NULL,NULL,'CNCBUD0001'),(58,'CNCRSM0001','CNCRSM0001',57,1,'All','All',NULL,NULL,NULL,NULL,'CNCNSD0001'),(59,'CNCRSM0002','CNCRSM0002',57,1,'All','All',NULL,NULL,NULL,NULL,'CNCNSD0001'),(60,'CNCRSM0003','CNCRSM0003',57,1,'All','All',NULL,NULL,NULL,NULL,'CNCNSD0001'),(61,'CNCRSM0004','CNCRSM0004',57,1,'All','All',NULL,NULL,NULL,NULL,'CNCNSD0001'),(62,'CNCRSM0005','CNCRSM0005',57,1,'All','All',NULL,NULL,NULL,NULL,'CNCNSD0001'),(63,'CNCRSM0006','CNCRSM0006',57,1,'All','All',NULL,NULL,NULL,NULL,'CNCNSD0001'),(64,'CNCRSM0007','CNCRSM0007',57,1,'All','All',NULL,NULL,NULL,NULL,'CNCNSD0001'),(65,'CNGBUD0001','CNGBUD0001',227,1,'All','All',NULL,NULL,NULL,'2015-06-20 15:23:54',''),(66,'CNGDSM0001','CNGDSM0001',137,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0001'),(67,'CNGDSM0002','CNGDSM0002',137,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0001'),(68,'CNGDSM0003','CNGDSM0003',137,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0001'),(69,'CNGDSM0004','CNGDSM0004',137,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0001'),(70,'CNGDSM0005','CNGDSM0005',137,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0001'),(71,'CNGDSM0006','CNGDSM0006',137,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0001'),(72,'CNGDSM0007','CNGDSM0007',138,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0002'),(73,'CNGDSM0008','CNGDSM0008',138,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0002'),(74,'CNGDSM0009','CNGDSM0009',138,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0002'),(75,'CNGDSM0010','CNGDSM0010',139,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0003'),(76,'CNGDSM0011','CNGDSM0011',139,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0003'),(77,'CNGDSM0012','CNGDSM0012',139,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0003'),(78,'CNGDSM0013','CNGDSM0013',139,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0003'),(79,'CNGDSM0014','CNGDSM0014',139,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0003'),(80,'CNGDSM0015','CNGDSM0015',139,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0003'),(81,'CNGDSM0016','CNGDSM0016',139,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0003'),(82,'CNGDSM0017','CNGDSM0017',140,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0004'),(83,'CNGDSM0018','CNGDSM0018',140,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0004'),(84,'CNGDSM0019','CNGDSM0019',140,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0004'),(85,'CNGDSM0020','CNGDSM0020',140,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0004'),(86,'CNGDSM0021','CNGDSM0021',140,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0004'),(87,'CNGDSM0022','CNGDSM0022',141,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0005'),(88,'CNGDSM0023','CNGDSM0023',141,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0005'),(89,'CNGDSM0024','CNGDSM0024',141,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0005'),(90,'CNGDSM0025','CNGDSM0025',141,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0005'),(91,'CNGDSM0026','CNGDSM0026',141,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0005'),(92,'CNGDSM0027','CNGDSM0027',141,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0005'),(93,'CNGDSM0028','CNGDSM0028',141,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0005'),(94,'CNGDSM0029','CNGDSM0029',142,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0006'),(95,'CNGDSM0030','CNGDSM0030',142,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0006'),(96,'CNGDSM0031','CNGDSM0031',142,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0006'),(97,'CNGDSM0032','CNGDSM0032',142,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0006'),(98,'CNGDSM0033','CNGDSM0033',142,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0006'),(99,'CNGDSM0034','CNGDSM0034',143,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0007'),(100,'CNGDSM0035','CNGDSM0035',143,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0007'),(101,'CNGDSM0036','CNGDSM0036',143,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0007'),(102,'CNGDSM0037','CNGDSM0037',143,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0007'),(103,'CNGDSM0038','CNGDSM0038',143,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0007'),(104,'CNGDSM0039','CNGDSM0039',143,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0007'),(105,'CNGDSM0040','CNGDSM0040',144,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0008'),(106,'CNGDSM0041','CNGDSM0041',144,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0008'),(107,'CNGDSM0042','CNGDSM0042',144,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0008'),(108,'CNGDSM0043','CNGDSM0043',145,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0009'),(109,'CNGDSM0044','CNGDSM0044',145,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0009'),(110,'CNGDSM0045','CNGDSM0045',145,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0009'),(111,'CNGDSM0046','CNGDSM0046',145,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0009'),(112,'CNGDSM0047','CNGDSM0047',145,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0009'),(113,'CNGDSM0048','CNGDSM0048',145,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0009'),(114,'CNGDSM0049','CNGDSM0049',145,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0009'),(115,'CNGDSM0050','CNGDSM0050',145,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0009'),(116,'CNGDSM0051','CNGDSM0051',145,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0009'),(117,'CNGDSM0052','CNGDSM0052',146,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0010'),(118,'CNGDSM0053','CNGDSM0053',146,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0010'),(119,'CNGDSM0054','CNGDSM0054',146,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0010'),(120,'CNGDSM0055','CNGDSM0055',146,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0010'),(121,'CNGDSM0056','CNGDSM0056',146,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0010'),(122,'CNGDSM0057','CNGDSM0057',146,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0010'),(123,'CNGDSM0058','CNGDSM0058',146,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0010'),(124,'CNGDSM0059','CNGDSM0059',147,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0011'),(125,'CNGDSM0060','CNGDSM0060',147,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0011'),(126,'CNGDSM0061','CNGDSM0061',147,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0011'),(127,'CNGDSM0062','CNGDSM0062',147,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0011'),(128,'CNGDSM0063','CNGDSM0063',147,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0011'),(129,'CNGDSM0064','CNGDSM0064',147,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0011'),(130,'CNGDSM0065','CNGDSM0065',148,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0012'),(131,'CNGDSM0066','CNGDSM0066',148,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0012'),(132,'CNGDSM0067','CNGDSM0067',148,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0012'),(133,'CNGDSM0068','CNGDSM0068',148,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSM0012'),(134,'CNGRSD0001','CNGRSD0001',65,1,'All','All',NULL,NULL,NULL,NULL,'CNGBUD0001'),(135,'CNGRSD0002','CNGRSD0002',65,1,'All','All',NULL,NULL,NULL,NULL,'CNGBUD0001'),(136,'CNGRSD0003','CNGRSD0003',65,1,'All','All',NULL,NULL,NULL,NULL,'CNGBUD0001'),(137,'CNGRSM0001','CNGRSM0001',134,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSD0001'),(138,'CNGRSM0002','CNGRSM0002',134,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSD0001'),(139,'CNGRSM0003','CNGRSM0003',134,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSD0001'),(140,'CNGRSM0004','CNGRSM0004',134,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSD0001'),(141,'CNGRSM0005','CNGRSM0005',135,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSD0002'),(142,'CNGRSM0006','CNGRSM0006',135,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSD0002'),(143,'CNGRSM0007','CNGRSM0007',135,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSD0002'),(144,'CNGRSM0008','CNGRSM0008',135,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSD0002'),(145,'CNGRSM0009','CNGRSM0009',136,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSD0003'),(146,'CNGRSM0010','CNGRSM0010',136,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSD0003'),(147,'CNGRSM0011','CNGRSM0011',136,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSD0003'),(148,'CNGRSM0012','CNGRSM0012',136,1,'All','All',NULL,NULL,NULL,NULL,'CNGRSD0003'),(149,'CNOBUD0001','CNOBUD0001',227,1,'All','All',NULL,NULL,NULL,'2015-06-20 15:26:29',''),(150,'CNODSM0001','CNODSM0001',183,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0001'),(151,'CNODSM0002','CNODSM0002',183,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0001'),(152,'CNODSM0003','CNODSM0003',183,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0001'),(153,'CNODSM0004','CNODSM0004',188,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0006'),(154,'CNODSM0005','CNODSM0005',183,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0001'),(155,'CNODSM0006','CNODSM0006',183,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0001'),(156,'CNODSM0007','CNODSM0007',183,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0001'),(157,'CNODSM0008','CNODSM0008',184,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0002'),(158,'CNODSM0009','CNODSM0009',184,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0002'),(159,'CNODSM0010','CNODSM0010',184,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0002'),(160,'CNODSM0011','CNODSM0011',184,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0002'),(161,'CNODSM0012','CNODSM0012',184,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0002'),(162,'CNODSM0013','CNODSM0013',184,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0002'),(163,'CNODSM0014','CNODSM0014',185,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0003'),(164,'CNODSM0015','CNODSM0015',185,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0003'),(165,'CNODSM0016','CNODSM0016',185,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0003'),(166,'CNODSM0017','CNODSM0017',185,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0003'),(167,'CNODSM0018','CNODSM0018',188,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0006'),(168,'CNODSM0019','CNODSM0019',186,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0004'),(169,'CNODSM0020','CNODSM0020',186,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0004'),(170,'CNODSM0021','CNODSM0021',186,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0004'),(171,'CNODSM0022','CNODSM0022',188,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0006'),(172,'CNODSM0023','CNODSM0023',188,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0006'),(173,'CNODSM0024','CNODSM0024',187,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0005'),(174,'CNODSM0025','CNODSM0025',187,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0005'),(175,'CNODSM0026','CNODSM0026',187,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0005'),(176,'CNODSM0027','CNODSM0027',187,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0005'),(177,'CNODSM0028','CNODSM0028',187,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0005'),(178,'CNODSM0029','CNODSM0029',187,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0005'),(179,'CNODSM0030','CNODSM0030',187,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0005'),(180,'CNODSM0031','CNODSM0031',183,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0001'),(181,'CNODSM0032','CNODSM0032',188,1,'All','All',NULL,NULL,NULL,NULL,'CNORSM0006'),(182,'CNONSD0001','CNONSD0001',149,1,'All','All',NULL,NULL,NULL,NULL,'CNOBUD0001'),(183,'CNORSM0001','CNORSM0001',182,1,'All','All',NULL,NULL,NULL,NULL,'CNONSD0001'),(184,'CNORSM0002','CNORSM0002',182,1,'All','All',NULL,NULL,NULL,NULL,'CNONSD0001'),(185,'CNORSM0003','CNORSM0003',182,1,'All','All',NULL,NULL,NULL,NULL,'CNONSD0001'),(186,'CNORSM0004','CNORSM0004',182,1,'All','All',NULL,NULL,NULL,NULL,'CNONSD0001'),(187,'CNORSM0005','CNORSM0005',182,1,'All','All',NULL,NULL,NULL,NULL,'CNONSD0001'),(188,'CNORSM0006','CNORSM0006',182,1,'All','All',NULL,NULL,NULL,NULL,'CNONSD0001'),(189,'CNRBUD0001','CNRBUD0001',227,1,'All','All',NULL,NULL,NULL,'2015-06-20 15:28:38',''),(190,'CNRDSM0001','CNRDSM0001',219,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0001'),(191,'CNRDSM0002','CNRDSM0002',219,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0001'),(192,'CNRDSM0003','CNRDSM0003',219,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0001'),(193,'CNRDSM0004','CNRDSM0004',219,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0001'),(194,'CNRDSM0005','CNRDSM0005',219,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0001'),(195,'CNRDSM0006','CNRDSM0006',219,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0001'),(196,'CNRDSM0007','CNRDSM0007',219,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0001'),(197,'CNRDSM0008','CNRDSM0008',219,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0001'),(198,'CNRDSM0009','CNRDSM0009',220,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0002'),(199,'CNRDSM0011','CNRDSM0011',220,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0002'),(200,'CNRDSM0012','CNRDSM0012',220,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0002'),(201,'CNRDSM0013','CNRDSM0013',220,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0002'),(202,'CNRDSM0014','CNRDSM0014',220,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0002'),(203,'CNRDSM0015','CNRDSM0015',221,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0004'),(204,'CNRDSM0016','CNRDSM0016',219,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0001'),(205,'CNRDSM0017','CNRDSM0017',220,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0002'),(206,'CNRDSM0018','CNRDSM0018',221,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0004'),(207,'CNRDSM0019','CNRDSM0019',220,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0002'),(208,'CNRDSM0021','CNRDSM0021',221,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0004'),(209,'CNRDSM0022','CNRDSM0022',221,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0004'),(210,'CNRDSM0023','CNRDSM0023',221,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0004'),(211,'CNRDSM0024','CNRDSM0024',221,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0004'),(212,'CNRDSM0025','CNRDSM0025',221,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0004'),(213,'CNRDSM0026','CNRDSM0026',221,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0004'),(214,'CNRDSM0027','CNRDSM0027',221,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0004'),(215,'CNRDSM0028','CNRDSM0028',219,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0001'),(216,'CNRDSM0029','CNRDSM0029',219,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0001'),(217,'CNRDSM0030','CNRDSM0030',220,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0002'),(218,'CNRDSM0031','CNRDSM0031',221,1,'All','All',NULL,NULL,NULL,NULL,'CNRRSM0004'),(219,'CNRRSM0001','CNRRSM0001',189,1,'All','All',NULL,NULL,NULL,NULL,'CNRBUD0001'),(220,'CNRRSM0002','CNRRSM0002',189,1,'All','All',NULL,NULL,NULL,NULL,'CNRBUD0001'),(221,'CNRRSM0004','CNRRSM0004',189,1,'All','All',NULL,NULL,NULL,NULL,'CNRBUD0001'),(222,'CVM&GM-MAM-01','CVM&GM-MAM-01',243,1,'All','All',NULL,NULL,NULL,NULL,''),(223,'CVM-MSLM-01','CVM-MSLM-01',243,1,'All','All',NULL,NULL,NULL,NULL,''),(224,'GBU-MM-01','GBU-MM-01',65,1,'All','All',NULL,NULL,NULL,'2015-06-20 15:40:47',''),(225,'GBU-PM-03','GBU-PM-03',65,1,'All','All',NULL,NULL,NULL,NULL,'CNGBUD0001'),(226,'GI&RE-MAM-01','GI&RE-MAM-01',233,1,'All','All',NULL,NULL,NULL,NULL,'MD-01'),(227,'GM-01','GM-01',0,1,'All','All',NULL,NULL,NULL,'2015-06-20 15:31:51',''),(228,'GM-MA-01','GM-MA-01',222,1,'All','All',NULL,NULL,NULL,NULL,'CVM&GM-MAM-01'),(229,'KA0002','KA0002',227,1,'All','All',NULL,NULL,NULL,NULL,'GM-01'),(230,'KA0003','KA0003',229,1,'All','All',NULL,NULL,NULL,NULL,'KA0002'),(231,'KA0011','KA0011',229,1,'All','All',NULL,NULL,NULL,NULL,'KA0002'),(232,'KA0014','KA0014',229,1,'All','All',NULL,NULL,NULL,NULL,'KA0002'),(233,'MD-01','MD-01',227,1,'All','All',NULL,NULL,NULL,NULL,''),(234,'MI&PVM-01','MI&PVM-01',243,1,'All','All',NULL,NULL,NULL,NULL,''),(235,'OBU-MM-01','OBU-MM-01',149,1,'All','All',NULL,NULL,NULL,NULL,'CNOBUD0001'),(236,'OBU-PM-03','OBU-PM-03',149,1,'All','All',NULL,NULL,NULL,'2015-06-20 15:42:10',''),(237,'ONCO-MAM-01','ONCO-MAM-01',243,1,'All','All',NULL,NULL,NULL,NULL,''),(238,'ONCO-MSLM-01','ONCO-MSLM-01',233,1,'All','All',NULL,NULL,NULL,NULL,'MD-01'),(239,'RBU-PM-01','RBU-PM-01',189,1,'All','All',NULL,NULL,NULL,NULL,'CNRBUD0001'),(240,'RE&GI-MSLM-01','RE&GI-MSLM-01',233,1,'All','All',NULL,NULL,NULL,NULL,'MD-01'),(241,'SFE-HO-0004','SFE-HO-0004',243,1,'All','All',NULL,NULL,NULL,NULL,''),(242,'SFE-HO-0011','SFE-HO-0011',243,1,'All','All',NULL,NULL,NULL,NULL,''),(243,'other','other',227,1,'All','All',NULL,NULL,NULL,NULL,'MD-01');
/*!40000 ALTER TABLE `depts` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `examanswer`
--

DROP TABLE IF EXISTS `examanswer`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `examanswer` (
  `ExamId` int(11) NOT NULL,
  `ProblemId` int(11) NOT NULL,
  `UserId` int(11) NOT NULL,
  `ProblemType` int(11) NOT NULL,
  `Score` float NOT NULL,
  `Answer` varchar(100) NOT NULL,
  `Result` int(11) NOT NULL,
  PRIMARY KEY (`ExamId`,`UserId`,`ProblemId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `examanswer`
--

LOCK TABLES `examanswer` WRITE;
/*!40000 ALTER TABLE `examanswer` DISABLE KEYS */;
/*!40000 ALTER TABLE `examanswer` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `examdetail`
--

DROP TABLE IF EXISTS `examdetail`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `examdetail` (
  `ExamId` int(11) NOT NULL,
  `ProblemId` int(11) NOT NULL,
  PRIMARY KEY (`ExamId`,`ProblemId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `examdetail`
--

LOCK TABLES `examdetail` WRITE;
/*!40000 ALTER TABLE `examdetail` DISABLE KEYS */;
INSERT INTO `examdetail` VALUES (1,66),(1,153),(1,188),(1,209),(1,275),(1,440),(1,487),(1,530),(1,553),(1,561),(1,688),(1,744),(1,845),(1,853),(1,869),(1,885),(1,982),(1,998),(1,1007),(1,1017),(1,1031),(1,1045),(1,1061),(1,1090),(1,1135),(1,1162),(1,1172),(1,1182),(1,1187),(1,1253),(1,1262),(1,1346),(1,1370),(1,1468),(1,1473),(1,1474),(1,1542),(1,1553),(2,714),(2,717),(2,733),(2,809),(2,813),(2,817),(2,820),(2,821),(2,822),(2,825),(2,865),(2,898),(2,902),(2,934),(2,977),(2,980),(2,989),(2,1002),(2,1010),(2,1058),(2,1060),(2,1093),(2,1097),(2,1100),(2,1111),(2,1117),(2,1134),(2,1143),(2,1146),(2,1147),(2,1149),(2,1178),(2,1197),(2,1202),(2,1208),(2,1214),(2,1227),(2,1260),(2,1285),(2,1287),(2,1288),(2,1292),(2,1294),(2,1295),(2,1297),(2,1306),(2,1308),(2,1312),(2,1314),(2,1320),(2,1323),(2,1327),(2,1340),(2,1382),(2,1389),(2,1393),(2,1400),(2,1438),(2,1440),(2,1441),(4,144),(4,151),(4,155),(4,165),(4,188),(4,193),(4,228),(4,255),(4,260),(4,262),(4,440),(4,498),(4,628),(4,671),(4,703),(4,707),(4,988),(4,1001),(4,1418),(4,1429),(8,3),(8,46),(8,49),(8,84),(8,103),(8,107),(8,118),(8,145),(8,180),(8,204),(8,205),(8,264),(8,268),(8,293),(8,348),(8,366),(8,382),(8,400),(8,443),(8,501),(8,519),(8,523),(8,587),(8,617),(8,631),(8,660),(8,679),(8,726),(8,739),(8,750),(8,756),(8,764),(8,797),(8,801),(8,805),(8,818),(8,842),(8,847),(8,882),(8,936),(8,948),(8,977),(8,997),(8,1001),(8,1014),(8,1023),(8,1039),(8,1041),(8,1062),(8,1081),(8,1088),(8,1103),(8,1107),(8,1112),(8,1136),(8,1143),(8,1163),(8,1183),(8,1186),(8,1191),(8,1209),(8,1213),(8,1220),(8,1256),(8,1300),(8,1310),(8,1313),(8,1320),(8,1331),(8,1351),(8,1374),(8,1384),(8,1387),(8,1412),(8,1434),(8,1457),(8,1467),(8,1490),(8,1501),(8,1504),(9,32),(9,35),(9,89),(9,95),(9,100),(9,103),(9,121),(9,129),(9,137),(9,138),(9,153),(9,156),(9,184),(9,228),(9,229),(9,239),(9,263),(9,271),(9,324),(9,342),(9,352),(9,367),(9,409),(9,424),(9,453),(9,485),(9,505),(9,528),(9,532),(9,539),(9,553),(9,556),(9,566),(9,590),(9,601),(9,604),(9,628),(9,637),(9,646),(9,649),(9,689),(9,693),(9,700),(9,756),(9,829),(9,844),(9,880),(9,923),(9,968),(9,987),(9,991),(9,1017),(9,1062),(9,1069),(9,1077),(9,1103),(9,1140),(9,1142),(9,1154),(9,1178),(9,1182),(9,1280),(9,1281),(9,1299),(9,1305),(9,1343),(9,1383),(9,1419),(9,1487),(9,1561),(10,29),(10,32),(10,44),(10,71),(10,85),(10,88),(10,90),(10,111),(10,112),(10,122),(10,142),(10,185),(10,187),(10,218),(10,233),(10,236),(10,251),(10,261),(10,266),(10,283),(10,319),(10,332),(10,352),(10,356),(10,357),(10,373),(10,411),(10,419),(10,423),(10,446),(10,466),(10,472),(10,482),(10,514),(10,559),(10,570),(10,574),(10,608),(10,615),(10,619),(10,628),(10,630),(10,665),(10,689),(10,699),(10,753),(10,762),(10,797),(10,811),(10,832),(10,838),(10,846),(10,919),(10,939),(10,949),(10,1008),(10,1011),(10,1026),(10,1027),(10,1115),(10,1117),(10,1156),(10,1160),(10,1165),(10,1178),(10,1199),(10,1206),(10,1221),(10,1268),(10,1272),(10,1274),(10,1304),(10,1328),(10,1366),(10,1401),(10,1408),(10,1416),(10,1436),(10,1529),(10,1538);
/*!40000 ALTER TABLE `examdetail` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `examroll`
--

DROP TABLE IF EXISTS `examroll`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `examroll` (
  `ExamId` int(11) NOT NULL,
  `UserId` int(11) NOT NULL,
  `IsSubmit` int(11) NOT NULL DEFAULT '0',
  `Status` int(11) NOT NULL DEFAULT '1',
  PRIMARY KEY (`ExamId`,`UserId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `examroll`
--

LOCK TABLES `examroll` WRITE;
/*!40000 ALTER TABLE `examroll` DISABLE KEYS */;
INSERT INTO `examroll` VALUES (8,19,0,1),(8,21,0,1),(8,38,0,1);
/*!40000 ALTER TABLE `examroll` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `exams`
--

DROP TABLE IF EXISTS `exams`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `exams` (
  `ExamId` int(11) NOT NULL AUTO_INCREMENT,
  `ExamName` varchar(200) NOT NULL,
  `ExamType` int(11) NOT NULL DEFAULT '0',
  `ExamLocation` int(11) DEFAULT NULL,
  `ExamBegin` datetime DEFAULT NULL,
  `ExamEnd` datetime DEFAULT NULL,
  `ExamAnsType` int(11) NOT NULL DEFAULT '2',
  `ExamPassword` varchar(100) DEFAULT NULL,
  `Status` int(11) NOT NULL DEFAULT '0',
  `ExamDesc` varchar(255) DEFAULT NULL,
  `ExamContent` varchar(1000) NOT NULL,
  `ExpireTime` datetime NOT NULL,
  `CreatedUser` int(11) NOT NULL,
  `CreatedTime` datetime NOT NULL,
  `EditUser` int(11) NOT NULL,
  `EditTime` datetime NOT NULL,
  PRIMARY KEY (`ExamId`),
  UNIQUE KEY `ExamName` (`ExamName`)
) ENGINE=InnoDB AUTO_INCREMENT=11 DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `exams`
--

LOCK TABLES `exams` WRITE;
/*!40000 ALTER TABLE `exams` DISABLE KEYS */;
INSERT INTO `exams` VALUES (1,'产品达考试',0,0,'1970-01-01 08:00:00','1970-01-01 08:00:00',2,'',0,'考试对象：新进代表时间：2015/00/00地点：北京其他注意事项：aweraetr大发生的发生的sdgsdfgvsf，阿萨德发噶舒服的','0,50,20,70,0,0,必洛斯,艾可拓,倍欣,尼欣那,潘针,潘片,抑那通,亚宁定,开思亭,爱宝疗','2015-06-17 00:00:00',1,'2015-06-21 11:29:12',1,'2015-06-21 11:35:32'),(4,'eric',0,0,'1970-01-01 08:00:00','1970-01-01 08:00:00',2,'',1,'eric','0,10,10,20,0,0,心血管,乳腺,尼欣那,市场策略','2015-06-15 00:00:00',1,'2015-06-21 11:36:40',1,'2015-06-21 11:36:40'),(8,'模拟考试80',0,0,'1970-01-01 08:00:00','1970-01-01 08:00:00',2,'',1,'考试对象：新进代表\n时间：2015/00/00\n地点：北京','0,50,30,80,0,0,必洛斯,艾可拓,倍欣,尼欣那,潘针,抑那通,亚宁定,开思亭','2015-06-30 00:00:00',1,'2015-06-21 11:42:36',1,'2015-06-21 11:42:36'),(9,'模拟考试70',0,0,'1970-01-01 08:00:00','1970-01-01 08:00:00',2,'',0,'考试对象：新进代表\n时间：2015/00/00\n地点：北京\n其他注意事项：\naweraetr\n大发生的发生的\nsdgsdfgvsf，阿萨德发噶舒服的','0,50,20,70,0,0,必洛斯,艾可拓,倍欣,尼欣那,潘针,潘片,抑那通,亚宁定,开思亭','2015-06-22 00:00:00',1,'2015-06-21 11:44:50',1,'2015-06-21 11:44:50'),(10,'模拟考试 2008',0,0,'1970-01-01 08:00:00','1970-01-01 08:00:00',2,'',1,'考试对象：新进代表\n时间：2015/00/00\n地点：北京\n其他注意事项：\naweraetr\n大发生的发生的\nsdgsdfgvsf，阿萨德发噶舒服的','0,60,20,80,0,0,必洛斯,艾可拓,倍欣,尼欣那,普托平,抑那通,亚宁定','2015-06-25 00:00:00',1,'2015-06-21 11:45:58',1,'2015-06-21 11:45:58');
/*!40000 ALTER TABLE `exams` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `examscore`
--

DROP TABLE IF EXISTS `examscore`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `examscore` (
  `ExamId` int(11) NOT NULL,
  `UserId` int(11) NOT NULL,
  `Score` float NOT NULL,
  PRIMARY KEY (`ExamId`,`UserId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `examscore`
--

LOCK TABLES `examscore` WRITE;
/*!40000 ALTER TABLE `examscore` DISABLE KEYS */;
/*!40000 ALTER TABLE `examscore` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `files`
--

DROP TABLE IF EXISTS `files`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `files` (
  `FileId` int(11) NOT NULL AUTO_INCREMENT,
  `FileName` varchar(255) NOT NULL,
  `FileTitle` varchar(255) DEFAULT NULL,
  `FileDesc` varchar(255) DEFAULT NULL,
  `FilePath` varchar(255) NOT NULL,
  `SmallGifPath` varchar(255) NOT NULL,
  `PageNo` int(11) NOT NULL,
  `FileType` int(11) NOT NULL,
  `Status` int(11) NOT NULL,
  `CreatedUser` int(11) DEFAULT NULL,
  `CreatedTime` datetime DEFAULT NULL,
  `EditUser` int(11) DEFAULT NULL,
  `EditTime` datetime DEFAULT NULL,
  `CategoryId` int(11) DEFAULT NULL,
  `ZipSize` int(11) DEFAULT NULL,
  PRIMARY KEY (`FileId`)
) ENGINE=InnoDB AUTO_INCREMENT=19 DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `files`
--

LOCK TABLES `files` WRITE;
/*!40000 ALTER TABLE `files` DISABLE KEYS */;
INSERT INTO `files` VALUES (1,'119.pdf','test1','test1','d:/tmp/file/2/1','',4,1,0,1,'2015-06-09 12:52:16',1,'2015-06-09 12:52:16',2,831106),(2,'119.pdf','test2','test2','d:/tmp/file/2/2','',4,1,0,1,'2015-06-09 13:04:45',1,'2015-06-09 13:04:45',2,831111),(3,'123.pdf','test2','test3','d:/tmp/file/2/3','',0,1,-1,1,'2015-06-12 11:45:23',1,'2015-06-12 11:45:23',4,NULL),(4,'123.pdf','test2','test3','d:/tmp/file/2/4','',0,1,-1,1,'2015-06-12 11:50:56',1,'2015-06-12 11:50:56',4,NULL),(5,'upload.pdf','test23','test22','d:/tmp/file/2/5','',0,1,-1,1,'2015-06-12 12:15:26',1,'2015-06-12 12:15:26',4,NULL),(6,'upload.pdf','test23','test22','d:/tmp/file/2/6','',4,1,0,1,'2015-06-12 12:17:49',1,'2015-06-12 12:17:49',4,831119),(7,'upload.pdf','test4','test4','d:/tmp/file/2/7','',4,1,0,1,'2015-06-12 12:46:48',1,'2015-06-12 12:46:48',4,831110),(8,'销售绩效流程介绍-SFE .pdf','销售绩效流程介绍','绩效流程介绍，绩效流程介绍，绩效流程介绍绩效流程介绍绩效流程介绍，绩效流程介绍','d:/tmp/file//6/7/8','',17,1,1,1,'2015-06-16 18:42:18',1,'2015-06-20 20:44:20',7,5450884),(9,'123.pdf','test17-1','test17-1','d:/tmp/file/3/9','',18,1,0,1,'2015-06-17 17:55:48',1,'2015-06-17 17:55:48',3,5639909),(10,'C&B新员工入职培训20141125.pdf','C&B新员工入职培训','C&B新员工入职培训，C&B新员工入职培训，C&B新员工入职培训，C&B新员工入职培训','d:/tmp/file/5/6/8/10','',0,1,-1,1,'2015-06-17 19:22:57',1,'2015-06-17 19:22:57',8,NULL),(11,'C&B新员工入职培训20141125.pdf','C&B新员工入职培训','C&B新员工入职培训，C&B新员工入职培训，C&B新员工入职培训，C&B新员工入职培训','d:/tmp/file/5/6/8/11','',0,1,-1,1,'2015-06-17 19:23:55',1,'2015-06-17 19:23:55',8,NULL),(12,'EMD模板制作规范2013.pdf','test17-32','test17-32','d:/tmp/file/5/6/8/12','',18,1,-1,1,'2015-06-17 19:25:03',1,'2015-06-17 19:25:03',8,5305283),(13,'C&B新员工入职培训20141125.pdf','abc','abc','d:/tmp/file/5/6/8/13','',0,1,-1,1,'2015-06-17 19:26:52',1,'2015-06-17 19:26:52',8,NULL),(14,'C&B新员工入职培训20141125.pdf','abc','abv','d:/tmp/file/5/6/8/14','',0,1,-1,1,'2015-06-17 19:28:32',1,'2015-06-17 19:28:32',8,NULL),(15,'abc.pdf','abc','abc','d:/tmp/file/5/6/8/15','',0,1,-1,1,'2015-06-17 19:29:39',1,'2015-06-17 19:29:39',8,NULL),(16,'C&B新员工入职培训20141125.pdf','abcd','abcd','d:/tmp/file/5/6/8/16','',19,1,0,1,'2015-06-17 19:35:18',1,'2015-06-17 19:35:18',8,7866332),(17,'FIN-2014 FY Finance operation training material 1208.pdf','Fin 操作培训2014','Fin 操作培训2014，Fin 操作培训2014，Fin 操作培训2014，','d:/tmp/file/5/6/8/17','',61,1,1,1,'2015-06-17 19:37:34',1,'2015-06-20 20:43:53',8,25418401),(18,'潘片-单页-药物相关性溃疡-心内老年其他科室.pdf','潘片DA','绩效流程介绍，绩效流程介绍，绩效流程介绍绩效流程介绍绩效流程介绍，绩效流程介绍','d:/Data/file/1/45/76//18','',2,2,0,1,'2015-06-21 00:08:54',1,'2015-06-21 00:08:54',533,292318);
/*!40000 ALTER TABLE `files` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `functions`
--

DROP TABLE IF EXISTS `functions`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `functions` (
  `FunctionId` int(11) NOT NULL AUTO_INCREMENT,
  `FunctionName` varchar(50) NOT NULL,
  `FunctionType` int(11) NOT NULL DEFAULT '0',
  `CreatedTime` datetime DEFAULT NULL,
  `Icon` varchar(100) DEFAULT NULL,
  `CodePath` varchar(200) DEFAULT NULL,
  `Rank` int(11) DEFAULT NULL,
  PRIMARY KEY (`FunctionId`)
) ENGINE=InnoDB AUTO_INCREMENT=62 DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `functions`
--

LOCK TABLES `functions` WRITE;
/*!40000 ALTER TABLE `functions` DISABLE KEYS */;
INSERT INTO `functions` VALUES (1,'公告管理',0,'2015-05-21 15:57:45','news','New\\News_list.php',1),(2,'人员管理',0,'2015-05-21 15:57:45','userMgmt','User\\Users_list.php',2),(3,'部门管理',0,'2015-05-21 15:57:45','depts','Dept\\Depts_list.php',3),(4,'分类管理',0,'2015-05-21 15:57:45','categories','Category\\Categories_list.php',4),(5,'后台权限管理',0,'2015-05-21 17:04:20','setting','Admin\\Privileges_list.php',100),(6,'文档管理',0,'2015-05-22 08:00:00','files','File\\Files_list.php',5),(7,'内分泌',2,'2015-06-04 10:37:33',NULL,NULL,NULL),(8,'必洛斯',1,'2015-06-04 10:38:00',NULL,NULL,NULL),(9,'艾可拓',1,'2015-06-04 10:38:00',NULL,NULL,NULL),(10,'倍欣',1,'2015-06-04 10:38:00',NULL,NULL,NULL),(11,'尼欣那',1,'2015-06-04 10:38:00',NULL,NULL,NULL),(12,'潘针',1,'2015-06-04 10:38:00',NULL,NULL,NULL),(14,'心血管',2,'2015-06-04 10:38:00',NULL,NULL,NULL),(15,'消化',2,'2015-06-04 10:38:00',NULL,NULL,NULL),(16,'乳腺',2,'2015-06-04 10:38:00',NULL,NULL,NULL),(17,'泌尿',2,'2015-06-04 10:38:00',NULL,NULL,NULL),(18,'潘片',1,'2015-06-11 12:00:43',NULL,NULL,NULL),(19,'达克普隆',1,'2015-06-11 12:00:43',NULL,NULL,NULL),(20,'普托平',1,'2015-06-11 12:00:43',NULL,NULL,NULL),(21,'抑那通',1,'2015-06-11 12:00:43',NULL,NULL,NULL),(22,'亚宁定',1,'2015-06-11 12:00:43',NULL,NULL,NULL),(23,'开思亭',1,'2015-06-11 12:00:43',NULL,NULL,NULL),(24,'爱宝疗',1,'2015-06-11 12:00:43',NULL,NULL,NULL),(25,'其他',1,'2015-06-11 12:00:43',NULL,NULL,NULL),(26,'儿科',2,'2015-06-11 12:03:58',NULL,NULL,NULL),(27,'妇科',2,'2015-06-11 12:03:58',NULL,NULL,NULL),(28,'危重症',2,'2015-06-11 12:03:58',NULL,NULL,NULL),(29,'抗过敏',2,'2015-06-11 12:03:58',NULL,NULL,NULL),(30,'溃疡',2,'2015-06-11 12:03:58',NULL,NULL,NULL),(31,'题目管理',0,'2015-05-21 17:04:20','problem','Problem/Problems_list.php',8),(32,'考卷管理',0,'2015-05-21 17:04:20','exam','Exam/Exams_list.php',7),(35,'疾病知识',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(36,'产品知识',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(37,'市场策略',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(38,'文献',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(39,'医学知识',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(40,'文献解读',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(41,'合规',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(42,'GERD',2,'2015-06-11 12:03:58',NULL,NULL,NULL),(43,'UGIB',2,'2015-06-11 12:03:58',NULL,NULL,NULL),(44,'SRMD',2,'2015-06-11 12:03:58',NULL,NULL,NULL),(45,'ZES',2,'2015-06-11 12:03:58',NULL,NULL,NULL),(46,'其他',2,'2015-06-11 12:03:58',NULL,NULL,NULL),(47,'竞品知识',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(48,'推广知识',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(49,'疾病知识-定义',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(50,'疾病知识-症状',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(51,'疾病知识-诊断',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(52,'疾病知识-治疗',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(53,'疾病知识-病理',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(54,'产品知识-适应症',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(55,'产品知识-作用机理',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(56,'产品知识-药物动力学',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(57,'产品知识-药效',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(58,'产品知识-安全性',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(59,'产品知识-说明书',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(60,'OBL',3,'2015-05-21 15:57:45',NULL,NULL,NULL),(61,'月考',3,'2015-05-21 15:57:45',NULL,NULL,NULL);
/*!40000 ALTER TABLE `functions` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `log`
--

DROP TABLE IF EXISTS `log`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `log` (
  `LogId` int(11) NOT NULL AUTO_INCREMENT,
  `UserId` varchar(200) NOT NULL,
  `FunctionName` varchar(200) NOT NULL,
  `ActionName` varchar(200) NOT NULL,
  `ActionTime` datetime NOT NULL DEFAULT CURRENT_TIMESTAMP,
  `ActionReturn` text NOT NULL,
  `ActionObject` varchar(200) NOT NULL,
  PRIMARY KEY (`LogId`)
) ENGINE=InnoDB AUTO_INCREMENT=2 DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `log`
--

LOCK TABLES `log` WRITE;
/*!40000 ALTER TABLE `log` DISABLE KEYS */;
INSERT INTO `log` VALUES (1,'UserId001logapi','FunctionName002logapi','ActionName002logapi','2015-06-01 18:18:18','ActionReturn--092logapi','ActionObject--003logapi');
/*!40000 ALTER TABLE `log` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `news`
--

DROP TABLE IF EXISTS `news`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `news` (
  `NewId` int(11) NOT NULL AUTO_INCREMENT,
  `NewTitle` varchar(255) NOT NULL,
  `NewMsg` varchar(255) NOT NULL,
  `DeptList` varchar(255) NOT NULL DEFAULT 'All',
  `Status` int(11) NOT NULL DEFAULT '0',
  `CreatedUser` int(11) DEFAULT NULL,
  `CreatedTime` datetime DEFAULT NULL,
  `EditUser` int(11) DEFAULT NULL,
  `EditTime` datetime DEFAULT NULL,
  `OccurTime` datetime DEFAULT NULL,
  PRIMARY KEY (`NewId`)
) ENGINE=InnoDB AUTO_INCREMENT=32 DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `news`
--

LOCK TABLES `news` WRITE;
/*!40000 ALTER TABLE `news` DISABLE KEYS */;
INSERT INTO `news` VALUES (1,'公告测试1','公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1公告测试1',',1,,2,,5,,3,,8,,9,,10,,21,,22,,23,,4,,11,,12,,13,,24,,25,,26,,15,,16,,17,',0,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13',NULL),(2,'公告测试2','公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2公告测试2',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13',NULL),(3,'公告测试3','公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3公告测试3',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13',NULL),(4,'公告测试4','公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4公告测试4',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13',NULL),(5,'公告测试5','公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5公告测试5',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13',NULL),(6,'公告测试6','公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6公告测试6',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13',NULL),(7,'公告测试7','公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7公告测试7',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13',NULL),(8,'公告测试8','公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8公告测试8',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13',NULL),(9,'公告测试9','公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9公告测试9',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13',NULL),(10,'公告测试10','公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10公告测试10',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13',NULL),(11,'活动测试1','活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1活动测试1',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13','2015-06-17 15:30:36'),(12,'活动测试2','活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2活动测试2',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13','2015-06-17 15:30:36'),(13,'活动测试3','活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3活动测试3',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13','2015-06-17 15:30:36'),(14,'活动测试4','活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4活动测试4',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13','2015-06-17 15:30:36'),(15,'活动测试5','活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5活动测试5',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13','2015-06-17 15:30:36'),(16,'活动测试6','活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6活动测试6',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13','2015-06-17 15:30:36'),(17,'活动测试7','活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7活动测试7',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13','2015-06-17 15:30:36'),(18,'活动测试8','活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8活动测试8',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13','2015-06-17 15:30:36'),(19,'活动测试9','活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9活动测试9',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13','2015-06-17 15:30:36'),(20,'活动测试10','活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10活动测试10',',1,',1,1,'2015-06-01 21:06:38',1,'2015-06-15 17:57:13','2015-06-17 15:30:36'),(21,'公告新增','老中医的忠告！有一个从医六十多年的老大夫建议，在学校工作的同志，夏天应该少开车，多坐公交或者步行，少喝饮料，多喝点白开水，在家尽量不要用空调，不要在外面吃饭，特别是吃烧烤。几番追究原由，老中医无奈直言道： 因为你们挣的太少了！','',1,1,'2015-06-18 14:50:16',1,'2015-06-18 14:50:16','2015-06-25 00:00:00'),(22,'公告新增','老中医的忠告！','',1,1,'2015-06-18 14:50:47',1,'2015-06-18 14:50:47','2015-06-25 00:00:00'),(23,'公告新增','老中医的忠告！','',1,1,'2015-06-18 14:51:01',1,'2015-06-18 14:51:01','2015-06-25 00:00:00'),(24,'顶戴sd','asdfasdf','',1,1,'2015-06-18 14:51:13',1,'2015-06-18 14:51:13','2015-06-25 00:00:00'),(25,'test1','test2',',1,',1,1,'2015-06-18 14:55:54',1,'2015-06-18 14:55:54','2015-06-25 00:00:00'),(26,'老中医的忠告','老中医的忠告！有一个从医六十多年的老大夫建议，在学校工作的同志，夏天应该少开车，多坐公交或者步行，少喝饮料，多喝点白开水，在家尽量不要用空调，不要在外面吃饭，特别是吃烧烤。几番追究原由，老中医无奈直言道： 因为你们挣的太少了！',',1,',1,1,'2015-06-18 15:06:39',1,'2015-06-18 15:06:39','2015-06-18 00:00:00'),(27,'没参加高考，却参加了高考的狂欢','是否还记得你当年的数学高考。那是个温暖午后，你坐在考场，轻轻闭上眼，深呼吸。听着大家笔锋与试卷摩擦的沙沙，听着墙上时钟的嘀嗒，听着自己内心的无数个草泥妈，度过了安静祥和的两小时。阳光透过窗帘洒进教室的那一瞬，试卷大题部分的空白，与你大脑的空白，交相辉映。。。这么巧，我也是这样。',',1,,5,',1,1,'2015-06-18 15:21:37',1,'2015-06-18 15:29:20',NULL),(28,'高考作文','1、原来广东卷的高考作文是《感知自然》。我想还大吃省呢，连孜然都不知道。  2、四川高考作文题：《老实与聪明》。上午考完语文，段子手是聪明的，下午考完数学，段子手都是老实的。  3、看到东北高考作文题《告诉自己，我能行》后不由得虎躯一震！我不用去男科医院了。',',1,,2,,5,',1,1,'2015-06-18 15:41:04',1,'2015-06-18 15:41:04',NULL),(29,'趣语话生活，极具幽默感1','1、记得前几年单身还被说是贵族的，怎么现在就TM变成狗了。  2、好人要想成佛，得经过九九八十一难。坏人要想成佛就简单的多了，放下屠刀立地成佛。。。  3、所谓粉丝，就是一群缺钱的人养着一群不差钱的人。  4、如果你也有个喜欢熬夜的朋友，请好好珍惜他，因为也许不知道什么时候，他就死了。。。  5、长辈以前总对我们说网上都是骗人的，结果现在自己却狂转朋友圈里的造谣贴。',',1,',1,1,'2015-06-18 17:23:26',1,'2015-06-18 17:24:49','2015-06-26 00:00:00'),(30,'短公告','hello world',',1,',1,1,'2015-06-18 20:49:29',1,'2015-06-18 20:49:29',NULL),(31,'怎么打造一个团结互助、士气高涨的团队。','刚开始创业合伙人团队打造好了还不够。因为事情一多了就需要扩展整个团队，不可能所有事情创始人都能够搞定，团队的战斗力直接影响了整个公司的战斗力。我觉得一个团队最基本的就是要互相信赖，不只是合伙人需要信赖，整体团队也需要。合伙人都不信任就别开公司了，团队不信任合作会举步维艰，推动不了任何事情。信任包括同事对同事、上级对下级、下级对上级，任何一个环节都很重要。',',1,',1,1,'2015-06-19 11:00:55',1,'2015-06-19 11:02:01','2015-06-27 00:00:00');
/*!40000 ALTER TABLE `news` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `privileges`
--

DROP TABLE IF EXISTS `privileges`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `privileges` (
  `PrivilegeId` int(11) NOT NULL AUTO_INCREMENT,
  `UserId` int(11) NOT NULL,
  `FunctionId` int(11) NOT NULL,
  `Status` int(11) NOT NULL DEFAULT '0',
  `CreatedUser` int(11) DEFAULT NULL,
  `CreatedTime` datetime DEFAULT NULL,
  `EditUser` int(11) DEFAULT NULL,
  `EditTime` datetime DEFAULT NULL,
  PRIMARY KEY (`PrivilegeId`)
) ENGINE=InnoDB AUTO_INCREMENT=36 DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `privileges`
--

LOCK TABLES `privileges` WRITE;
/*!40000 ALTER TABLE `privileges` DISABLE KEYS */;
INSERT INTO `privileges` VALUES (5,2,2,1,1,'2015-05-21 16:01:48',1,'2015-05-21 16:01:48'),(6,2,4,1,1,'2015-05-21 16:01:48',1,'2015-05-21 16:01:48'),(20,1,1,0,1,'2015-05-21 18:22:57',1,'2015-05-21 18:22:57'),(21,1,2,0,1,'2015-05-21 18:22:57',1,'2015-05-21 18:22:57'),(22,1,3,0,1,'2015-05-21 18:22:57',1,'2015-05-21 18:22:57'),(23,1,4,0,1,'2015-05-21 18:22:57',1,'2015-05-21 18:22:57'),(24,1,5,0,1,'2015-05-21 18:22:57',1,'2015-05-21 18:22:57'),(25,1,6,0,1,'2015-05-26 10:37:43',1,'2015-05-26 10:37:43'),(26,1,31,0,1,'2015-06-21 10:32:34',1,'2015-06-21 10:32:34'),(27,1,32,0,1,'2015-06-21 10:32:37',1,'2015-06-21 10:32:37'),(28,38,1,0,1,'2015-06-21 11:35:11',1,'2015-06-21 11:35:11'),(29,38,2,0,1,'2015-06-21 11:35:11',1,'2015-06-21 11:35:11'),(30,38,3,0,1,'2015-06-21 11:35:11',1,'2015-06-21 11:35:11'),(31,38,4,0,1,'2015-06-21 11:35:11',1,'2015-06-21 11:35:11'),(32,38,5,0,1,'2015-06-21 11:35:11',1,'2015-06-21 11:35:11'),(33,38,6,0,1,'2015-06-21 11:35:11',1,'2015-06-21 11:35:11'),(34,38,31,0,1,'2015-06-21 11:35:11',1,'2015-06-21 11:35:11'),(35,38,32,0,1,'2015-06-21 11:35:11',1,'2015-06-21 11:35:11');
/*!40000 ALTER TABLE `privileges` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `problems`
--

DROP TABLE IF EXISTS `problems`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `problems` (
  `ProblemId` int(11) NOT NULL AUTO_INCREMENT,
  `ProblemType` int(11) DEFAULT NULL,
  `ProblemDesc` varchar(512) NOT NULL,
  `ProblemSelectA` varchar(512) DEFAULT NULL,
  `ProblemSelectB` varchar(512) DEFAULT NULL,
  `ProblemSelectC` varchar(512) DEFAULT NULL,
  `ProblemSelectD` varchar(512) DEFAULT NULL,
  `ProblemSelectE` varchar(512) DEFAULT NULL,
  `ProblemSelectF` varchar(512) DEFAULT NULL,
  `ProblemSelectG` varchar(512) DEFAULT NULL,
  `ProblemSelectH` varchar(512) DEFAULT NULL,
  `ProblemSelectI` varchar(512) DEFAULT NULL,
  `ProblemAnswer` varchar(512) DEFAULT NULL,
  `Status` int(11) NOT NULL DEFAULT '0',
  `ProblemCategory` varchar(50) NOT NULL,
  `ProblemLevel` int(11) NOT NULL DEFAULT '1',
  `ProblemMemo` varchar(1000) DEFAULT NULL,
  PRIMARY KEY (`ProblemId`)
) ENGINE=InnoDB AUTO_INCREMENT=1577 DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `problems`
--

LOCK TABLES `problems` WRITE;
/*!40000 ALTER TABLE `problems` DISABLE KEYS */;
INSERT INTO `problems` VALUES (1,3,'DOHSAM研究中主要终点包括','试验期间SBP变化','试验期间DBP变化','试验期间清晨SBP变化','清晨心率变化','','','','',NULL,'CD',1,',8,,36,,38,',1,''),(2,3,'DOHSAM研究二中采用哪些药物做了对照试验','缬沙坦','坎地沙坦','赖诺普利','氨氯地平','','','','',NULL,'AB',1,',8,,36,,38,',1,''),(3,2,'以下描述DOHSAM研究设计，那个是正确的？','随机对照双盲','随机对照多中心双盲','随机对照大样本','前瞻性随机开放标签','','','','',NULL,'D',1,',8,,36,,38,',1,''),(4,3,'对DOHSAM试验中，清晨心率的变化描述正确的是','必洛斯组明显非劣于氨氯地平组','氨氯地平与坎地沙坦有相似作用','坎地沙坦与氨氯地平无显著性差异','必洛斯组优于氨氯地平组','','','','',NULL,'BC',1,',8,,36,,38,',1,''),(5,3,'DOHSAM研究中，清晨SBP降低情况那个是正确的','必洛斯组在六个月时明显优于氨氯地平组','必洛斯组在九个月时明显优于氨氯地平','必洛斯组九个月时与氨氯地平相似','必洛斯组十二个月时优于氨氯地平','','','','',NULL,'BD',1,',8,,36,,38,',1,''),(6,3,'涉及晨峰血压研究的必洛斯主要试验包括','CHARM','SMART','DOHSAM','COORDINATE','','','','',NULL,'CD',1,',8,,36,,38,',1,''),(7,3,'ＤＯＨＳＡＭ研究II中主要结论包括','由其他ARB转为必洛斯治疗后显著降低清晨血压','由奥美沙坦转为必洛斯治疗后，清晨血压降幅相似。','由其他ARB转为必洛斯治疗后显著降低清晨心率','由奥美沙坦转为必洛斯治疗后，清晨心率降幅相似。','','','','',NULL,'BC',1,',8,,36,,38,',1,''),(8,2,'在DOHSAM研究中清晨血压终点，必洛斯不能证实优于哪个ARB','氯沙坦','缬沙坦','赖诺普利','奥美沙坦','','','','',NULL,'D',1,',8,,36,,38,',1,''),(9,2,'DOHSAM研究中，入组人群血压特征为','有清晨高血压(>135/90mmhg）','有清晨高血压(>140/90mmhg)','有清晨高血压(>135/85mmhg) ','有昼夜节律改变的高血压患者','','','','',NULL,'C',1,',8,,36,,38,',1,''),(10,2,'DOHSAMII研究中，入组患者血压特征为','有顽固性高血压，无法达标','二级以上高血压','高血压合并糖尿病','使用其他ARB晨峰血压不达标','','','','',NULL,'D',1,',8,,36,,38,',1,''),(11,3,'对于DIRECT研究描述正确的是','适用于I型糖尿病已经出现视网膜病变患者','适用于二型糖尿病出现视网膜病变患者','适用于内分泌科/老年（干）科推广','没有关于蛋白尿的相关数据','','','','',NULL,'ABC',1,',8,,36,,38,',1,''),(12,3,'对于DIRECT研究描述正确的是：','发表于2009年LANCET','全球20个国家参与','研究重点为二型糖尿病患者IR逆转','与安慰剂相比二型糖尿病视网膜好转增加34%','','','','',NULL,'AD',1,',8,,36,,38,',1,''),(13,3,'以下DIRECT研究中的数据，哪些是正确的并具有统计学价值','I型糖尿病视网膜病变发生减少18%','I型糖尿病视网膜病变恶化减少35%','II型糖尿病视网膜好转增加34% ','II型糖尿病视网膜好转增加35%','','','','',NULL,'BC',1,',8,,36,,38,',1,''),(14,3,'DIRECT主要用于以下哪个科室推广','内分泌门诊','眼科门诊','老年科','内分泌病房','','','','',NULL,'ACD',1,',8,,36,,38,',1,''),(15,2,'DIRECT-RENAL探究中，主要终点为','在一、二型糖尿病患者中蛋白尿的发生率','在一、二型糖尿病患者中出现微量蛋白尿的进展','在二型糖尿病患者中坎地沙坦干预肾衰进展','在二型糖尿病患者中ARB对血脂谱的影响','','','','',NULL,'B',1,',8,,36,,38,',1,''),(16,2,'DIRECT研究发表于哪一年','2012','1999','2008','2002','','','','',NULL,'C',1,',8,,36,,38,',1,''),(17,2,'DRIECT-保护2研究主要针对哪类患者','轻中度糖尿病视网膜病变的二型糖尿病患者','轻度糖尿病视网膜病变的二型糖尿病患者','轻中度糖尿病视网膜病变的患者','轻中度糖尿病病人','','','','',NULL,'A',1,',8,,36,,38,',1,''),(18,2,'DRIECT研究共涵盖多少个国家？','28','30','32','22','','','','',NULL,'B',1,',8,,36,,38,',1,''),(19,2,'坎地沙坦对2型糖尿病患者的视网膜进展事件降低？','0.11','0.12','0.13','0.14','','','','',NULL,'C',1,',8,,36,,38,',1,''),(20,2,'DRIECT研究中坎地沙坦每天最大用量','32mg','16mg','48mg','128mg','','','','',NULL,'A',1,',8,,36,,38,',1,''),(21,2,'CHARM研究共有多少国家参加？','22','34','26','40','','','','',NULL,'C',1,',8,,36,,38,',1,''),(22,3,'CHARM研究的主要终点为','心血管死亡','CHF住院','全因死亡','择期冠脉重建术','','','','',NULL,'ABC',1,',8,,36,,38,',1,''),(23,3,'CHARM研究的次要终点包括','非致死性心梗','非致死性卒中','全因死亡','择期冠脉重建术','','','','',NULL,'ABCD',1,',8,,36,,38,',1,''),(24,2,'在CHARM研究中，入选患者心功能分级为NYHA哪一级？','2-4级','2级','2-3级','3级','','','','',NULL,'A',1,',8,,36,,38,',1,''),(25,2,'CHARM研究中共入组多少患者','7500','7599','7608','7598','','','','',NULL,'B',1,',8,,36,,38,',1,''),(26,2,'CHARM总体研究次要终点：降低心血管死亡风险','0.23','0.22','0.2','0.15','','','','',NULL,'A',1,',8,,36,,38,',1,''),(27,2,'CHARM研究中，必洛斯使心血管死亡和心衰住院的风险降低','0.12','0.1','0.22','0.18','','','','',NULL,'D',1,',8,,36,,38,',1,''),(28,2,'CHARM研究中，必洛斯使新发生糖尿病的风险降低','0.21','0.18','0.2','0.22','','','','',NULL,'D',1,',8,,36,,38,',1,''),(29,2,'CONCH研究中入组人数为','128','366','110','80','','','','',NULL,'D',1,',8,,36,,38,',1,''),(30,2,'CONCH研究中入组患者排除标准包含','冠心病','心律失常','心梗','陈旧性卒中','','','','',NULL,'C',1,',8,,36,,38,',1,''),(31,2,'CONCH研究的终点为','整体心血管事件发生率','非致死性卒中','肾衰竭','致死性心梗','','','','',NULL,'A',1,',8,,36,,38,',1,''),(32,2,'CONCH研究的共观察','2年','1年','3年','4年','','','','',NULL,'A',1,',8,,36,,38,',1,''),(33,2,'REAL-LIFE研究入组人群数为','9700','2970','14100','14000','','','','',NULL,'C',1,',8,,36,,38,',1,''),(34,2,'以下针对REAL-LIFE研究的说法，正确的是','一项前瞻性随机对照研究','一项回顾性队列研究，多个国家参加','回顾性队列研究','大型临床观察','','','','',NULL,'C',1,',8,,36,,38,',1,''),(35,2,'REAL—LIFE研究的主要复合终点包括','CVD住院','非致死性卒中','肾脏事件','CVD死亡率','','','','',NULL,'D',1,',8,,36,,38,',1,''),(36,2,'在REAL-LIFE研究中，与坎地沙坦做对照研究的活性药物是','缬沙坦','氯沙坦','氨氯地平','依那普利','','','','',NULL,'B',1,',8,,36,,38,',1,''),(37,2,'Real Life研究中，坎地沙坦组降低心血管发生率','0.134','0.114','0.1','0.144','','','','',NULL,'D',1,',8,,36,,38,',1,''),(38,2,'Real Life研究中，坎地沙坦组降低心衰发生率','0.36','0.24','0.23','0.18','','','','',NULL,'A',1,',8,,36,,38,',1,''),(39,2,'Real Life研究中，坎地沙坦组降低外周动脉疾病发生率','0.38','0.37','0.39','0.35','','','','',NULL,'C',1,',8,,36,,38,',1,''),(40,2,'Real Life研究中，坎地沙坦组降低心律失常发生率','0.21','0.2','0.22','0.23','','','','',NULL,'B',1,',8,,36,,38,',1,''),(41,2,'SCOPE研究入组人群年龄范围是','65岁以上','70岁以上','70至89岁','65至89岁','','','','',NULL,'C',1,',8,,36,,38,',1,''),(42,2,'SCOPE研究中，坎地沙坦剂量范围是','8-16mg','8mg','8-12mg','4-16mg','','','','',NULL,'A',1,',8,,36,,38,',1,''),(43,2,'SCOPE研究中，主要终点不包含','择期冠脉重建术','心血管死亡','非致死性卒中','非致死性心梗','','','','',NULL,'A',1,',8,,36,,38,',1,''),(44,2,'SCOPE研究中，MMSE含义是？','简短精神状态检查','精神障碍排除','认知障碍状态检查','认知功能检查','','','','',NULL,'A',1,',8,,36,,38,',1,''),(45,2,'SCOPE研究随访是在哪一年结束？','2003','2000','2002','2004','','','','',NULL,'C',1,',8,,36,,38,',1,''),(46,2,'SCOPE研究中，有既往卒中史的患者，使用坎地沙坦后，主要心脑血管事件发生风险下降了','0.62','0.66','0.64','0.46','','','','',NULL,'C',1,',8,,36,,38,',1,''),(47,2,'FDA荟萃研究中，与坎地沙坦对比的药物不包括','缬沙坦','氯沙坦','厄贝沙坦','奥美沙坦','','','','',NULL,'D',1,',8,,36,,38,',1,''),(48,2,'COORDINATE研究中，被必洛斯替换的活性药物不包含：','美卡素','厄贝沙坦','傲坦','科素亚','','','','',NULL,'B',1,',8,,36,,38,',1,''),(49,2,'COORDINATE研究中，其他ARB被必洛斯替换后，哪个指标有所改善：','舒张压','收缩压','清晨血压','昼夜节律','','','','',NULL,'C',1,',8,,36,,38,',1,''),(50,3,'必洛斯的目标客户包括','心内医生','神经外科医生','肾内科医生','CCU医生','','','','',NULL,'AC',1,',11,,37,',1,''),(51,3,'必洛斯的目标患者是','T2DM患者合并高血压','新发高血压患者','透析患者','高血压伴卒中患者','','','','',NULL,'ABCD',1,',11,,37,',1,''),(52,3,'必洛斯的市场定位是','必洛斯强效降压始于晨','必洛斯有效保护不稳定心绞痛患者生命','必洛斯全程保护心脑肾','必洛斯有效干预高血压前期患者高血压发病进展','','','','',NULL,'AC',1,',11,,37,',1,''),(53,3,'必洛斯在心脏保护方面的研究包括','CHARM','SMART','REAL-LIFE','DIRECT','','','','',NULL,'AC',1,',11,,37,',1,''),(54,3,'2014年必洛斯生意来源包括','新病人','转换其他ARB','联合治疗（BLO+ β受体阻断剂）','ACEI不耐受的替换','','','','',NULL,'ABD',1,',11,,37,',1,''),(55,3,'中国2014年心衰指南指出的金三角治疗药物包括','ACEI','ARB','醛固酮拮抗剂','β受体阻断剂','','','','',NULL,'ABCD',1,',11,,37,',1,''),(56,2,'英国NHS批准哪些ARB有心衰适应症，但属于黑三角警示药物','替米沙坦','必洛斯','氯沙坦','奥美沙坦','','','','',NULL,'C',1,',11,,37,',1,''),(57,2,'DIRECT研究中使用必洛斯的2型糖尿病患者视网膜病变好转率为','35%','32% ','33% ','34% ','','','','',NULL,'D',1,',11,,37,',1,''),(58,2,'持续透析ESRD人群首要死亡原因为','心血管死亡30.1% ','卒中20.3% ','卒中31% ','心血管死亡31%','','','','',NULL,'D',1,',11,,37,',1,''),(59,2,'Victory研究发表于哪一年','2002年','2006年','2009年','2012年','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(60,2,'Victory研究发表于哪一个期刊','柳叶刀','新英格兰','中华内分泌','美国医学会杂志','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(61,3,'Victory研究入组患者中需要合并危险因素，入选的患者包含的危险因素有','高血压（≧130/85mmHg','血脂异常','肥胖（BMI≧25）','糖尿病家族史（两代以内）','','','','',NULL,'ABCD',1,',9,,10,,36,,38,',1,''),(62,2,'Victory研究入组患者年龄范围为','30-60岁','30-70岁','40-60岁','40-70岁','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(63,2,'Victory研究观察时间为','1年','2年','3年','4年','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(64,2,'Victory研究主要终点是','向NGT转换','血脂变化','CIMT变化','新发糖尿病','','','','',NULL,'D',1,',9,,10,,36,,38,',1,''),(65,2,'Victory研究显示伏格列波糖显著降低T2DM发生风险','25%','72%','40%','40.5%','','','','',NULL,'D',1,',9,,10,,36,,38,',1,''),(66,2,'Victory研究显示伏格列波糖显著提高患者血糖正常化概率','43.9%','53.9%','63.9%','73.9%','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(67,2,'Victory研究的结论是','伏格列波糖：增加2型糖尿病的发生','伏格列波糖：延缓2型糖尿病的发生','伏格列波糖：延缓1型糖尿病的发生','伏格列波糖对糖尿病发生无影响','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(68,2,'Victory研究研究地在','中国','美国','欧洲','日本','','','','',NULL,'D',1,',9,,10,,36,,38,',1,''),(69,2,'STOP-NIDDM研究：(paper 1)发表于哪一年','2001年','2002年','2003年','2004年','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(70,2,'STOP-NIDDM研究：(paper 1）发表在什么期刊','柳叶刀','新英格兰','中华内分泌','美国医学会杂志','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(71,2,'STOP-NIDDM研究地在','中国','日本','欧美','全球','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(72,2,'STOP-NIDDM研究入组人群年龄在','30-60岁','30-70岁','40-60岁','40-70岁','','','','',NULL,'D',1,',9,,10,,36,,38,',1,''),(73,2,'STOP-NIDDM研究主要终点是','T2DM的新发病','血压变化','血脂变化','向NGT转换','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(74,2,'STOP-NIDDM研究显示阿卡波糖降低IGT进展为T2DM风险','20%','25%','30%','35%','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(75,2,'STOP-NIDDM研究中¼早期停止试验的患者中，约一半是由于哪种不良反应？','心血管','过敏','胃肠道','癌症','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(76,3,'STOP-NIDDM常见的胃肠道反应包括','排气','腹泻','腹胀','呕吐','','','','',NULL,'ABC',1,',9,,10,,36,,38,',1,''),(77,2,'STOP-NIDDM研究阿卡波糖的最大剂量是','25mgtid','50mgtid','75mgtid ','100mgtid','','','','',NULL,'D',1,',9,,10,,36,,38,',1,''),(78,2,'STOP-NIDDM研究体现额外的获益是','心血管','胃肠道','脑血管','无','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(79,2,'ACT NOW研究的主要目的是','是否吡格列酮可以预防或者延缓IGT患者发展为2型糖尿病','改善血糖控制','提高胰岛素敏感性','改善β细胞功能','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(80,2,'ACT NOW研究入组患者数是','1827例','602例','5238例','206例','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(81,2,'ACT NOW研究平均随访期为','1.2年','2.4年','3.6年','4.8年','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(82,3,'ACT NOW研究显示艾可拓对血脂的哪些方面会有影响','HDL','TG','TC','LDL','','','','',NULL,'ABC',1,',9,,10,,36,,38,',1,''),(83,2,'ACT NOW研究主要结论是与安慰剂相比，吡格列酮降低IGT进展为T2DM的风险达','25%','40%','60%','72%','','','','',NULL,'D',1,',9,,10,,36,,38,',1,''),(84,3,'ACT NOW研究显示与安慰剂相比，吡格列酮治疗与下列哪些指标水平显著下降相关','FPG','2小时血糖','HbA1c','胰岛素敏感性','','','','',NULL,'ABCD',1,',9,,10,,36,,38,',1,''),(85,2,'ACT NOW研究中转为正常的患者比例为','28%','49%','48%','54%','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(86,2,'ACT NOW发表于哪一年','2002年','2005年','2006年','2009年','','','','',NULL,'D',1,',9,,10,,36,,38,',1,''),(87,2,'ACT NOW发表在哪一期刊','柳叶刀','新英格兰','美国医学会杂志','中华内分泌','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(88,3,'ACT NOW显示艾可拓对比安慰剂组会有两项不良反应升高，分别是','体重','水肿','心血管','胃肠道','','','','',NULL,'AB',1,',9,,10,,36,,38,',1,''),(89,2,'Chicago研究发表于哪一年','2002年','2006年','2008年','2010年','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(90,2,'Chicago研究中考核指标是','CIMT','PAV','HbA1c','TG','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(91,2,'Chicago研究目的是','观察吡格列酮疗效','观察吡格列酮安全性','观察对2型糖尿病患者颈总动脉内膜-中层厚度改变的影响','观察吡格列酮对动脉粥样硬化的影响','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(92,2,'Chicago入组人数是','462例','5238例','190000例','602例','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(93,2,'Chicago研究治疗周期是','52周','72周','104周','26周','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(94,2,'Chicago主要衡量的结果是','左侧和右侧颈总动脉的后壁内膜-中层厚度的平均值从基线到最后随访的绝对改变','HbA1c自基线变化','PAV变化','无指标','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(95,2,'Chicago研究显示艾可拓可以降低CIMT达','0.012','0.001','0.12','0.01','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(96,2,'Chicago研究显示格列美脲增加CIMT达','0.012','0.001','0.12','0.01','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(97,2,'Chicago研究显示吡格列酮对血脂有很好的影响，尤其能明显提升','TG','TC','HDL','LDL','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(98,2,'Chicago研究显示艾可拓在多长时间内持续降低血糖','4周','8周','16周','24周','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(99,2,'PRO active发表于哪一年？','2005年','2006年','2008年','2011年','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(100,2,'PRO active发表于哪个期刊','柳叶刀','新英格兰','JAMA','糖尿病','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(101,2,'PRO active入组的患者特点是','合并心血管疾病','合并肾脏疾病','合并消化疾病','合并脑血管疾病','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(102,2,'PRO active总入组人数为','462','502','5238','5380','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(103,2,'PRO active一级终点艾可拓组较对照组降低','16%','20%','10%','15%','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(104,2,'PRO active次级终点艾可拓组较对照组降低','16%','20%','10%','15%','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(105,2,'PRO active显示艾可拓可使心脏复合终点风险降低','16%','19%','27%','47%','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(106,2,'PRO active艾可拓使致死性或非致死性心梗风险降低','16%','19%','28%','47%','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(107,2,'PRO active艾可拓可使致死性卒中或复发性卒中风险降低','10%','19%','28%','47%','','','','',NULL,'D',1,',9,,10,,36,,38,',1,''),(108,2,'PRO active研究结论是','艾可拓对心血管高危糖尿病患者无影响','艾可拓对心血管高危糖尿病患者降低主要终点事件','艾可拓对心血管高危糖尿病患者增加终点事件发生','艾可拓对心血管高危糖尿病患者无结论','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(109,2,'Persicope研究发表于哪年','2005年','2006年','2008年','2011年','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(110,2,'Persicope研究发表于哪个期刊','JAMA','Lancet','新英格兰','糖尿病','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(111,2,'Persicope研究目的','对比吡格列酮与格列美脲，对2型糖尿病患者冠状动脉粥样硬化进展的影响','对比吡格列酮与格列美脲，对2型糖尿病患者疗效','对比吡格列酮与格列美脲，对2型糖尿病患者安全性','对比吡格列酮与格列美脲，对2型糖尿病患者CIMT影响','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(112,2,'Persicope研究入组患者特点是','合并高血压','合并肾脏疾病','合并胃肠道疾病','合并冠状动脉疾病','','','','',NULL,'D',1,',9,,10,,36,,38,',1,''),(113,2,'Persicope研究观察指标是','PAV','CIMT','HbA1c','HDL','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(114,2,'Persicope研究显示艾可拓可以降低PAV达','0.72%','0.16%','1.6%','7.2%','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(115,2,'Persicope研究中和格列美脲增加PAV达','0.72%','0.16%','1.6%','7.2%','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(116,2,'Persicope研究显示艾可拓可降低中位空腹胰岛素水平达','5.0 μU/mL','5.1 μU/mL','5.2 μU/mL','5.3 μU/mL','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(117,2,'Persicope研究结论是','2型糖尿病伴有冠状动脉疾病的患者中，与格列美脲相比，吡格列酮显著减慢冠状动脉硬化的进展速度','3型糖尿病伴有冠状动脉疾病的患者中，与格列美脲相比，吡格列酮显著加快冠状动脉硬化的进展速度','4型糖尿病伴有冠状动脉疾病的患者中，与格列美脲相比，吡格列酮对冠状动脉硬化的进展速度无影响','5型糖尿病伴有冠状动脉疾病的患者中，与格列美脲相比，吡格列酮冠状动脉硬化的进展速度不确定','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(118,2,'Persicope研究显示艾可拓可降低中位空腹胰岛素水平提示艾可拓可以','改善血脂','改善高胰岛素血症','改善血压','无影响','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(119,2,'KPNC研究期间是','2001-2011年','2002-2012年','2003-2013年','2004-2014年','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(120,2,'KPNC研究目的是','评价使用吡格列酮心衰影响','评价使用吡格列酮长期使用疗效','评价使用吡格列酮与膀胱癌发生风险的相关性','评价使用吡格列酮心血管安全性','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(121,2,'艾可拓可能引起膀胱癌事件是由哪个国家提出来的','美国','中国','德国','法国','','','','',NULL,'D',1,',9,,10,,36,,38,',1,''),(122,2,'KPNC每几年发表一次报告','2年','4年','5年','1年','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(123,2,'KPNC研究结论是','吡格列酮不增加膀胱癌发生率','吡格列酮增加膀胱癌发生率','吡格列酮与膀胱癌发生率不确定','吡格列酮有效治疗膀胱癌','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(124,2,'KPNC入组人数为','193099例','1491060例','5238例','5380例','','','','',NULL,'A',1,',9,,10,,36,,38,',1,''),(125,2,'KPNC研究地点是','法国','德国','日本','美国','','','','',NULL,'D',1,',9,,10,,36,,38,',1,''),(126,2,'KPNC研究于哪一年发表','2012年','2013年','2014年','2015年','','','','',NULL,'C',1,',9,,10,,36,,38,',1,''),(127,2,'KPNC入组患者年纪为','〉30岁','〉40岁','〉50岁','〉60岁','','','','',NULL,'B',1,',9,,10,,36,,38,',1,''),(128,2,'EXAMINE研究发表于哪个期刊','JAMA','Lancet','新英格兰','ADA','','','','',NULL,'C',1,',11,,36,,38,',1,''),(129,2,'EXAMINE研究目的是','评估阿格列汀与安慰剂对近期发生急性冠脉综合征的1型糖尿病患者的心血管风险的影响','评估阿格列汀与安慰剂对近期发生急性冠脉综合征的2型糖尿病患者的心血管风险的影响','评估阿格列汀与安慰剂对发生急性冠脉综合征的2型糖尿病患者的心血管风险的影响','评估阿格列汀与安慰剂对发生急性冠脉综合征的1型糖尿病患者的心血管风险的影响','','','','',NULL,'B',1,',11,,36,,38,',1,''),(130,2,'EXAMINE研究入选近期发生ACS的患者，近期指的是','15天之内','15-60天','15-90天','90天以上','','','','',NULL,'C',1,',11,,36,,38,',1,''),(131,2,'EXAMINE研究设计是','优效研究','非优效研究','劣性研究','非劣性研究','','','','',NULL,'D',1,',11,,36,,38,',1,''),(132,3,'EXAMINE研究主要终点包括','心血管死亡','非致死性心肌梗死','非致死性卒中','不稳定心绞痛急需血运重建','','','','',NULL,'ABC',1,',11,,36,,38,',1,''),(133,2,'EXAMINE研究显示无论是主要终点事件还是次要终点事件，阿格列汀组与安慰剂组相比','优于安慰剂组','劣于安慰剂组','非劣于安慰剂组','不确定','','','','',NULL,'C',1,',11,,36,,38,',1,''),(134,2,'EXAMINE研究结论：与安慰剂相比，在近期发生急性冠脉综合征的2型糖尿病中使用阿格列汀（ ）其主要不良心血管事件发生率','不增加','增加','不确定','有影响','','','','',NULL,'A',1,',11,,36,,38,',1,''),(135,2,'EXAMINE研究中观察的副反应中对比胰腺炎，阿格列汀组对比安慰剂组','增加','减少','不增加','不确定','','','','',NULL,'C',1,',11,,36,,38,',1,''),(136,2,'EXAMINE & SAVOR主要结果对比中阿格列汀优于沙格列汀的是','卒中','冠心病','心衰','肾衰','','','','',NULL,'C',1,',11,,36,,38,',1,''),(137,2,'EXAMINE 研究入组人数','5238','5380','2701','2679','','','','',NULL,'B',1,',11,,36,,38,',1,''),(138,2,'ENDURE研究对比的活性药物是','格列美脲','格列齐特','格列吡嗪','那格列奈','','','','',NULL,'C',1,',11,,36,,38,',1,''),(139,2,'ENDURE研究为期是几年？这也是大多数促泌剂开始继发性失效的时间','1年','2年','3年','4年','','','','',NULL,'B',1,',11,,36,,38,',1,''),(140,2,'ENDURE研究观察指标是','血压变化','血脂变化','HbA1c变化','以上三项','','','','',NULL,'C',1,',11,,36,,38,',1,''),(141,2,'ENDURE研究显示，对比格列吡嗪，阿格列汀显示优效的剂量 是','6.75mg','12.5mg','25mg','50mg','','','','',NULL,'C',1,',11,,36,,38,',1,''),(142,2,'ENDURE研究显示，12.5mg阿格列汀对比格列吡嗪效果是','劣于格列吡嗪','优于格列吡嗪','非劣于格列吡嗪','不确定','','','','',NULL,'C',1,',11,,36,,38,',1,''),(143,2,'ENDURE研究入组人数为','2639','5380','2701','2679','','','','',NULL,'A',1,',11,,36,,38,',1,''),(144,2,'ENDURE研究中格列吡嗪的平均用量是','2mg','4mg','5.2mg','8mg','','','','',NULL,'C',1,',11,,36,,38,',1,''),(145,3,'ENDURE研究的次要终点包括','至其他时间点HbA1c变化情况','FPG','临床反应: HbA1c ≤6.5% 及<7%的发生率','体重变化','','','','',NULL,'ABCD',1,',11,,36,,38,',1,''),(146,3,'ENDURE研究同样探索了阿格列汀的安全性，包括','不良事件','严重不良事件','死亡的发生率','低血糖发生率 ','','','','',NULL,'ABCD',1,',11,,36,,38,',1,''),(147,3,'ENDURE研究显示阿格列汀可以降低','空腹血糖','餐后血糖','糖化血糖蛋白','HDL','','','','',NULL,'ABC',1,',11,,36,,38,',1,''),(148,2,'308研究的目的是评价阿格列汀单药、联用二甲双胍、联用吡格列酮用于治疗（  ）2型糖尿病患者的有效性和安全性','日本地区','欧洲地区','美国地区','中国地区','','','','',NULL,'D',0,',11,,36,,38,',1,''),(149,2,'308研究的治疗时间为','16周','26周','52周','104周','','','','',NULL,'A',1,',11,,36,,38,',1,''),(150,2,'308研究的主要终点观察指标是','血压变化','血脂','糖化血红蛋白','都检测','','','','',NULL,'C',1,',11,,36,,38,',1,''),(151,3,'308研究的次要终点包括','第4、8、12及 16 周时空腹血糖的变化','高血糖事件的发生率','临床疗效：HbA1c ≤ 6.5%、≤ 7.0%和≤ 7.5%的发生率','第8及16周时的体重变化','','','','',NULL,'ABCD',1,',11,,36,,38,',1,''),(152,2,'308研究显示阿格列汀单药治疗16周显著降低HbA1c','1%','0.99%','0.72%','0.66%','','','','',NULL,'B',1,',11,,36,,38,',1,''),(153,2,'308研究显示阿格列汀联合二甲双胍治疗16周显著降低HbA1c达','0.91%','0.99%','0.72%','0.66%','','','','',NULL,'A',1,',11,,36,,38,',1,''),(154,3,'308研究的结论包括','与安慰剂相比，单药治疗、联用二甲双胍或联用吡格列酮治疗，阿格列汀25mg QD都显著降低HbA1c','阿格列汀25mg QD可显著改善达到A1c ≤ 7%目标的受试者比例','阿格列汀25mg QD可显著降低空腹血糖并减少明显高血糖事件的发生率','阿格列汀25mg QD不会增加体重','','','','',NULL,'ABCD',1,',11,,36,,38,',1,''),(155,3,'308研究主要的安全性结论包括','减少胰腺炎风险','增加低血糖发生率','阿格列汀25 mg QD表现出的安全性特征与安慰剂相似','不增加低血糖发生率','','','','',NULL,'CD',1,',11,,36,,38,',1,''),(156,2,'308研究入组人数为','506','5380','5238','605','','','','',NULL,'A',1,',11,,36,,38,',1,''),(157,3,'老年研究的次要目的包括','胰腺炎发生率','低血糖事件的发生率','体重变化','总体不良事件','','','','',NULL,'BCD',1,',11,,36,,38,',1,''),(158,2,'老年研究的观察时间为','半年','一年','一年半','2年','','','','',NULL,'B',1,',11,,36,,38,',1,''),(159,3,'老年研究的结论包括','第52周时，阿格列汀25mg降低HbA1c水平非劣于格列吡嗪5-10mg','阿格列汀组发生低血糖事件的受试者比例显著低于格列吡嗪','与格列吡嗪相比，阿格列汀组的体重降低具有统计学意义','§阿格列汀安全且耐受良好','','','','',NULL,'ABCD',1,',11,,36,,38,',1,''),(160,2,'老年研究中患者的平均年龄是','60岁','65岁','70岁','75岁','','','','',NULL,'C',1,',11,,36,,38,',1,''),(161,2,'老年研究的入组人数是','441例','602例','5380例','543例','','','','',NULL,'A',1,',11,,36,,38,',1,''),(162,3,'老年研究显示在疗效方面阿格列汀与格列吡嗪类似但在以下三方面就有显著优势，包括','低血糖发生率','血脂调节','疗效','体重变化','','','','',NULL,'ABD',1,',11,,36,,38,',1,''),(163,2,'老年研究发表于','2011年','2012年','2013年','尚未发表','','','','',NULL,'C',1,',11,,36,,38,',1,''),(164,2,' 半衰期是指:','使50%物质失活所需要的时间','使50%物质起效所需要的时间','使50%物质进入血液所需要的时间','使50%物质排出体外所需要的时间','','','','',NULL,'A',1,',11,,39,',1,''),(165,3,'艾可拓的目标客户包括','心内医生','内分泌医生','糖尿病专科医生','妇产科医生','','','','',NULL,'BC',1,',9,,37,',1,''),(166,3,'艾可拓的目标患者是','早期T2DM患者合并血脂紊乱','脂肪肝','高胰岛素血症','PCOS','','','','',NULL,'ABC',1,',9,,37,',1,''),(167,3,'在临床中医生的某些现状会影响对艾可拓的判断和使用包括','血脂异常在T2DM病人群中意味着明确的胰岛素抵抗，但是临床医生并未将两者做明确联系。在处方时更未考虑添加艾可拓来同时控制血糖以及调节血脂','医生了解T2DM合并血脂异常意味着胰岛素抵抗，但是处方时分别使用了降糖药和他汀类降脂药。','临床上常见注射胰岛素剂量不断增加，但是仍然不能控制血糖','医生仅关注血糖，但是目前T2DM治疗趋势是关注及并发症的发生发展。','','','','',NULL,'ABCD',1,',9,,37,',1,''),(168,3,'艾可拓®作为胰岛素增敏作用最强的降糖药物，直击2型糖尿病脂代谢紊乱中心环节，其改善血脂能力包括','降低甘油三酯','升高高密度脂蛋白胆固醇','显著降低LDL颗粒浓度','增加LDL颗粒大小','','','','',NULL,'ABCD',1,',9,,37,',1,''),(169,3,'高胰岛素血症是艾可拓的目标患者，高胰岛素血症有哪些危害','加快血糖控制失效','加重低血糖反应','使体重增加','增加癌症风险','','','','',NULL,'ABCD',1,',9,,37,',1,''),(170,2,'中国2型糖尿病合并血脂紊乱的患者比例大致为','1/2','2/3','3/4','4/5','','','','',NULL,'D',1,',9,,37,',1,''),(171,3,'T2DM合并血脂紊乱的患者也是艾可拓的目标患者人群，血脂紊乱有哪些危害','增加心血管风险','促进动脉粥样硬化进程','促进β细胞功能障碍','加重脂代谢紊乱','','','','',NULL,'ABCD',1,',9,,37,',1,''),(172,3,'2014年艾可拓推广的科室会幻灯包括','吡格列酮-直击病因，锦上添花','高胰岛素血症','T2DM脂代谢紊乱及治疗探讨','胰岛素抵抗：NAFLD—一个与T2DM并存的疾病','','','','',NULL,'ABCD',1,',9,,37,',1,''),(173,3,'2014年艾可拓推广的患者卡片包括','2型糖尿病合并NAFLD','2型糖尿病合并腰高比超标患者','2型糖尿病合并高胰岛素血症','2型糖尿病合并血脂紊乱','','','','',NULL,'ACD',1,',9,,37,',1,''),(174,3,'NAFLD的定义是','非酒精性脂肪肝病','患者肝脏脂肪超过总量的10%','一种与胰岛素抵抗和遗传易感性密切相关的代谢疾病','其病理学改变与酒精性肝病相似但患者无过量饮酒史','','','','',NULL,'ABCD',1,',9,,37,',1,''),(175,3,'肠促胰素是一种来源于小肠，能调节胰腺内分泌素的激素，包括','GLP-1','GIP','GDP','GIP-1','','','','',NULL,'AB',1,',11,,39,',1,''),(176,2,'促泌剂是指磺脲类药物和格列奈类药物，\n他们能促进胰岛素的分泌，下列药物是促泌剂的是','唐力','格华止 ','拜糖平','文迪雅','','','','',NULL,'A',1,',11,,39,',1,''),(177,2,'胰岛素分泌分为第一时相和第二时\n相，第一时相大概维持的时间为','25分钟','20分钟','15分钟','10分钟','','','','',NULL,'D',1,',11,,39,',1,''),(178,2,'DPP-4是人体内广泛存在的一种酶，它的主要作用是','抑制胃酸的分泌，减缓胃排空的速度','增加小肠对葡萄糖的吸收','可以降解GLP-1和GIP，降低胰岛素的合成和分泌','促进胰岛素的合成','','','','',NULL,'C',1,',11,,39,',1,''),(179,2,'武田公司无论是倍欣还是尼欣娜都出自一种合\n理的药物设计，所谓合理的药物设计是指','根据药物的三维结构进行设计','根据药物的结合位点进行设计','根据药物的相互作用进行设计','以上均是','','','','',NULL,'D',1,',11,,39,',1,''),(180,2,'葡萄糖依赖性促胰岛素肽（GIP）由（）分泌','K细胞 ','L细胞','F细胞','G细胞','','','','',NULL,'A',1,',11,,39,',1,''),(181,2,'胰高血糖素样肽-1由（）分泌','K细胞 ','L细胞','G细胞','F细胞','','','','',NULL,'B',1,',11,,39,',1,''),(182,2,'类似物的定义是','一种结构相似的化合物，作用机理和效果完全相同','一种结构相似的化合物，\n作用机理和效果完全不同','一种结构相似的化合物，但在某些方面存在差异','结构不一定相似或相同，但作用一定一致','','','','',NULL,'C',1,',11,,39,',1,''),(183,2,'肽的定义是','由肽键结合在一起，由两个或多个葡萄糖组成的化合物','由肽键结合在一起，由两个或多个脂肪酸组成的化合物','由肽键结合在一起，由两个或多个蛋白质组成的化合物','由肽键结合在一起，由两个或多个氨基酸组成的化合物','','','','',NULL,'D',1,',11,,39,',1,''),(184,2,'肽酶指的是','可以裂解肽键的酶','可以消化肽的酶','可以组成肽键的酶','可以合成肽的酶','','','','',NULL,'A',1,',11,,39,',1,''),(185,2,'晚期肾脏疾病的定义','一种慢性疾病，肾脏不能正常发挥作用','体内液体潴留，有害物质不能排除体外','简写为ESRD，需要透析或肾移植','以上均是','','','','',NULL,'D',1,',11,,39,',1,''),(186,2,'药物的效力指','药物全部进入血液循环的50%的药物量','达到最大疗效50%所需要的药物量','药物起效的时间','药物维持药效的时间','','','','',NULL,'B',1,',11,,39,',1,''),(187,2,'药物的最大疗效指','药物的最大反应，与剂量无关','药物的最大反应，与剂量有关','药物最大服用剂量','药物发挥效果时间','','','','',NULL,'A',1,',11,,39,',1,''),(188,2,'下列哪一项在空腹或饥饿状态下不会发生','血浆脂肪酸水平降低','糖原耗竭','酮体形成  ','脂解作用','','','','',NULL,'A',1,',11,,39,',1,''),(189,2,'胰岛素和胰高糖素对血糖调节有重要的作用，\n根据需要来增加或降低血糖水平。当血糖水平升高时，_____分泌胰岛素以促进身体内多个组织对葡萄糖的摄取；当血糖水平降低时，______分泌胰高糖素以促进组织中储存的葡萄糖释放',' 胰岛β细胞；胰岛α细胞','胰岛α细胞；胰岛β细胞','胰岛α细胞；胰岛α细胞 ','胰岛β细胞；胰岛β细胞','','','','',NULL,'A',1,',11,,39,',1,''),(190,2,'哪一项不是胰岛素的作用','加速葡萄糖进入到细胞\n中，尤其是骨骼肌纤维中','促进糖原生成（将葡萄糖\n转化成糖原），脂肪生成（合成脂肪酸），以及摄取氨基酸用于蛋白质合成','促进糖原分解（\n将贮存的糖原转化为葡萄糖）和糖异生（从乳酸和某些氨基酸生成葡萄糖','减缓糖原分解（\n将贮存的糖原转化为葡萄糖）和糖异生（从乳酸和某些氨基酸生成葡萄糖','','','','',NULL,'C',1,',11,,39,',1,''),(191,2,'体重指数(BMI)达到()可以称做肥胖','≥24kg/m2','≥27kg/m2','≥30kg/m2 ','≥35kg/m2','','','','',NULL,'C',1,',11,,39,',1,''),(192,2,'糖尿病是一组病因不明的内分泌代谢疾病，其最主\n要的特征是','多饮、多尿、多食，体重减轻','乏力','肥胖','慢性高血糖','','','','',NULL,'A',1,',11,,39,',1,''),(193,2,'1型糖尿病与2型糖尿病的区别不包括以下','典型症状不同','发生酮症酸中毒的倾向不同','危险因素不同','胰岛素的基础水\n平与释放曲线不同','','','','',NULL,'A',1,',11,,39,',1,''),(194,2,'2型糖尿病最基本的病理生理改变是','极度肥胖','长期大量摄糖','长期使用糖皮质激素','胰岛素分泌绝对\n或相对不足及靶组织对胰岛素敏感性下降','','','','',NULL,'D',1,',11,,39,',1,''),(195,2,'对2型糖尿病的发病机制，以下说法错误的是','糖耐量异常具有遗传易\n感性','普遍认为2型糖尿病患者存在胰岛素抵抗','2型糖尿病患者常出现α细胞功能紊乱','2型糖尿病患者\n的β细胞功能紊乱在高血糖之前，并可预示高血糖的发生','','','','',NULL,'C',1,',11,,39,',1,''),(196,2,'我国2型糖尿病防治指南(2010版)指出，正常的空\n腹血糖范围应为','70-100mg/dL(3.9-\n5.6mmol/L)','70-110mg/dL(3.9-\n6.1mmol/L)','70-120mg/Dl\n(3.9-6.7mmol/L)','70-125mg/dL(\n3.9-6.9mmol/L)','','','','',NULL,'B',1,',11,,39,',1,''),(197,2,'空腹血糖一般作为糖尿病最常用的检测指标，一\n般代表_____的分泌功能','餐时胰岛素','基础胰岛素','以上均是','以上均否','','','','',NULL,'B',1,',11,,39,',1,''),(198,2,'当体检时发现空腹血糖5.8 mmol/L时，应该做下列\n哪项检查','口服葡萄糖耐量试验(OGTT)试验','心电图','脑电图 ','测血压','','','','',NULL,'A',1,',11,,39,',1,''),(199,2,'我国2型糖尿病防治指南(2010版)指出，对于接受\n药物治疗的糖尿病患者来说，低血糖是指','血糖≤2.52mmol/L','血糖≤3.08mmol/L','血糖≤3.36mmol/L ','血糖≤3.9mmol/L','','','','',NULL,'D',1,',11,,39,',1,''),(200,2,'接受药物治疗的糖尿病患者低血糖的定义是',' <2.8 mmol/L ','≤3.0 mmol/L ','<3.5 mmol/L','≤3.9 mmol/L','','','','',NULL,'D',1,',11,,39,',1,''),(201,2,'哪些人容易发生低血糖','老年人',' 肾功能减退的患者','有严重微血管和\n大血管并发症的患者','以上都是','','','','',NULL,'D',1,',11,,39,',1,''),(202,2,'低血糖能够导致严重的并发症，不包括以下','重要的血管事件(例如\n中风、心肌梗塞、急性心力衰竭以及室性心律失常)','意识受损和抽搐','肝肾功能损害','跌倒，引起外伤风险和骨折风险增加','','','','',NULL,'C',1,',11,,39,',1,''),(203,2,'以下属于糖尿病筛查的高危人群的是','超重，肥胖（BMI≥\n24 kg/m 2），男性腰围≥90cm，女性腰围≥85cm','空腹血糖超过5.6 mmol/L者','年龄≥ 45岁，\n有糖尿病家族史者','以上都是','','','','',NULL,'D',1,',11,,39,',1,''),(204,2,'关于2型糖尿病的说法正确的是','起病早，且急','多为青少年患者','必须使用胰岛素治疗','常见于老年人','','','','',NULL,'D',1,',11,,39,',1,''),(205,2,'关于2型糖尿病的代谢因素的控制目标，下列说法\n错误的是','空腹血糖3.9-7.2mmol/L','糖化血红蛋白＜7.0%','血压＜150/90mmHg','甘油三酯＜1.7mmol/L','','','','',NULL,'C',1,',11,,39,',1,''),(206,2,'糖尿病患者的运动原则是','循序渐进','量力而行','持之以恒','以上都是','','','','',NULL,'D',1,',11,,39,',1,''),(207,2,'对我国2型糖尿病防治的三级预防的概念，下列\n说法错误的是','一级预防的目标是预\n防2型糖尿病的发生','二级预防的目标是通过\n饮食、运动、药物、血糖监测及糖尿病教育等预防糖尿病的发生','二级预防的目标\n是在已诊断的2型糖尿病患者中预防糖尿病并发症的发生','三级预防的目标\n是减少已发生的糖尿病并发症的进展、降低致残率和死亡率，并改变患者的生存质量','','','','',NULL,'B',1,',11,,39,',1,''),(208,2,'导致糖尿病患病率不断增加的主要危险因素有','遗传因素','环境因素','人口老龄化','以上均是','','','','',NULL,'D',1,',11,,39,',1,''),(209,2,'以下______不是糖尿病的诊断标准','糖负荷后2h静脉血浆葡\n萄糖在7.8 mmol/L到11.1 mmol/L之间','空腹血糖≥7.0 mmol/L','葡萄糖负荷后\n2h血糖无糖尿病症状者，改日重复检查静脉血浆葡萄糖水平≥11.1mmol/L','糖尿病症状加上\n随机血糖监测≥11.1mmol/L','','','','',NULL,'A',1,',11,,39,',1,''),(210,2,'糖化血红蛋白反映的是过去______的血糖水平','2-3周','2-3个月','2-3年','以上均不是','','','','',NULL,'B',1,',11,,39,',1,''),(211,2,'糖化血红蛋白是红细胞中____与葡\n萄糖缓慢持续且不可逆的进行非酶促蛋白糖化反应的产物','白蛋白','转铁蛋白','血红蛋白','前白蛋白','','','','',NULL,'C',1,',11,,39,',1,''),(212,2,'以下关于口服葡萄糖耐量试验(OGTT)方法描述错误的是','试验过程中，受试者\n可进行剧烈运动','受试者空腹(8-14小时)后\n口服溶于300 ml水内的无水葡萄糖粉75 g','从服糖第一口开\n始计时，于服糖前和服糖后2小时分别在前臂采血测血糖','试验过程中，\n受试者不能喝茶及咖啡','','','','',NULL,'A',1,',11,,39,',1,''),(213,2,'大多数糖尿病患者糖化血红蛋白理想目标值为','＜8%','＜7%','＜5%','＜4%','','','','',NULL,'B',1,',11,,39,',1,''),(214,2,'在对2型糖尿病进行降糖治疗时，应该将以下哪项\n降至正常范围以内','空腹血糖','餐后血糖','糖化血红蛋白','以上均是','','','','',NULL,'D',1,',11,,39,',1,''),(215,2,'糖尿病是将以下哪一项做为衡量标准来进行诊断的','全血血糖','静脉血浆血糖','毛细血管血糖','以上皆是','','','','',NULL,'B',1,',11,,39,',1,''),(216,2,'下列哪种并发症是引起糖尿病患者死亡的最主要原因','心血管疾病','糖尿病肾病','视网膜病变','糖尿病神经病变','','','','',NULL,'A',1,',11,,39,',1,''),(217,2,'下列哪项属于糖尿病大血管并发症','糖尿病肾病','糖尿病神经病变','冠心病','眼底病变','','','','',NULL,'C',1,',11,,39,',1,''),(218,2,'以下选项中属于糖尿病急性并发症的有','冠心病',' 高血脂 ','酮症酸中毒','糖尿病肾病','','','','',NULL,'C',1,',11,,39,',1,''),(219,2,' 糖尿病酮症酸中毒是糖尿病急性并发症\n之一，以下对它的说法错误的是','轻度酮症酸中毒可表\n现出酸中毒症状','重度酮症酸中毒的二氧化\n碳结合力＜10mmol/L','主要表现为多\n尿、烦渴多饮和乏力症状加重','尿糖、尿酮体阳\n性或强阳性','','','','',NULL,'A',1,',11,,39,',1,''),(220,2,'以下哪种说法准确描述了与2型糖尿病有关的肠\n促胰素分泌缺陷','.加速GIP和GLP-1的失活','肠促胰素效应降低','降低GIP和G\nLP-1的分泌','影响GLP-1分\n泌并降低肠促胰素受体活性','','','','',NULL,'B',1,',11,,39,',1,''),(221,3,'摄食的食物主要以______形式进入到血流中','葡萄糖','.脂肪酸','氨基酸','甘油三酯','','','','',NULL,'ACD',1,',11,,39,',1,''),(222,3,'下列属于营养治疗的原则的是','合理控制总热量摄入','平衡膳食，各种营养\n物质摄入均衡','称重饮食，定时\n定量进餐','少量多餐，每日\n3-6餐','','','','',NULL,'ABCD',1,',11,,39,',1,''),(223,3,'每个胰岛由4个细胞组成，对于他们的功能，以下\n说法正确的是','α细胞，分泌胰高糖素','β细胞，分泌胰岛素','δ细胞，分泌胰多肽','F细胞，分泌生长抑素','','','','',NULL,'AB',1,',11,,39,',1,''),(224,3,'血糖波动幅度增大，给糖尿病患者带来的危害有','增加低血糖风险','损伤内皮细胞功能','损伤β细胞功能','增加心血管事件风险','','','','',NULL,'ABCD',1,',11,,39,',1,''),(225,3,'对于血糖的调节，以下说法正确的是','膳食状态时，食物→葡萄糖→能量','餐后状态时，体内储存的葡萄糖→能量','空腹或者饥饿态时，除葡萄糖之外的燃料→能量','以上说法均不对','','','','',NULL,'ABC',1,',11,,39,',1,''),(226,3,'以下关于血糖监测描述正确的是','所有糖尿病患者都应该进行血糖监测','使用胰岛素的患者均需要监测血糖','自我血糖监测是调整血糖达标的重要措施','不是所有糖尿病患者都应监测血糖','','','','',NULL,'ABC',1,',11,,39,',1,''),(227,3,'低血糖易感人群包括以下哪些','.肾功或肝功不全','老年、衰弱和营养不良的患者','肾上腺或垂体功能不全的患者','热量摄入不足、剧烈和长时间运动、饮酒或应用一种以上的降糖药物者','','','','',NULL,'ABCD',1,',11,,39,',1,''),(228,3,'2型糖尿病最基本的病理变化就是','胰高糖素分泌增加','胰高糖素分泌减少','胰岛素抵抗','胰岛素分泌减少\n及其分泌节律异常','','','','',NULL,'CD',1,',11,,39,',1,''),(229,3,'下列哪些是糖尿病的慢性并发症','糖尿病酮症酸中毒','糖尿病肾病','糖尿病足 ','眼底出血','','','','',NULL,'BCD',1,',11,,39,',1,''),(230,3,'肠促胰素对胰腺分泌具有显著影响，但失活速度过快，提高肠促胰素效果的策略包括：','采取类似物但抑制其失活','抑制肠促胰素失活','加大分泌量','加快起效时间','','','','',NULL,'AB',1,',11,,39,',1,''),(231,2,'口服相同剂量的葡萄糖与静脉注射葡萄\n糖相比，胰岛素的分泌变得','更低','一样','更高','不一定','','','','',NULL,'C',1,',11,,39,',1,''),(232,2,'胰腺的激素分泌不仅受肠道吸收的营养物\n质血液水平的调节，也受小肠分泌激素\n的调节，这些来自肠道的激素称为','GLP-1','GIP  ','抑胃肽','肠促胰素','','','','',NULL,'D',1,',11,,39,',1,''),(233,2,'下列不是GLP-1的作用的是','刺激葡萄糖依赖性胰岛素分泌','抑制餐后高血糖素分泌','延缓胃排空','改善α细胞功能','','','','',NULL,'D',1,',11,,39,',1,''),(234,3,'哪些物质可以快速刺激GLP-1的释放','碳水化合物','脂肪','蛋白质','胰岛素','','','','',NULL,'AB',1,',11,,39,',1,''),(235,3,'GLP-1的分泌与哪些因素有关','胰岛素水平','进餐量','胃排空速率','体重','','','','',NULL,'BC',1,',11,,39,',1,''),(236,3,'GLP-1与GLP-1受体结合，受体主要位于胰岛\n细胞，在肺部、胃和大脑也有分布，因此导\n致了GLP-1有不同的作用，如果作用在胰岛\n的话作用是','刺激β细胞分泌胰岛素','抑制α细胞分泌胰高血糖素','增加饱腹感','以上都是','','','','',NULL,'AB',1,',11,,39,',1,''),(237,3,'GLP-1与胃肠道的受体结合作用是','明显抑制胃肠道上段的分泌和动力','降低营养物质在胃肠道的吸收率','抑制胃肠道下段的分泌和动力','加快营养物质在胃肠道的吸收率','','','','',NULL,'AB',1,',11,,39,',1,''),(238,3,'GLP-1与位于中枢神经系统的受体结合，可以起到','增加饱腹感','终止食物的摄取','增加饥饿感','加快食物的摄取','','','','',NULL,'AB',1,',11,,39,',1,''),(239,2,'分泌GLP-1的L细胞位于小肠的','上端','中端','下段','全部','','','','',NULL,'C',1,',11,,39,',1,''),(240,2,'分泌GIP的K细胞位于小肠的','上端','中端','下段','全部','','','','',NULL,'D',1,',11,,39,',1,''),(241,2,'GIP的分泌的特点不包括','只有碳水化合物或脂肪到达肠道时才会分泌','时时刻刻都在分泌','餐食是GIP的必须的','在十二指肠处浓度最高','','','','',NULL,'B',1,',11,,39,',1,''),(242,2,'GIP区别于GLP-1的最突出的作用是','促进餐后脂质的清除','促进胰岛素的分泌','对胰岛细胞的保护作用','无突出优势','','','','',NULL,'A',1,',11,,39,',1,''),(243,3,'DPP-4优先裂解氨基酸序列倒数第二位\n是（）的肽类激素','脯氨酸','谷氨酸','丙氨酸','谷丙氨酸','','','','',NULL,'AC',1,',11,,39,',1,''),(244,2,'口服葡萄糖后，肠促胰素可以增加胰岛素\n的生成，口服和静脉服用葡萄糖后胰岛素\n应答的差异称为','胰岛素增敏作用','肠促胰素效应','糖耐量增强 ','食物诱导','','','','',NULL,'B',1,',11,,39,',1,''),(245,2,'口服葡萄糖后超过（）的肠促胰素效应是\n由GLP-1和GIP产生的','0.6','0.7','0.8','0.9','','','','',NULL,'D',1,',11,,39,',1,''),(246,2,'肠促胰素促使胰岛分泌胰岛素与磺脲类药物\n的促使胰岛分泌胰岛素的区别是','葡萄糖依赖性','非葡萄糖依赖性','无区别','时间更短','','','','',NULL,'A',1,',11,,39,',1,''),(247,3,'肠促胰素释放从而引起胰岛素分泌增强，\n需要哪两种独立的信号','胰岛素','胰高血糖素','肠促胰素','葡萄糖','','','','',NULL,'CD',1,',11,,39,',1,''),(248,2,'肠促胰素与磺脲类促泌剂相比发生低血糖的概率','更高','一样','更低','不一定','','','','',NULL,'C',1,',11,,39,',1,''),(249,2,'肠促胰素的主要作用是降低','空腹血糖','餐后血糖','24H血糖','空腹和餐后','','','','',NULL,'B',1,',11,,39,',1,''),(250,2,'口服葡萄糖对以下哪个选项的分子水平没有升高作用','GIP','GLP-1','胰高糖素','胰岛素','','','','',NULL,'C',1,',11,,39,',1,''),(251,2,'关于肠促胰素的分布，以下说法错误的是','GIP和GLP-1均能在胰腺中找到','GIP和GLP-1均能在消化道中找到','GIP和GLP-1可在中枢神经系统中找到','GIP和GLP-1均可在心脏组织中找到','','','','',NULL,'D',1,',11,,39,',1,''),(252,2,'下列哪类药物是以葡萄糖依赖方式刺激胰岛素分泌的','双胍类','DPP4抑制剂','噻唑烷二酮类','α-葡萄糖苷酶抑制剂','','','','',NULL,'B',1,',11,,39,',1,''),(253,3,'GLP-1还可以起到保护β细胞功能的作用，作用机制是','增加β细胞增殖','增加α细胞增殖','减少α细胞凋亡','减少β细胞凋亡','','','','',NULL,'AD',1,',11,,39,',1,''),(254,2,'2型糖尿病患者会出现口服葡萄糖后胰岛素效应没有增强,这种现象称为','胰岛素缺陷','肠促胰素分泌缺陷','胰高血糖素缺陷','DPP缺陷','','','','',NULL,'B',1,',11,,39,',1,''),(255,3,'GLP-1类似物的效应包括','增加饱腹感，延缓食物摄取','减缓胃排空，延缓餐后葡萄糖的入学速率','调节胰高血糖素','促进胰岛素的释放','','','','',NULL,'ABCD',1,',11,,39,',1,''),(256,2,'艾塞那肽导致的比较严重的不良反应是','甲状腺C细胞肿瘤','肾功能损害','胰腺炎','低血糖','','','','',NULL,'C',1,',11,,39,',1,''),(257,2,'利拉鲁肽的黑框警告的不良反应是','甲状腺C细胞肿瘤','肾功能损害','胰腺炎   ','低血糖','','','','',NULL,'A',1,',11,,39,',1,''),(258,3,'GLP-1介导的降糖作用包括','提高葡萄糖依赖性胰岛素分泌','抑制胰高糖素分泌，延缓胃排空','抑制食欲','增加β细胞的胰岛素储存','','','','',NULL,'ABCD',1,',11,,39,',1,''),(259,3,'DPP-4抑制剂有多种治疗效应，主要是','增加胰腺β细胞葡萄糖依赖性胰岛素的分泌','降低胰腺α细胞葡萄糖依赖性胰高血糖素的分泌','降低肝脏葡萄糖的输出','减缓胃排空','','','','',NULL,'ABCD',1,',11,,39,',1,''),(260,2,'DPP-4抑制剂不但能起到降低血糖的作用还能起到','改善血脂','降低体重','降低血压','减缓心率','','','','',NULL,'A',1,',11,,39,',1,''),(261,2,'所有DPP-4抑制剂的唯一禁忌症是','对产品过敏的患者','胰腺炎患者','肝功能异常患者','肾功能异常患者','','','','',NULL,'A',1,',11,,39,',1,''),(262,3,' GLP-1类似物的作用机制与DPP-4抑制剂的不同点','类似物模拟肠促胰素；DPP-4抑制剂增加体内肠促胰素的半衰期','类似物抑制酶降解；DPP-4抑制剂延长肠促胰素活性','类似物激活肠促胰素受体；DPP-4抑制剂使酶失活，不能降解肠促胰素','以上皆不是','','','','',NULL,'ABC',1,',11,,39,',1,''),(263,3,'对于肠促胰素效应，下列说法正确的是','正常个体在口服葡萄糖后，刺激胰岛素释放的作用比静脉葡萄糖输注后的效果更强','口服葡萄糖比静脉注射葡萄糖分泌的胰岛素多','肠促激素的作用至少 占正常胰岛素分泌总量的50%','在2型糖尿病中，患者的肠促胰素的作用明显降低','','','','',NULL,'ABCD',1,',11,,39,',1,''),(264,2,'对DPP-4酶抑制剂的特性，下列说法错误的是','口服治疗','可延长内源性的GLP-1的活性','直接参与肝糖生成','提高外周组织葡萄糖利用','','','','',NULL,'C',1,',11,,39,',1,''),(265,2,'对于中度和重度肾功能不全患者西格列汀的剂量分别需要如何调整','1/4剂量','不需要调整剂量','1/2剂量和1/4剂量','1/2剂量','','','','',NULL,'C',1,',11,,39,',1,''),(266,2,'目前上市的DPP-4抑制剂均可能会出现的不良反应是','肾衰竭','甲状腺C细胞瘤','胰腺炎','甲状腺肥大','','','','',NULL,'C',1,',11,,39,',1,''),(267,2,'第一个采用三维结构设计的DPP-4酶抑制剂是','西格列汀','维格列汀','沙格列汀','阿格列汀','','','','',NULL,'D',1,',11,,39,',1,''),(268,2,'2013年AACE指南推荐的治疗2型糖尿病的药物中，不良反应少或可能获益的是','噻唑烷二酮类','DPP4酶抑制剂 ','钠-葡萄糖协同转运蛋白2','以上均是','','','','',NULL,'B',1,',11,,39,',1,''),(269,2,'GLP-1类似物的作用机制与DPP-4抑制剂的不同点是','类似物模拟肠促胰素，DPP-4抑制剂增加体内肠促胰素的半衰期','类似物抑制酶降解，DPP-4抑制剂延长肠促胰素活性','类似物激活肠促胰素受体，DPP-4抑制剂使酶失活，不能降解肠促胰素','以上都是','','','','',NULL,'D',1,',11,,39,',1,''),(270,2,'特定药物的效力是指产生最大疗效50%所需的药物量，一般简写为EC50，EC50越低，则药效力：','越低','一样','越高','不一定','','','','',NULL,'C',1,',11,,39,',1,''),(271,2,'DPP-4抑制剂必须要求具有较高的选择性主要原因是','为了发挥更大的效果','抑制DPP-8和9会产生很大的毒性','可以降低药物的使用量','尽快的起到发生效果的时间','','','','',NULL,'B',1,',11,,39,',1,''),(272,2,'肠促胰素影响哪个器官的激素分泌','胆囊','肝脏','胰腺','胃','','','','',NULL,'C',1,',11,,39,',1,''),(273,3,'DPP-4酶抑制剂的治疗策略包括','减少服药种类，提高依从性','大幅减少胰岛素用量，减少注射次数，减轻经济负担','降糖疗效好，不良事件少','花费合理','','','','',NULL,'ABCD',1,',11,,39,',1,''),(274,3,'作用于肠促胰素靶点的药物包括DPP-4酶抑制剂和GLP-1激动剂，对于DPP-4酶抑制剂和GLP-1激动剂的说法，以下哪些是正确的','DPP-4酶抑制剂多以片剂或胶囊形式口服给药，依从性强，而GLP-1激动剂则必须注射给药','DPP-4酶抑制剂能延长血浆中GIP的活性','DPP-4酶抑制剂可口服给药，较之于GLP-1激动剂静脉注射方便','DPP-4酶抑制剂常引起恶心和呕吐','','','','',NULL,'ABC',1,',11,,39,',1,''),(275,2,'哪两种因素决定胰高血糖素样肽-1的餐后分泌量','饮食脂类清除和餐量大小','肝脏葡萄糖生产和饮食脂类清除','胃排空速率和咁葡萄糖生成水平','餐量大小和胃排空速率','','','','',NULL,'D',1,',11,,39,',1,''),(276,2,'药物可抑制DDP-4并不会抑制其他DPP酶，这种属性称为','亲和力','疗效','效力','选择性','','','','',NULL,'D',1,',11,,39,',1,''),(277,2,'GIP和GLP的共同特征是','抑制胰高血糖素的分泌','改善β细胞功能','增加饱腹感','体重减低','','','','',NULL,'B',1,',11,,39,',1,''),(278,2,'下列DPP-4酶抑制剂中，最少通过CYP代谢的是','西格列汀','阿格列汀','沙格列汀','维格列汀','','','','',NULL,'B',1,',11,,39,',1,''),(279,2,'目前临床上最常用的心脏功能指标是：','血压','心脏输出量','射血分数','心率','心脏指数','','','',NULL,'C',1,',8,,39,',1,''),(280,2,'高压状态下的肺部的静脉血通过下面的那个血管运输？','肺静脉 ','大动脉','肺动脉','毛细血管','','','','',NULL,'C',1,',8,,39,',1,''),(281,2,'心脏中最大的肌性部分为?','右心房壁','右心室壁','左心房壁','左心室壁','中间隔','','','',NULL,'D',1,',8,,39,',1,''),(282,2,'测血压的注意事项不包括哪项：','对偏瘫病人，可在患侧手臂上测量','血压计要定期检查','打气不可过高、过猛','测量血压时，血压计“0”点应和肱动脉、心脏处在同一水平','须密切观察血压者，应尽量做到四定：定时间、定部位、定体位、定血压计','','','',NULL,'A',1,',8,,39,',1,''),(283,2,'循环系统血流阻力主要来源于哪种血管','动脉','微动脉','毛细血管','静脉','','','','',NULL,'B',1,',8,,39,',1,''),(284,3,'心血管疾病从根据致病因素分为先天性和后天性，以下哪些属于后天性心血管病','动脉粥样硬化','原发性高血压','心律失常','肺源性心脏病(肺心病)','','','','',NULL,'ABD',1,',8,,39,',1,''),(285,3,'人体中的血液分为静脉血和动脉血，通过血管在身体中循环，以下那些血管中的血液是动脉血','主动脉血管','动脉血管','肺动脉血管','肺静脉血管','','','','',NULL,'ABD',1,',8,,39,',1,''),(286,3,'决定血压的因素主要分为两种，是指','年龄','心输出量','体重指数','总外周阻力','','','','',NULL,'BD',1,',8,,39,',1,''),(287,2,'人体中80%的血液储存在：','动脉','血管 ','心脏','脑','','','','',NULL,'B',1,',8,,39,',1,''),(288,2,'射血分数是指心脏每次收缩左室排出血量的百分比，通常作为反应收缩力的指标。正常的射血分数是多少？','75-95％','35-55％','55-75％','1','','','','',NULL,'C',1,',8,,39,',1,''),(289,3,'身体通过某些组织感知血压的变化，以下那些是：','颈动脉窦','心脏','主动脉压力感受器','血管','','','','',NULL,'AC',1,',8,,39,',1,''),(290,2,'肾素-血管紧张素-醛固酮系统（RAAS）产生的血管紧张素II（AII）在体液调节机制中起重要作用，身体中哪个器官在RAAS中起到非常重要的作用','心脏','肾脏','胰腺','大脑','','','','',NULL,'B',1,',8,,39,',1,''),(291,2,'以下说法是否正确？在高血压的治疗过程中，只要血压得到了有效控制即可停药观察、待血压再次升高时才再次用药。','正确','不正确','','','','','','',NULL,'B',1,',8,,39,',1,''),(292,3,'长期高血压导致全身小动脉病变，主要是管腔内径缩小和壁腔比值增加，导致以下哪些哪些靶器官受损？','心脏','肾脏','脑','视网膜','','','','',NULL,'ABCD',1,',8,,39,',1,''),(293,2,'高血压的定义是：','收缩压>140mmHg和（或）舒张压> 90mmHg','收缩压>160mmHg和（或）舒张压>100mmHg','收缩压>180mmHg和（或）舒张压> 110mmHg','收缩压>120mmHg和（或）舒张压>80mmHg','','','','',NULL,'A',1,',8,,39,',1,''),(294,3,'有关高血压分级以下哪些是正确的？','1级高血压（轻度）SBP≧140-159mmHg和（或）DBP≧90-99mmHg','2级高血压（中度）SBP≧160-179mmHg和（或）DBP≧100-109mmHg','3级高血压（重度）SBP≧180mmHg和（或）DBP≧180mmHg','单纯收缩期高血压SBP>140mmHg，DBP>90mmHg','','','','',NULL,'AB',1,',8,,39,',1,''),(295,2,'2级高血压是指：','收缩压<120mmHg和（或）舒张压<80mmHg ','收缩压120~139mmHg和（或）舒张压80~89mmHg','收缩压140~159mmHg和（或）舒张压90~99mmHg  ','收缩压160~179mmHg和（或）舒张压100~109mmHg','收缩压≥180mmHg和（或）舒张压≥110mmHg','','','',NULL,'D',1,',8,,39,',1,''),(296,3,'有关高血压的病因、以下哪些说法是正确的？','高血压具有明显的家族聚集性','在遗传表型上，不仅血压升高发生率体现遗传性，而且在血压高度、并发症的发生以及其他有关因素方面，如肥胖，也有遗传性','高血压与饮食中平均钠盐摄入无显著关系','体力劳动者高血压患病率超过脑力劳动者','','','','',NULL,'AB',1,',8,,39,',1,''),(297,3,'高血压与以下因素相关?','体重','口服避孕药','睡眠呼吸暂停低通气综合征','从事精神紧张度低的职业','','','','',NULL,'ABC',1,',8,,39,',1,''),(298,2,'血压的调控机制不包括哪项：','压力感受器机制','容量压力调节机制','体液调节机制','中枢神经系统','体温调节机制','','','',NULL,'E',1,',8,,39,',1,''),(299,2,'影响血压的总外周阻力，不包括哪项：','吸烟','血管直径','平滑肌的自身调节','周围神经系统调节','中枢神经系统调节','','','',NULL,'A',1,',8,,39,',1,''),(300,2,'影响血压的三种主要因素为血容量，总外周阻力和什么。','血压粘度','心输出量','体重','吸烟','肾血管阻力','','','',NULL,'B',1,',8,,39,',1,''),(301,2,'2014年流调显示高血压的患病率、知晓率、治疗率、控制率分别为？','24.7%、30.2%、18.8%、6.1%','29.6%%、42.6%、34.1%、9.3%','30.2%、18.8%、24.7%、6.1%','24.7%、18.8%、30.2%、6.1%','','','','',NULL,'B',1,',8,,39,',1,''),(302,2,'随着年龄增长，高血压的发病率?','增加','85岁以后开始增加','保持不变','下降','85岁以后开始下降','','','',NULL,'A',1,',8,,39,',1,''),(303,2,'高血压中，原发性高血压所占的比例是:','0.7','0.8','0.85','0.9','0.95','','','',NULL,'E',1,',8,,39,',1,''),(304,2,'高血压流行的一般规律不包括：','高血压患病率与年龄呈正比','男女发病率一样','女性更年期前患病率低于男性，更年期后高于男性','有地理分布差异','与饮食习惯有关','','','',NULL,'B',1,',8,,39,',1,''),(305,2,'高血压病人的心脑血管事件多发生在何时?','午后','白天','凌晨','傍晚','','','','',NULL,'C',1,',8,,39,',1,''),(306,2,'正常人血压呈明显的昼夜波动，动态血压曲线呈现        —— 血压最低。','清晨起床','夜间','上午','下午','傍晚','','','',NULL,'B',1,',8,,39,',1,''),(307,3,'有关高血压的发病机制有以下哪几个？','交感神经系统活性亢进','肾性水钠储留','细胞膜离子转运异常','胰岛素抵抗','','','','',NULL,'ABCD',1,',8,,39,',1,''),(308,3,'RASS包括哪些环节？','肾素','血管紧张素I','血管紧张素II','AT1','AT2','','','',NULL,'ABCDE',1,',8,,39,',1,''),(309,3,'RAS与哪些病理改变相关：','高血压','动脉粥样硬化','心肌肥厚','血管中层硬化','心衰','','','',NULL,'ABCDE',1,',8,,39,',1,''),(310,3,'RAS系统的生理作用包括：','血压调控','水盐代谢','肾循环调节','以上都错','','','','',NULL,'AB',1,',8,,39,',1,''),(311,2,'高血压最早期和最重要的血管损害是?','微循环毛细血管稀疏','血管内皮功能障碍','毛细血管扭曲','静脉顺应性下降','','','','',NULL,'B',1,',8,,39,',1,''),(312,3,'高血压对心脏的影响包括：','左心室肥厚','心衰','冠心病','心梗','心律失常','','','',NULL,'ABCDE',1,',8,,39,',1,''),(313,2,'长期高血压主要引起?','左心房肥厚和扩大','右心室肥厚和扩大','左心室肥厚和扩大','右心房肥厚和扩大','','','','',NULL,'C',1,',8,,39,',1,''),(314,2,'糖尿病的治疗方法中，哪种方法能更好地降低糖尿病终点、糖尿病死亡率？','严格的血糖控制','严格的血压控制','严格的血脂控制','有效干扰蛋白尿','改善代谢综合症','','','',NULL,'B',1,',8,,39,',1,''),(315,2,'2007 AHA/ACC STEMI指南明确推荐可用于心梗后的住院治疗及长期二级预防有药物有：','ACEI','ARB','ACEI/ARB','β受体阻滞剂','CCB','','','',NULL,'C',1,',8,,39,',1,''),(316,3,'关于血压与心血管病危险，下列描述正确的是：','血压升高是中国人群脑卒中发病的最重要危险因素','血压升高是中国人群冠心病发病的危险因素','血压升高增加心力衰竭的危险','血压升高增加肾脏疾病的危险','血压升高与心血管疾病无关','','','',NULL,'ABCD',1,',8,,39,',1,''),(317,2,'中国人群脑卒中发病的最重要危险因素是：','冠心病','血压升高','动脉粥样硬化','血脂升高','血液粘度升高','','','',NULL,'B',1,',8,,39,',1,''),(318,2,'中国人群冠心病发病的危险因素是：','血糖升高','血压升高','血流缓慢','血脂升高','血液粘度升高','','','',NULL,'B',1,',8,,39,',1,''),(319,2,'增加心力衰竭和肾脏疾病的危险因素包括：','血糖升高','血压升高','冠心病','血脂升高','血液粘度升高','','','',NULL,'B',1,',8,,39,',1,''),(320,3,'为什么说微量蛋白尿（MAU）是心血管疾病的危险因素？','MAU代表肾小球内皮功能的受损','MAU是全身血管内皮细胞受损的一个重要标志','MAU是反映肾脏受血流动力学影响的敏感指标','MAU是反映血脂代谢异常的敏感指标','MAU是反映糖代谢异常的敏感指标','','','',NULL,'ABCDE',1,',8,,39,',1,''),(321,2,'“心血管事件链”的起始环节是        。','高血脂','高血糖','高血压','冠心病','心肌梗死','','','',NULL,'C',1,',8,,39,',1,''),(322,3,'“心血管事件链”中，除了控制好血压，还需要减少危险因素，这些危险因素包括：','高血脂','高血糖','卒中','心血管事件','慢性肾病','','','',NULL,'ABCDE',1,',8,,39,',1,''),(323,3,'高血压的临床表现以下哪些说法是正确的？','所有高血压患者都会有症状','21%的高血压患者无症状','会出现头晕、头痛、颈项板紧、疲劳、心悸等症状','血压有明显的昼夜波动，夜晚增高、晨起降低','','','','',NULL,'BC',1,',8,,39,',1,''),(324,2,'高血压的症状体征不包括：','血压升高','主动脉瓣第二心音亢进','左心室肥厚','二尖瓣狭窄','左心室肥厚 ','','','',NULL,'D',1,',8,,39,',1,''),(325,2,'大规模临床试验表明，SBP下降10-20mmHg或者DBP下降5-6mmHg,则3-5年脑卒中、心脑血管病的死亡率及冠心病事件、心力衰竭分别减少百分比?','38%;20%;16%；50%','50%;38%;20%;16%','16%’;20%;38%;50%','20%;38%;16%;50%','','','','',NULL,'A',1,',8,,39,',1,''),(326,2,'由于脑卒中的预防效果和降压程度呈线性相关，所以，当治疗能耐受时，应该将目标血压控制在           以下。','140/100mmHg','130/90mmHg','120/80mmHg','110/70mmHg','100/70mmHg','','','',NULL,'B',1,',8,,39,',1,''),(327,3,'原发性高血压的治疗目标','长期、有效控制血压在正常范围','预防(逆转)心、肾等靶器官的损害','减少心、脑血管并发症的病死率和病残率','','','','','',NULL,'ABC',1,',8,,39,',1,''),(328,3,'以下哪些人群是降压药治疗对象？','高血压二级或以上患者（血压大于等于160/90mmHg）','高血压合并糖尿病或者已经有心、脑、肾靶器官损害和合并症患者','凡血压持续增高、改善生活行为后血压仍未获得有效控制患者','凡是血压SBP大于140mmHg和（或）DBP大于90mmHg高血压患者','','','','',NULL,'ABC',1,',8,,39,',1,''),(329,3,'有关血压控制的目标值，以下哪些是不正确的？','一般主张血压控制的目标值应至少控制在小于140/90mmHg','糖尿病或者慢性肾病合并高血压患者血压控制目标值应小于130/80mmHg','老年收缩性高血压控制目标值SBP应介于140-150mmHg,DBP小于90mmHg,但不应低于65-70mmHg','所有患者目标血压都应控制在小于140/90mmHg','','','','',NULL,'ABC',1,',8,,39,',1,''),(330,2,'以下说法是否正确？降压治疗的方案除了有效控制血压水平以外和依从治疗外，还应顾及对糖代谢、脂代谢、尿酸代谢等的影响。','正确','不正确','','','','','','',NULL,'A',1,',8,,39,',1,''),(331,2,'中国高血压联盟指南中说明糖尿病患者的治疗目标是将血压降到','<150/90mmHg','<140/85mmHg','<140/80mmHg','<130/80mmHg','<120/80mmHg','','','',NULL,'D',1,',8,,39,',1,''),(332,3,'高血压的饮食治疗包括：','增加水果和蔬菜饮食量','降低饱和脂肪酸的摄入量','增加多元不饱和脂肪酸的摄入','增加单元不饱和脂肪酸鱼油的摄入','降低单元不饱和脂肪酸鱼油的摄入','','','',NULL,'ABCD',1,',8,,39,',1,''),(333,3,'合理的血压控制应该包括：','对24小时血压进行有效持续的控制','降低血压变异','阻遏清晨血压急骤上升','保持或恢复血压的正常昼夜节律','耐受性更好','','','',NULL,'ABCD',1,',8,,39,',1,''),(334,2,'老年患者的收缩压可降至：','150mmHg','140mmHg','130mmHg','120mmHg','110mmHg','','','',NULL,'A',1,',8,,39,',1,''),(335,2,'伴有糖尿病的高血压患者的血压应降低至：','150mmHg/100mmHg','140mmHg/90mmHg','130mmHg/90mmHg','130mmHg/80mmHg','120mmHg/80mmHg','','','',NULL,'D',1,',8,,39,',1,''),(336,3,'以下哪些是目前常用的降压药物？','利尿剂和CCB','ACEI和ARB','交感神经抑制剂和直接血管扩张剂','β受体阻滞剂','','','','',NULL,'ABD',1,',8,,39,',1,''),(337,3,'以下哪几项是钙通道阻滞剂的不良反应？','心率增快','面部潮红','下肢水肿','头痛','','','','',NULL,'ABCD',1,',8,,39,',1,''),(338,3,'以下哪几项是ACEI的不良反应？',' 面部潮红','刺激性干咳','头痛','血管性水肿','','','','',NULL,'BD',1,',8,,39,',1,''),(339,2,'ARB类药物的最大特点是不良反应狠少，不引起刺激性干咳，持续治疗的依从性高。','正确','不正确','','','','','','',NULL,'A',1,',8,,39,',1,''),(340,3,'以下哪几项是β受体阻滞剂的禁忌症？','急性心衰','支气管哮喘','房室传导阻滞','外周血管疾病','','','','',NULL,'ABCD',1,',8,,39,',1,''),(341,2,'血管紧张素对心血管系统所有的不利影响均是通过AT1受体介导，不包括哪项：','血管收缩','水/盐吸收','醛固酮的分泌','交感神经的激活','扩张血管','','','',NULL,'E',1,',8,,39,',1,''),(342,3,'降压药物的治疗评价原则包括：','降压效果确切','耐受性好','24小时平稳降压','改善肾功能','降低心血管并发症和死亡率','','','',NULL,'ABCDE',1,',8,,39,',1,''),(343,2,'下列哪种抗高血压药物对脂类和葡萄糖耐量无明显影响？','血管紧张素转换酶抑制剂','利尿剂','钙离子通道阻滞剂','血管紧张素II 受体阻滞剂','β-受体阻滞剂','','','',NULL,'D',1,',8,,39,',1,''),(344,2,'哪种抗血压药物最可能引起电解质紊乱？','ß受体阻滞剂','利尿剂','ARB','钙拮抗剂','α受体阻滞剂','','','',NULL,'B',1,',8,,39,',1,''),(345,2,'哪种抗血压药物耐受性最佳？','ß受体阻滞剂','利尿剂','ARB','钙拮抗剂','ACEI','','','',NULL,'C',1,',8,,39,',1,''),(346,2,'CCB的主要不良反应是','咳嗽','外周水肿','低血压','骨质疏松','肾功能减退','','','',NULL,'B',1,',8,,39,',1,''),(347,2,'ACEI的主要不良反应是','咳嗽','外周水肿','低血压','骨质疏松','肾功能减退','','','',NULL,'A',1,',8,,39,',1,''),(348,2,'ACEI的不良反应除咳嗽外还包括：','高血钾','肾功能减退','高血钾和急性肾功能衰竭','低血压','高血鉀和低血压','','','',NULL,'C',1,',8,,39,',1,''),(349,2,'低血压发生率较高的ARBs药物是         。','氯沙坦','坎地沙坦','缬沙坦','厄贝沙坦','替米沙坦','','','',NULL,'E',1,',8,,39,',1,''),(350,2,'血管紧张素转换酶抑制剂最常见的副作用为：','低血压','肾脏损伤','高钾血症','咳嗽','血管神经性水肿','','','',NULL,'D',1,',8,,39,',1,''),(351,2,'以下说法是否正确？联合治疗有利于血压在较短时间内达到目标值，并能减少不良反应。','正确','不正确','','','','','','',NULL,'A',1,',8,,39,',1,''),(352,2,'以下说法是否正确？三种降压药合理的联合治疗方案除有禁忌症外必须包含利尿剂。','正确','不正确','','','','','','',NULL,'A',1,',8,,39,',1,''),(353,3,'高危高血压包括：','1级高血压','三种以上危险因素的1-2级高血压','合并糖尿病的1-2级高血压','有并存临床情况的1-2级高血压','1-2种危险因素的2级高血压','','','',NULL,'BCD',1,',8,,39,',1,''),(354,2,'继发性高血压病因不包括哪项：','慢性肾小球肾炎','肾动脉狭窄','白大衣高血压','嗜铬细胞瘤','柯氏综合征','','','',NULL,'C',1,',8,,39,',1,''),(355,3,'继发性高血压包括：','肾性高血压','嗜铬细胞瘤','原发性醛固酮增多症','柯氏综合症','中枢性高血压','','','',NULL,'ABCD',1,',8,,39,',1,''),(356,3,'根据2004 年中国高血压防治指南，认为血压应降低到','没有糖尿病的患者血压应降低到<140/90mmHg','老年患者的SBP 可降至150mmHg 以下','伴发糖尿病的患者血压应降低到<130/80mmHg','没有糖尿病的患者血压应降低到<120/80mmHg','','','','',NULL,'ABC',1,',8,,39,',1,''),(357,2,'老年高血压患者的收缩压可降至：','150mmHg','140mmHg','130mmHg','120mmHg','','','','',NULL,'A',1,',8,,39,',1,''),(358,3,'2007 AHA/ACC STEMI指南明确推荐可用于心梗后的住院治疗及长期二级预防有药物有','ACEI','ARB','CCB','β受体阻滞剂','','','','',NULL,'AB',1,',8,,39,',1,''),(359,3,'脑卒中的二级预防主要通过那些方式实现？','降压治疗','抗凝治疗','降糖治疗','降脂治疗','','','','',NULL,'ABD',1,',8,,39,',1,''),(360,2,'ACE－I 的副作用如血管性水肿和干咳，可能与什么相关？','醛固酮','肾素','缓激肽','交感神经兴奋','','','','',NULL,'C',1,',8,,39,',1,''),(361,3,'目前已通过FDA 批准具有心衰适应症的有那些？','必洛斯','代文','美卡素','安博维','','','','',NULL,'AB',1,',8,,39,',1,''),(362,2,'当血管紧张素转换酶和噻嗪类利尿剂，钙拮抗剂合用时，其抗高血压作用_______二者作用之和','好于','等于','差于','','','','','',NULL,'A',1,',8,,39,',1,''),(363,2,'ACE-I能否与补钾剂和保钾利尿剂联用？','能','不能','','','','','','',NULL,'B',1,',8,,39,',1,''),(364,2,'CCB药物是痛过如何影响钙离子的运动达到降压的作用?','抑制钙离子从细胞经过钙通道进入血液','抑制钙离子从血浆经过钙通道进入细胞','影响钙离子在肾小管的重吸收','抑制肠道对钙离子的吸收','','','','',NULL,'B',1,',8,,39,',1,''),(365,2,'β-阻断剂能否用于哮喘的高血压病人？','能','不能','','','','','','',NULL,'B',1,',8,,39,',1,''),(366,3,'对于高血压的治疗原则','采用较小的有效剂量以获得可能的疗效而使不良反应最小，如效果不满意，可逐步增加剂量以获得最佳治疗效果','为了有效地防治靶器官损害，要求每天24 小时内血压稳定于目标范围内，最好使用一天一次给药且有持续24 小时作用的药物','为使降压效果增大而不增加不良反应，可以采用两种或多种降压药联合治疗。2 级以上高血压为达到目标血压常需降压药联合治疗','为使降压效果增大而不增加不良反应，避免采用两种或多种降压药联合治疗。2 级以上高血压为达到目标血压需降压药联合治疗','','','','',NULL,'ABC',1,',8,,39,',1,''),(367,3,'高血压病人通过检查和全面评估其总危险性后，判断病人属低危、中危、高危或很高危，采取不同的治疗策略，以下那些是正确的？','很高危和高危病人：如果患者病情允许，先观察患者的血压及其它危险因素数周，进一步了解病情，然后决定是否开始药物治疗，或由临床医师决定何时开始药物治疗','低危病人：观察患者数月，然后决定是否开始药物治疗。治疗方针既定，医生应为每例病人制定具体的全面治疗方案：监测病人的血压和各种危险因素','中危病人：如果患者病情允许，先观察患者的血压及其它危险因素数周，进一步了解病情，然后决定是否开始药物治疗，或由临床医师决定何时开始药物治疗','很高危和高危病人：无论经济条件如何，必须立刻开始对高血压及并存的危险因素和临床情况进行药物治疗','','','','',NULL,'BCD',1,',8,,39,',1,''),(368,2,'为达到降压效果，临床中经常会多种降压药物联合使用，以下那些联用是不合理的？','钙拮抗剂和 ACEI 或ARB','利尿剂和 ACEI 或ARB','钙拮抗剂和利尿剂','ACEI 和ARB','','','','',NULL,'D',1,',8,,39,',1,''),(369,3,'针对患有心血管疾病的高血压患者，降压药物的选择会有不同，以下那些说法是正确的？','脑卒中：有短暂性脑缺血发作或脑卒中历史（非急性期）者，不论血压是否增高均应进行降压治疗','糖尿病高血压：要求将血压降至130/80mmHg 以下，因此常须联合用药。噻嗪类利尿剂、β 阻滞剂、ACEI、ARB 和钙拮抗剂均对减少心血管事件有益；ACEI 对1 型糖尿病、ARB 对2 型糖尿病防治肾损害有益','心力衰竭：症状少者用ACEI 和β阻滞剂；症状多者可将ACEI、 β 阻滞剂、ARB 和醛固酮拮抗剂与袢利尿剂合用','冠心病：稳定性心绞痛首选β 阻滞剂或长效钙拮抗剂；急性冠脉综合征时选用β 阻滞剂和ACEI；心肌梗赛病人用ACEI、β 阻滞剂和醛固酮拮抗剂','','','','',NULL,'ABCD',1,',8,,39,',1,''),(370,2,'以下说法是否正确？伴有相关症状的心功能不全称之为心力衰竭，而有心功能不全者、不一定全是心力衰竭。','正确','不正确','','','','','','',NULL,'A',1,',8,,39,',1,''),(371,2,'为什么合理干预高血压可以有效预防和治疗心衰？','高血压是心衰的始动因素','心衰是高血压的必然结果','高血压可导致心衰','低血压可以降低心衰发生','高血压与心衰没有任何关联','','','',NULL,'A',1,',8,,39,',1,''),(372,2,'心力衰竭的诱发因素不包括：','高血压','高血脂','高血糖','精神紧张','剧烈运动','','','',NULL,'D',1,',8,,39,',1,''),(373,2,'         是高血压引起心力衰竭的始动因素。','左室肥厚','收缩压过高','脉压差过大','心肌重构','舒张压过高 ','','','',NULL,'A',1,',8,,39,',1,''),(374,2,'心力衰竭的症状以什么的表现为主。','体循环静脉淤血','体循环动脉淤血','肺循环静脉淤血','肺循环动脉淤血','以上均是','','','',NULL,'A',1,',8,,39,',1,''),(375,3,'根据杰瑟普博士的心衰分级治疗理论，是将心衰发生、发展的过程，分为哪些阶段？','无任何危险因素','具有高血压等心衰的高危因素','已经出现心脏的结构性改变，如心脏肥大等','已经出现心衰的临床表现','严重的、难治性的心衰','','','',NULL,'BCDE',1,',8,,39,',1,''),(376,2,'心力衰竭的NYHA分级中，Ⅲ级表现为','患者有心脏病，但日常活动量不受限制，一般体力活动不引起过度疲劳、心悸、气喘或心绞痛','心脏病患者的体力活动轻度受限制。休息时无自觉症状，一般体力活动引起过度疲劳、心悸、气喘或心绞痛','患者有心脏病，以致体力活动明显受限制。休息时无症状，但小于一般体力活动即可引起过度疲劳、心悸、气喘或心绞痛','心脏病患者不能从事任何体力活动，休息状态下也出现心衰症状，体力活动后加重','呼吸困难','','','',NULL,'C',1,',8,,39,',1,''),(377,3,'以下哪些是急性左心衰竭的临床表现？','程度不同的呼吸困难','咳嗽、咳痰、咯血','乏力、疲倦、头晕心慌','消化道症状、身体最低部位出现水肿','','','','',NULL,'ABC',1,',8,,39,',1,''),(378,3,'关于ARBs类药物降低心衰发生率的描述正确的是：','对于高血压患者，如果存在高度危险因素，ARB类药物仅可以强效降压，并不可以控制心衰的高危因素','对于高血压患者，ARB类药物可以强效降压，控制心衰的高危因素','对于已经出现心脏肥大的患者，ARB类药物可显着减轻左心室肥厚，改善左心室重构，使高危患者初发心衰风险降低37%','对于已经出现心衰的临床表现的患者，ARB类药物可使死亡和并发症发生风险降低13.2%','对于严重的、难治性的心衰的高血压患者，ARBs类药物没有任何作用','','','',NULL,'BCD',1,',8,,39,',1,''),(379,2,'动脉硬化闭塞症的症状不包括','主动脉粥样硬化','脑动脉粥样硬化','肾动脉粥样硬化','四肢动脉粥样硬化','硬皮病','','','',NULL,'E',1,',8,,39,',1,''),(380,2,'动脉硬化性心血管病的诱因不包括','低血糖','高血脂','高血压','糖尿病','肥胖','','','',NULL,'A',1,',8,,39,',1,''),(381,2,'急性冠脉疾病的诱因不包括','甲状腺亢进','高血脂','高血压','糖尿病','肥胖','','','',NULL,'A',1,',8,,39,',1,''),(382,2,'动脉硬化性心血管病的治疗不包括：','饮食治疗','降脂药物','溶栓治疗','抗血小板药物','介入治疗','','','',NULL,'C',1,',8,,39,',1,''),(383,2,'心绞痛的症状，不包括','阵发性的前胸压榨性疼痛感觉','劳动或情绪激动时发作','男性多见','女性多见','急性循环衰竭等为常见的诱因','','','',NULL,'D',1,',8,,39,',1,''),(384,3,'心绞痛的治疗包括','硝酸酯类药物','α受体阻滞剂','ß受体阻滞剂','钙通道阻滞剂','利尿剂','','','',NULL,'ACD',1,',8,,39,',1,''),(385,3,'心绞痛的常规治疗方法包括','ARB','ACEI','CCB','B受体阻滞剂','以上均不是','','','',NULL,'CD',1,',8,,39,',1,''),(386,2,'不考虑禁忌症的情况下，高血压合并心绞痛的一线用药：','β-受体阻滞剂','非甾体抗炎药','噻嗪类利尿剂','钙拮抗剂','α受体阻断剂','','','',NULL,'A',1,',8,,39,',1,''),(387,2,'心肌梗死的诱发因素不包括','过重的体力劳动','腹泻','过度运动','精神紧张','重度创伤','','','',NULL,'B',1,',8,,39,',1,''),(388,2,'心肌梗死的症状不包括','突然发作剧烈持久的胸骨后压榨性疼痛','心绞痛，休息和含硝酸甘油可缓解','急性心力衰竭','心律失常','呼吸困难','','','',NULL,'B',1,',8,,39,',1,''),(389,2,'心肌梗死的治疗不包括','吸氧','降血脂药物','镇静止痛药物','调整血容量','溶栓治疗','','','',NULL,'B',1,',8,,39,',1,''),(390,2,'心肌梗死的常规治疗方法包括','ARB','ACEI','CCB','B受体阻滞剂','以上均不是','','','',NULL,'E',1,',8,,39,',1,''),(391,2,'心律失常的诱因不包括','冠状动脉粥样硬化性心脏病','心肌病','心力衰竭或急性心肌梗塞','心肌炎和风湿性心脏病','发热','','','',NULL,'E',1,',8,,39,',1,''),(392,3,'心律失常的常规治疗方法包括','ARB','ACEI','CCB','B受体阻滞剂','以上均不是','','','',NULL,'CD',1,',8,,39,',1,''),(393,2,'美国指南（JNC-7）推荐伴有糖尿病和慢性肾脏疾病的患者目标血压应为多少？','140/90mmHg','130/85mmHg','130/80mmHg','160/100mmHg','','','','',NULL,'C',1,',8,,39,',1,''),(394,3,'给心脏自身供给氧和营养的血管就是冠状动脉，主要分为？','右冠状动脉','前降支','回旋支','左冠状动脉','','','','',NULL,'ABCD',1,',8,,39,',1,''),(395,2,'心梗发生以后，既往和继发的血压状态影响患者的预后。既往有高血压病史的患者，急性心梗后一年内总死亡率为多少？而既往血压正常的患者急性心梗后一年内死亡率为多少？','25%，35%','35%，25%','35%，45%','45%，35%','','','','',NULL,'B',1,',8,,39,',1,''),(396,2,'心脏的收缩／舒张是通过自身发出的电刺激完成的。这种电刺激是右心房和上腔静脉之间存在的什么组织产生的动作电位所带来的','房室结','主动脉窦','窦房结','心房结','','','','',NULL,'C',1,',8,,39,',1,''),(397,3,'心绞痛根据发生机制分为：','器质性心绞痛','冠状动脉痉挛性心绞痛','冠状动脉血栓性心绞痛','劳力型心绞痛','','','','',NULL,'ABC',1,',8,,39,',1,''),(398,2,'所有心脏病的终末表现为：','慢性心功能不全','心绞痛','卒中','心梗','','','','',NULL,'A',1,',8,,39,',1,''),(399,2,'脑部负责循环中枢，呼吸中枢的的组织是：','大脑','小脑','脑干','脊柱','','','','',NULL,'C',1,',8,,39,',1,''),(400,2,'将血液送入脑的动脉包括左右的颈内动脉和椎动脉。左右椎动脉构成的基底动脉和左右颈内动脉互相连接，构成大脑动脉环，又称为：','Wisper动脉环','Willis动脉环','triple动脉环','circuit动脉环','','','','',NULL,'B',1,',8,,39,',1,''),(401,2,'心源性脑梗塞的危险因子是？','心律不齐','高血压','高血糖','高血脂','','','','',NULL,'A',1,',8,,39,',1,''),(402,2,'心力衰竭的简称是：','HF','MI','HI','CVD','','','','',NULL,'A',1,',8,,39,',1,''),(403,2,'心功能不全的患者导致心力衰竭，那么是不是所有的心功能不全的患者都是心力衰竭？','是的','不是','','','','','','',NULL,'B',1,',8,,39,',1,''),(404,2,'左心衰指左心室代偿功能不全而发生的心力衰竭，临床上较为常见，以______为特征','肺循环淤血','体循环淤血','肾循环淤血','脑循环淤血','','','','',NULL,'A',1,',8,,39,',1,''),(405,2,'单纯的右心衰竭主要见于肺源性心脏病及某些先天性心脏病，以______为主要表现','肺循环淤血','体循环淤血','肾循环淤血','脑循环淤血','','','','',NULL,'B',1,',8,,39,',1,''),(406,3,'急性心衰是由于什么原因引起？系因或','突然的血糖升高','急性的严重心肌损害','突然加重的负荷','急性胃肠炎','','','','',NULL,'BC',1,',8,,39,',1,''),(407,2,'通常LVEF在______以下即诊断为收缩功能障碍(心功能不全)','0.3','0.4','0.5','0.6','','','','',NULL,'B',1,',8,,39,',1,''),(408,3,'欧洲心血管病学会心律失常工作组（WGA-ESC）和北美起搏和电生理学会（NASPE） 联合组织了一个研究小组建议采用临床分类方法， 将房颤分:','初发房颤','阵发性房颤','持续性房颤','永久性房颤','','','','',NULL,'ABCD',1,',8,,39,',1,''),(409,2,'房颤引起的主要栓塞性事件','心梗','脑栓塞','肺梗阻','肾衰','','','','',NULL,'B',1,',8,,39,',1,''),(410,2,'房颤时控制心室率的一线药物是：','β-受体阻滞剂','ＣＣＢ','ＡＲＢ','降压药','','','','',NULL,'A',1,',8,,39,',1,''),(411,3,'肾小管主要分为哪三个部分：','远曲小管','近曲小管','髓袢','肾小球','','','','',NULL,'ABC',1,',8,,39,',1,''),(412,2,'葡萄糖、氨基酸和一些小分子蛋白在肾小管的那个部分几乎完全被重吸收','远曲小管','近曲小管','髓袢','肾小球','','','','',NULL,'C',1,',8,,39,',1,''),(413,2,'钠离子和氯离子的重吸收过程主要发生肾小管的那个部分？','远曲小管','近曲小管','髓袢','肾小球','','','','',NULL,'C',1,',8,,39,',1,''),(414,3,'肾脏的主要功能包括：','过滤血液生成尿液','过滤血液所得的废料和有害物质','调节血压','调节血液（红细胞）的生成、活化钙（Ca）的吸收所必需的维生素D等','','','','',NULL,'ABCD',1,',8,,39,',1,''),(415,2,'远端肾小管中存在什么的感知肾小管中Na、Cl等尿液成分减少，使得肾小球旁器就会向血液中释放肾素','致密斑','离子感受器','尿液感受器','静脉窦','','','','',NULL,'A',1,',8,,39,',1,''),(416,2,'血管紧张素原是那个器官合成的？','肾','心脏','肺脏','肝脏','','','','',NULL,'D',1,',8,,39,',1,''),(417,3,'慢性肾病（CKD：Chronic Kidney Disease）的诊断主要包括以下几点：','尿异常、影像诊断、血液、病理检查证实存在肾损伤','GFR＜60 mL/min/1.73m2','以上两种的任意一种或两种持续3个月以上','蛋白尿的存在尤为重要','','','','',NULL,'ABCD',1,',8,,39,',1,''),(418,2,'血管紧张素转化酶主要由那个器官分泌？','肾','心脏','肺脏','肝脏','','','','',NULL,'C',1,',8,,39,',1,''),(419,2,'动脉血压的英文缩写是：','BBP','VBP','ABP','BAP','','','','',NULL,'C',1,',8,,39,',1,''),(420,2,'ABPM是以下哪一个词汇的英文缩写：','静息时血压监测','动态血压监测','动态心电图','动态心功能监测','','','','',NULL,'B',1,',8,,39,',1,''),(421,2,'以下哪个选项是动态心电图的英文缩写？','ACEG','AGEC','AECG','AEGC','','','','',NULL,'C',1,',8,,39,',1,''),(422,2,'血管紧张素转化酶的英文缩写是？','ACIE','AEIC','ACE','ACEI','','','','',NULL,'C',1,',8,,39,',1,''),(423,2,'以下哪个选项是心血管系统的英文缩写?','CVS','VCS','SCV','VSC','','','','',NULL,'A',1,',8,,39,',1,''),(424,2,'肾素-血管紧张素-醛固酮系统的英文缩写是?','RAAA','RASS','RAS','RAAS','','','','',NULL,'D',1,',8,,39,',1,''),(425,2,'AHA是哪个学术组织的英文缩写？','美国高血压协会','美国心脏协会','美国肾脏病协会','美国心血管协会','','','','',NULL,'B',1,',8,,39,',1,''),(426,2,'NYHA是哪个学术组织的英文简写？','纽约高血压协会','纽约肾脏病协会','纽约心血管协会','纽约心脏协会','','','','',NULL,'D',1,',8,,39,',1,''),(427,2,'美国成人高血压管理指南的英文缩写是哪个？','JNC','ABG','RAS','AHA','','','','',NULL,'A',1,',8,,39,',1,''),(428,2,'PCI治疗是指','冠脉搭桥手术','经皮冠脉介入治疗','射频消融手术','生活方式干预治疗','','','','',NULL,'B',1,',8,,39,',1,''),(429,2,'心血管疾病的简称','CVS','CVD','HBD','HBS','','','','',NULL,'B',1,',8,,39,',1,''),(430,2,'DBP是指','舒张压','收缩压','平均血压','','','','','',NULL,'A',1,',8,,39,',1,''),(431,2,'纽约心脏学会的简写?','NYHA','NYAH','NYAHA','NAHA','','','','',NULL,'A',1,',11,,10,,39,',1,''),(432,2,'欧洲药品管理局的简写?','EMA','FDA','SFDA','ADA','','','','',NULL,'A',1,',11,,10,,39,',1,''),(433,2,'美国食品药品管理局的简写?','EMA','FDA','SFDA','ADA','','','','',NULL,'B',1,',11,,10,,39,',1,''),(434,2,'中国食品药品监督管理局的简写?','EMA','FDA','SFDA','ADA','','','','',NULL,'C',1,',11,,10,,39,',1,''),(435,2,'肾小球滤过率的简写是：','GFR','FPG','IPG','PPG','','','','',NULL,'A',1,',8,,39,',1,''),(436,2,'终末期肾病的简写是：','MI','ESRD','T2D','HF','','','','',NULL,'B',1,',8,,39,',1,''),(437,2,'ARB是指哪一类降压药的简称？','钙离子拮抗剂','血管紧张素转换酶抑制剂','血管紧张素 II 受体拮抗剂','血管紧张素受体 1','','','','',NULL,'C',1,',8,,39,',1,''),(438,2,'体重指数（BMI）正常值是','<20','20~25','>30','22','','','','',NULL,'B',1,',11,,10,,39,',1,''),(439,2,'CHF是那种疾病的简写','舒张期心力衰竭','充血性心力衰竭','不稳定心绞痛','冠心病','','','','',NULL,'B',1,',8,,39,',1,''),(440,2,'关于糖尿病中常用的 FPG 的描述，错误的是：','空腹血糖','空腹血糖受损','评估受试者在空腹8-12小时后的血糖水平','用于诊断糖尿病前期和糖尿病','','','','',NULL,'B',1,',11,,10,,39,',1,''),(441,2,'正常人的 FPG 值为：','3.6~6.2mmol/L','3.6~6.1mmol/L','3.6~6.0mmol/L','3.6~7.0mmol/L','','','','',NULL,'B',1,',11,,10,,39,',1,''),(442,2,'空腹血糖的简写为?','FPG','PPG','2hPG','FFG','','','','',NULL,'A',1,',11,,10,,39,',1,''),(443,2,'糖尿病中常用的 PPG 指的是：','餐后血糖受损','空腹血糖受损','空腹血糖，禁食8~12小时后测得的血糖值','餐后血糖，进食后1~2小时测得的血糖值','','','','',NULL,'D',1,',11,,10,,39,',1,''),(444,2,'糖尿病中常用的PPG的值，描述正确的是：','7.9mmol/L≤餐后1h血糖 ＜11.1mmol/L为糖耐量受损，餐后2h血糖 ≥11.1mmol/L考虑糖尿病','7.8mmol/L<餐后2h血糖 ＜11.1mmol/L为糖耐量受损，餐后2h血糖 ≥11.1mmol/L考虑糖尿病','7.9mmol/L≤餐后1h血糖 ＜11.1mmol/L为糖耐量受损，餐后2h血糖 >11.1mmol/L考虑糖尿病','7.8mmol/L≤餐后2h血糖 ＜11.1mmol/L为糖耐量受损，餐后2h血糖 ≥11.1mmol/L考虑糖尿病','','','','',NULL,'D',1,',11,,10,,39,',1,''),(445,2,'餐后血糖（PPG）在什么范围即可认定为血糖受损?','<7.8mmol/L','7.8mmol/L≤ OGTT 2h＜11.1mmol/L','≥11.1 mmol/L','连续两次≥11.1 mmol/L','','','','',NULL,'B',1,',11,,10,,39,',1,''),(446,2,'餐后血糖的简写为?','FPG','PPG','2hPG','FFG','','','','',NULL,'B',1,',11,,10,,39,',1,''),(447,2,'餐后两小时血糖的简写为?','PPG','FPG','2hPG','FFG','','','','',NULL,'C',1,',11,,10,,39,',1,''),(448,2,'正常人的 HbA1C 值应该是：','3~7%','4~7%','4-6%','5~7%','','','','',NULL,'C',1,',11,,10,,39,',1,''),(449,3,'下列哪些是关于糖化血色蛋白HbA1C的正确描述','血糖升高时引起携带氧气的血红素之糖化作用，形成HbA1c。','HbA1c形成后就会存在红血球内，一直到红血球被破坏。','HbA1c约可反映病人过去2~3月内的血糖变化情形。','HbA1c反应的是血糖的平均数值，看不出血糖波动的幅度。','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(450,2,'糖化血红蛋白（HbA1C）最重要的作用是通过观测到的HbA1C水平可以了解患者120天的内的血糖控制情况，是糖尿病患者非常重要的控制指标。','是','否','','','','','','',NULL,'A',1,',11,,10,,39,',1,''),(451,2,'我国糖尿病指南2010版建议HbA1C的控制水平是','<6.5%','6.0~7.0%','<7.0%','>7.0%','','','','',NULL,'C',1,',11,,10,,39,',1,''),(452,2,'关于 IFG 的描述，错误的是：','空腹血糖受损','葡萄糖耐量受损','是糖尿病前期的指标','该水平高于正常值不足以以诊断为糖尿病','','','','',NULL,'B',1,',11,,10,,39,',1,''),(453,2,'血糖值在什么范围即可认定为空腹血糖受损','<3.6mmol/L','3.6~6.1 mmol/L','6.1-6.9 mmol/L','>7.0 mmol/L','','','','',NULL,'C',1,',11,,10,,39,',1,''),(454,2,'关于 IGT 的描述，正确的是','空腹血糖受损','葡萄糖耐量受损','空腹血糖','餐后血糖','','','','',NULL,'B',1,',11,,10,,39,',1,''),(455,2,'关于糖尿病中常用的 IGT 描述错误的是','服糖或者进食后2小时血糖值在6.1~7mmol/L之间','服糖或者进食后2小时血糖值在7.8~11.1mmol/L之间','是糖尿病前期的指标','该水平高于正常值不足以以诊断为糖尿病','','','','',NULL,'A',1,',11,,10,,39,',1,''),(456,2,'葡萄糖耐量受损的简写为?','IGT','IFG','IR','PPG','','','','',NULL,'A',1,',11,,10,,39,',1,''),(457,2,'无论是IGT还是IFG都是可以逆转的。','是','否','','','','','','',NULL,'A',1,',11,,10,,39,',1,''),(458,2,'糖尿病中常用的 OGTT 的中文解释正确的是','口服治疗糖尿病药物','口服治疗2型糖尿病药物','口服糖耐量实验','口服糖尿病药物临床实验','','','','',NULL,'C',1,',11,,10,,39,',1,''),(459,2,'糖尿病中 OGTT 的要求，正确的是：','餐后，口服75g葡萄糖','餐后，口服100g葡萄糖','空腹8~12小时，口服100g葡萄糖','空腹8~12小时，口服75g葡萄糖','','','','',NULL,'D',1,',11,,10,,39,',1,''),(460,2,'糖尿病中 OGTT 的标准，正确的是：','2小时后测血糖，7.9mmol/L≤ OGTT 2h血糖 ＜11.1mmol/L为糖耐量受损，≥11.1mmol/L考虑糖尿病','3小时后测血糖，7.8mmol/L≤ OGTT 2h血糖 ＜11.1mmol/L为糖耐量受损，≥11.1mmol/L考虑糖尿病',' 2小时后测血糖，7.8mmol/L≤ OGTT 2h血糖 ＜11.1mmol/L为糖耐量受损，≥11.1mmol/L考虑糖尿病','3小时后测血糖，7.9mmol/L≤ OGTT 2h血糖 ＜11.1mmol/L为糖耐量受损，≥11.1mmol/L考虑糖尿病','','','','',NULL,'C',1,',11,,10,,39,',1,''),(461,2,'口服葡萄糖耐量试验（OGTT）2h后什么范围为糖耐量受损?','<7.8mmol/L','7.8mmol/L≤ OGTT 2h＜11.1mmol/L','≥11.1 mmol/L','连续两次≥11.1 mmol/L','','','','',NULL,'B',1,',11,,10,,39,',1,''),(462,2,'胰岛素抵抗的简写为?','MI','DKA','CHF','IR','','','','',NULL,'D',1,',11,,10,,39,',1,''),(463,2,'糖尿病中常用的 BMI，指的是：','腰臀比','踝肱指数','体重指数','血糖指数','','','','',NULL,'C',1,',11,,10,,39,',1,''),(464,2,'糖尿病中常用的简称，以下中文解释错误的是','T1D-1型糖尿病','T2D-2型糖尿病','DM-糖尿病','IR-胰岛素敏感','','','','',NULL,'D',1,',11,,10,,39,',1,''),(465,2,'血管清道夫指的是哪种蛋白?','HDL','LDL','TG','TC','','','','',NULL,'A',1,',11,,10,,39,',1,''),(466,2,'导致动脉粥样硬化，从而引发冠心病的是哪种蛋白?','HDL','LDL','TC','TG','','','','',NULL,'B',1,',11,,10,,39,',1,''),(467,2,'以下糖尿病中常用的简称中，中文解释错误的是：','DPP-4-二肽基肽酶4','GLP-1-胰高血糖素样肽-1','AGE-高度糖基化终产物','ATP-二磷酸腺苷','','','','',NULL,'D',1,',11,,10,,39,',1,''),(468,2,'下列关于GLP-1的叙述哪项是错误的?  ','GLP-1增加了胰高血糖素的分泌','GLP-1促进了餐后饮食中脂质的清除 ','GLP-1刺激B细胞分泌胰岛素 ','GLP-1强烈抑制了上消化道的分泌和运动','','','','',NULL,'A',1,',11,,10,,39,',1,''),(469,2,'OAD中文解释正确的是：','OAD-注射降糖药','OAD-胰岛素','OAD-口服降糖药','OAD-促泌剂','','','','',NULL,'C',1,',11,,10,,39,',1,''),(470,2,'糖尿病中常说的 TZD，以下说法错误的是：','TZD是噻唑烷二酮类药物的简称','是治疗1型糖尿病的一类口服降糖药','主要作用是改善细胞对胰岛素的敏感性','常见药物包括包括吡格列酮（Actos®）和罗格列酮（文迪雅®）','','','','',NULL,'B',1,',11,,10,,39,',1,''),(471,2,'关于糖尿病的类型，以下错误的是：','T1D','T2D','脆性糖尿病','妊娠糖尿病','','','','',NULL,'C',1,',11,,10,,39,',1,''),(472,2,'细胞内各种化合物都有其特殊的功能。在动物体内作为储能物质的主要是','乳糖和蔗糖','蛋白质和核酸','葡萄糖和ATP','脂肪和糖原','','','','',NULL,'D',1,',11,,10,,39,',1,''),(473,2,'蛋白质在身体内起到很多作用，不包括','结构性','调节性','储存性','运输性','','','','',NULL,'C',1,',11,,10,,39,',1,''),(474,2,'不能被人体吸收的营养物质是','单糖','多糖','麦芽糖','纤维素','','','','',NULL,'D',1,',11,,10,,39,',1,''),(475,2,'由碳水化合物分解产生的简单糖为','氨基酸','甘油','单糖','肽','','','','',NULL,'C',1,',11,,10,,39,',1,''),(476,2,'哪一项不是由葡萄糖组成的多糖?','糖原','淀粉','麦芽糖','纤维素','','','','',NULL,'C',1,',11,,10,,39,',1,''),(477,2,'单糖和双糖被称为简单碳水化合物，他们含有1个或2个糖分子，下列不是单糖的是','葡萄糖','果糖','半乳糖','麦芽糖','','','','',NULL,'D',1,',11,,10,,39,',1,''),(478,2,'双糖是由2种单糖结合在一起形成的，下列不是双糖的是','蔗糖','核糖','乳糖','麦芽糖','','','','',NULL,'B',1,',11,,10,,39,',1,''),(479,2,'双糖是由2种单糖结合在一起形成的，下列组成表述错误的是','蔗糖（葡萄糖和果糖）','乳糖（两个半乳糖）','麦芽糖（葡萄糖和葡萄糖）','乳糖（葡萄糖和半乳糖）','','','','',NULL,'B',1,',11,,10,,39,',1,''),(480,2,'下列哪个是附属消化器官','阑尾','肝脏','口腔','咽','','','','',NULL,'B',1,',11,,10,,39,',1,''),(481,2,'大部分消化和营养吸收发生在：','大肠','口腔','小肠','胃脏','','','','',NULL,'C',1,',11,,10,,39,',1,''),(482,2,'消化系统由两组器官组成包括消化道和消化器官，在整个系统中对糖尿病患者最重要的部位是?','胃','口腔','大肠','小肠','','','','',NULL,'D',1,',11,,10,,39,',1,''),(483,2,'淀粉的消化开始于','口腔','胃脏','小肠','大肠','','','','',NULL,'A',1,',11,,10,,39,',1,''),(484,2,'胃脏中含有丰富的消化酶，具有很重要的作用，胃脏不具有的作用是?','杀灭食物中的微生物','活化一种酶，开始蛋白质的分解','助于维生素B12的吸收','产生适合消化的PH值','','','','',NULL,'D',1,',11,,10,,39,',1,''),(485,2,'肝脏在消化过程中最主要的最要的作用是?','分泌胆汁','停止胃蛋白酶的作用','吸收大约90%的营养和水分','消化碳水化合物','','','','',NULL,'A',1,',11,,10,,39,',1,''),(486,2,'关于胰腺的描述，错误的是：','分为内分泌腺和外分泌腺','有内、外分泌功能的副消化器官','胰液外分泌腺由大小不同的细胞团──胰岛所组成','分泌胰岛素和胰高血糖素等激素，调节糖代谢','','','','',NULL,'C',1,',11,,10,,39,',1,''),(487,2,'胰岛素分泌疾病可能是由于下列哪种细胞类型异常所致？','α细胞','β细胞','δ细胞','γ细胞','','','','',NULL,'B',1,',11,,10,,39,',1,''),(488,3,'关于胰脏的描述正确的是','属于内分泌系统，也属于外分泌中的消化系统。','细胞负责分泌胰岛素。','细胞负责分泌升糖素。','副交感神经刺激胰岛素的释放，交感神经则抑制胰岛素的释放。','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(489,2,'胰腺是由上皮细胞构成的。','是','否','','','','','','',NULL,'A',1,',11,,10,,39,',1,''),(490,2,'胰腺包括外分泌和内分泌功能，下列不是胰腺外分泌的是?','汗液','唾液','消化酶','淀粉酶','','','','',NULL,'D',1,',11,,10,,39,',1,''),(491,2,'胰腺外分泌胰液，胰液中包含碳酸氢钠用来中和胃酸，同时还含有很多的消化酶，不是胰液中包含的消化酶是?','淀粉酶','肽酶','脂肪酶','胆汁','','','','',NULL,'D',1,',11,,10,,39,',1,''),(492,2,'胰岛只占有1%的胰腺，主要由4种类型的细胞组成，胰高血糖素是由哪种细胞分泌?','α细胞','β细胞','F细胞','δ细胞','','','','',NULL,'A',1,',11,,10,,39,',1,''),(493,2,'胰岛只占有1%的胰腺，主要由4种类型的细胞组成，胰岛素是由哪种细胞分泌?','α细胞','β细胞','F细胞','δ细胞','','','','',NULL,'B',1,',11,,10,,39,',1,''),(494,2,'胰岛只占有1%的胰腺，主要由4种类型的细胞组成，生长抑素是由哪种细胞分泌?','α细胞','β细胞','F细胞','δ细胞','','','','',NULL,'D',1,',11,,10,,39,',1,''),(495,2,'胰岛只占有1%的胰腺，主要由4种类型的细胞组成，胰多肽是由哪种细胞分泌?','α细胞','β细胞','F细胞','δ细胞','','','','',NULL,'C',1,',11,,10,,39,',1,''),(496,2,'所有下列功能都是由肝脏执行的，除了','胆汁产生','胰高血糖素分泌','糖原分解','脂蛋白合成','','','','',NULL,'B',1,',11,,10,,39,',1,''),(497,2,'下列哪个器官帮助身体把血糖维持在一个正常水平?','胃','小肠','肝脏','大肠','','','','',NULL,'C',1,',11,,10,,39,',1,''),(498,2,'人体的第二大器官是?','肝脏','皮肤','胃脏','大肠','','','','',NULL,'A',1,',11,,10,,39,',1,''),(499,2,'当葡萄糖可用时，机体优先用于合成:','氨基酸','ATP','糖原','甘油三酯','','','','',NULL,'B',1,',11,,10,,39,',1,''),(500,2,'葡萄糖是身体首选的燃料来源，当需要即刻能量时，葡萄糖就被分解释放活细胞中主要的能量转运分子，释放的是?','三磷酸腺苷（ATP）','二磷酸腺苷（ADP）','一磷酸腺苷','酸腺苷','','','','',NULL,'A',1,',11,,10,,39,',1,''),(501,3,'脂蛋白的由哪些分子构成?','蛋白','磷脂','胆固醇','甘油三脂','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(502,2,'脂蛋白主要根据它们的密度进行定性和命名，负责将身体细胞和血液中多余的总胆固醇移除，并将之转运至肝脏进行清除的是?','乳糜颗粒','VLDLs','LDLs','HDLs','','','','',NULL,'D',1,',11,,10,,39,',1,''),(503,2,'脂蛋白主要根据它们的密度进行定性和命名，负责将饮食中的脂质转运至脂肪组织来进行贮存的是?','乳糜颗粒','VLDLs','LDLs','HDLs','','','','',NULL,'A',1,',11,,10,,39,',1,''),(504,2,'脂蛋白主要根据它们的密度进行定性和命名，负责将肝细胞中的合成的甘油三酯转运至脂肪细胞中贮存的是?','乳糜颗粒','VLDLs','LDLs','HDLs','','','','',NULL,'B',1,',11,,10,,39,',1,''),(505,2,'脂蛋白主要根据它们的密度进行定性和命名，携带血液中大概75%的总胆固醇，并将其转运至身体内各处的细胞，用于修复细胞膜和合成类固醇激素和胆盐的是?','乳糜颗粒','VLDLs','LDLs','HDLs','','','','',NULL,'C',1,',11,,10,,39,',1,''),(506,2,'胰岛素促进了所有下列活动，除了：','将葡萄糖转化成糖原 ','增加糖原分解作用 ','移动氨基酸至细胞内 ','抑制糖异生作用','','','','',NULL,'B',1,',11,,10,,39,',1,''),(507,3,'关于胰岛素的描述正确的是','可帮助葡萄糖进入身体的肌肉脂肪细胞利用。','经由细胞膜上的胰岛素受体传递讯息给细胞。','可影响离子进出细胞，维护电解质的平衡。','可透过调控基因作用来影响蛋白质的表现，刺激细胞生长与分化。','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(508,2,'胰岛素是胰岛的那种细胞分泌的?','α细胞','β细胞','δ细胞','F细胞','','','','',NULL,'B',1,',11,,10,,39,',1,''),(509,2,'胰岛素的作用是?','升高血糖','降低血糖','对血糖无影响','既能升高也能降低','','','','',NULL,'B',1,',11,,10,,39,',1,''),(510,2,'胰岛素是由胰岛β细胞分泌，主要作用是促进所摄入营养的储存和利用，下列不是胰岛素作用靶点的是？','肌肉','骨骼','肝脏','脂肪组织','','','','',NULL,'B',1,',11,,10,,39,',1,''),(511,2,'胰岛素作用于肌肉，肝脏，和脂肪组织，不是胰岛素的作用的是?','加速葡萄糖进入到细胞中，尤其是骨骼肌纤维','促进合成反应，糖原生成，脂肪生成，蛋白质合成','减缓分解反应，糖原分解和糖异生','提高体内血糖含量，以维持餐后血糖浓度','','','','',NULL,'D',1,',11,,10,,39,',1,''),(512,2,'与人体胰岛素结构最接近的动物是?','牛','羊','猪','马','','','','',NULL,'C',1,',11,,10,,39,',1,''),(513,2,'胰岛素的结构是?','2个肽链组成的51个氨基酸胰岛素蛋白','1个肽链组成的51个氨基酸胰岛素蛋白','2个肽链组成的52个氨基酸胰岛素蛋白','1个肽链组成的54个氨基酸胰岛素蛋白','','','','',NULL,'A',1,',11,,10,,39,',1,''),(514,2,'胰岛素分泌最重要的触发器是?','高血糖症','低血糖症','胰高血糖素','乙酰胆碱','','','','',NULL,'A',1,',11,,10,,39,',1,''),(515,2,'人体自身分泌胰岛素的半衰期为:','5-10分钟','10-20分钟','4-5分钟','30分钟','','','','',NULL,'C',1,',11,,10,,39,',1,''),(516,2,'胰岛素的清除主要在哪些部位？','肝脏和脂肪组织','肝脏和肾脏','肾脏和骨骼','肾脏和肌肉','','','','',NULL,'B',1,',11,,10,,39,',1,''),(517,2,'基础胰岛素分泌的主要生理作用是:','调节肝脏的葡萄糖输出速度以达到与大脑及其他器官对葡萄糖需要间的平衡','调节非进餐时的血糖','提高对餐后血糖的控制','抑制肝脏葡萄糖的输出和促进进餐时吸收的葡萄糖的利用和储存','','','','',NULL,'A',1,',11,,10,,39,',1,''),(518,2,'以下哪个不是胰岛的组成细胞','α细胞(分泌胰高血糖素)','β细胞(分泌胰岛素)','γ细胞(分泌生长激素抑制素)','F 细胞(分泌胰多肽)','','','','',NULL,'C',1,',11,,10,,39,',1,''),(519,2,'胰高血糖素是何细胞释放?','α细胞','β细胞','δ细胞','F细胞','','','','',NULL,'A',1,',11,,10,,39,',1,''),(520,2,'胰高血糖素的作用是?','升高血糖','降低血糖','对血糖无影响','既能升高也能降低','','','','',NULL,'A',1,',11,,10,,39,',1,''),(521,2,'胰高血糖素是由胰岛α细胞分泌的一种29—氨基酸多肽，作用靶点是?','肌肉','骨骼','肝脏','脂肪组织','','','','',NULL,'C',1,',11,,10,,39,',1,''),(522,2,'葡萄糖依赖性胰岛素释放肽（GIP）和胰高血糖素样肽—1(GLP-1)的分泌细胞是?','大肠细胞','小肠细胞','胰岛细胞','肝脏细胞','','','','',NULL,'B',1,',11,,10,,39,',1,''),(523,2,'葡萄糖依赖性胰岛素释放肽（GIP）的作用不包括:','刺激胰岛素的分泌','影响脂质代谢，尤其是饮食中脂质的餐后消除','抑制胃酸的分泌','抑制蛋白质的合成','','','','',NULL,'D',1,',11,,10,,39,',1,''),(524,2,'胰高血糖素样肽-1（GLP-1）的作用不包括:','促进分泌胰岛素，抑制胰高血糖素的分泌','抑制上消化道的分泌和运动','抑制食欲和食物摄取','影响脂质代谢','','','','',NULL,'D',1,',11,,10,,39,',1,''),(525,2,'下列哪项机制正确地描述了葡萄糖是如何转运至肌细胞的？','由GLUT2主动转运','与钠协同转运','通过GLUT4易化扩散','通过葡萄糖通道进行简单扩散','','','','',NULL,'C',1,',11,,10,,39,',1,''),(526,2,'接受胰岛素刺激，在肌肉与脂肪细胞中作用的葡萄糖输送小体是?','GLUT-1','GLUT-2','GLUT-3','GLUT-4','','','','',NULL,'D',1,',11,,10,,39,',1,''),(527,2,'作用于胰岛素敏感组织（肌肉和脂肪），以及心脏，增加葡萄糖的吸收的转运子是?','GLUT-1','GLUT-2','GLUT-3','GLUT-4','','','','',NULL,'D',1,',11,,10,,39,',1,''),(528,2,'你认为下列哪一项在空腹或饥饿状态下不会发生?','血浆脂肪酸水平降低','糖原耗竭','酮体形成增加','脂解作用','','','','',NULL,'A',1,',11,,10,,39,',1,''),(529,2,'葡萄糖吸收后优先利用顺序为','脂肪合成，糖原合成，糖酵解','糖原合成，糖酵解，脂肪合成','糖原合成，脂肪合成，糖酵解','糖酵解，糖原合成，脂肪合成','','','','',NULL,'D',1,',11,,10,,39,',1,''),(530,2,'葡萄糖进入细胞的方式是?','主动运输','被动运输','易化扩散','协助运输','','','','',NULL,'C',1,',11,,10,,39,',1,''),(531,2,'糖原生成是由肝细胞和骨骼肌细胞对（）的反应进行的。','胰岛素','胰高血糖素','生长抑素','胰多肽','','','','',NULL,'A',1,',11,,10,,39,',1,''),(532,2,'餐后状态的主要挑战是维持正常的血糖水平（3.6~6.1mmol/L），这就需要葡萄糖的产生和保存之间保持一个动态平衡，其中肝细胞从肝糖原贮存中释放葡萄糖的过程被称为?','糖原分解','糖异生','脂解作用','生酮作用','','','','',NULL,'A',1,',11,,10,,39,',1,''),(533,2,'餐后状态的主要挑战是维持正常的血糖水平（3.6~6.1mmol/L），这就需要葡萄糖的产生和保存之间保持一个动态平衡，利用脂肪和蛋白质的分解产生新的葡萄糖的作用是?','糖原分解','糖异生','脂解作用','生酮作用','','','','',NULL,'B',1,',11,,10,,39,',1,''),(534,2,'从非碳水化合物原料形成葡萄糖的过程就称为?','糖原分解','糖异生','脂解作用','生酮作用','','','','',NULL,'B',1,',11,,10,,39,',1,''),(535,2,'为了肌肉、肝脏和脂肪组织能利用甘油三酯产生ATP，他们必须首先被分解为甘油和脂肪酸，这个过程被称为?','糖原分解','糖异生','脂解作用','生酮作用','','','','',NULL,'C',1,',11,,10,,39,',1,''),(536,2,'糖尿病最初的分类方式以是否需要胰岛素而分为胰岛素依赖型糖尿病(IDDM)和非胰岛素依赖型糖尿病（NIDDM），现在主要是根据导致高血糖症的致病机制进行分类，哪一类不是以这种形式分类的。','I型糖尿病','II型糖尿病','妊娠糖尿病','青少年糖尿病','','','','',NULL,'D',1,',11,,10,,39,',1,''),(537,2,'哪种糖尿病是免疫系统破坏胰岛β细胞，造成胰岛素绝对缺乏？','I型糖尿病','II型糖尿病','妊娠糖尿病','成人糖尿病','','','','',NULL,'A',1,',11,,10,,39,',1,''),(538,2,'下列哪个选项不属于1型糖尿病的主要发病特点?','发病年龄较早','对胰岛素较敏感','胰岛素释放高峰延迟 ','不易发生酮症酸中毒','','','','',NULL,'C',1,',11,,10,,39,',1,''),(539,2,'2型糖尿病占所有糖尿病患者的:','0.2','0.5','0.9','0.7','','','','',NULL,'C',1,',11,,10,,39,',1,''),(540,3,'2型糖尿病治疗目的:','保存β细胞功能，改善胰岛素抵抗','控制血糖','延缓、减少并发症的发生率和死亡率','以上都不是','','','','',NULL,'ABC',1,',11,,10,,39,',1,''),(541,2,'2型糖尿病的始动因素是?','胰岛素抵抗','葡萄糖酮症','高血糖症','低血糖症','','','','',NULL,'A',1,',11,,10,,39,',1,''),(542,2,'下列选项中哪项属于2型糖尿病的临床特点?','常以慢性并发症为首发症状','患者从不需使用胰岛素治疗','中老年患者多见，从不发生酮症','胰岛功能正常','','','','',NULL,'A',1,',11,,10,,39,',1,''),(543,2,'以下哪一类疾病不属于代谢综合症','胰岛素抵抗','高血压，脂代谢异常和肥胖','伴有内皮细胞功能障碍，血栓形成和心血管系统疾病加速','上呼吸道感染','','','','',NULL,'D',1,',11,,10,,39,',1,''),(544,2,'糖尿病的诊断标准，空腹血糖及餐后血糖为','≥ 7.0mmol/L(126mg /dl)，≥ 11.1mmol/L(200mg /dl)','≥ 7.8mmol/L(140mg /dl)，≥ 11.1mmol/L(200mg /dl)','≥ 6.1mmol/L(110mg /dl)，≥ 11.1mmol/L(200mg /dl)','≥ 6.0mmol/L(108mg /dl)，≥ 7.8mmol/L(140mg /dl)','','','','',NULL,'A',1,',11,,10,,39,',1,''),(545,2,'糖尿病的诊断标准，如果有糖尿病症状，随机血浆葡萄糖浓度为','≥7.8mmol/L','≥11.1mmol/L','≥7.0mmol/L','≥6.1mmol/','','','','',NULL,'B',1,',11,,10,,39,',1,''),(546,2,'下列哪一项不是代谢综合征的诊断标准?','甘油三酯≥150mg/Dl','HDL：男性＜40mg/ dL， 女性＜50 mg/ dL','血压 SBP≥130mmHg，DBP≥85 mmHg','空腹血糖≤113 mg/dL','','','','',NULL,'D',1,',11,,10,,39,',1,''),(547,2,'下列有关统计学关于患病率定义描述正确的是:','某一特定时间内总人口中某病新旧病例所占比例','某一特定时间内总人口中某病新病例所占比例','某一时间内总人口中某病新旧病例所占比例','某一特定时间内总人口中某病旧病例所占比例','','','','',NULL,'A',1,',11,,10,,39,',1,''),(548,2,'糖尿病是导致很多疾病的主要原因，下列不是糖尿病导致的主要病症是：','肾衰竭','成人失明','非创伤性下肢截肢','胃溃疡','','','','',NULL,'D',1,',11,,10,,39,',1,''),(549,2,'糖尿病患者有很多并发症，导致糖尿病患者死亡的主要并发症是：','心血管疾病','脑血管疾病','肾脏疾病','神经系统疾病','','','','',NULL,'A',1,',11,,10,,39,',1,''),(550,2,'2型糖尿病的特征是3种异常，不包括：','外周胰岛素抵抗','胰岛素分泌受损','肝糖输出过多','糖异生过多','','','','',NULL,'D',1,',11,,10,,39,',1,''),(551,2,'糖尿病由____ 引起。','仅基因易感性 ','仅环境因素 ','仅生活方式选择 ','以上全是','','','','',NULL,'D',1,',11,,10,,39,',1,''),(552,2,'下列哪个关于2型糖尿病的说法是错误的？','它占所有已诊断糖尿病病例的90%至95% ','它是由导致胰岛素绝对缺乏的β细胞破坏引起的','它可能由导致高糖血症的任何失衡引起 ','它原先被分类为NIDDM和成人发病型糖尿病','','','','',NULL,'B',1,',11,,10,,39,',1,''),(553,2,'糖尿病的风险因素分为遗传因素和环境因素，遗传因素不包括：','家族史','种族','饮食','易感基因','','','','',NULL,'C',1,',11,,10,,39,',1,''),(554,2,'糖尿病的风险因素分为遗传因素和环境因素，环境因素不包括：','家族史','出生体重','胎儿时期的糖尿病暴露','肥胖','','','','',NULL,'A',1,',11,,10,,39,',1,''),(555,2,'2型糖尿病的显著病生理是:','继发于严重胰岛素抵抗的胰腺β细胞衰竭','原发胰岛素分泌缺陷','胰岛素抵抗','继发于严重胰岛素抵抗的胰腺α细胞衰竭','','','','',NULL,'A',1,',11,,10,,39,',1,''),(556,2,'下列哪种酶是肌肉中控制糖原生成的酶，可由胰岛素激活?','糖原合成酶','络氨酸激酶','已糖激酶','已糖激酶II','','','','',NULL,'A',1,',11,,10,,39,',1,''),(557,2,'2型糖尿病情况下，从正常葡萄糖耐量发展至已诊断糖尿病的进行性失调典型地发生在下列哪个时间框架内？','12至14周','6至9个月','1年','多年','','','','',NULL,'D',1,',11,,10,,39,',1,''),(558,2,'关于糖尿病前期的描述，以下错误的是：','葡萄糖耐量受损和空腹葡萄糖受损统称为“糖尿病前期”','是2型糖尿病和心血管疾病高危人群的标志','身体内血糖水平超过正常值但不足以诊断糖尿病的状态','是1型糖尿病和心血管疾病高危人群的标志','','','','',NULL,'D',1,',11,,10,,39,',1,''),(559,2,'IGT与IFG统称为?','糖尿病前期','糖尿病中期','糖尿病后期','糖尿病末期','','','','',NULL,'A',1,',11,,10,,39,',1,''),(560,2,'糖尿病患者最初可以检验到的血糖异常是？','IFG','IGT','PPG','FPG','','','','',NULL,'B',1,',11,,10,,39,',1,''),(561,2,'T2DM的病理开始标志是?','胰岛α细胞无法进行代偿','胰岛β细胞无法进行代偿','IGT','IFG','','','','',NULL,'B',1,',11,,10,,39,',1,''),(562,2,'2型糖尿病和肥胖症之间的密切关联与游离脂肪酸（FFA）有关，循环血浆中游离脂肪酸的水平上升不会导致:','肝脏的胰岛素抵抗，导致葡萄糖输出增加','肌细胞的胰岛素抵抗，导致葡萄糖摄取减少','β细胞功能障碍，导致胰岛素分泌减少','α细胞功能障碍，导致胰高血糖素分泌减少','','','','',NULL,'D',1,',11,,10,,39,',1,''),(563,2,'脂肪组织肌肉和肝脏的胰岛素抵抗导致葡萄糖摄取 __________ 及肝糖输出____________ 。','增加；增加','增加；减少','减少；增加','减少；减少','','','','',NULL,'C',1,',11,,10,,39,',1,''),(564,2,'胰岛素抵抗是哪一型糖尿病的病因','1型糖尿病','2型糖尿病','妊娠型糖尿病','内分泌疾病','','','','',NULL,'B',1,',11,,10,,39,',1,''),(565,2,'伴随胰岛素抵抗的2型糖尿病患者前期，胰岛素抵抗上升，其胰岛素分泌—肝糖输出—空腹血糖为','上升—上升—上升','上升—不变—不变','下降—上升—不变','不变—上升—不变','','','','',NULL,'A',1,',11,,10,,39,',1,''),(566,2,'伴随胰岛素抵抗的2型糖尿病患者，处于高胰岛素抵抗，其胰岛素分泌—肝糖输出—空腹血糖为','上升—上升—上升','上升—不变—不变','下降—上升—上升','不变—上升—不变','','','','',NULL,'A',1,',11,,10,,39,',1,''),(567,2,'继发于严重胰岛素抵抗的胰腺β细胞衰竭是2型糖尿病的显著病生理学，导致β细胞功能障碍的不包括:','遗传性的β细胞衰竭','糖毒性','脂毒性','低血糖','','','','',NULL,'D',1,',11,,10,,39,',1,''),(568,3,'人体发生胰岛素抵抗会产生2个直接后果:','外周葡萄糖摄取减少，导致餐后高血糖','肝糖输出增加，导致空腹血糖水平升高','糖异生增加，导致空腹血糖水平升高','葡萄糖吸收减少，导致餐后高血糖产生','','','','',NULL,'AB',1,',11,,10,,39,',1,''),(569,2,'关于体重指数的描述，以下错误的是：','体重相对身高的测量','用来评估个体的脂肪含量',' 计算公式为体重（单位kg）除以身高（单位m）','计算公式为体重（单位kg）除以身高（单位m）的平方（kg/m2）','','','','',NULL,'C',1,',11,,10,,39,',1,''),(570,3,'肠促胰岛素包括:','葡萄糖依赖型胰岛素释放肽（GIP）','胰高血糖素样肽—1（GLP-1）','肠高血糖素','非葡萄糖依赖型胰岛素释放肽','','','','',NULL,'AB',1,',11,,10,,39,',1,''),(571,2,'相同的葡萄糖负荷，相对于静脉注入，口服摄取胰岛素反应更强，原因是:','肠促胰岛素作用','胰岛素作用','糖毒性','脂毒性','','','','',NULL,'A',1,',11,,10,,39,',1,''),(572,2,'肠促胰岛素作用减弱可能是部分由于胰腺以及外周组织细胞上的胰高血糖素样肽-1受体的去敏感化，去敏感化不会导致:','导致胰岛素分泌减少','导致肝糖输出增加','导致胰岛素抵抗','导致糖异生增加','','','','',NULL,'D',1,',11,,10,,39,',1,''),(573,2,'多少比例的糖尿病患者至少出现一种并发症，并且多少比例的患者出现多种并发症？','五分之一；将近十分之一 ','四分之一；将近六分之一 ','三分之一；将近五分之一 ','一半以上；将近四分之一','','','','',NULL,'D',1,',11,,10,,39,',1,''),(574,2,'尿液中出现蛋白提示哪种临床情况? ','高血糖高渗状态     ','酮症酸中毒    ','肾病      ','尿路感染','','','','',NULL,'C',1,',11,,10,,39,',1,''),(575,2,'下列何者并非糖尿病并发症的小血管病变。','黄斑部水肿','白内障','蛋白尿','中风','','','','',NULL,'B',1,',11,,10,,39,',1,''),(576,2,'糖尿病会伴发很多的并发症，下列不是糖尿病慢性并发症的是?','眼部疾病','肾病','冠状动脉疾病','乳酸中毒','','','','',NULL,'D',1,',11,,10,,39,',1,''),(577,2,'糖尿病并发症十分常见，有一种或几种并发症的患者占总体人数的:','0.6','0.5','0.25','0.7','','','','',NULL,'D',1,',11,,10,,39,',1,''),(578,2,'糖尿病的并发症分为急性并发症和慢性并发症，下列是急性并发症的是:','糖尿病酮症酸中毒（DKA）','高血压','冠心病','青光眼','','','','',NULL,'A',1,',11,,10,,39,',1,''),(579,2,'糖尿病患者血脂异常最常用的降脂药物是:','他汀类药物','纤维酸衍生物','烟酸','胆酸树脂类','','','','',NULL,'A',1,',11,,10,,39,',1,''),(580,2,'慢性高糖血症是微血管并发症的关键起始因子，微血管损伤的综合作用不包括:','视网膜损伤','肾脏损伤','神经损伤','冠状动脉损伤','','','','',NULL,'D',1,',11,,10,,39,',1,''),(581,2,'糖尿病持续时间和血糖控制程度是视网膜发展的最重要的预测标志，所有患者糖尿病超过20年的患者存在非增生性的视网膜病的比例是:','1','0.8','0.6','0.4','','','','',NULL,'A',1,',11,,10,,39,',1,''),(582,2,'出现高血压的糖尿病患者的病死率比具有正常血压的糖尿病患者_________ 。','高3倍','高4倍','高5倍','高10倍','','','','',NULL,'B',1,',11,,10,,39,',1,''),(583,2,'引起糖尿病大血管病变危险性增加的是','LDL-c增加','HDL-c增加','TG减少','VLDL-c减少','','','','',NULL,'A',1,',11,,10,,39,',1,''),(584,3,'内皮细胞功能障碍是糖尿病大血管并发症的基础，内皮细胞功能障碍如何加重动脉粥样硬化和随之而来的疾病状态?','血管对脂蛋白的通透性增加','吸引血小板和炎症细胞并促进血管壁粘附的趋化因子和粘附分子的分泌增加','血管收缩、炎症、平滑肌增加和胶原蛋白分解','动脉粥样硬化斑块的加速产生及动摇斑块的蛋白水解酶的产生','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(585,2,'高血压是糖尿病的一种强烈并发症，ADA2008糖尿病诊断治疗标准向糖尿病患者推荐以下的血压目标','SBP<130mmHg  DBP<80mmHg','SBP<140mmHg  DBP<90mmHg','SBP<130mmHg  DBP<90mmHg','SBP<140mmHg  DBP<80mmHg\n','','','','',NULL,'A',1,',11,,10,,39,',1,''),(586,2,'资料显示大血管病变是糖尿病常见的并发症，目前认为在糖尿病的_____阶段会开始发生心血管病变。','作为一种大血管并发症，在糖尿病起病早期开始与微血管并发症同时启动','糖尿病晚期，高血糖对大血管危害效应才开始显现','作为大血管并发症，其启动时间可能早于微血管病变，甚至在IGT阶段就已经出现','一般患者首先出现微血管并发症，然后才发生大血管病变','','','','',NULL,'C',1,',11,,10,,39,',1,''),(587,2,'2型糖尿病患者的推荐血压控制目标为? ','< 110/60 mmHg   ','< 120/70 mmHg     ','< 130/80 mmHg   ','< 140/90 mmHg','','','','',NULL,'C',1,',11,,10,,39,',1,''),(588,2,'糖尿病患者血压的目标值是:','130/80mmHg','140/90mmHg','140/80mmHg','130/90mmHg','','','','',NULL,'A',1,',11,,10,,39,',1,''),(589,3,'糖尿病合并高血压患者降压的首选药物是:','ARB','ACEI','CCB','利尿剂','','','','',NULL,'AB',1,',11,,10,,39,',1,''),(590,2,'下列哪项研究显示，强化葡萄糖导向疗法减轻糖尿病视网膜病的发生和恶化风险？ ','DCCT ','UKPDS ','DCCT和UKPDS ','DCCT和UKPDS都不是','','','','',NULL,'A',1,',11,,10,,39,',1,''),(591,2,'糖尿病酮症酸中毒产生酮体是由于什么物质大量动员','蛋白质','脂肪','碳水化合物','葡萄糖','','','','',NULL,'B',1,',11,,10,,39,',1,''),(592,2,'患有糖尿病的患者，下列何者不是','有20%死于感染','有55％的糖尿病患者死于冠心病','40%的糖尿病患者死于缺血性心脏病','糖尿病患者死亡危险性比正常人高出2－4倍','','','','',NULL,'B',1,',11,,10,,39,',1,''),(593,3,'糖尿病并发症有不同的途径导致，主要包括:','氧化应激','游离脂肪酸','高糖血症','炎症','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(594,3,'患有糖尿病时，患者所有细胞都暴露在高血糖中，细胞若不能下调葡萄糖转运至细胞内，将持续遭受到高血糖的损上，主要会影响:','内皮细胞','血管平滑肌','血小板','不会影响细胞','','','','',NULL,'ABC',1,',11,,10,,39,',1,''),(595,2,'2型糖尿病有很多的危险因素，患者发生糖尿病的概率随所存在的危险因素个数增加而增加，下列不是危险因素的是:','高血压病','血脂异常','PCOS妇女','消化不良','','','','',NULL,'D',1,',11,,10,,39,',1,''),(596,3,'2型糖尿病患者在明确诊断前往往会存在一段很长的无症状期，在无症状的成年人中，糖尿病前期和糖尿病的筛查标准是:','超重且存在其他任意一项危险因素的成年人','出现过IGT或IFG的成年人','年龄在45岁以上的所有成年人','筛查结果正常，但实施检查的时间距现在超三年','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(597,2,'与成年人中推荐的一样，2型糖尿病危险增加的儿童和青少年应当每几年检测空腹血糖。','1年','2年','3年','4年','','','','',NULL,'B',1,',11,,10,,39,',1,''),(598,3,'当怀疑某位患者患有糖尿病时，需要有收集完整的病史，主要包括：','糖尿病的危险因素','饮食模式，营养模式和体重史','既往的治疗以及对治疗的应答','可能会影响糖尿病进程的因素（运动，饮食，吸烟情况，饮酒情况）','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(599,3,'高糖血症的典型症状包括:','三多一少','疲劳无力','视线模糊','感染发生率升高，皮肤愈合缓慢','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(600,2,'空腹血糖（FPG）试验中，糖尿病诊断的临界值为?','100 mg/dL','126 mg/dL','175 mg/dL','200 mg/dL','','','','',NULL,'B',1,',11,,10,,39,',1,''),(601,3,'糖尿病是依据什么来判断的?','IFG','IGT','血糖异常升高','高血糖症状','','','','',NULL,'CD',1,',11,,10,,39,',1,''),(602,2,'患者诊断为糖尿病的标准很多但不包括:','FPG>7.0mmol/L','OGTT>11.1 mmol/L','高血糖症状合并随机血糖>11.1 mmol/L','IFG或IGT','','','','',NULL,'D',1,',11,,10,,39,',1,''),(603,2,'糖尿病前期的诊断标准的标准为：','FPG>7.0mmol/L','OGTT>11.1 mmol/L','高血糖症状合并随机血糖>11.1 mmol/L','IFG或IGT','','','','',NULL,'D',1,',11,,10,,39,',1,''),(604,2,'儿童和非妊娠成年人中诊断糖尿病的首选方法是：','FPG','PPG','OGTT','2h PG','','','','',NULL,'A',1,',11,,10,,39,',1,''),(605,2,'糖尿病是一种需要患者自我管理的慢性疾病，特别强调血糖的自我监测，ADA对血糖的控制目标是:','FPG5.0~7.2 mmol/L ，PPG<10.0 mmol/L','FPG5.0~7.2 mmol/L，PPG<11.0 mmol/L','FPG5.6~6.9 mmol/L，PPG<10.0 mmol/L','FPG5.6~6.9 mmol/L，PPG<11.0 mmol/L','','','','',NULL,'A',1,',11,,10,,39,',1,''),(606,2,'并非是诊断糖尿病的指标但是是监测血糖的首选指标是：','糖化血红蛋白','血压','血脂','白蛋白','','','','',NULL,'A',1,',11,,10,,39,',1,''),(607,3,'糖尿病患者中因为血脂异常会有很强的脂毒性，进而损害靶器官，建议每年都要常规检测血脂，每次的项目有:','总胆固醇','HDL','LDL','甘油三酯','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(608,3,'血糖浓度低于2.8~3.0 mmol/L时开始出现低血糖症，症状包括:','发热感，无力','难以思考，行为改变','情绪不稳，癫痫','大脑损伤及死亡','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(609,3,'在糖尿病治疗中，低血糖可以导致休克甚至死亡，高血糖也会导致很重的生命危象包括:','DKA','HHS','IR','MI','','','','',NULL,'AB',1,',11,,10,,39,',1,''),(610,2,'国家糖尿病教育计划（NDEP）提出糖尿病治疗的ABC，用简练的语言描述了糖尿病的治疗基本框架，其中的A是:','糖化血红蛋白水平','血压','胆固醇水平','胰岛素','','','','',NULL,'A',1,',11,,10,,39,',1,''),(611,2,'国家糖尿病教育计划（NDEP）提出糖尿病治疗的ABC，用简练的语言描述了糖尿病的治疗基本框架，其中的B是:','糖化血红蛋白水平','血压','胆固醇水平','胰岛素','','','','',NULL,'B',1,',11,,10,,39,',1,''),(612,2,'国家糖尿病教育计划（NDEP）提出糖尿病治疗的ABC，用简练的语言描述了糖尿病的治疗基本框架，其中的C是:','糖化血红蛋白水平','血压','胆固醇水平','胰岛素','','','','',NULL,'C',1,',11,,10,,39,',1,''),(613,3,'糖尿病的治疗重点在干预包括:','一级干预：预防发生糖尿病','二级干预：预防糖尿病患者发生并发症','三级干预：预防并发症相关发病率和死亡率','四级干预：预防将糖尿病遗传至下一代','','','','',NULL,'ABC',1,',11,,10,,39,',1,''),(614,3,'一级预防的核心为改变生活方式，应当鼓励具有高糖尿病危险性的患者:','减肥（减去大约7%的体重）','保证规律性运动（每周150分钟）','改变饮食，减少热量和脂肪摄入','增加膳食纤维摄入，并包含全谷食物','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(615,2,'二级干预中，主要是关注ABC的水平，ADA及ACE/AACE对糖化血红蛋白的目标值分别是:','7%和6.5%','7%和7%','6.5%和6.5%','6.5%和7%','','','','',NULL,'A',1,',11,,10,,39,',1,''),(616,2,'对于2型糖尿病患者，ADA和ACE/AACE推荐的血糖控制目标分别为? ','< 6%；< 7 % ',' < 6.5%；< 7.5% ','< 7%；< 6.5% ','< 7.5%；< 7%','','','','',NULL,'C',1,',11,,10,,39,',1,''),(617,2,'A1C水平作为重要的糖尿病观测目标，当A1C水平降至7%之后，至少（）查一次。','3个月','6个月','9个月','12个月','','','','',NULL,'B',1,',11,,10,,39,',1,''),(618,2,'二级干预中，主要是关注ABC的水平，血压的目标是:','130/90mmHg','130/80mmHg','140/90mmHg','140/80mmHg','','','','',NULL,'B',1,',11,,10,,39,',1,''),(619,2,'二级干预中，主要是关注ABC的水平，血脂的的主要控制目标LDL的的水平为:','<100mg/dL/<70mg/dL','>40mg/dL/>50mg/dL','<150mg/dL','<110mg/dL/<80mg/dL','','','','',NULL,'A',1,',11,,10,,39,',1,''),(620,3,'达到血糖控制的初始方式包括生活方式干预，后续就要进行药物治疗调整，通常应用口服降糖药物，其中的主要药物治疗包括:','胰岛素促泌剂和双胍类','TZD','α糖苷酶抑制剂','强化肠促胰岛素治疗','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(621,2,'二甲双胍降低血糖水平的主要机制是什么？','减少肝脏葡萄糖输出','增加胰岛素分泌 ','保护胰腺β细胞免于脂毒性 ','减慢胃肠道吸收','','','','',NULL,'A',1,',11,,10,,39,',1,''),(622,2,'哪一组术语最符合噻唑烷二酮类药物吡格列酮的风险-效益特性？','增加胰岛素分泌，体重增加、严重低血糖的风险 ','增加胰岛素的外周敏感性、改善血脂，充血性心力衰竭的风险 ','增加胰岛素的外周敏感性、对血脂无影响，充血性心力衰竭和缺血事件的风险 ','减少肝脏葡萄糖输出，体重减轻、胃肠道不耐受、乳酸酸中毒的风险','','','','',NULL,'B',1,',11,,10,,39,',1,''),(623,2,'哪一种治疗禁忌用于具有肾脏疾病或者肾功能不全的患者？ ','α-糖苷酶抑制剂 ','二肽基肽酶4抑制剂 ','二甲双胍 ','磺脲类','','','','',NULL,'D',1,',11,,10,,39,',1,''),(624,2,'哪一种药物与治疗类别正确对应？','格列美脲：双胍类 ','二甲双胍：噻唑烷二酮类 ','那格列奈：磺脲类 ','西他列汀：二肽基肽酶4抑制剂','','','','',NULL,'D',1,',11,,10,,39,',1,''),(625,2,'以迅速起效为特征的胰岛素适用于哪种胰岛素替代治疗类型？','基础量 ','校正剂量 ','餐后量 ','餐前量','','','','',NULL,'C',1,',11,,10,,39,',1,''),(626,2,'使用胰岛素获得接近正常血糖控制的最大限制因素是：','对针的抵制 ','心血管疾病 ','低血糖 ','体重增加','','','','',NULL,'C',1,',11,,10,,39,',1,''),(627,2,'在治疗进行强化后，即服用多种降糖药物，AIC水平可以在一定程度上提示后续选择何种药物，必须要进行胰岛素治疗的患者A1C的水平为:','>7.5%','>8%','>8.5%','>9%','','','','',NULL,'C',1,',11,,10,,39,',1,''),(628,3,'患有重度未控制的糖尿病的，处于分解代谢状态的患者应当选择胰岛素联合生活方式干预，患有重度未控制糖尿病的，处于分解代谢状态的患者包括哪些症状?','FPG>13.9mmol/L或随机血糖水平持续>16.7mmol/L','糖化血红蛋白>10%','出现酮尿','有症状的糖尿病出现三多一少的症状','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(629,2,'在美国胰岛素除外还有6类口服药物及2类注射用药物被批准用于2型糖尿病的治疗，胰岛素促泌剂的靶点和作用是:','刺激胰腺β细胞分泌更多的胰岛素，其中包括磺脲类药物和氯茴苯酸类','能减少肝脏的葡萄糖输出，并在较小程度上，能增加肌肉和脂肪组织对胰岛素的敏感性','能刺激肌肉和脂肪组织摄取葡萄糖，减少肝脏的葡萄糖输出，而且能改善血脂代谢','减少肠道对葡萄糖的吸收','','','','',NULL,'A',1,',11,,10,,39,',1,''),(630,2,'在学术沟通和会议中各类药物的简写也会经常被提及磺脲类药物的缩写:','TZD','DPP-4','MET','SU','','','','',NULL,'D',1,',11,,10,,39,',1,''),(631,2,'在美国胰岛素除外还有6类口服药物及2类注射用药物被批准用于2型糖尿病的治疗，双胍类药物的靶点和作用是:','刺激胰腺β细胞分泌更多的胰岛素，其中包括磺脲类药物和氯茴苯酸类','能减少肝脏的葡萄糖输出，并在较小程度上，能增加肌肉和脂肪组织对胰岛素的敏感性','能刺激肌肉和脂肪组织摄取葡萄糖，减少肝脏的葡萄糖输出，而且能改善血脂代谢','减少肠道对葡萄糖的吸收','','','','',NULL,'B',1,',11,,10,,39,',1,''),(632,2,'在学术沟通和会议中各类药物的简写也会经常被提及二甲双胍药物的缩写:','TZD','DPP-4','MET','SU','','','','',NULL,'C',1,',11,,10,,39,',1,''),(633,2,'在美国胰岛素除外还有6类口服药物及2类注射用药物被批准用于2型糖尿病的治疗，TZD药物的靶点和作用是:','刺激胰腺β细胞分泌更多的胰岛素，其中包括磺脲类药物和氯茴苯酸类','能减少肝脏的葡萄糖输出，并在较小程度上，能增加肌肉和脂肪组织对胰岛素的敏感性','能刺激肌肉和脂肪组织摄取葡萄糖，减少肝脏的葡萄糖输出，而且能改善血脂代谢','减少肠道对葡萄糖的吸收','','','','',NULL,'C',1,',11,,10,,39,',1,''),(634,2,'在学术沟通和会议中各类药物的简写也会经常被提及噻唑烷二酮类药物的缩写:','TZD','DPP-4','MET','SU','','','','',NULL,'A',1,',11,,10,,39,',1,''),(635,2,'TZD类药物的主要作用靶点是:','PPAR-α','PPAR-δ','PPAR-γ','PPAR-β','','','','',NULL,'C',1,',11,,10,,39,',1,''),(636,2,'在美国胰岛素除外还有6类口服药物及2类注射用药物被批准用于2型糖尿病的治疗，α糖苷酶抑制剂的靶点和作用是:','刺激胰腺β细胞分泌更多的胰岛素，其中包括磺脲类药物和氯茴苯酸类','能减少肝脏的葡萄糖输出，并在较小程度上，能增加肌肉和脂肪组织对胰岛素的敏感性','能刺激肌肉和脂肪组织摄取葡萄糖，减少肝脏的葡萄糖输出，而且能改善血脂代谢','减少肠道对葡萄糖的吸收','','','','',NULL,'D',1,',11,,10,,39,',1,''),(637,2,'在学术沟通和会议中各类药物的简写也会经常被提及肠促胰岛素药物的缩写:','TZD','DPP-4','MET','SU','','','','',NULL,'B',1,',11,,10,,39,',1,''),(638,3,'胰高血糖素样肽-1（GLP-1）作用于多个靶点，主要有:','刺激葡萄糖依赖的胰岛素释放','抑制餐后胰高血糖素释放','延缓胃排空','促进饱食感和体重减轻','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(639,2,'哪两种治疗类别被共同称为胰岛素促泌剂？','双胍类和噻唑烷二酮类','二肽基肽酶抑制剂和磺脲类 ','氯茴苯酸类和双胍类 ','磺脲类和氯茴苯酸类','','','','',NULL,'D',1,',11,,10,,39,',1,''),(640,2,'磺脲类药物是一类大家已经很接受的药物，第一个磺脲类药物甲苯磺丁脲在1957年获得批准，最后一个格列美脲在1986年获得批准，磺脲类的作用机制是:','与胰腺β细胞表面的蛋白质结合使得细胞内钾离子外流减少，反过来使得钙通道打开，随之钙离子的内流促进胰岛素的释放','通过过氧化物酶体增殖物刺激受体（PPARs）增强胰岛素的作用','阻断肠道中将多糖；裂解为单糖的酶，延缓胃肠道中碳水化合物的排空','抑制肠促胰岛素的降解','','','','',NULL,'A',1,',11,,10,,39,',1,''),(641,3,'磺脲类药物由于是通过刺激胰腺β细胞释放更多的胰岛素而发挥作用，所以在哪些患者中无效?','1型患者','2型早期','妊娠患者','2型晚期','','','','',NULL,'AD',1,',11,,10,,39,',1,''),(642,2,'磺脲类药物的主要作用是:','降低空腹血糖','降低餐后血糖','降低随机血糖','降低24小时血糖','','','','',NULL,'A',1,',11,,10,,39,',1,''),(643,2,'磺脲类药物有两类比较重要的禁忌人群一类是I型糖尿病患者一类是伴或不伴昏迷的糖尿病酮症酸中毒患者。','是','否','','','','','','',NULL,'A',1,',11,,10,,39,',1,''),(644,3,'在服用磺脲类药物时，哪些患者应该警惕？','有较强心血管危险的','易发生低血糖危险的','肾功能不全','活动量经常变化的','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(645,3,'磺脲类药物可能会导致严重的低血糖，增加低血糖风险的情况包括:','虚弱或营养不良','能量摄入不足','饮酒','老年患者','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(646,3,'氯茴苯酸类药物禁忌的患者包括:','1型糖尿病','伴或不伴昏迷的糖尿病酮症酸中毒','已知药物过敏','糖尿病早期患者','','','','',NULL,'ABC',1,',11,,10,,39,',1,''),(647,2,'氯茴苯酸类药物与磺脲类药物同样作为促泌剂，但发生低血糖的概率明显下降，可以作为容易发生低血糖患者的一种选择。','是','否','','','','','','',NULL,'A',1,',11,,10,,39,',1,''),(648,2,'市场上只有两种氯茴苯酸类降糖药物，分别是瑞格列奈和那格列奈。','是','否','','','','','','',NULL,'A',1,',11,,10,,39,',1,''),(649,2,'如果患者正在服用磺脲类药物进行治疗而血糖未能充分控制，可以选择氯茴苯酸类药物进行替换治疗。','是','否','','','','','','',NULL,'B',1,',11,,10,,39,',1,''),(650,3,'磺脲类继发性失效的原因是:','胰腺β细胞功能下降','外周组织的胰岛素抵抗','神经组织胰岛素抵抗','以上均不是','','','','',NULL,'AB',1,',11,,10,,39,',1,''),(651,2,'2009年ADA对2型糖尿病代谢处理的共识中提出，第一步的治疗策略为生活方式加:','二甲双胍','磺脲类药物','吡格列酮','胰岛素','','','','',NULL,'A',1,',11,,10,,39,',1,''),(652,2,'下列哪类糖尿病患者可选用双胍类药物?','妊娠、哺乳期妇女','糖尿病合并感染','BMI>30','酮症酸中毒患者','','','','',NULL,'C',1,',11,,10,,39,',1,''),(653,3,'以下药物中有心衰禁忌的是?','双胍类药物','噻唑烷二酮类药物','α-糖苷酶抑制剂类药物','那格列奈','','','','',NULL,'AB',1,',11,,10,,39,',1,''),(654,2,'下列只有哪种病人适合使用双胍类药物?','需要进行血管造影的患者','有乳酸中毒史','肥胖的2型糖尿病患者','年老及肝肾功能不全者','','','','',NULL,'C',1,',11,,10,,39,',1,''),(655,2,'ADA和EASD指南指出对于心衰和严重心肺疾病患者慎用二甲双胍，其原因是?','缺氧情况下容易诱发乳酸酸中毒','易引起液体潴留导致或加重心衰','导致体重增加从而加重心血管风险','以上均不对','','','','',NULL,'A',1,',11,,10,,39,',1,''),(656,3,'下列哪些情况属于二甲双胍的禁忌症?','肾功能衰竭患者','酮症酸中毒患者','心力衰竭患者','无禁忌症\n','','','','',NULL,'ABC',1,',11,,10,,39,',1,''),(657,2,'在使用二甲双胍治疗的患者，在进行外科手术及使用碘剂X线造影检查前应该:','减少剂量','增加剂量','停药','维持剂量','','','','',NULL,'C',1,',11,,10,,39,',1,''),(658,2,'应用二甲双胍治疗的患者，下列不良反应发生率低但后果严重的是:','低血糖','乳酸中毒','肝功能异常','胃肠道功能障碍','','','','',NULL,'B',1,',11,,10,,39,',1,''),(659,3,'哪些患者应慎用二甲双胍?','65岁以上的老年患者','喂乳期妇女','酮症酸中毒患者','心衰患者','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(660,3,'PPAR的激活具有多效性，可以激活','脂质和凝血','脂肪分布','血管作用和炎症','骨代谢','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(661,2,'噻唑烷二酮类药物的作用机制是:','与胰腺β细胞表面的蛋白质结合使得细胞内钾离子外流减少，反过来使得钙通道打开，随之钙离子的内流促进胰岛素的释放','通过过氧化物酶体增殖物刺激受体（PPARs）增强胰岛素的作用','阻断肠道中将多糖；裂解为单糖的酶，延缓胃肠道中碳水化合物的排空','抑制肠促胰岛素的降解','','','','',NULL,'B',1,',11,,10,,39,',1,''),(662,3,'2009年ADA对2型糖尿病代谢处理的共识中提出了两层治疗方案，分为经过良好验证的核心治疗和较少证据的治疗，在较少证据的治疗方案中患者被处方二甲双胍联合:','TZD','GLP-1','磺脲类','胰岛素','','','','',NULL,'AB',1,',11,,10,,39,',1,''),(663,2,'TZD类药物起效的前提是:','具有功能性的胰腺β细胞能释放胰岛素进入血循环','胰岛素抵抗','完善的胰腺α细胞','外周组织的PPAR-γ活性','','','','',NULL,'A',1,',11,,10,,39,',1,''),(664,3,'TZD类药物对代谢的作用是:','增加肌肉和脂肪组织对葡萄糖的摄取而减轻外周胰岛素抵抗','减少肝脏糖异生和葡萄糖输出','减缓脂解反应，减少从脂肪组织释放游离脂肪酸','无作用','','','','',NULL,'ABC',1,',11,,10,,39,',1,''),(665,2,'下列关于降糖药的不良反应错误的是?','老年人随年龄增长多器官功能减退，伴肾、心、肺、肝功能不全者，忌用二甲双胍','有心功不全者避免使用噻唑烷二酮类药物','TZD类除了常见的水钠潴留作用外，研究还发现TZD类可能增加骨折风险','格列奈类不同于一般的促泌剂，因此不会发生低血糖','','','','',NULL,'D',1,',11,,10,,39,',1,''),(666,2,'ADA和EASD指南指出对于心衰和严重心肺疾病患者慎用TZD，其原因是?','缺氧情况下容易诱发乳酸酸中毒','易引起液体潴留导致或加重心衰','导致体重增加从而加重心血管风险','以上均不对','','','','',NULL,'B',1,',11,,10,,39,',1,''),(667,2,'2010年在欧洲退市美国限制使用的TZD类药物是:','吡格列酮','罗格列酮','曲格列酮','全部','','','','',NULL,'B',1,',11,,10,,39,',1,''),(668,2,'吡格列酮与罗格列酮对脂代谢有不同的影响，原因是:','吡格列酮除了PPAR-γ作用之外还能作用于PPAR-α','分子结构不同自然不同','罗格列酮除了PPAR-γ作用之外还能作用于PPAR-α','无本质原因','','','','',NULL,'A',1,',11,,10,,39,',1,''),(669,3,'噻唑烷二酮类药物与哪些合用易产生低血糖?','二甲双胍','α-糖苷酶抑制剂','胰岛素','促泌剂','','','','',NULL,'CD',1,',11,,10,,39,',1,''),(670,3,'哪些患者服用噻唑烷二酮类要慎重?','心衰患者','I型糖尿病患者','糖尿病酮症酸中毒','活动型肝脏疾病','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(671,3,'服用TZD类药物可能会出现的不良反应有:','水肿','骨质疏松','黄斑水肿','排卵','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(672,2,'α糖苷酶抑制剂的作用机制是:','与胰腺β细胞表面的蛋白质结合使得细胞内钾离子外流减少，反过来使得钙通道打开，随之钙离子的内流促进胰岛素的释放','通过过氧化物酶体增殖物刺激受体（PPARs）增强胰岛素的作用','阻断肠道中将多糖；裂解为单糖的酶，延缓胃肠道中碳水化合物的排空','抑制肠促胰岛素的降解','','','','',NULL,'C',1,',11,,10,,39,',1,''),(673,2,'α-糖苷酶抑制剂的作用的临床疗效是:','抑制和减慢碳水化合物的消化和吸收，限制餐后高血糖','促进组织对胰岛素的敏感度','促进胰岛素的释放','增加肝糖代谢','','','','',NULL,'A',1,',11,,10,,39,',1,''),(674,3,'α-糖苷酶抑制剂的禁忌症是:','糖尿病酮症酸中毒','炎症性肠病，结肠溃疡或者肠根阻患者','与消化和吸收功能显著紊乱的慢性肠道疾病，或者患有能使肠道内气体产生增加加重的疾病的患者','对药物过敏的患者','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(675,2,'口服二肽基肽酶—4（DPP-4）抑制剂和注射用肠促胰岛素类似物的作用机制是:','能延长营养物质摄入后在肠道释放的肠促胰岛素作用','减慢胃排空及降低胰高血糖素分泌而有助于控制餐后血糖','刺激胰腺β细胞分泌更多的胰岛素','能刺激肌肉和脂肪组织摄取葡萄糖，减少肝脏的葡萄糖输出','','','','',NULL,'A',1,',11,,10,,39,',1,''),(676,2,'DPP-4抑制剂的作用机制是:','与胰腺β细胞表面的蛋白质结合使得细胞内钾离子外流减少，反过来使得钙通道打开，随之钙离子的内流促进胰岛素的释放','通过过氧化物酶体增殖物刺激受体（PPARs）增强胰岛素的作用','阻断肠道中将多糖；裂解为单糖的酶，延缓胃肠道中碳水化合物的排空','抑制肠促胰岛素的降解','','','','',NULL,'D',1,',11,,10,,39,',1,''),(677,3,'DPP-4抑制剂是近年来上市的新一类口服降糖药物，作用机制和特点是:','DPP-4抑制剂的主要作用在于减少GLP-1的降解，延长其活性，使之持续分泌胰岛素，并减少肝脏葡萄糖的合成，从而控制糖尿病患者的血糖水平。','葡萄糖浓度依赖性','单独使用没有低血糖副作用','可以保护β细胞','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(678,3,'2型糖尿病患者在2个水平存在肠促胰岛素缺陷?','GIP分泌数量正常，但对胰腺作用敏感性受损','进食后GLP-1分泌减少，但敏感性正常','GIP分泌数量减少，但对胰腺作用敏感性正常','进食后GLP-1分泌正常，但敏感性降低','','','','',NULL,'AB',1,',11,,10,,39,',1,''),(679,3,'使用DPP-4抑制剂，餐后有活性的肠促胰岛素水平升高了2-3倍，通过延长有活性的肠促胰岛素的作用。可以起到什么作用?','增加胰岛素的合成和释放','减少胰高血糖素的分泌，从而减少肝脏葡萄糖的生成，延缓胃排空，并增加饱食感','增加组织对胰岛素的敏感度','以上都不对','','','','',NULL,'AB',1,',11,,10,,39,',1,''),(680,2,'需要关注患者肾脏功能的药物是?','磺脲类','双胍类','DPP-4抑制剂','TZD类','','','','',NULL,'C',1,',11,,10,,39,',1,''),(681,3,'DPP-4抑制剂常见的不良反应是:','呼吸道不适','头痛','发痒','皮疹','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(682,2,'中度肾功能不全的糖尿病患者，DPP-4抑制剂的剂量应该:','不变','减半','四分之一','三分之一','','','','',NULL,'B',1,',11,,10,,39,',1,''),(683,2,'重度肾功能不全的糖尿病患者，DPP-4抑制剂的剂量应该:','不变','减半','四分之一','三分之一','','','','',NULL,'C',1,',11,,10,,39,',1,''),(684,2,'哪种药物可以用于降低高凝血状态和预防血液凝集? ','ACE抑制剂 ','血管紧张素受体阻滞剂 ','阿司匹林 ','β阻滞剂','','','','',NULL,'C',1,',11,,10,,39,',1,''),(685,2,'哪种药物可以用于降低LDL-胆固醇水平?','ACE抑制剂','β阻滞剂 ','贝特类药物 ','他汀类药物','','','','',NULL,'D',1,',11,,10,,39,',1,''),(686,3,'英国前瞻性糖尿病研究（UKPDS）显示糖尿病患者血压控制具有很重要的作用，平均收缩压每降低10mmHg，可使相关危险分别降低:','所有糖尿病相关并发症减少12%','糖尿病相关死亡事件下降15%','心肌梗死降低11%','微血管并发症降低13%','','','','',NULL,'ABCD',1,',11,,10,,39,',1,''),(687,3,'TZD药物的一个副反应是患者会出现体液潴留，虽然因为体液潴留导致患者停药的比例不足1%，但在（）心衰患者中必须禁止使用TZD药物。','I级','II级','III级','Ⅳ级','','','','',NULL,'CD',1,',11,,10,,39,',1,''),(688,2,'纽约心脏病协会（NYHA）评分在症状上对功能的影响方面对心衰进行了分类，I级指的是:','轻度，体力活动不限日常体力劳动不会引起异常疲劳，心悸或呼吸困难','轻度，体力活动受限，静息时无不适，但日常体力活动会引起疲劳，心悸或呼吸困难','中度，体力活动明显受限，静息时无不适，但低于正常的体力活动就会引起疲劳，心悸或呼吸困难','重度：无法负荷任何体力活动，活动时有不适感，静息状态存在心功能不全的症状，如进行任何体力活动，不适感增加','','','','',NULL,'A',1,',11,,10,,39,',1,''),(689,2,'纽约心脏病协会（NYHA）评分在症状上对功能的影响方面对心衰进行了分类，II指的是:','轻度，体力活动不限日常体力劳动不会引起异常疲劳，心悸或呼吸困难','轻度，体力活动受限，静息时无不适，但日常体力活动会引起疲劳，心悸或呼吸困难','中度，体力活动明显受限，静息时无不适，但低于正常的体力活动就会引起疲劳，心悸或呼吸困难','重度：无法负荷任何体力活动，活动时有不适感，静息状态存在心功能不全的症状，如进行任何体力活动，不适感增加','','','','',NULL,'B',1,',11,,10,,39,',1,''),(690,2,'纽约心脏病协会（NYHA）评分在症状上对功能的影响方面对心衰进行了分类，III级指的是:','轻度，体力活动不限日常体力劳动不会引起异常疲劳，心悸或呼吸困难','轻度，体力活动受限，静息时无不适，但日常体力活动会引起疲劳，心悸或呼吸困难','中度，体力活动明显受限，静息时无不适，但低于正常的体力活动就会引起疲劳，心悸或呼吸困难','重度：无法负荷任何体力活动，活动时有不适感，静息状态存在心功能不全的症状，如进行任何体力活动，不适感增加','','','','',NULL,'C',1,',11,,10,,39,',1,''),(691,2,'纽约心脏病协会（NYHA）评分在症状上对功能的影响方面对心衰进行了分类，Ⅳ级指的是:','轻度，体力活动不限日常体力劳动不会引起异常疲劳，心悸或呼吸困难','轻度，体力活动受限，静息时无不适，但日常体力活动会引起疲劳，心悸或呼吸困难','中度，体力活动明显受限，静息时无不适，但低于正常的体力活动就会引起疲劳，心悸或呼吸困难','重度：无法负荷任何体力活动，活动时有不适感，静息状态存在心功能不全的症状，如进行任何体力活动，不适感增加','','','','',NULL,'D',1,',11,,10,,39,',1,''),(692,2,'心衰患者往往合并很多的的其他病症，因此在治疗中更应该注意药物的选择，下列药物不用太在意避免的是:','抗心律失常药物','利尿剂','钙离子通道阻滞剂','非甾体类抗炎药物','','','','',NULL,'B',1,',11,,10,,39,',1,''),(693,2,'糖尿病患者患者伴发的缺血事件不包括:','心绞痛','粥样硬化','梗死','心肌梗塞','','','','',NULL,'B',1,',11,,10,,39,',1,''),(694,2,'糖尿病中常用的 HbA1C，以下描述错误的是：','血红蛋白，反映了在过去2-3个月中的平均血糖水平','糖化血红蛋白，反映了在过去2-3个月中的平均血糖水平','是检测血糖状态随时间变化的首选测试','糖尿病时升高','','','','',NULL,'A',1,',11,,10,,39,',1,''),(695,2,'空腹血糖受损的简写为?','IGT','IFG','IR','PPG','','','','',NULL,'B',1,',11,,10,,39,',1,''),(696,2,'糖尿病中常用的简称，以下中文解释错误的是：','DPP-4-二肽基肽酶4','GLP-1-胰高血糖素样肽-1','AGE-高度糖基化终产物','ATP-二磷酸腺苷','','','','',NULL,'D',1,',11,,10,,39,',1,''),(697,2,'糖尿病中常用的简称，以下中文解释错误的是（）','ADA-亚洲食品药品监督管理局','FDA-美国食品药品管理局','EMA-欧洲药品管理局','CFDA-中国食品药品监督管理局','','','','',NULL,'A',1,',11,,10,,39,',1,''),(698,2,'美国糖尿病协会简写?','IDF','AHA','ACE','ADA','','','','',NULL,'D',1,',11,,10,,39,',1,''),(699,2,'AHA的中文解释正确的是：','美国心脏协会','美国心脏学会','欧洲心脏协会','美国糖尿病协会','','','','',NULL,'A',1,',11,,10,,39,',1,''),(700,2,'疾病控制与预防中心的简写?','CDC','CCC','CAC','DDC','','','','',NULL,'A',1,',11,,10,,39,',1,''),(701,2,'欧洲糖尿病研究协会的简写?','EASD','ESDA','ESAD','EACD','','','','',NULL,'A',1,',11,,10,,39,',1,''),(702,2,'国际糖尿病联盟简写?','IDF','AHA','ACE','ADA','','','','',NULL,'A',1,',11,,10,,39,',1,''),(703,2,'关于协会的简称，以下错误的是：','AACE美国临床内分泌医师协会','ACE美国内分泌学院','ADA美国糖尿病协会','NYHA美国心脏协会','','','','',NULL,'D',1,',11,,10,,39,',1,''),(704,2,'美国临床内分泌医师协会的简写?','AACE','AHA','ACE','ADA','','','','',NULL,'A',1,',11,,10,,39,',1,''),(705,2,'美国内分泌学院的简写?','IDF','AHA','ACE','ADA','','','','',NULL,'C',1,',11,,10,,39,',1,''),(706,2,'TZD类药物也能直接或间接保护胰腺β细胞，作用是：','改善胰岛素敏感性，减低对β细胞的需求','降低游离脂肪酸水平，减少脂毒性','减少胰腺β细胞凋亡','无作用','','','','',NULL,'C',1,',11,,10,,39,',1,''),(707,2,'胰腺包括外分泌和内分泌功能，下列不是胰腺内分泌的是?','胰岛素','胰高血糖素','胰多肽','胰蛋白酶','','','','',NULL,'D',1,',11,,10,,39,',1,''),(708,3,'兰索拉唑独特的氟导入机制的作用','药物脂溶性增强','生物利用度提升','起效更快','药物作用更强','','','','',NULL,'ABCD',1,',19,,20,',1,''),(709,3,'普托平®口崩片适用于更广泛的特殊患者人群','老年患者','GRED患者','合并糖尿病患者','吞咽困难的患者','','','','',NULL,'ABCD',1,',19,,20,',1,''),(710,3,'说明书中达克普隆/普托平可以治疗的适应症有','胃溃疡','十二指肠溃疡','吻合口溃疡','卓-艾综合症','','','','',NULL,'ABCD',1,',19,,20,',1,''),(711,3,'第三代PPI剂型普托平的特点有','口腔内迅速崩解，容易吞咽','可不用水服药，给药方便','草莓味道病人容易接受','可以用于鼻饲','','','','',NULL,'ABCD',1,',19,,20,',1,''),(712,3,' 与消化性溃疡相关的因素有','高血脂','HP感染','NSAIDs药物的使用','应激','','','','',NULL,'BCD',1,',19,,20,',1,''),(713,3,'氯吡格雷说明书中，不推荐奥美拉唑与氯吡格雷合用；（        ）  对CYP2C19酶的抑制作用较弱，可作为与氯吡格雷合用的供选方案 ','兰索拉唑','奥美拉唑','潘托拉唑','埃索美拉唑 ','','','','',NULL,'AC',1,',19,,20,',1,''),(714,3,'2012年在JACC（美国心脏病学会杂志）发表了旨在评估不同PPIs对氯吡格雷PK/PD（药代学/药效学）的影响的研究，主要采用的PPI为','兰索拉唑和右兰索拉唑','潘托拉唑','雷贝拉唑','奥美拉唑和埃索美拉唑','','','','',NULL,'AD',1,',19,,20,',1,''),(715,3,'达克普隆®独特氟基结构带来利益是','强结合','快透膜','利分布','促吸收','','','','',NULL,'ABCD',1,',19,,20,',1,''),(716,3,'兰索拉唑三氟乙基的引入，对药物分子带来的改变是：','增强了负电性','提高了水溶性','提高了脂溶性','提高了溶解度','','','','',NULL,'AC',1,',19,,20,',1,''),(717,3,'普托平口崩片的微粒包括哪些结构','无活性核心','活性药物层','底部包裹层','第一二三肠溶衣层','保护膜层','','','',NULL,'ABCDE',1,',19,,20,',1,''),(718,3,'允许连续5小时缓慢静脉滴注的PPI注射剂包括','潘妥洛克注射剂','洛赛克静滴剂型','耐信注射液','国产兰索拉唑注射液','国产泮托拉唑注射液','','','',NULL,'ABC',1,',12,',1,''),(719,3,'国内对 2004 ~ 2009 年 1 5 20 例 上消化道出血患者临床资料进行回顾性调查分析.上消化道出血前 3 位病因    ','消化性溃疡','食道胃底静脉曲张','食管 - 贲门黏膜撕裂症',' 胃癌','','','','',NULL,'ABD',1,',12,',1,''),(720,3,'SRMD也曾经称为','应激性溃疡','急性胃黏膜病变','急性糜烂性胃炎','急性出血性胃炎','','','','',NULL,'ABCD',1,',12,',1,''),(721,3,'2009年“普通外科应激性黏膜病变的预防与治疗—中国普通外科专家建议”显示：有效地防治SRMD将显著改善外科病人的预后。该指南指出，SRMD的危险因素众多，在胰腺外科中常见的主要包括：','重症急性胰腺炎','胰腺外伤','各种类型的胰腺外科手术','梗阻性黄疸','','','','',NULL,'ABCD',1,',12,',1,''),(722,3,'肝胆疾病导致急性胃粘膜病变的相关机制','肝功能不全，凝血功能障碍','感染中毒','胆汁反流入胃','术后合并症导致器官功能衰竭','低血压','','','',NULL,'ABCDE',1,',12,',1,''),(723,3,'与注射用泮托拉唑仿制药、注射用兰索拉唑仿制药、注射用奥美拉唑原研药和注射用埃索美拉唑原研药相比，潘妥洛克注射液具有以下特点：','静推时间短（＞2分钟）','静滴时间范围宽（15-60分钟）','配置液保存时间长（12小时）','即可静滴，又可静推','配液无需专业溶媒','','','',NULL,'ABCDE',1,',12,',1,''),(724,3,'非静脉曲张性UGIB病因包括：','急性胃黏膜病变','胃癌','  消化性溃疡','食管裂孔疝','吻合口出血','','','',NULL,'ABCDE',1,',12,',1,''),(725,3,'潘妥洛克针剂与0.9%生理盐水混合制成待用液后可以：','与100ml 0.9%生理盐水混合后静脉输入','与100ml 5%葡萄糖溶液混合后静脉输入','与100ml 10%葡萄糖溶液混合后静脉输入','直接静脉推注','与100ml 5%果糖溶液混合后静脉输入','','','',NULL,'ABD',1,',12,',1,''),(726,3,'允许快速静脉推注的PPI注射剂包括','潘妥洛克注射液               ','洛赛克两种剂型',' 国产泮托拉唑   ','耐信注射液','','','','',NULL,'AD',1,',12,',1,''),(727,3,'潘妥洛克注射剂在国内的注册适应症为','中重度反流性食管炎','胃、十二指肠溃疡','应激性溃疡','十二指肠溃疡、胃溃疡、急性胃粘膜病变、复合性胃溃疡等引起的急性上消化道出血','','','','',NULL,'ABD',1,',12,',1,''),(728,3,'注射用埃索美拉唑国内注册适应症为：','中重度反流性食管炎','胃、十二指肠溃疡','作为口服疗法不适用时GERD的替代疗法','十二指肠溃疡、胃溃疡、急性胃粘膜病变、复合性胃溃疡等引起的急性上消化道出血','口服疗法不适用的急性胃或十二指肠溃疡出血的低危患者（胃镜下Forrest分级IIc--III级）','','','',NULL,'CE',1,',12,',1,''),(729,3,'超出适应症使用药物的风险：','由于缺乏安全性研究，增加临床用药发生不良反应风险','直接威胁到患者用药安全','医保拒付','医生难辞其咎，如果发生纠纷，得不到法律保护','','','','',NULL,'ABCD',1,',12,',1,''),(730,3,'潘妥洛克®在UGIB治疗中的应用的优势：','安全性：药物相互作用少，肝肾功能不全者无需调整剂量\n','疗效可靠：持久强效抑酸\n\n','品质可靠：配液稳定，使用方便\n','处方可靠：适应症广泛，放心选择，减少医疗风险\n','','','','',NULL,'ABCD',1,',12,',1,''),(731,3,'SRMD常见病因有？','心脑血管意外','严重烧伤','严重心理应激','大手术','','','','',NULL,'ABCD',1,',12,',1,''),(732,3,'以下引起SRMD的危险因素中属于主要危险因素的有？','烧伤>35%','器官移植','机械通气＞48小时','凝血功能障碍（INR）','','','','',NULL,'CD',1,',12,,18,,19,,20,,39,',1,''),(733,3,'以下属于SRMD临床特点的有？','病情愈重、发病率越高','一旦发病、死亡率很高','发病时间集中在24H-10天，尤其3-5天内','主要临床表现为出血','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(734,3,'胃粘膜血流的作用包括？','提供营养和氧气','排出废物与CO2','快速稀释及运走逆向扩散的H+','提供修复受损粘膜恢复所需的物质','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(735,3,'以下属于SRMD预防药物的有？','抗酸剂','H2受体拮抗剂','质子泵抑制剂','黏膜保护剂','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(736,3,'使用抗血小板药物易发生消化道损伤的高危人群：','65岁以上的老年患者','合用抗凝药物(如华法林)、NSAIDs或糖皮质激素的患者','Hp感染、吸烟、饮酒的患者','双联抗血小板治疗的患者','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(737,3,'在进行抗血小板治疗使用氯吡格雷时，也同时会带来消化道损伤的风险，以下说法正确的是：','氯吡格雷是ADP受体拮抗剂，通过阻断血小板膜ADP受体发挥抗血小板作用','氯吡格雷不直接损伤消化道黏膜','氯吡格雷可加重已存在的胃肠道黏膜损伤，包括NSAIDs、阿司匹林和HP+感染导致的消化道损伤','氯吡格雷通过抑制血小板衍生的生长因子和血小板释放的血管内皮生长因子，阻碍新生血管生成，影响溃疡愈合1','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(738,3,'部分PPI可抑制CYP2C19通路而影响氯吡格雷的活化，其程度取决于PPI的（）及其与CYP2C19的（）”\n','代谢途径','分子量大小','亲和力','脂溶性','','','','',NULL,'AC',1,',18,',1,''),(739,3,'GERD诊断方法',' 症状-GERD Q\n','PPI试验治疗','内镜检查','食管测压','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(740,3,'潘妥洛克配置液可以用哪种溶液混合后静脉滴注','0.9%生理盐水注射液','5%葡萄糖注射液\n','10%葡萄糖溶液      ','20%果糖溶液','','','','',NULL,'AB',1,',12,',1,''),(741,3,'泮托拉唑可以选择性的作用在质子泵上的那些位点','Cys813','Cys822','Cys321','Cys892','','','','',NULL,'AB',1,',18,',1,''),(742,2,'潘妥洛克是德国原创专利产品，片剂在多少个国家/地区上市','110','111','112','113','','','','',NULL,'C',1,',18,',1,''),(743,2,'潘妥洛克肠溶片是德国原创专利产品，（）年在德国上市','1990','1992','1996','2001','','','','',NULL,'C',1,',18,',1,''),(744,2,'潘妥洛克肠溶片每片含有有效成分潘妥洛克钠的含量是','40毫克 ','38毫克','43.1毫克 ','45.1毫克','','','','',NULL,'D',1,',18,',1,''),(745,2,'实验证明使用潘妥洛克后的酸分泌恢复的半数时间为','12.9小时','27.5小时','45.9小时 ','51.9小时','','','','',NULL,'C',1,',18,',1,''),(746,2,'潘妥洛克可以用于老年和肾功能不全的患者，其机理是作用','线性药代动力学','与质子泵靶向性结合','生物利用度高且稳定','独特的二相代谢','','','','',NULL,'D',1,',18,',1,''),(747,2,'潘妥洛克首次用药的生物利用度是','0.89','0.72','0.77','0.6','','','','',NULL,'C',1,',18,',1,''),(748,2,'与其他PPIs相比，为什么潘妥洛克的抑酸时间更长','潘妥洛克与H+/K+-ATP酶的共价结合       ','潘妥洛克与质子泵核心的半胱氨酸813特异性结合','潘妥洛克与质子泵核心的半胱氨酸822特异性结合','潘妥洛克与质子泵核心的半胱氨酸823特异性结合','','','','',NULL,'C',1,',12,',1,''),(749,2,'各种PPI药物的酸稳定性是有差异的，请问哪一种PPI的酸稳定性最好','奥美拉唑                ','泮托拉唑','兰索拉唑           ','雷贝拉唑','','','','',NULL,'B',1,',12,',1,''),(750,2,'下例哪种质子泵抑制剂口服剂量的尿排泄率最低的','奥美拉唑','雷贝拉唑','兰索拉唑','埃索美拉唑','','','','',NULL,'A',1,',18,',1,''),(751,2,'PPIs与CYP2c19的亲和力哪种说法是错误的？','奥美拉唑与之亲和力最低','泮托拉唑与之亲和力最低','雷贝拉唑与之亲和力最高','泮托拉唑与之亲和力最高','','','','',NULL,'B',1,',18,',1,''),(752,2,'SRMD发作时间集中在？','24h内','24h-10d','15d-30d','半年内','','','','',NULL,'B',1,',18,',1,''),(753,2,'潘妥洛克的生物利用度是多少？','0.54','0.77','0.67','0.8','','','','',NULL,'B',1,',18,',1,''),(754,2,'影响潘妥洛克吸收的因素为？','制酸剂','食物','抗生素','以上皆非','','','','',NULL,'B',1,',18,',1,''),(755,2,'潘妥洛克标准剂量（40mg）的抑酸作用与奥美拉唑多少mg相同？','10(半数标准剂量)','20(标准剂量)','40(双倍标准剂量)','80(四倍标准剂量)','','','','',NULL,'C',1,',18,',1,''),(756,2,'潘妥洛克联合抗生素Hp根除率≥？','0.5','0.6','0.8','0.9','','','','',NULL,'C',1,',18,',1,''),(757,2,'\"一项头对头比较泮托拉唑和埃索美拉唑在缓解GERD相关症状方面的疗效的研究，结果显示：泮托拉唑 (40 mg/d.) 与埃索美拉唑 (40 mg/d) 在缓解GERD相关症状方面疗效相似的情况下，泮托拉唑较埃索美拉唑缓解日间和夜间的GERD相关症状的速度： ','更快','相当','更慢','不好说','','','','',NULL,'A',1,',18,',1,''),(758,2,'在连续服用40mg潘妥洛克5年的患者中，潘妥洛克引起的不良反应发生率小于 ？','0.01','0.05','0.08','0.11','','','','',NULL,'A',1,',18,',1,''),(759,2,'每日1片（ 40 mg ）潘妥洛克，对于胃溃疡患者标准疗程为？','1w-2w','2w-4w','3w-4w','4w-8w','','','','',NULL,'D',1,',18,',1,''),(760,2,'每日1片（ 40 mg ）潘妥洛克，对于十二指肠溃疡患者标准疗程为？','1w-2w','2w-4w','3w-4w','4w-8w','','','','',NULL,'B',1,',18,',1,''),(761,2,'每日1片（ 40 mg ）潘妥洛克，对于反流性食管炎患者标准疗程为？','1w-2w','2w-4w','3w-4w','4w-8w','','','','',NULL,'D',1,',18,',1,''),(762,2,'潘妥洛克，对于根除hp标准疗程为？','1w-2w','2w-4w','3w-4w','4w-8w','','','','',NULL,'A',1,',18,',1,''),(763,2,'潘妥洛克用于根除hp时剂量为？','40mg qd','40mg bid','80mg qd','80mg bid','','','','',NULL,'B',1,',18,',1,''),(764,2,'潘妥洛克用于胃溃疡或十二指肠溃疡时剂量为？','40mg qd','40mg bid','80mg qd','80mg bid','','','','',NULL,'A',1,',18,',1,''),(765,2,'潘妥洛克用于治疗反流性食管炎时剂量为？','40mg qd','40mg bid','80mg qd','80mg bid','','','','',NULL,'A',1,',18,',1,''),(766,2,'以下PPI胃壁细胞选择性最高的是','潘托拉唑','兰索拉唑','奥美拉唑','雷贝拉唑','','','','',NULL,'A',1,',18,',1,''),(767,2,'对于GERD相关的糜烂性食管炎的治愈和症状缓解，PPI治疗的通常疗程为多久',' 一周','4~8周','2~4周','10周','','','','',NULL,'B',1,',18,',1,''),(768,2,'PPIs与氯吡格雷，一项观察药物间相互作用的巢式病例研究显示： 90天内由于心梗再入院与以下哪项有关？       ','再入院前30天内服用PPI','再入院前31-90天服用PPI ','再入院前91-180天服用PPI ','以上均相关','','','','',NULL,'A',1,',18,',1,''),(769,2,'PPIs与氯吡格雷，一项观察药物间相互作用的巢式病例研究显示： 在需氯吡格雷和PPI合并用药时，其他PPIs较泮托拉唑增加复发性心梗的风险                        ','0.32','0.35','0.4','0.44','','','','',NULL,'C',1,',18,',1,''),(770,2,'一项对比奥美拉唑和泮托拉唑在人体内的药代动力学和药效学研究，结果显示，被抑制后质子泵半数恢复胃酸分泌所需的时间，泮托拉唑为（）小时，比奥美拉唑长66.9%','27.5','30.6','45.9','72','','','','',NULL,'C',1,',12,',1,''),(771,2,'PACA是一项前瞻、随机的研究，纳入104例置入冠脉支架的NSTE ACS患者（非ST段抬高的急性冠脉综合症），出院时给予阿司匹林（）mg和氯吡格雷（）mg长期口服，','75，75','75，150','150，75','300，300','','','','',NULL,'B',1,',18,',1,''),(772,2,'PACA是一项前瞻、随机的研究，纳入104例置入冠脉支架的NSTE ACS患者（非ST段抬高的急性冠脉综合症），随机分为奥美拉唑或泮托拉唑组，给药剂量分别是：','奥美拉唑20mg，泮托拉唑20mg','奥美拉唑40mg，泮托拉唑20mg','奥美拉唑20mg，泮托拉唑40mg','奥美拉唑40mg，泮托拉唑40mg','','','','',NULL,'A',1,',18,',1,''),(773,2,'PACA是一项前瞻、随机的研究，纳入104例置入冠脉支架的NSTE ACS患者（非ST段抬高的急性冠脉综合症），出院时给予阿司匹林75mg和氯吡格雷150mg长期口服，并随机分为奥美拉唑20mg组或泮托拉唑20mg组，经治疗1个月后，泮托拉唑组氯吡格雷的血小板反应性显著优于奥美拉唑组，PRI VASP(%)分别为（） 和（），有明显统计学差异','23%，44%','44%，23%','48%，36%','36%，48%','','','','',NULL,'D',1,',18,',1,''),(774,2,'药物相互作用最少的PPI是','潘妥洛克','洛赛克','耐信','兰索拉唑           ','','','','',NULL,'A',1,',12,',1,''),(775,2,'2013年发表的抗血小板药物消化道损伤的预防和治疗中国专家共识指出：服用抗血小板药物后，（）个月内为消化道损伤的多发阶段','1','3','6','12','','','','',NULL,'D',1,',18,',1,''),(776,2,'2013年发表的抗血小板药物消化道损伤的预防和治疗中国专家共识指出：服用抗血小板药物后， （）个月时消化道损伤达到高峰','1','3','6','12','','','','',NULL,'B',1,',18,',1,''),(777,2,'每日一次潘妥洛克的最佳服用时间是：','早餐前30~60分钟','早餐后30~60分钟','与餐同服',' 晚餐前','','','','',NULL,'A',1,',18,',1,''),(778,2,'泮托拉唑在FDA妊娠用药安全级别中为哪一级？','分类A：在有对照组的早期妊娠妇女中未显示对+F11胎儿有危险(并在中、晚期妊娠中亦无危险的证据),可能对胎儿的伤害极小。\n','分类B：动物生殖实验未显示对胎仔有危害，但尚缺乏临床对照观察资料，或者动物生殖实验中观察到对胎仔有损害，但尚未在妊娠早期临床试验中得到证实。','分类C：在动物的研究中证实对胎儿有副反应(致畸或使胚胎致死或其他)，但在妇女中无对照组或在妇女和动物研究中无可以利用的资料。药物仅在权衡对胎儿的利大于弊时给予','分类D：对人类胎儿的危险有肯定的证据，但尽管有害，对孕妇需肯定其有利，方予应用(如对生命垂危或疾病严重而无法应用较安全的药物或药物无效)，','分类X：动物或人的研究中已证实可使胎儿异常，或基于人类的经验知其对胎儿有危险，对人或对两者均有害，而且该药物对孕妇的应用，其危险明显地大于任何有益之处。该药禁用于已妊娠或将妊娠的妇女。','','','',NULL,'B',1,',12,',1,''),(779,2,'患者晚上服用PPI后，胃PH值       的持续时间超过       就称为夜间酸突破(NAB)','pH值<3，60min以上','pH值<4，60min以上','pH值<3，120min以上','pH值<4，120min以上','','','','',NULL,'B',1,',19,,20,',1,''),(780,2,'目前可与Cys822结合的PPI是？','雷贝拉唑','埃索美拉唑','泮托拉唑','奥美拉唑','','','','',NULL,'C',1,',12,',1,''),(781,2,'潘妥洛克®不良反应发生率与安慰剂相比','与安慰剂相当','低于安慰剂','略高于安慰剂','远高于安慰剂','','','','',NULL,'A',1,',12,',1,''),(782,2,'潘妥洛克®片的性状为','白色肠溶衣片，除去包衣后显白色或类白色','黄色普通片','白色普通片','黄色肠溶衣片，除去包衣后显白色或类白色','','','','',NULL,'D',1,',18,',1,''),(783,2,'严重肝功能受损的患者潘妥洛克®片剂量为','1 片泮托拉唑肠溶片（40mg 泮托拉唑肠溶片）×2 次/日','每日一次，每次1片泮托拉唑肠溶片（40mg 泮托拉唑肠溶片）','隔日1 片（40mg 泮托拉唑肠溶片）。','严禁使用','','','','',NULL,'C',1,',18,',1,''),(784,2,'潘妥洛克®片的服用方式为：','餐前，整片吞服','餐后，整片吞服','餐前，咀嚼或咬碎服用','餐后，咀嚼或咬碎服用','','','','',NULL,'A',1,',18,',1,''),(785,2,'潘妥洛克®静脉输入或口服10-80 mg 后，AUC（ 浓度时间曲线下面积）和Cmax（血药浓度峰值）均随剂量的增加如何变化','略有降低','不可预知的变化','无明显变化','成比例增加','','','','',NULL,'D',1,',12,',1,''),(786,2,'泮托拉唑的代谢产物大部分（约     ）由肾脏排出，其余由胆汁分泌从粪便中排出。','0.8','0.45','0.25','0.55','','','','',NULL,'A',1,',12,',1,''),(787,2,'潘妥洛克片的有效期是：','12个月','24个月','36个月','60个月','','','','',NULL,'C',1,',18,',1,''),(788,2,'泮托拉唑在老年人体内的药代动力学对比正常人群总清除率      ，半衰期       。 ','增加，变短','降低，延长','无明显变化，无明显变化','不可知，不可知','','','','',NULL,'C',1,',18,',1,''),(789,2,'雷贝拉唑在老年人体内的药代动力学对比正常人群总清除率      ，半衰期       。 ','增加，变短','降低，延长','无明显变化，无明显变化','不可知，不可知','','','','',NULL,'B',1,',18,',1,''),(790,2,'奥美拉唑在老年人体内的药代动力学对比正常人群总清除率      ，半衰期       。 ','增加，变短','降低，延长','无明显变化，无明显变化','不可知，不可知','','','','',NULL,'B',1,',18,',1,''),(791,2,'中国2014GERD专家共识指出对于长期使用PPI治疗的患者，应使用      剂量，包括按需服药与间歇服药。','最高','最低','最低有效','最高有效','','','','',NULL,'C',1,',18,',1,''),(792,2,'泮托拉唑的血浆蛋白结合率是多少','0.92','0.85','0.98','0.95','','','','',NULL,'C',1,',12,',1,''),(793,2,'泮托拉唑的主要代谢物为，','泮托拉唑磺酸盐','去甲基泮托拉唑','泮托拉唑去甲基硫酸酯','泮托拉唑原型','','','','',NULL,'C',1,',18,',1,''),(794,2,'正常胃液PH值约为？','1--3','3.1--4.5','4.5-7.5','3.5--7','','','','',NULL,'A',1,',18,',1,''),(795,3,'潘妥洛克的临床特点有哪些','溃疡愈合率更高','症状缓解更快','UGIB再出血率更低','安全性更好','','','','',NULL,'ABCD',1,',18,',1,''),(796,3,'潘妥洛克制剂形式？','胶囊','冻干粉针剂','肠溶片','分散颗粒剂','','','','',NULL,'BC',1,',18,',1,''),(797,3,'下述哪项有关潘妥洛克的描述是正确的？','潘妥洛克发生药物相互作用的可能比其它PPIs低','进食可影响潘妥洛克的生物利用度','潘妥洛克的药代动力学分布呈线性、且更可预见','潘妥洛克的个体间差异大','','','','',NULL,'AC',1,',18,',1,''),(798,3,'2010年10月FDA的警示内容是什么？','对氯吡格雷与奥美拉唑联合应用发出警示','前两者合用会发生药物相互作用的风险','泮托拉唑对氯吡格雷的影响较小','联合应用时泮托拉唑应作为优先的选择','','','','',NULL,'ABCD',1,',18,',1,''),(799,3,'潘妥洛克口服40mg的适应症为？','中度和重度反流性食管炎的治疗','胃、十二指肠溃疡','病理性高分泌，如Zollinger-Ellison综合症','根除幽门螺旋杆菌感染，以减少该微生物所致的十二指肠溃疡和胃溃疡的复发','','','','',NULL,'ABD',1,',18,',1,''),(800,3,'以下属于潘妥洛克产品特点的有？','愈合率更高','症状缓解更快','再出血率更低','安全性更好','','','','',NULL,'ABCD',1,',18,',1,''),(801,3,'以下属于潘妥洛克药理学特点的有？','生物利用度高','酸稳定性最高','与质子泵靶向结合','药物相互作用最少','','','','',NULL,'ABCD',1,',18,',1,''),(802,3,'以下抗生素可与潘妥洛克合用根治hp的有？','甲硝唑','泰能','阿莫西林','克拉霉素','','','','',NULL,'ACD',1,',18,',1,''),(803,3,'酸分泌恢复的半数时间中说法正确的是','潘托拉唑为45.9小时\n预期如质子泵的合成','奥美拉唑、埃索美拉唑27.5小时，速度快于质子泵的合成','雷贝拉唑为27.5小时，速度快于质子泵的合成','潘妥洛克抑酸更持久，避免了“夜间酸突破”的发生','','','','',NULL,'ABCD',1,',18,',1,''),(804,3,'潘妥洛克的药代动力学描述正确的有','线性','曲线','可预测血药浓度及药物作用','保证用药合理、安全\n','','','','',NULL,'ACD',1,',18,',1,''),(805,3,'GERD 症状以下列哪些方式影响患者生活质量？','睡眠障碍',' 提高工作能力','抑郁',' 降低社会功能','','','','',NULL,'ACD',1,',12,,18,,19,,20,,39,',1,''),(806,3,'以下有关潘妥洛克片描述正确的是 ','根除HP治疗中有甲硝唑的方案仅在其他方案不能根除HP的情况下方予使用','肾功能受损及老年患者每日剂量一般不应超过40mg，但根除HP时，老年患者在一周治疗中也使用常规剂量（40mg*2次/日）','严重肝功能受损患者应减少至隔日一片','在根除HP治疗中，有中、重肝肾功能障碍的患者禁用本品','','','','',NULL,'ABCD',1,',18,',1,''),(807,3,'以下那个药理特性说明潘妥洛克安全性？','线性药代动力学特征','独特II相代谢，对CYP2C19亲和力更低','德国制造，配置液稳定性高','与质子泵Cys822靶向性结合',' 酸稳定性高, 高组织选择性','','','',NULL,'ABCE',1,',18,',1,''),(808,3,'以下对于胃溃疡和十二指肠溃疡描述正确的是','胃溃疡发生年龄较大，多为40-60岁左右，十二指肠溃疡发生年龄相对年轻，在20-40岁左右','胃溃疡和十二指肠溃疡都有可能发生癌变','十二指肠溃疡的发生机制主要是胃酸分泌过高','胃和十二指肠溃疡都是以男性为多。','','','','',NULL,'ACD',1,',12,,18,,19,,20,,39,',1,''),(809,3,'以下属于消化性溃疡发病机制中的攻击因素为','胃酸','胃蛋白酶','幽门螺杆菌','非甾体抗炎药','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(810,3,'以下属于消化性溃疡发病机制中粘膜防御因素为','粘膜粘液','粘膜血液','HCO3','上皮细胞再生','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(811,3,'以下属于美国FDA要求所有NSAIDs在说明书中增加黑框警告的是','心血管风险','呼吸系统风险','消化道风险','神经系统风险','','','','',NULL,'AC',1,',12,,18,,19,,20,,39,',1,''),(812,3,'与幽门螺杆菌Hp相关的疾病有','胃炎','消化性溃疡','胃癌','胃粘膜相关淋巴组织淋巴瘤','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(813,3,'GERD的主要症状为','反酸','烧心','呃气','吞咽困难','','','','',NULL,'AB',1,',12,,18,,19,,20,,39,',1,''),(814,3,'GERD的食管外并发症可以有','哮喘','慢性咽喉炎','肾炎','慢性咳嗽','','','','',NULL,'ABD',1,',12,,18,,19,,20,,39,',1,''),(815,3,'属于GERD生活方式调整的有','戒烟','减肥','床头抬高','避免过紧的裤子/皮带','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(816,3,'GERD的治疗药物有','制酸剂','抑酸剂','促胃肠蠕动剂','粘膜保护剂','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(817,3,'对CYP2C19酶影响较大的PPI有','埃索美拉唑','泮托拉唑','兰索拉唑','奥美拉唑','','','','',NULL,'AD',1,',12,,18,,19,,20,,39,',1,''),(818,3,'PPI为何会与氯吡格雷发生药物相互作用？','PPI和氯吡格雷有药物冲突','共同竞争P450酶，影响药物通过CYP2c19的代谢','PPI降低胃酸使氯吡格雷失活','氯吡格雷降低PPI的抑酸能力','','','','',NULL,'AB',1,',12,,18,,19,,20,,39,',1,''),(819,3,'为什么抑酸能够止痛？','减少胃酸对溃疡的刺激','缓解胃壁痉挛','减少胃酸对溃疡及其周围组织炎症','降低局部肌张力增高','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(820,3,'以下属于应激性溃疡预防药物的有？','抗酸剂','H2受体拮抗剂','质子泵抑制剂','黏膜保护剂','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(821,3,'使用抗血小板药物易发生消化道损伤的高危人群，包括：','有消化道出血、溃疡病史','有消化不良或有胃食管反流症状','双联抗血小板治疗的患者','合用抗凝药物(如华法林)、NSAIDs或糖皮质激素的患者','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(822,3,'GERD的治疗目标：',' 缓解症状','治愈食管炎','提高生活质量','预防复发和并发症','','','','',NULL,'ABCD',1,',12,,18,,19,,20,,39,',1,''),(823,3,'哪些因素参与消化性溃疡形成','幽门螺杆菌(H. pylori)感染','使用阿斯匹林和其他非类固醇消炎药 (NSAIDs)','吸烟','胃排空延迟','遗传','','','',NULL,'ABCDE',1,',12,,18,,19,,20,,39,',1,''),(824,3,'下面有关于幽门螺旋杆菌的描述那一个是正确的？','在慢性十二指肠溃疡患者中根除感染可预防溃疡进展。','部分消化性溃疡患者伴有细菌感染。','此种感染在美国罕见。','单用PPI可有效治愈此类感染。','','','','',NULL,'AB',1,',12,,18,,19,,20,,39,',1,''),(825,2,'以下叙述哪个最准确描述了消化性溃疡？','由十二指肠向胃的酸反流导致','定义为损坏超过胃粘膜下层','只发生在胃','发生在25%的美国人一生中的某一时间','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(826,2,'酸反流导致的胃食管反流病主要是由于','唾液腺分泌障碍','食管收缩减低','胃酸分泌过多','食管下括约肌功能障碍','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(827,2,'卓-艾综合症的特点不包括','食管狭窄。','血液中高水平胃泌素。','胃酸分泌过多','小肠溃疡','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(828,2,'下列哪一个不是胃的功能?','吸收水和盐','消化蛋白质','酶解碳水化合物','分泌内因子','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(829,2,'小肠的第一段称为','盲肠','十二指肠','回肠','空肠','','','','',NULL,'B',1,',19,,20,',1,''),(830,2,'胰腺产生以下物质帮助消化，除了','淀粉酶.','胆汁','脂肪分解酶','胰蛋白酶','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(831,2,'胃腺包含以下细胞类型，除了','主细胞','胃泌素分泌细胞.','粘液细胞','壁细胞','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(832,2,'胃酸通过激活胃蛋白酶原消化','碳水化合物','脂肪','脂质','蛋白质','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(833,2,'壁细胞内质子泵的其他名称包括','H+/Cl-ATP酶.','氢钾泵.','氢氧根离子泵.','以上都不是','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(834,2,'下列哪一个是迷走神经释放的刺激胃酸分泌的物质？','乙酰胆碱','胃泌素','组胺','生长抑素','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(835,2,'以下都是胃肠道的重要防御机制，除了','碳酸氢盐分泌.','血流减少.','粘液分泌.','前列腺素合成.','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(836,2,'消化性溃疡是一种胃和/或十二指肠壁的浅表破损，通常愈合不会留下瘢痕。','正确','错误，消化性溃疡不是浅表的，涉及深层组织，会导致疤痕。','错误，消化性溃疡通常不会愈合，但是症状能缓解','','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(837,2,'下列哪一项不参与消化性溃疡的形成','吸烟','幽门螺杆菌感染','前列腺素','非甾体抗炎药','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(838,2,'正常保护食管免受胃酸损伤的因素包括以下，除了','重力','唾液','食管下括约肌','幽门括约肌','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(839,2,'在美国，胃食管反流病影响人群','0.05','0.1','0.15','0.2','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(840,2,'胃泌素瘤通常发生在','十二指肠','食管','胰腺','胃','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(841,2,'口腔中唾液开始分解','碳水化合物','脂肪','脂质','蛋白质','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(842,2,'小肠的哪一段与大肠的盲肠相连?','十二指肠','回肠','空肠','直肠','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(843,2,'消化中胆汁帮助','帮助蛋白质消化.','增加胰腺分泌','促进脂肪吸收.','保护胃黏膜.','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(844,2,'以下哪个器官在毒物到达身体其它部分前解毒?','胆囊','大肠','肝脏','小肠溃疡','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(845,2,'胃肠道组织层具有保护、分泌和吸收功能的是','粘膜层.','外肌层. ','浆膜层','粘膜下层','','','','',NULL,'A',1,',19,,20,',1,''),(846,2,'胃内调节食糜进入十二指肠的区域是','胃窦','贲门.','胃底','幽门','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(847,2,'内因子由细胞产生','主细胞','胃泌素分泌细胞','粘液细胞','壁细胞','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(848,2,'壁细胞中的质子泵','通过与氢离子交换获得氯离子.','交换细胞外的氢离子和细胞内的钾离子.','交换细胞内的氢离子和细胞外的钾离子.','.被动运输，不需要能量.','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(849,2,'下列哪种离子从血液中顺浓度梯度进入细胞？','氯离子','氢离子','钾离子','以上都不是','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(850,2,'壁细胞包括以下受体，除了','乙酰胆碱','胃泌素','组胺','生长抑素','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(851,2,'以下物质刺激胃酸分泌，除了','乙酰胆碱','氨基酸','胃泌素','促胰液素','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(852,2,'下列哪一个降低胃酸分泌速率？','乙酰胆碱','胃泌素','组胺','生长抑素','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(853,2,'碳酸氢盐由分泌','十二指肠腺','胰腺细胞','表面粘液细胞','以上所有','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(854,2,'以下那个不是胃肠道产生前列腺素的功能？','增加氢离子产生','促进上皮细胞更新','减少酸分泌','刺激碳酸氢盐分泌','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(855,2,'溃疡的手术治疗','通常必要。','对于出血性溃疡而言优于内镜治疗。','可能涉及迷走神经切断。','通常需要切除胃贲门。','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(856,2,'下面哪一项检查可用于确诊消化性溃疡？','钡餐','X线平片','粪检','胃镜','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(857,2,'在正常剂量下，下面哪一项的药物在降低胃酸度有效性方面是按由弱至强的顺序排列的？','制酸剂，H2RA，PPIs','H2Ras，制酸剂，PPIs','PPIs，制酸剂，H2RAs','三种药物在降低胃酸度方面效果相同','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(858,2,'在出血性溃疡患者中下面哪一项是不常见的？','黑便','血尿','头晕','低血压','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(859,2,'就幽门螺旋杆菌相关性溃疡患者的PPI应用而言，下面哪一项是错误的？','在治疗溃疡方面PPI不如H2RA有效','PPI可减轻与消化性溃疡相关的疼痛','PPI可加速溃疡愈合。','','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(860,2,'下面哪一个是GERD的常见症状','哮喘','慢性咳嗽','声嘶','反流','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(861,2,'当患者伴有典型烧心症状，常处理是:','开始胃酸抑制经验性治疗','利用24小时pH值监测诊断','进行内镜检查','食管压力测定','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(862,2,'糜烂性食管炎患者','低剂量H2RA可有效治愈.','粘膜层完整','往往需要维持治疗','治愈后不会复发','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(863,2,'Barrett食管:','胃细胞转变为食管细胞','50%的GERD患者可出现','是一种癌前病变','需要切除食管','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(864,2,'下面哪一项描述是错误的？','OTC制酸剂可能足以治疗轻度GERD','PPI抑制胃酸能力强于H2RA','就消除患者症状而言PPI可能需要长期治疗','在抑制胃酸分泌治疗开始前应试用胃动力药','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(865,2,'抗反流手术','任何外科医生均能胜任','是控制症状的最后手段','基本由腹腔镜尼森胃底折叠术完成','需要长期恢复','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(866,2,'ZES患者的肿瘤可分泌','胆汁','胃酸','胰岛素','胃泌素','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(867,2,'下面哪一项描述是错误的','全胃切除经常被用于治疗ZES。','大剂量胃酸抑制药物常用','通过手术切除肿瘤患者可能获得痊愈。','胃泌素瘤可为恶性。','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(868,2,'下面哪一项不是ZES的常见表现。','消化性溃疡出血','慢性咳嗽','腹泻','糜烂性食管炎','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(869,2,'下面有关于消化性溃疡的描述哪一项是正确的？','约有50%的患者每年需卧床一周以上','胃和十二指肠溃疡通常同时出现在一个患者身上','其随着年龄增长而减少','粘膜被破坏，导致粘膜肌层暴露于胃酸和胃蛋白酶','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(870,2,'与消化性溃疡相关的最重要因素是','胃酸高分泌','HP感染','吸烟','应激','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(871,2,'下面哪一项不是消化性溃疡的危险因素','HP感染','严重应激事件','NSAID应用','妊娠','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(872,2,'下面哪一项不是消化性溃疡的并发症','食管炎','慢性瘢痕形成','溃疡出血','溃疡穿孔','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(873,2,'PPI通过什么抑制胃酸分泌','与受体竞争性结合','抑制H+/K+-ATP酶活动。','中和胃酸','上述机制均不是','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(874,2,'为了减少HP相关的消化性溃疡复发，治疗应包括','抗生素和抗胃酸分泌药物','NSAIDs','PPI治疗','H2RA处方药','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(875,2,'下面哪一项不是PPI治疗消化性溃疡的优势？','有效抑制胃酸','能够根除HP感染','使抗生素更为有效','减轻疼痛。','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(876,2,'Barrett食管','导致鳞状细胞转化为柱状细胞。','是消化性溃疡的并发症之一。','是一种遗传性疾病','约半数GERD患者可出现。','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(877,2,'下面哪一项在诊断GERD时最少应用？','24小时pH值监测','钡餐检查','测压','胃镜','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(878,2,'食管下括约肌压力可能被下述因素所降低，除了','含咖啡因饮料','巧克力','果冻','薄荷','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(879,2,'缓解GERD症状的生活方式转化不包括','改变睡眠姿势','饮食转变','定期应用制酸剂','减肥','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(880,2,'GRED可接受何种治疗','制酸剂','H2RA','PPI ','胃肠动力药','上述全部','','','',NULL,'E',1,',19,,20,',1,''),(881,2,'非处方药H2RA通常用于','治愈糜烂性食管炎','食管炎的治愈及维持','缓解轻度烧心症状','治疗慢性重度GERD症状','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(882,2,'下面哪一项能够最有效治疗GERD？','抗生素和制酸剂','H2RA','PPI','手术','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(883,2,'卓-艾综合征是下述因素的结果，除了','胃酸高分泌','胃上皮化生','胃泌素瘤','I型多发性内分泌瘤病综合征','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(884,2,'正常人空腹24小时胃液分泌量是','1.5－2.5L/24H','1－2.5L/24H','1.5－2L/24H','2－2.5L/24H','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(885,2,'胃痛的原因有','胃酸对溃疡的刺激','胃壁痉挛和痛域降低，局部肌张力增高','溃疡及其周围组织炎症及局部肌张力增高','以上均正确','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(886,2,'患者服用PPI之后，胃PH值（）的持续时间超过60min以上，就称为夜间酸突破','<2 ','<3  ','<4 ','<5','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(887,2,'胃粘膜通常有五个防御层次，其第二线防御层次是','粘膜表面粘液','粘膜上皮层','粘膜微循环','粘膜免疫细胞','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(888,2,'以下不属于酸相关疾病的有','胃食管反流病','消化性溃疡','酸相关性消化不良','腹泻','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(889,2,'质子泵抑制剂最为普遍的不良反应','头痛和腹泻','慢性胃炎','肠化生','良性肿瘤的发展','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(890,2,'PPIs在什么部位的得到活化','肝脏的P450酶','壁细胞中的分泌小管','胃液中','胰腺','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(891,2,'PPIs在什么环境下的到活化','酸性','中性','碱性','以上皆可','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(892,2,'PUD指的是什么？','十二指肠溃疡',' 吻合口溃疡','消化性溃疡',' 胃溃疡','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(893,2,'DU 指的是什么？',' 吻合口溃疡','十二指肠溃疡','消化性溃疡',' 胃溃疡','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(894,2,' GU指的是什么？','十二指肠溃疡',' 吻合口溃疡','消化性溃疡',' 胃溃疡','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(895,2,'MU指的是什么？','十二指肠溃疡',' 吻合口溃疡','消化性溃疡',' 胃溃疡','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(896,2,'GERD指的是什么？',' 胃食管反流病','反流性食管炎','糜烂性食管炎','非糜烂性反流病','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(897,2,'NERD  指的是什么？','反流性食管炎',' 胃食管反流病','糜烂性食管炎','非糜烂性反流病','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(898,2,'RE  指的是什么？','反流性食管炎',' 胃食管反流病','糜烂性食管炎','非糜烂性反流病','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(899,2,'EE  指的是什么？','反流性食管炎',' 胃食管反流病','糜烂性食管炎','非糜烂性反流病','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(900,2,'BE 指的是什么？','反流性食管炎',' 胃食管反流病',' Barrett 食管','非糜烂性反流病','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(901,2,'ZES 指的是什么？','反流性食管炎','卓-艾综合征','糜烂性食管炎','非糜烂性反流病','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(902,2,'SRMD  指的是什么？',' 胃溃疡','应激性黏膜病变','消化性溃疡','上消化道出血','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(903,2,'SU 指的是什么？','应激性溃疡',' 吻合口溃疡','消化性溃疡','上消化道出血','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(904,2,'UGIB 指的是什么？','应激性溃疡','应激性黏膜病变','十二指肠溃疡','上消化道出血','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(905,2,'ANVUGIB指的是什么？','下消化道出血','上消化道出血','急性非静脉曲张性上消化道出血','急性静脉曲张性上消化道出血','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(906,2,'AVUGIB 指的是什么？','下消化道出血','上消化道出血','急性非静脉曲张性上消化道出血','急性静脉曲张性上消化道出血','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(907,2,'FD指的是什么？',' 功能性消化不良','上腹痛综合征','急性胰腺炎','餐后不适综合征','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(908,2,'AP  指的是什么？','餐后不适综合征','上腹痛综合征','急性胰腺炎',' 功能性消化不良','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(909,2,'SAP  指的是什么？','重症急性胰腺炎','消化性溃疡','上消化道出血','反流性食管炎','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(910,2,'HP 指的是什么？','结核杆菌','金黄色葡萄球菌','链球菌','幽门螺杆菌','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(911,2,'LES  指的是什么？','上食管括约肌','下食管括约肌','幽门','十二指肠','','','','',NULL,'B',1,',12,,18,,19,,20,,39,',1,''),(912,2,'NSAIDs 指的是什么？',' H2 受体拮抗剂','糖皮质激素','非甾体抗炎药','质子泵抑制剂','','','','',NULL,'C',1,',12,,18,,19,,20,,39,',1,''),(913,2,'PPIs 指的是什么？',' H2 受体拮抗剂','糖皮质激素','非甾体抗炎药','质子泵抑制剂','','','','',NULL,'D',1,',12,,18,,19,,20,,39,',1,''),(914,2,'H2RA 指的是什么？',' H2 受体拮抗剂','糖皮质激素','非甾体抗炎药','质子泵抑制剂','','','','',NULL,'A',1,',12,,18,,19,,20,,39,',1,''),(915,2,'活化后PPIs与H+/K+-ATP 酶结合的复合物是','在肝脏内形成',' 在壁细胞内形成。',' 在小肠内形成','存在于达克普隆/普托平胶囊中','','','','',NULL,'B',1,',19,,20,',1,''),(916,2,'达克普隆/普托平最常见并且发生率高于安慰剂对照人群的副作用是','腹痛','腹泻','头痛','恶心','','','','',NULL,'B',1,',19,,20,',1,''),(917,2,'鉴于达克普隆/普托平在老年人体内半衰期延长，下列哪种说法是正确的？','无需调整剂量','需减少剂量','需增加剂量','','','','','',NULL,'A',1,',19,,20,',1,''),(918,2,'服用达克普隆/普托平30 mg QD 5 天后，一天中有多少比例的时间内胃pH 值大于4.0?','0.45','0.59','0.66','1','','','','',NULL,'C',1,',19,,20,',1,''),(919,2,'普托平相比传统口服PPI的主要优点？','微粒直径仅0.3mm','草莓口味，患者依从性更高','七层肠溶包衣结构，药物更稳定','以上都是','','','','',NULL,'D',1,',19,,20,',1,''),(920,2,'下列哪些药物可能降低兰索拉唑的生物利用度?','阿莫西林','硫糖铝','茶碱','华法林','','','','',NULL,'B',1,',19,,20,',1,''),(921,2,'对症状的快速抑制是治疗胃食管反流病的要素之一. 兰索拉唑起效时间','1小时','1.75小时','1.25小时','1.5小时','','','','',NULL,'A',1,',19,,20,',1,''),(922,2,'兰索拉唑首剂给药后的生物利用度是多少?','0.85',' 55%    ','0.45','0.5','','','','',NULL,'A',1,',19,,20,',1,''),(923,2,'下列不是兰索拉唑口崩片技术的优点','能快速通过幽门避免胃酸的降解',' 可以通过鼻饲管或胃造口术导管给药',' 快速通过胃部进入肠道','必须等到胃排空才能进入肠道','','','','',NULL,'D',1,',19,,20,',1,''),(924,2,'下列不是兰索拉唑速崩片剂型的方便性是哪一选项？','用水口服或仅用唾液即可吞咽','快速崩解','首剂给药后4小时，兰索拉唑即能升高pH值','患者依从性更高','','','','',NULL,'C',1,',19,,20,',1,''),(925,2,'下列质子泵抑制剂的生物利用度最高的是','奥美拉唑','雷贝拉唑','兰索拉唑','埃索美拉唑','','','','',NULL,'C',1,',19,,20,',1,''),(926,2,'胃溃疡、吻合口溃疡达克普隆的用法和用量','成人每日一次，口服30mg，连续服用8周','成人每日一次，口服15mg，连续服用8周','成人每日一次，口服30mg，连续服用6周','成人每日一次，口服15mg，连续服用6周','','','','',NULL,'A',1,',19,,20,',1,''),(927,2,'普托平的超细微粒结构仅为达克普隆颗粒的？','1/2','1/3','1/4','1/5','','','','',NULL,'B',1,',19,,20,',1,''),(928,2,'达克普隆在服药1-3天能缓解多少患者的夜间烧心症状','0.4','0.5','0.6','0.7','','','','',NULL,'C',1,',19,,20,',1,''),(929,2,'达克普隆（普托平）在哪种情形下需减少用量','与硫糖铝联合用药','与茶碱联合用药','严重肝功能障碍','严重肾功能障碍','','','','',NULL,'C',1,',19,,20,',1,''),(930,2,'达克普隆可供护士选择的给药方式包括','粉碎微粒于苹果酱混合','让病人将胶囊和食物一起咀嚼','静脉注射','与番茄汁混合','','','','',NULL,'D',1,',19,,20,',1,''),(931,2,'胃泌素瘤（ZES综合症）通常发生在','十二指肠','食管','胰腺','胃','','','','',NULL,'C',1,',19,,20,',1,''),(932,2,'酸反流所致的胃食管反流病主要是由于','唾液腺分泌障碍','食管收缩减低','胃酸分泌过多','食管下括约肌功能障碍','','','','',NULL,'D',1,',19,,20,',1,''),(933,2,'消化性溃疡抗HP治疗最主要的是','抗生素和抗胃酸分泌药物','NSAID','PPI 治疗','H2RA 处方药','','','','',NULL,'A',1,',19,,20,',1,''),(934,2,'NSAID 主要通过什么刺激胃','增加胃酸分泌','增加粘液生成','抑制前列腺素合成','促进HP 生长','','','','',NULL,'C',1,',19,,20,',1,''),(935,2,'Barrett 食管','导致鳞状细胞转化为柱状细胞，是一种癌前病变','是消化性溃疡的并发症之一','是一种遗传性疾病','约半数GERD 患者可出现','','','','',NULL,'A',1,',19,,20,',1,''),(936,2,'达克普隆/普托平的肠溶衣防止','兰索拉唑被胃吸收','兰索拉唑在胃的酸性环境中分解','兰索拉唑在十二指肠的碱性环境中分解','嚼胶囊中的颗粒','','','','',NULL,'B',1,',19,,20,',1,''),(937,2,'关于三氟乙氧基描述不正确的是','三氟乙氧基提升兰索拉唑的生物利用度',' 三氟乙氧基是兰索拉唑的独特结构','三氟乙氧基使兰索拉唑的脂溶性高，迅速通过壁细胞膜','三氟乙氧基延长兰索拉唑的半衰期','','','','',NULL,'D',1,',19,,20,',1,''),(938,2,'2013GERD指南指出对于长期使用PPI治疗的患者，应使用      剂量，包括按需服药与间歇服药。','最高','最低','最低有效','最高有效','','','','',NULL,'C',1,',19,,20,',1,''),(939,2,'兰索拉唑具有独特的         结构，起效迅速。','甲氧基','三氟乙氧基结构','乙氧基','咪唑环','','','','',NULL,'B',1,',19,,20,',1,''),(940,2,'兰索拉唑具有非常优异的药代动力学特点，说明书中提到的高生物利用度为      。','0.88','0.8','0.95','0.9','','','','',NULL,'D',1,',19,,20,',1,''),(941,2,'可以单独进行鼻饲给药的是','达克普隆','洛赛克','潘妥洛克','波利特','','','','',NULL,'A',1,',19,,20,',1,''),(942,2,'在18名幽门螺杆菌阴性的受试者中进行了一项试验，比较了单剂量的雷贝拉唑、兰索拉唑、泮托拉唑及奥美拉唑的抑制分泌活性及起效时间，所有质子泵抑制剂抑制分泌活性的起效时间都在2小时内。兰索拉唑起效时间为：','1小时','1.25小时','1.5小时','1.75小时','','','','',NULL,'A',1,',19,,20,',1,''),(943,2,'唯一的PPI口崩片是','奥美拉唑口崩片','兰索拉唑口崩片','泮托拉唑口崩片','雷贝拉唑口崩片','','','','',NULL,'B',1,',19,,20,',1,''),(944,2,'达克普隆的有效期是','12个月','24个月','36个月','60个月','','','','',NULL,'C',1,',19,,20,',1,''),(945,2,'普托平片的性状是','棕红色片','浅蓝色异形片','白色或微黄色带红棕色斑点片','白色或类白色片','','','','',NULL,'C',1,',19,,20,',1,''),(946,2,'普托平的有效期是','12个月','24个月','36个月','48个月','','','','',NULL,'C',1,',19,,20,',1,''),(947,2,'达克普隆的性状是','白色胶囊，内容物为棕红色肠溶球状颗粒','白色胶囊，内容物为白色或类白色粉末','红色胶囊，内容物为白色或类白色肠溶球状颗粒','白色胶囊，内容物为白色或类白色肠溶球状颗粒','','','','',NULL,'D',1,',19,,20,',1,''),(948,2,'普托平口崩片服药     小时即可有效控制胃酸分泌','0.5','1','1.5','2','','','','',NULL,'B',1,',19,,20,',1,''),(949,2,'普托平口崩片用药首日即可缓解      患者夜间烧心症状','0.45','0.6','0.49','0.54','','','','',NULL,'C',1,',19,,20,',1,''),(950,2,'普托平服药后       迅速崩解','15秒','30秒','45秒','60秒','','','','',NULL,'B',1,',19,,20,',1,''),(951,2,'普托平口崩片的超细肠溶微粒直径为','0.2mm','1mm','0.5mm','0.3mm','','','','',NULL,'D',1,',19,,20,',1,''),(952,2,'兰索拉唑首剂给药后多长时间即能升高胃内的pH值','1-2小时','  3-4小时',' 4-6小时',' 6-12小时','','','','',NULL,'A',1,',19,,20,',1,''),(953,2,'2009年指南推荐静脉PPI初始剂量后的维持量为：','2mg/h静滴    ',' 4mg/h静滴','8mg/h静滴','10mg/h静滴','','','','',NULL,'C',1,',12,',1,''),(954,2,'针对急性上消化道大出血，PPI最佳给药方式为','一次性大剂量口服','一次性大剂量静脉推注','初始高剂量静脉推注＋持续静滴   ','持续大剂量静滴','','','','',NULL,'C',1,',12,',1,''),(955,2,'消化道出血患者出院多久后应再次进行内镜检查以确定溃疡愈合并排除恶性肿瘤可能？','一个月','6周','2个月','半年','','','','',NULL,'B',1,',12,',1,''),(956,2,'潘妥洛克冻干粉可以用哪些溶液直接溶解','0.9%生理盐水注射液','  5%葡萄糖注射液\n','10%葡萄糖溶液      ','20%果糖溶液','','','','',NULL,'A',1,',12,',1,''),(957,2,'埃索美拉唑又称为什么奥美拉唑？','右旋','    左旋','消旋','双相','','','','',NULL,'B',1,',12,',1,''),(958,2,'泮托拉唑II相代谢的代谢产物是（），其亲水性增加，更有利于从肾脏排泄                                          ','泮托拉唑磺酸盐','去甲基泮托拉唑','泮托拉唑去甲基硫酸酯','以上都是','','','','',NULL,'C',1,',12,',1,''),(959,2,'一项泮托拉唑与内镜结合治疗消化溃疡出血患者的前瞻性、随机、对照研究证实，泮托拉唑组的再出血率为       （数值）低于安慰剂组的再出血率      （数值），P值是0.01，两组间差异有统计学意义。  ','7.8%，19.8%','5.6%，7.7%','2.9%，7.9%','1.9%，3.9%','','','','',NULL,'A',1,',12,',1,''),(960,2,'比较连续输注泮托拉唑80mg+8mg/h和与奥美拉唑80mg+8mg/h对治疗非静脉曲张型上消化道出血的疗效研究,主要终点为     ','住院时间','再出血率','急救治疗','输血','','','','',NULL,'B',1,',12,',1,''),(961,2,'一项泮托拉唑与内镜结合治疗消化溃疡出血患者的前瞻性、随机、对照研究证实，泮托拉唑注射液输注后 （    ） 分钟（中位数时间）胃内pH值即可达到6                                           ','15','30','45','60','','','','',NULL,'C',1,',12,',1,''),(962,2,'一项与抑酸药物相关的综述指出，抑酸的程度取决于患者自身的治疗条件，该综述还总结了胃内不同pH值对生理活动的影响，如上表所示，例如pH＞（ ）是预防应激相关黏膜出血的目标pH','3.5','4','5','6','','','','',NULL,'B',1,',12,',1,''),(963,2,'FDA第一个批准的注射用PPI','兰索拉唑注射液','奥美拉唑注射液','潘妥洛克注射液','埃索美拉唑注射液','','','','',NULL,'C',1,',12,',1,''),(964,2,'潘妥洛克针剂禁用于','肾脏衰竭患者','孕妇及哺乳期妇女','老年','对该药的某种成份过敏的患者','中度肝脏衰竭患者','','','',NULL,'D',1,',12,',1,''),(965,2,'中华医学杂志编辑委员会推荐SRMD治疗疗程为？','2周 ','4-6周','1个月','半年','','','','',NULL,'B',1,',12,',1,''),(966,2,'约多少上消化道出血可自行停止？','0.5','0.6','0.8','0.9','','','','',NULL,'C',1,',12,',1,''),(967,2,'约多少严重上消化道出血患者死于严重出血？','0.1','0.2','0.3','0.5','','','','',NULL,'A',1,',12,',1,''),(968,2,'潘妥洛克注射剂有效期为？','1年;','2年','2.5年','3年','','','','',NULL,'B',1,',12,',1,''),(969,2,'2009年指南推荐静脉PPI初始剂量为多少mg快速静推？','20','40','80','100','','','','',NULL,'C',1,',12,',1,''),(970,2,'2009年指南推荐静脉PPI初始剂量后的维持量持续时间为？','24h;','48h',' 72h','96h','','','','',NULL,'C',1,',12,',1,''),(971,2,'潘妥洛克针配置后保存时间是？','2h;','6h','12h','24h','','','','',NULL,'C',1,',12,',1,''),(972,2,'下列哪些静脉用PPI是完全国外生产，纯进口产品？','耐信','洛赛克','潘妥洛克','奥维加','','','','',NULL,'C',1,',12,',1,''),(973,2,'注射用兰索拉唑国内说明书适应症为','中重度反流性食管炎','胃、十二指肠溃疡','用于口服疗法不适用的伴有出血的十二指肠溃疡','十二指肠溃疡、胃溃疡、急性胃粘膜病变、复合性胃溃疡等引起的急性上消化道出血','口服疗法不适用的急性胃或十二指肠溃疡出血的低危患者（胃镜下Forrest分级IIc--III级）','','','',NULL,'C',1,',12,',1,''),(974,2,'潘妥洛克针剂的规格是什么？','40mg/瓶，每瓶含42.3mg泮托拉唑钠（相当于40mg泮托拉唑）','30g/瓶，每瓶含31.7mg泮托拉唑钠（相当于30mg泮托拉唑）','40mg/瓶，每瓶含40mg泮托拉唑钠','50mg/瓶，每瓶含52.9mg泮托拉唑钠（相当于50mg泮托拉唑）','','','','',NULL,'A',1,',12,',1,''),(975,2,'潘妥洛克针配置液的PH值为多少','7','8','9','6','','','','',NULL,'C',1,',12,',1,''),(976,2,'潘妥洛克针配置液需要在多长时间内使用完','6小时','8小时','10小时','12小时','','','','',NULL,'D',1,',12,',1,''),(977,3,'日本J-CaP数据库说法正确的是','分析日本与美国患者对内分泌治疗反应的不同之处\n','观察内分泌治疗效果，为最佳内分泌治疗方案提供依据','由日本前列腺癌研究学组建立','得到了武田公司的大力支持','','','','',NULL,'ABCD',1,',21,',1,''),(978,3,'美国CaPSURE数据库建立的目的？','不同治疗方式对于临床结局的影响','不同治疗方式对于经济负担的影响','不同治疗方式对于生活质量的影响','为广大临床医生提供科研思路和学习的平台','','','','',NULL,'ABCD',1,',21,',1,''),(979,3,'以下对于HR（风险比）说法正确的是？','HR（风险比）资料的类型通常是临床治疗性研究，也可以是流行病学的队列观察性研究','95%CI指95%可信区间','HR值〉1说明该暴露因素/治疗方式增加风险','95%CI在1的左侧说明该暴露因素/治疗方式增加风险','','','','',NULL,'AB',1,',21,',1,''),(980,3,'关于PSA筛查，不同国家的意见说法正确的是','美国不建议使用PSA筛查前列腺癌','欧洲大型RCT临床研究发现，PSA筛检10，000万人可以减少12.8死亡','PSA筛查发现的前列腺癌也存在过度诊断，活检风险等问题','加拿大认为，PSA筛查应与患者沟通，最好借助决策辅助工具增进理解。','','','','',NULL,'ABCD',1,',21,',1,''),(981,3,'以下哪一种治疗方式得到了FDA批准，用于多西他赛/化疗前的CRPC患者？','Abiraterone(阿比特龙)','Enzalutamide(蒽杂鲁胺)','Sipuleucel','Radium—223','','','','',NULL,'ABCD',1,',21,',1,''),(982,2,'在2014 CONCORD-2全球癌症生存调查数据中，参与调查的中国乳腺癌患者在1995-99，2000-04，2005-09年间的总体5年生存率趋势为___________','无明显差异\n','逐渐下降趋势\n','逐渐上升趋势\n','波动式无规律趋势','','','','',NULL,'C',1,',21,,33,,37,',1,''),(983,3,'ECOG-3193临床试验的结论虽然与SOFT试验结果类似，但也有区别，请问这些区别有____________','药物去势患者仅占联合治疗组患者的36%','样本量为345，在III期临床试验设计中略显不足','随访时间9.9年\n','50岁以上患者比例较大','','','','',NULL,'ABCD',1,',21,,33,,37,',1,''),(984,2,'TEXT与SOFT试验的中文名称分别为____________','他莫昔芬依西美坦联合试验；卵巢功能测试试验','他莫昔芬与依西美坦分别联合卵巢功能抑制的疗效对比试验；\n卵巢功能抑制试验','他莫昔芬依西美坦联合卵巢功能抑制试验；卵巢功能测试试验','他莫昔芬依西美坦联合试验；卵巢功能抑制试验','','','','',NULL,'B',1,',21,,33,,37,',1,''),(985,3,'卵巢功能抑制(OFS)治疗在TEXT和SOFT试验中分别扮演什么角色：_____________','基础用药（干预组和对照组均要使用）；干预用药（仅干预组使用）','干预用药（仅干预组使用）；基础用药（干预组和对照组均要使用）','联合用药（与其他内分泌药物联合使用）\n','单一用药','','','','',NULL,'AC',1,',21,,33,,37,',1,''),(986,2,'TEXT&SOFT试验联合分析及SOFT试验的核心结论分别为____________','依西美坦联合OFS治疗优于他莫昔芬联合OFS治疗；\n他莫昔芬联合OFS治疗与TAM单药治疗疗效无差异','他莫昔芬联合OFS治疗优于依西美坦联合OFS治疗；\n他莫昔芬联合OFS治疗与TAM单药治疗疗效无差异\n','依西美坦联合OFS治疗与他莫昔芬联合OFS治疗疗效无差异；\n他莫昔芬联合OFS治疗优于TAM单药治疗','依西美坦联合OFS治疗与他莫昔芬联合OFS治疗疗效无差异；\nTAM单药治疗优于他莫昔芬联合OFS治疗','','','','',NULL,'A',1,',21,,33,,37,',1,''),(987,2,'2014年国内乳腺癌晚期抑那通联合芳香化酶抑制剂观察研究显示，提高患者ORR达：','0.58','0.68','0.72','0.82','','','','',NULL,'C',1,',21,,33,,37,',1,''),(988,3,'SOFT试验< 35岁的患者联合OFS获益更多，并不意味>35岁就不能应用，原因是：','< 35岁不是一个用药界限，而是临床试验设计的高危因素评价指标','< 35岁是2010-ASCO指南推荐的高危因素 ','< 35岁在试验中更容易体现结果的差异，使亚组分析更有意义\n','肿瘤治疗是一个综合性的治疗，要根据患者的复发风险因素综合评定\n','','','','',NULL,'ACD',1,',21,,33,,37,',1,''),(989,3,'SOFT试验中，哪类患者联合OFS应用获益更多？','<35岁患者','<30岁患者','不需要化疗的低危患者','接受化疗的高危患者','','','','',NULL,'AD',1,',21,,33,,37,',1,''),(990,3,'SOFT试验中，已经接受化疗的部分患者具备显著高危特征，他们的特征分别是：','57% 淋巴结+\n','47% 肿瘤大小>2cm','49% <40岁','18%Her2+','','','','',NULL,'ABCD',1,',21,,33,,37,',1,''),(991,3,'SOFT试验中应用曲普瑞林和亮丙瑞林疗效是否相似？','相似，2012年ESMO指南共同推荐曲普瑞林和亮丙瑞林为LHRHa选择','通过不同试验的降低雌激素水平对照，两药在降雌水平相似','不相似，两药没有头对头研究','两药的化学结构相似，作为参考因素之一','','','','',NULL,'ABD',1,',21,,33,,37,',1,''),(992,2,'Table study证明：抑那通在几周左右开始降低雌激素水平？','2周','3周','4周','5周','','','','',NULL,'B',1,',21,,33,,37,',1,''),(993,3,'在< 35岁的乳腺癌患者，与单独使用T比较，OFS+T和OFS+E分别提高了多少5年无乳腺癌复发生存率？','0.112','0.157','0.113','0.156','','','','',NULL,'AB',1,',21,,33,,37,',1,''),(994,2,'2010年卫生部CPP治疗指南中，GnRh-a治疗维持剂量范围是______','30-90 ug/kg','30-180 ug/kg','80-100 ug/kg','60-120 ug/kg','','','','',NULL,'C',1,',21,,26,,37,',1,''),(995,3,'2014Peter A Lee最新发表在JCEM上关于抑那通治疗CPP的研究，以下正确的是_','一项美国的III期、开放性、多中心研究，是一项为期6个月的观察研究。','一项美国的III期、开放性、多中心研究，是之前一项6个月研究的延长研究。','纳入72例CPP患儿，抑那通11.25 mg组34例； 30 mg组38例，抑那通每3个月肌肉注射一次1','纳入72例CPP患儿，抑那通3.75 mg组34例； 11.25 mg组38例，抑那通每3个月肌肉注射一次1','','','','',NULL,'BC',1,',21,,26,,37,',1,''),(996,3,'2015财年抑那通CPP的产品关键信息是______','• 抑那通®显著降低性激素至青春期发动前水平，有效抑制性腺轴','• 抑那通®首剂足量，疗程充分有效治疗CPP，有效改善CPP患儿成年身高','• 抑那通®不良反应少，远期安全性良好','• 抑那通®独创微球技术，细短针头注射畅通、几乎无痛，可多部位注射，室温保存，使用储存方便','• 抑那通®更广的剂量范围，满足更多的治疗需求','','','',NULL,'ABCDE',1,',21,,26,,37,',1,''),(997,3,'2015财年抑那通CPP的核心策略是______','通过优化信息和DPS的上市，强化抑那通品牌差异化优势\n','聚焦重点医院，扩大带组医生数量/质量；\n','患者教育提高疾病知晓和改进就诊\n','强化销售队伍的专业化培训\n','','','','',NULL,'ABCD',1,',21,,26,,37,',1,''),(998,2,'CPP首剂足量的具体剂量是指_','1.88mg','2mg','3mg','3.75mg','','','','',NULL,'D',1,',21,,26,,37,',1,''),(999,2,'在CPP治疗中，抑那通停药_月后，性腺轴恢复正常。','3','6','9','12','','','','',NULL,'B',1,',21,,26,,37,',1,''),(1000,3,'2015 子宫内膜异位症诊疗规范给GnRHa（抑那通)带来的主要机会','痛经复发患者，可以先使用抑那通3-6个月，之后使用COC 等一线药物后续治疗','合并不育或者附件包块者，首选保守治疗，使用抑那通3-6个月','术后使用抑那通3-6个月，之后可使用其他口服药后续治疗 ','年轻肌腺症患者，先使用抑那通3-6个月再使用曼月乐','','','','',NULL,'ACD',1,',21,,27,,37,',1,''),(1001,3,'请从选项中，选出合适选项完成妇科目标医生画像','三级综合&妇保医院\n有处方权的EM 腔镜手术医生\n','三级综合&妇保医院\n有处方权的治疗EM疾病的门诊医生\n','具有较好的抑那通认知度\n','具有较好的GnRHa认知度\n且处方此类药物给患者\n','','','','',NULL,'ACD',1,',21,,27,,37,',1,''),(1002,3,'抑那通的注射部位有_','上臂','腹部','头部','臀部','','','','',NULL,'ABD',1,',21,,27,,37,',1,''),(1003,3,'针对肌腺症患者，我们推广的要点是','LNG-IUS治疗初期现淋漓出血患者，可在使用LNG-IUS后使用抑那通3-6个月','抑那通联合LNG-IUS可显著改善腺肌症患者的子宫大小、经量和痛经\n','对于年轻有生育需求子宫肌腺症患者，抑那通联合LNG-IUS可显著改善疼痛，提高妊娠率','保守性手术联合抑那通可显著改善腺肌症伴不孕患者的妊娠率\n','','','','',NULL,'BC',1,',21,,27,,37,',1,''),(1004,3,'针对子宫内异症合并不育患者，我们推广要点是','抑那通®治疗有效降低内异症患者r-AFS评分达47%，改善子宫内坏境','指南推荐:辅助生育之前GnRHa治疗3-6个月可以提高子宫内膜异位症不孕患者妊娠率','抑那通®治疗抑制E2浓度到临床获益 最佳水平，有效改善EM患者的子宫内环境','EM 患者使用抑那通可显著提高妊娠率','','','','',NULL,'ABC',1,',21,,27,,37,',1,''),(1005,3,'子宫内膜异位症复发率高，已经得到临床医生更多关注。针对接受了手术治疗的EM患者，我们推广要点是:_','术后联合抑那通®治疗可改善EM分期,且获得EM治疗的最高治愈率60%（EEC 0期)','术后联合抑那通®治疗6个月Vs3个月复发时间延长2个月','术后联合抑那通®治疗降低r-AFS评分达47% 有效改善子宫内环境','术后首选一线药物COC,如复发使用GnRHa 药物可显著降低疼痛','','','','',NULL,'ABC',1,',21,,27,,37,',1,''),(1006,3,'2015年抑那通PC市场策略中，前列腺癌的三类患者人群是？','生化复发','局部进展及转移性前列腺癌','去势抵抗性前列腺癌（CRPC）','术后切缘阳性','','','','',NULL,'BCD',1,',21,,34,,37,',1,''),(1007,2,'目前中国泌尿外科医生的观念中，哪项是错误的？','３个月剂型的GnRHa药物使用更方便','去势抵抗性前列腺癌（CRPC）维持去势治疗','PC患者内分泌治疗时长为9-12个月','TIIb以上的PＣ患者，应进行内分泌辅助治疗','','','','',NULL,'B',1,',21,,34,,37,',1,''),(1008,2,'以下哪项不是抑那通PC领域15年的市场活动？','“抑通百通”手术视频分享会','前列腺癌青年联盟城市会','\"Best of EAU\"巡讲','\"Best of AUA\"巡讲','','','','',NULL,'D',1,',21,,34,,37,',1,''),(1009,2,'以下哪项不属于ＰＣ领域抑那通的市场策略？　','促进医生对抑那通品牌差异化了解','在抑那通重点医院教育医生，延长患者治疗时间','扩大医院覆盖，纳入更多的目标医生','3.75DPS/11.25DPS的快速开发和上量','','','','',NULL,'C',1,',21,,34,,37,',1,''),(1010,3,'抑那通3M DPS 6号细短针头与戈舍瑞林16号粗针头比较，带来的优势是什么？','降低注射部位不良反应','降低患者注射不适感','医生/护士操作简单方便','降低因注射造成的医患纠纷','','','','',NULL,'BCD',1,',21,,34,,37,',1,''),(1011,2,'在PC领域，抑那通的市场份额是？','0.16','0.19','0.23','0.26','','','','',NULL,'A',1,',21,,34,,37,',1,''),(1012,2,'子宫腺肌病患者子宫增大明显或者疼痛症状严重者，可____________','使用OCs或LNG-IUS后，应用GnRHa治疗3-6个月','应用GnRHa治疗3-6个月后，再使用OCs或LNG-IUS','应用GnRHa 治疗3-6个月或持续OCs治疗或LNG-IUS持续治疗','应用GnRHa治疗3-6个月后再使用LNG-IUS','','','','',NULL,'B',1,',21,',1,''),(1013,3,'下列哪些说法正确的是____________','ASRM分数越高，病情越严重',' ASRM分数越低，病情越严重','EFI评分越高，妊娠概率越低',' EFI评分越低，妊娠概率越高','EFI评分越高，妊娠概率越高','','','',NULL,'AE',1,',21,',1,''),(1014,2,'2015中国子宫内膜异位症诊疗指南指出，目前公认的治疗成人内异症最有效的药物是____________','Ocs','孕激素','孕三烯酮','GnRHa',' LNG-IUS','','','',NULL,'D',1,',21,',1,''),(1015,3,'下列哪些说法不正确的是____________','术后药物治疗及长期管理可有效减少疼痛和卵巢子宫内膜异位囊肿的复发','DIE 手术术后症状复发率高，复发率达10%,术后应辅助药物长期治疗','疼痛和不孕是内异症管理中的难题','内异症的治疗需要制定终身管理计划，以手术治疗为核心，最大化药物治疗为目标','','','','',NULL,'CD',1,',21,',1,''),(1016,3,'各国指南不推荐内异症手术前后使用药物治疗增强手术效果（2013WSE,  2014ESHRE,  2015中国内异症指南），但下列哪些情况推荐术前术后联合药物治疗____________','手术后若有残余病灶、疼痛无缓解','对病变较重，估计手术困难者，术前可短暂应用GnRHa3个月，从而一定程度上减少手术难度，提高手术安全性',' 为了延长术后无疼痛间隔期可以使用术后药物治疗','有数据支持术后使用GnRHa来延长术后无疼痛期；复方口服避孕药、LNG-IUS也可作为手术后药物治疗内异症疼痛','','','','',NULL,'ABCD',1,',21,',1,''),(1017,2,'PR（partialrelease）是什么？','完全缓解，所有目标病灶消失','部分缓解，与基线病灶比，靶病灶直径之和比基线水平减少至少30%。\n','疾病稳定，与基线病灶比，目标病灶长径总和有缩小但未达PR或有增加但未达PD','疾病进展，与基线病灶比，目标病灶长径总和增加≥20%或出现新病灶','','','','',NULL,'B',1,',21,,33,',1,''),(1018,2,'PFS（progression-freesurvival）','无进展生存，指从随机分组开始到肿瘤进展','无复发生存，从随机分组至最早局部或区域复发,远处转移,或死亡的时间','无进展生存，指从随机分组开始到肿瘤进展或死亡时间','无病生存期','','','','',NULL,'C',1,',21,,33,',1,''),(1019,2,'RFS（relapse-freesurvival）','无复发生存，从随机分组至最早局部或区域复发','无进展生存，指从随机分组开始到肿瘤进展或死亡时间','无病生存期','无复发生存，从随机分组至最早局部或区域复发，远处转移,或死亡的时间','','','','',NULL,'D',1,',21,,33,',1,''),(1020,2,'关于乳腺癌发病症状不正确的是？','最常见的症状是发现乳房肿块','乳头形状可能发生改变','可能发现肿大的腋窝淋巴结','发生乳头溢液则一定是恶性乳腺癌','','','','',NULL,'D',1,',21,,33,',1,''),(1021,2,'哪项不是乳腺癌常见的转移方式？','局部扩散','淋巴转移','血性转移','种植转移','','','','',NULL,'D',1,',21,,33,',1,''),(1022,2,'乳腺癌的诊断金标准是？','超声','CT','MRI','病理','','','','',NULL,'D',1,',21,,33,',1,''),(1023,2,'关于乳腺癌预后不正确的是？','乳腺癌是不可治愈疾病','应该针对患者的个体情况制定适合的个体化治疗策略','HER-2既是预后因子，又是疗效预测因子','三阴乳腺癌一般预后较差','','','','',NULL,'A',1,',21,,33,',1,''),(1024,2,'关于肿瘤学常用术语不正确的是？','OS是总生存是最常用的指标','PFS可以视为等同于OS，所以很多试验用PFS代替OS','人们越来越重视QOL即生活质量','TTP不同于PFS','','','','',NULL,'B',1,',21,,33,',1,''),(1025,3,'对于BC,抑那通的适用患者的有','40岁以上的高危患者','不愿意做化疗的患者','三苯氧胺治疗中出现副作用或禁忌症的患者','晚期绝经前一线复发患者','','','','',NULL,'ABCD',1,',21,,33,',1,''),(1026,3,'针对于BC治疗，以下属于抑那通重要的要点是','A,目前唯一获得乳腺癌适应症的3月长效LHRHa药物','3月剂型使用简单、方便，与1月剂型疗效一致','NCCN指南推荐抑那通为受体激素阳性绝经前乳腺癌患者的选择','抑那通卵巢抑制起效快，3周即可达到效果','1月剂型在医保范围内，减低患者负担','','','',NULL,'ABCDE',1,',21,,33,',1,''),(1027,3,'中国抗癌协会乳腺癌诊治指南与规范(2011版)推荐卵巢去势类药物可用于如下绝经前患者','高度风险且化疗后未导致闭经的患者，可同时与他莫昔芬联合应用。','低度风险且化疗后未导致闭经的患者，可同时与他莫昔芬联合应用','中度风险且化疗后未导致闭经的患者，可同时与他莫昔芬联合应用。','不愿意接受辅助化疗的中度风险患者，可同时与他莫昔芬联合应用。','对他莫昔芬有禁忌者。','','','',NULL,'ADE',1,',21,,33,',1,''),(1028,3,'以下达到绝经状态的是：','双侧卵巢切除术后。','年龄≥60岁。','年龄＜60岁，自然停经≥12个月（在近1年未接受化疗、三苯氧胺、托瑞米芬或卵巢去势的情况下，FSH和雌二醇水平在绝经后范围内）。','年龄＜60岁，正在服用三苯氧胺或托瑞米芬的的患者，FSH和雌二醇水平在绝经后范围内','','','','',NULL,'ABC',1,',21,,33,',1,''),(1029,2,'以下产品有乳腺癌适应症的是','达菲林3M剂型','诺雷德3M剂型','抑那通3MDPS剂型','以上均有','','','','',NULL,'C',1,',21,,33,',1,''),(1030,2,'GnRH是？','促卵泡刺激素','促黄体生成素','促性腺激素释放激素类似物','促性腺激素释放激素','','','','',NULL,'D',1,',21,,33,',1,''),(1031,2,'GnRHa是','促卵泡刺激素','促黄体生成素','促性腺激素释放激素类似物','促性腺激素释放激素','','','','',NULL,'C',1,',21,,33,',1,''),(1032,2,'GnRH的来源','由下丘脑分泌','由垂体分泌','由睾丸或卵巢分泌','由下丘脑-垂体-性腺轴分泌','','','','',NULL,'A',1,',21,,33,',1,''),(1033,2,'LH及FSH的来源','由下丘脑分泌','由垂体分泌','由睾丸或卵巢分泌','由下丘脑-垂体-性腺轴分泌','','','','',NULL,'B',1,',21,,33,',1,''),(1034,2,'LHRH是','促卵泡刺激素','促黄体生成素','促性腺激素释放激素类似物','黄体生成激素刺激激素','','','','',NULL,'D',1,',21,,33,',1,''),(1035,2,'ERpositive是','雌激素受体','雌激素受体阳性','孕激素受体','孕激素受体阳性','','','','',NULL,'B',1,',21,,33,',1,''),(1036,2,'PRpositive','雌激素受体','雌激素受体阳性','孕激素受体','孕激素受体阳性','','','','',NULL,'D',1,',21,,33,',1,''),(1037,2,'Her2positive','人类表皮生长因子受体阳性','雌激素受体阳性','人类表皮生长因子','孕激素受体阳性','','','','',NULL,'A',1,',21,,33,',1,''),(1038,2,'RFS是','无复发生存','无进展生存','至肿瘤进展时间','意向治疗人群','','','','',NULL,'A',1,',21,,33,',1,''),(1039,2,'PFS是','无复发生存','无进展生存','至肿瘤进展时间','意向治疗人群','','','','',NULL,'B',1,',21,,33,',1,''),(1040,3,'CMF包括','阿霉素','环磷酰胺','甲氨蝶呤','氟尿嘧啶','','','','',NULL,'BCD',1,',21,,33,',1,''),(1041,3,'TAC包括','多西紫衫','阿霉素（多柔比星）','环磷酰胺','甲氨蝶呤','','','','',NULL,'ABC',1,',21,,33,',1,''),(1042,3,'AI类代表药物有','瑞宁得（AZ—阿那曲唑）','弗隆（诺华—来曲唑）','法玛新（辉瑞—依西美坦）','三苯氧氨','','','','',NULL,'ABC',1,',21,,33,',1,''),(1043,2,'CR是指','部分缓解，与基线病灶比，目标病灶长径总和缩小≥30%','完全缓解，所有目标病灶消失','疾病稳定，与基线病灶比，目标病灶长径总和有缩小但未达PR或有增加但未达PD','疾病进展，与基线病灶比，目标病灶长径总和增加≥20%','','','','',NULL,'B',1,',21,,33,',1,''),(1044,2,'SD是指','完全缓解，所有目标病灶消失','部分缓解，与基线病灶比，目标病灶长径总和缩小≥30%','疾病稳定，与基线病灶比，目标病灶长径总和有缩小但未达PR或有增加但未达PD','疾病进展，与基线病灶比，目标病灶长径总和增加≥20%','','','','',NULL,'C',1,',21,,33,',1,''),(1045,2,'下面那些组织不是构成乳腺的组织?','乳腺腺体','导管','脂肪组织','淋巴结','','','','',NULL,'D',1,',21,,33,',1,''),(1046,2,'乳腺癌的流行病学当中，下面哪一个是中国年龄别发病率高峰？','40-49岁','30-40岁','40-50岁','50-60岁','','','','',NULL,'A',1,',21,,33,',1,''),(1047,2,'年轻乳腺癌的流行病学相较于老年乳腺癌，其特点表现为：','肿瘤小','发展快','转移少','分化较好','','','','',NULL,'B',1,',21,,33,',1,''),(1048,2,'下列哪一个不是乳腺癌内分泌疗法的药物？','托瑞米芬','吉西他滨','亮丙瑞林','阿那曲唑','','','','',NULL,'B',1,',21,,33,',1,''),(1049,3,'TABLE研究（3个月剂量LADvs.CMF治疗绝经前乳腺癌）的结论是什么？','醋酸亮丙瑞林能有效治疗雌激素受体阳性的绝经前乳腺癌，5年生存率(OS)可达81%','醋酸亮丙瑞林起效时间快，中位时间22天','醋酸亮丙瑞林无严重不良反应，主要是雌激素抑制症状','醋酸亮丙瑞林停用后恢复月经快，90%患者在2给月内恢复正常','','','','',NULL,'ABC',1,',21,,33,',1,''),(1050,3,'乳腺癌治疗前作雌激素受体测定可以更有效的拟定治疗方案，受体与内分泌疗效的关系是？','雌激素受体阳性者内分泌治疗的有效率为50-60%；','同时孕激素受体阳性者，有效率可达70%以上','雌孕激素受体阴性者内分泌治疗的有效性低于10%','受体阳性者的预后较阴性者好','','','','',NULL,'ABCD',1,',21,,33,',1,''),(1051,3,'芳香化酶抑制剂的作用机理是阻断下列那些途径转化而产生雌激素？','肾上腺','脂肪','肝脏','肌肉','','','','',NULL,'ABCD',1,',21,,33,',1,''),(1052,2,'Table研究的全称是：','亮丙瑞林3月剂型（LAD-3M,抑那通®）对比环磷酰胺、甲氨蝶呤和氟尿嘧啶治疗绝经前淋巴结阳性乳腺癌研究','亮丙瑞林（抑那通®）对比环磷酰胺、甲氨蝶呤和氟尿嘧啶治疗绝经前淋巴结阳性乳腺癌研究','亮丙瑞林3月剂型（LAD-3M,抑那通®）对比环磷酰胺、甲氨蝶呤和氟尿嘧啶治疗乳腺癌研究','亮丙瑞林（,抑那通®）对比环磷酰胺、甲氨蝶呤和氟尿嘧啶治疗淋巴结阳性乳腺癌研究','','','','',NULL,'A',1,',21,,33,',1,''),(1053,2,'Table研究的目的是：','评估醋酸亮丙瑞林（抑那通®）3月剂型辅助治疗绝经前雌激素受体阳性、淋巴结阳性乳腺癌的有效性','评估醋酸亮丙瑞林（抑那通®）辅助治疗绝经前雌激素受体阳性、淋巴结阳性乳腺癌的有效性和耐受性','评估醋酸亮丙瑞林（抑那通®）3月剂型辅助治疗绝经前雌激素受体阳性、淋巴结阳性乳腺癌的有效性和耐受性','评估醋酸亮丙瑞林（抑那通®）辅助治疗绝经前雌激素受体阳性、淋巴结阳性乳腺癌的有效性','','','','',NULL,'C',1,',21,,33,',1,''),(1054,2,'Table的研究设计是：','一项多中心、双盲、随机对照的Ⅲ期临床研究','一项单中心、开放、随机对照的Ⅲ期临床研究','一项多中心、开放、随机对照的Ⅲ期临床研究','一项单中心、双盲、随机对照的Ⅲ期临床研究','','','','',NULL,'C',1,',21,,33,',1,''),(1055,2,'Table研究共纳入病例_____例，其中抑那通®组意向分析人群____例，CMF组意向分析人群___例:','A)599,300,299','B)589,294,295','C)599,299,300','D)589,295,294','','','','',NULL,'B',1,',21,,33,',1,''),(1056,2,'Table研究的中位随访时间是','6个月','2.5年','5.8年','8年','','','','',NULL,'C',1,',21,,33,',1,''),(1057,2,'Table研究中，抑那通®的使用剂量及时间是','抑那通®3月剂型11.25mg/3月×2年','抑那通®3月剂型11.25mg/月×2年','抑那通®3.75mg/月×2年','抑那通®1.88mg/月×2年','','','','',NULL,'A',1,',21,,33,',1,''),(1058,2,'Table研究显示，抑那通®3月剂型组与化疗组相比，能提高5年总生存率','0.125','0.091','0.067','0.103','','','','',NULL,'B',1,',21,,33,',1,''),(1059,3,'Table研究的评估终点是：','无复发生存率','总体生存率','E2水平','不良反应','','','','',NULL,'ABCD',1,',21,,33,',1,''),(1060,3,'根据BMCCancer2011报告，中国乳腺癌发病情况与西方国家相比：','发病年龄早，比西方国家早10年，发病年龄高峰为40-49岁（38.4%）','发病年龄晚，比西方国家晚10年，发病年龄高峰为50-49岁（38.4%）','发病年龄和西方国家相似，发病年龄高峰为50-59岁','发病年龄低于35岁的年轻乳腺癌患者所占比例明显高于西方','','','','',NULL,'AD',1,',21,,33,',1,''),(1061,2,'我国每年新发乳腺癌病例中，35岁以下的年轻患者所占比例高达：','10-20%','20-30%','10-15%','5-10%','','','','',NULL,'C',1,',21,,33,',1,''),(1062,3,'乳腺癌的主要危险因素','年龄','家族史','患乳腺不典型增生或乳头状瘤病','致密性乳腺','精神压抑','','','',NULL,'ABCDE',1,',21,,33,',1,''),(1063,3,'乳腺癌内分泌治疗的药物有：','A)抗雌激素药物','B)芳香化酶抑制剂','C)孕激素类','D)GnRHa类','','','','',NULL,'ABCD',1,',21,,33,',1,''),(1064,2,'GnRHa类药物适用于：','绝经前患者，晚期或复发，受体阳性的患者','用于绝经前、绝经后的患者','绝经后或人工造成假绝经的患者','复发及转移性乳腺癌的解救治疗','','','','',NULL,'A',1,',21,,33,',1,''),(1065,2,'HER-2基因扩增或蛋白过表达预示着','A)病情进展迅速，化疗缓解期短，对三苯氧胺容易产生耐药，无病生存和总生存低。','B)病情进展受到抑制，对三苯氧胺容易产生耐药，无病生存和总生存率较高。','C)与病情进展无相关性，对三苯氧胺容易产生耐药','','','','','',NULL,'A',1,',21,,33,',1,''),(1066,3,'中国抗癌协会乳腺癌专业委员会诊治指南与规范2011中指出，以下哪种情况适合适用GnRHa药物：','高度风险且化疗后未导致闭经的患者，可同时与他莫昔芬联合应用','不愿意接受辅助化疗的中度风险患者，可同时与他莫昔芬联合应用','他莫西芬有禁忌的患者','','','','','',NULL,'ABC',1,',21,,33,',1,''),(1067,2,'抑那通®3.75mg的溶媒是1ml，抑那通®3月剂型的溶媒是','1ml','2ml','3ml','2.5ml','','','','',NULL,'A',1,',21,,33,',1,''),(1068,2,'下列哪一个不是乳腺癌的分子标志物？','ER/PR','PPAR','Ki-67','HER-2','','','','',NULL,'B',1,',21,,33,',1,''),(1069,2,'2013年抑那通在中枢性性早熟适应症的剂量被调整为','30-90ug/kg','30-180ug/kg','90-180ug/kg','','','','','',NULL,'B',1,',21,,26,',1,''),(1070,2,'接受醋酸亮丙瑞林治疗CPP的长期随访结果：治疗有效性和性腺功能恢复的评估结果中关于患者目标身高哪项是正确的',' 86.5%的女童和87.9%的男童达到了目标身高范围内的成年身高',' 87.5%的女童和88.9%的男童达到了目标身高范围内的成年身高','88.5%的女童和89.9%的男童达到了目标身高范围内的成年身高','89.5%的女童和90.9%的男童达到了目标身高范围内的成年身高','','','','',NULL,'D',1,',21,,26,',1,''),(1071,2,'女孩性功能发育的主要标志是?','乳房发育','腋毛发育','月经初潮','阴毛发育','','','','',NULL,'C',1,',21,,26,',1,''),(1072,2,'一般女孩第二性征发育顺序依次为？','乳房、阴毛、初潮、腋毛','腋毛，初潮，阴毛，乳房','','','','','','',NULL,'A',1,',21,,26,',1,''),(1073,2,'CPP是指？','中枢性性早熟','外周性性早熟','假性性早熟','非GnRH依赖性性早熟','','','','',NULL,'A',1,',21,,26,',1,''),(1074,2,'PPP是指？','中枢性性早熟','外周性性早熟','真性性早熟','完全性性早熟','','','','',NULL,'B',1,',21,,26,',1,''),(1075,2,'骨龄是预测成人身高的重要依据，其是否对诊断CPP有特异性？','对。有诊断特异性','错。CPP患儿可有骨龄提前，但无诊断特异性','','','','','','',NULL,'B',1,',21,,26,',1,''),(1076,2,'ICPP的全称是？','外周性性早熟','假性性早熟','非GnRH依赖性性早熟','特发性中枢性性早熟','','','','',NULL,'D',1,',21,,26,',1,''),(1077,2,'黄体生成素和卵泡刺激素由_____产生','肾脏','前列腺','下丘脑','垂体','','','','',NULL,'D',1,',21,,26,',1,''),(1078,2,'LH刺激睾丸间质细胞使其分泌','睾酮','促性腺激素','卵泡刺激素','A和B','','','','',NULL,'A',1,',21,,26,',1,''),(1079,2,'以下产品说明书中，没有中枢性性早熟适应症的药品是？','抑那通®','诺雷德®','达菲林®','达必佳®','','','','',NULL,'B',1,',21,,26,',1,''),(1080,2,'达菲林®的通用名？','醋酸戈舍瑞林缓释植入剂','注射用醋酸曲普瑞林','注射用曲普瑞林控释剂','注射用醋酸亮丙瑞林微球','','','','',NULL,'B',1,',21,,26,',1,''),(1081,2,'诺雷德®的通用名？','醋酸戈舍瑞林缓释植入剂','注射用醋酸曲普瑞林','注射用曲普瑞林控释剂','注射用醋酸亮丙瑞林微球','','','','',NULL,'A',1,',21,,26,',1,''),(1082,2,'达必佳®生产厂家？','英国阿斯利康有限公司生产','博福－益普生（天津）有限公司生产','德国辉凌制药有限公司生产','日本武田药品工业株式会社','','','','',NULL,'C',1,',21,,26,',1,''),(1083,2,'诺雷德®生产厂家？','英国阿斯利康有限公司生产','博福－益普生（天津）有限公司生产','德国辉凌制药有限公司生产','日本武田药品工业株式会社','','','','',NULL,'A',1,',21,,26,',1,''),(1084,2,'达菲林®生产厂家？','英国阿斯利康有限公司生产','博福－益普生（天津）有限公司生产','德国辉凌制药有限公司生产','日本武田药品工业株式会社','','','','',NULL,'B',1,',21,,26,',1,''),(1085,2,'诺雷德®有效期是？','1年','2年','3年','5年','','','','',NULL,'B',1,',21,,26,',1,''),(1086,2,'达菲林®有效期是？','1年','2年','3年','5年','','','','',NULL,'B',1,',21,,26,',1,''),(1087,2,'抑那通®在GnRHa药物中全球市场占有率为?','0.33','0.5','0.66','1','','','','',NULL,'C',1,',21,,26,',1,''),(1088,2,'抑那通®的主要成分是？','醋酸戈舍瑞','醋酸曲普瑞林','醋酸萘瑞林','醋酸亮丙瑞林','','','','',NULL,'D',1,',21,,26,',1,''),(1089,2,'ENA治疗CPP的用法用量（说明书）?','通常，每４周１次，皮下注射醋酸亮丙瑞林30μg／kg，根据患者症状可增量至180μg／kg。','通常，每2周１次，皮下注射醋酸亮丙瑞林30μg／kg，根据患者症状可增量至180μg／kg。','','','','','','',NULL,'A',1,',21,,26,',1,''),(1090,2,'抑那通○R停药后____性腺轴即可恢复正常,对成年后生殖功能无影响','1个月','3个月','6个月','9个月','','','','',NULL,'C',1,',21,,26,',1,''),(1091,2,'临床数据证明，使用抑那通○R治疗后，可使____的患儿达到靶身高','1','0.895','0.765','0.5','','','','',NULL,'B',1,',21,,26,',1,''),(1092,2,'青春期是指_','是指从第二性征出现发育到完全成熟这一时段','是指青少年12—18岁学龄时期','是指出现性功能到发育完全成熟这一时段','是指12—22岁之间的时段','','','','',NULL,'A',1,',21,,26,',1,''),(1093,2,'中枢性性早熟实验室检查包括_____、骨龄测定、B超、CT或MR及其他检查','GnRH激发试验','FSH激发试验','LH激发试验','E2激发试验','','','','',NULL,'A',1,',21,,26,',1,''),(1094,3,'抑那通长期用药临床结果表明','治疗期间能够有效抑制性腺轴，抑制第二性征发育和激素水平','停药后性腺轴功能恢复良好','长期随访显示不影响生育功能','治疗期间身高增速控制良好，成年身高达到靶身高范围','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1095,3,'性早熟按照下丘脑-垂体-性腺轴功能是否提前发动分为？','中枢性','外周性','中央性','边缘性','','','','',NULL,'AB',1,',21,,26,',1,''),(1096,3,'中国孩子青春期开始的时间？','通常女孩10-12岁时开始','通常女孩8-10岁时开始','男孩则在12-14岁时开始，女孩比男孩早2年左右','男孩则在10-12岁时开始，女孩比男孩早2年左右','','','','',NULL,'AC',1,',21,,26,',1,''),(1097,3,'FSH和LH的全称分别是?','促卵泡激素','甲状旁腺激素','促黄体生成激素','促肾上腺皮质激素','','','','',NULL,'AC',1,',21,,26,',1,''),(1098,3,'生长发育的两个高峰为?','第一个生长高峰为出生后第二年','第一个生长高峰为出生后第一年','第二个生长高峰出现在幼儿期','第二个生长高峰出现在青春期','','','','',NULL,'BD',1,',21,,26,',1,''),(1099,3,'促性腺激素有哪两种？','卵泡刺激素激素','甲状旁腺激素','黄体生成素','促肾上腺皮质激素','','','','',NULL,'AC',1,',21,,26,',1,''),(1100,3,'中枢性性早熟是？','GnRH依赖性性早熟','CPP','真性性早熟','完全性性早熟','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1101,3,'外周性性早熟是？','PPP','外周性性早熟','假性性早熟','非GnRH依赖性性早熟','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1102,3,'中枢性性早熟与外周性性早熟的差别？','PPP是下丘脑－垂体－性腺轴真正的启动，不仅有第二性征的提前出现，同时有性功能的提前发育成熟','CPP仅有某些第二性征的出现，无性腺和性功能的发育成熟，即无性腺轴的启动','CPP是下丘脑－垂体－性腺轴真正的启动，不仅有第二性征的提前出现，同时有性功能的提前发育成熟','PPP仅有某些第二性征的出现，无性腺和性功能的发育成熟，即无性腺轴的启动','','','','',NULL,'CD',1,',21,,26,',1,''),(1103,3,'中枢性性早熟的诊断依据？','第二性征提前出现，并按照正常发育程序进展','有性腺发育依据：女孩子宫卵巢B超（单独使用不能作为CPP诊断依据）：单侧卵巢容积≥1-3ml且多个直径≥4mm的卵泡；男孩睾丸容积≥4ml','发育过程中身高增长突增','促性腺激素升高至青春期水平','可有骨龄提前，但无诊断特异性','','','',NULL,'ABCDE',1,',21,,26,',1,''),(1104,3,'中枢性性早熟的治疗目标？','抑制过早或过快的性发育','防止或缓解患儿或家长因性早熟所致的相关的社会或心理问题','改善因骨龄提前而减损的成年身高','','','','','',NULL,'ABC',1,',21,,26,',1,''),(1105,3,'GnRH治疗特发性性早熟常见的副作用？','注射部位局部反应如红斑，硬化，水庖，无菌性水肿','首次应用可能出现阴道分泌物增多或阴道出血等','','','','','','',NULL,'AB',1,',21,,26,',1,''),(1106,3,'人体生殖系统的发育和功能维持的控制通路包括','下丘脑','垂体','性腺','大脑皮质','','','','',NULL,'ABC',1,',21,,26,',1,''),(1107,3,'不完全性性早熟','是中枢性性早熟的变异','包括单纯性乳房早发育（prematurethelarche）','包括单纯性乳房早现（prematurepubarche）','包括单纯性早初潮（prematuremenarche）','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1108,3,'以下关于性早熟哪种说法正确','继发性性早熟多见于中枢神经系统异常','少数未经治疗的原发性甲状腺功能降低症患者可伴发中枢性性早熟','外周性性早熟有第二性征和性腺发育','外周性性早熟下丘脑-垂体-性腺轴不成熟','','','','',NULL,'ABC',1,',21,,26,',1,''),(1109,3,'以下关于性早熟的临床表现哪种说法正确','性早熟以女孩多见','女孩发生特发性性早熟约为男孩的9倍','男孩性早熟者的中枢神经系统异常发生率较高','中枢性性早熟临床表现比较单一','','','','',NULL,'ABC',1,',21,,26,',1,''),(1110,3,'确定中枢性或外周性性早熟，除按临床特征初步判断外，需作哪些辅助检查','基础性激素测定','促性腺激素释放激素激发试验','B超','MRI','骨龄','','','',NULL,'ABCE',1,',21,,26,',1,''),(1111,3,'下列哪些情况在确诊中枢性性早熟后需做脑CT或MRI检查','确诊为CPP的所有患儿','确诊为CPP的所有男孩','确诊为CPP的所有女孩','性成熟过程迅速或有其他中枢病变表现者','','','','',NULL,'BD',1,',21,,26,',1,''),(1112,3,'中枢性性早熟的治疗目的是','抑制或减慢性发育，特别是阻止女孩月经来潮','抑制骨骼成熟，改善成人期最终身高','预防与性发育有关的精神社会问题','所有的ICPP都需要治疗','','','','',NULL,'ABC',1,',21,,26,',1,''),(1113,3,'哪些情况下中枢性性早熟不需要治疗','性成熟进程缓慢，骨龄年龄不超越年龄进展','骨龄虽然提前，但是身高生长速度也快，预测成年身高不受损者','暂不治疗者均需定期复查和评估，调整治疗方案','','','','','',NULL,'ABC',1,',21,,26,',1,''),(1114,3,'有关抑那通®治疗特发性性早熟正确的是','抑那通®能显著缩小女性患儿卵巢容积','抑那通®能显著缩小女性患儿子宫容积','那通®能显著消退早现的第二性征','抑那通®能显著改善患儿预测成人身高','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1115,3,'以下关于抑那通®哪些说法是正确的','抑那通®治疗中枢性性早熟效果显著','抑那通®通过有效抑制下丘脑-垂体-性腺轴来治疗中枢性性早熟','抑那通®可显著消退第二性征','抑那通®可有效抑制提早发育，改善成人身高','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1116,3,'有关抑那通®治疗特发性性早熟正确的是：','抑那通®能显著降低患儿血清促性腺激素基础值','抑那通®能显著降低患儿血清促性腺激素激发实验峰值','抑那通®能显著降低男性患儿血清雄激素水平','抑那通®能显著降低女性患儿血清雌激素水平','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1117,3,'为什么说ENA是治疗CPP的理想选择?','抑那通®可有效抑制下丘脑－垂体－性腺轴','抑那通®可显著消退第二性征','抑那通®可有效抑制提早发育，改善成人身高','抑那通®停药后，生殖、发育恢复良好','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1118,3,'与其它GnRHa相比ENA治疗CPP的优势？','ENA具有独创的微球缓释技术，注射时仅需使用6号针头','痛感低','创伤小','减少小朋友的恐惧感','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1119,3,'临床/研究显示，抑那通®停药后','患儿性腺轴功能能够良好恢复，促性腺激素峰值可基本恢复至正常水平','患儿睾丸发育可恢复正常','患儿月经可恢复正常','患儿骨骼发育恢复良好','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1120,3,'抑那通○R的注射部位可以是','上臂','臀部','腹部','皮下埋植','','','','',NULL,'ABC',1,',21,,26,',1,''),(1121,3,'体格生长的常用指标包括____','身高、体重','坐高','头/胸/上臂围','皮下脂肪','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1122,3,'中枢性性早熟的诊断包含有','病史（第二性征出现的时间和顺序）','体格检查（身高、体重）','分期判断（Tanner标准对女孩乳房分期及评估Tanner标准和睾丸模型对男孩第二性征评估）','实验室检查','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1123,2,'性早熟是指女孩在8岁以前，男孩在9岁以前呈现第二性征','对','错','','','','','','',NULL,'A',1,',21,,26,',1,''),(1124,2,'以下说法哪种错误','中枢性性早熟因下丘脑-垂体-性腺轴功能过早启动产生，患儿除有第二性征的发育外，没有卵巢或睾丸的发育','中枢性性早熟是由于下丘脑-垂体-性腺轴功能过早启动，患儿除有第二性征的发育外，还有卵巢或睾丸的发育','中枢性性早熟的性发育过程和正常青春期发育的顺序一致，只是年龄提前','进入青春期后，下丘脑对性激素的负反馈作用的敏感度下降，GnRH的分泌脉冲数和分泌峰值逐渐增加','','','','',NULL,'A',1,',21,,26,',1,''),(1125,2,'骨龄是预测成年身高的重要依据，对于诊断中枢性性早熟有特异性','对','错','','','','','','',NULL,'B',1,',21,,26,',1,''),(1126,2,'促性腺激素释放激素类似物（GnRHa）是中枢性性早熟治疗的主要选择','对','错','','','','','','',NULL,'A',1,',21,,26,',1,''),(1127,3,'以下属于青春期性早熟的治疗目标的是：','达到正常的青春期年龄之前阻止性成熟的发生。\n，减退现已出现的第二性征\n','抑制骨成熟，获得正常的成年身高\n','防止性心理发育的失衡\n','保护未来的生育力\n','防止月经初潮提前所引起的乳腺癌风险 ','','','',NULL,'ABCDE',1,',21,,26,',1,''),(1128,2,'中枢性性早熟的治疗，为了使身高达到最高水平，什么时候停止治疗？','最好在骨龄12岁左右、\n实际年龄11岁左右停止治疗','最好在骨龄15岁左右、\n实际年龄14岁左右停止治疗。','最好在骨龄10岁左右、\n实际年龄9岁左右停止治疗','最好在骨龄14岁左右、\n实际年龄13岁左右停止治疗','','','','',NULL,'A',1,',21,,26,',1,''),(1129,3,'用于中枢性性早熟，Leuplin的禁忌事项 ','对本药的成分或合成LH-RH、LH-RH衍生物有过敏史的患者','孕妇或可能怀孕的患者、哺乳期患者\n','未经诊断的异常生殖器出血患者 ','','','','','',NULL,'ABC',1,',21,,26,',1,''),(1130,3,'中枢性性早熟，女童的明显症状是：','7岁6个月以前乳房发育','8岁以前长出阴毛，或者\n   出现小阴唇色素沉着等外阴部早熟、\n   或长出腋毛\n','9以前月经初潮\n','身高增长速度过快，骨成熟加速。','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1131,3,'中枢性性早熟，男童的明显症状是：','9岁以前睾丸、阴茎、阴囊明显发育\n','10岁以前长出阴毛\n','11岁以前长出腋毛、胡须或变声 \n','遗精现象的出现','','','','',NULL,'ABC',1,',21,,26,',1,''),(1132,2,'抑那通在中枢性性早熟适应症的剂量被调整为','30-90ug/kg\n\n','30-180ug/kg\n','90-180ug/kg','90-120ug/kg','','','','',NULL,'B',1,',21,,26,',1,''),(1133,3,'在治疗中枢性性早熟方面，抑那通长期用药临床结果表明','治疗期间能够有效抑制性腺轴，抑制第二性征发育和激素水平','停药后性腺轴功能恢复良好',' 长期随访显示不影响生育功能','治疗期间身高增速控制良好，成年身高达到靶身高范围','','','','',NULL,'ABCD',1,',21,,26,',1,''),(1134,3,'子宫内膜异位症的治疗目标\n','减灭和消除病灶','改善和促进生育','缓解并解除疼痛','减少和避免复发\n','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1135,2,'关于EM的手术治疗以下说法不正确的是','保守性手术：保留患者的生育功能\n','半根治手术：切除卵巢和病灶保留子宫\n\n','根治性手术：切除全子宫和双附件以及所有肉眼可见的病灶\n','辅助性手术：如子宫神经去除术以及骶前神经切除术\n','','','','',NULL,'B',1,',21,,27,',1,''),(1136,3,'下列药物中可以治疗EM的是','口服避孕药\n','高效孕激素如醋酸甲羟孕酮\n','雄激素衍生物如达那唑\n\n','GnRHa\n','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1137,3,'在EM的诊断与治疗流程中以下说法不正确的是\n','对于痛经的患者在使用非甾体类镇痛剂、避孕药3-6个月仍无效者应使用GnRHa联合反加','对于痛经的患者在使用非甾体类镇痛剂、避孕药6-12个月仍无效者应使用GnRHa联合反加\n\n','对于盆腔囊肿大于3CM或提示其他肿瘤的EM患者应选择腹腔镜。','对于盆腔囊肿大于5CM或提示其他肿瘤的EM患者应选择腹腔镜。','','','','',NULL,'BC',1,',21,,27,',1,''),(1138,2,'关于EM的半根治手术以下描述正确的是','切除卵巢和病灶保留了子宫\n','保留了患者的内分泌功能\n','保留了患者的生育功能\n','有效防止复发\n','','','','',NULL,'B',1,',21,,27,',1,''),(1139,2,'GnRH翻译成中文是','促黄体生成素释放激素\n','促性腺素释放激素\n','促卵泡激素释放激素\n','促黄体生成激素释放激素\n','','','','',NULL,'B',1,',21,,27,',1,''),(1140,2,'子宫内膜异位症是指？','一种良性疾病是指子宫内膜组织生长在子宫内。\n\n','一种恶性疾病是指子宫内膜组织生长在子宫内膜外。\n','一种恶性疾病是指子宫内膜组织生长在子宫内膜内。\n\n','一种良性疾病是指子宫内膜组织生长在子宫内膜以外的部位。\n','','','','',NULL,'D',1,',21,,27,',1,''),(1141,2,'在女性生殖区域哪个部位是五个最常见的子宫内膜异位受累的位置之一三分之二的病人会诊断出在此存在EM。','输卵管\n','子宫','卵巢','阴道\n','','','','',NULL,'C',1,',21,,27,',1,''),(1142,2,'在GnRH激动剂出现之前哪种药物被认为是EM药物治疗的“金标准”？\n','达那唑','米非司酮','芳香化抑制剂\n\n','口服避孕药\n','','','','',NULL,'A',1,',21,,27,',1,''),(1143,2,'哪种激素可增加钙质吸收和新骨形成也可增加骨质密度？\n','孕激素','雌激素','GnRH激动剂\n','免疫抑制剂\n','','','','',NULL,'B',1,',21,,27,',1,''),(1144,3,'EM的根治性手术是指？','摘除子宫（子宫切除）\n','摘除双侧卵巢和输卵管（双侧输卵管卵巢切除术）\n','摘除尿道（尿道切除）','摘除膀胱（膀胱切除）\n','','','','',NULL,'AB',1,',21,,27,',1,''),(1145,2,'子宫最内的一层是？\n','子宫内膜','腺层','子宫肌层','子宫浆膜层\n','','','','',NULL,'A',1,',21,,27,',1,''),(1146,3,'控制子宫内膜的生长的激素为？\n','雌激素','雄激素','孕酮','甲状旁腺激素','','','','',NULL,'AC',1,',21,,27,',1,''),(1147,2,'Add-backtherapy是指？\n','激素反加疗法','雌激素替代疗法','新辅助疗法','雄激素去势','','','','',NULL,'A',1,',21,,27,',1,''),(1148,3,'关于EM的药物治疗哪二类药物获得了FDA的批准？\n','GnRH激动剂\n','口服避孕药','达那唑','米非司酮','','','','',NULL,'AC',1,',21,,27,',1,''),(1149,3,'四种特别重要的子宫韧带？\n','圆韧带\n','阔韧带','主韧带','子宫骶韧带','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1150,3,'至关重要的女性生殖器官包括？\n','子宫','卵巢','输卵管','阴道','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1151,2,'HRT(HormoneReplacementTherapy)是指？','激素反加疗法','激素替代疗法\n','新辅助疗法','雄激素去势','','','','',NULL,'B',1,',21,,27,',1,''),(1152,2,'子宫内膜异位症的诊断在病人出现症状并去看医生时开始通常的症状是？\n','疼痛和／或不孕\n','阴道分泌物增多','外阴瘙痒','心慌出汗','','','','',NULL,'A',1,',21,,27,',1,''),(1153,2,'哪种药物是目前唯一被FDA批准的反向添加疗法的药物？\n','孕酮','雄激素','小剂量雌激素','醋酸炔诺酮','','','','',NULL,'D',1,',21,,27,',1,''),(1154,3,'目前FDA（美国食品药品监督管理局）已批准了3种GnRH激动剂药物用于治疗子宫内膜异位症分别是？','醋酸亮丙瑞林（抑那通）','醋酸戈舍瑞林（诺雷德）\n','醋酸曲普瑞林（达菲林）','醋酸萘瑞林（Synarel萘瑞林）','','','','',NULL,'ABC',1,',21,,27,',1,''),(1155,3,'目前子宫内膜异位症的治疗目标是？\n','缓解疼痛;','对有生育愿望的妇女提高怀孕几率;\n','延迟疾病复发','对有症状的病人进行经验性治疗','','','','',NULL,'ABC',1,',21,,27,',1,''),(1156,3,'子宫内膜异位症常见的症状及发生率？\n','痛经：60-80%；','慢性盆腔痛：40-50%；','深部性交痛：40-50%；','不育：30-50%；\n','严重的痛经和不规则出血和/或经前点状出血：10-20%','','','',NULL,'ABCDE',1,',21,,27,',1,''),(1157,3,'常见的子宫内膜异位症的区域包括？','子宫直肠窝的前穹隆和后穹隆\n\n','直肠阴道隔','子宫骶韧带\n','阔韧带','卵巢','','','',NULL,'ABCDE',1,',21,,27,',1,''),(1158,3,'子宫内膜异位症治疗的四类药物？','诱导假孕的药物（口服避孕药孕激素）','诱导假绝经的药物（雄激素GnRH激动剂）\n','干扰引发EM的激素的局部作用如米非司酮','针对EM炎症过程的药物（免疫抑制剂抗血管药和芳香化抑制剂）。','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1159,2,'诺雷德®的通用名及生产厂家？\n\n','醋酸戈舍瑞林缓释植入剂英国阿斯利康有限公司生产','注射用醋酸曲普瑞林博福－益普生（天津）有限公司生产\n','注射用曲普瑞林控释剂德国辉凌制药有限公司生产','注射用醋酸亮丙瑞林微球日本武田药品工业株式会社','','','','',NULL,'A',1,',21,,27,',1,''),(1160,2,'达菲林®的通用名及生产厂家？\n','醋酸戈舍瑞林缓释植入剂英国阿斯利康有限公司生产\n','注射用醋酸曲普瑞林博福－益普生（天津）有限公司生产\n','注射用曲普瑞林控释剂德国辉凌制药有限公司生产','注射用醋酸亮丙瑞林微球日本武田药品工业株式会社','','','','',NULL,'B',1,',21,,27,',1,''),(1161,2,'达必佳®的通用名及生产厂家？\n','醋酸戈舍瑞林缓释植入剂英国阿斯利康有限公司生产\n','注射用醋酸曲普瑞林博福－益普生（天津）有限公司生产','注射用曲普瑞林控释剂德国辉凌制药有限公司生产\n','注射用醋酸亮丙瑞林微球日本武田药品工业株式会社','','','','',NULL,'C',1,',21,,27,',1,''),(1162,2,'曲普瑞林微球平均直径？\n','19微米\n','50微米\n','100微米','150微米','','','','',NULL,'B',1,',21,,27,',1,''),(1163,2,'以下产品说明书中没有子宫肌瘤适应症的药品是？\n','抑那通®\n','诺雷德®','达菲林®\n','达必佳®','','','','',NULL,'B',1,',21,,27,',1,''),(1164,2,'达必佳®的储藏温度是？\n','2-8℃避光储藏\n','8℃以下\n','室温（10-30℃）\n','高温储藏','','','','',NULL,'A',1,',21,,27,',1,''),(1165,2,'诺雷德®、达菲林®1M剂型的有效期是？\n','1年','2年','3年','5年','','','','',NULL,'B',1,',21,,27,',1,''),(1166,2,'戈舍瑞林的给药方式？\n','皮下注射','肌肉注射','鼻喷给药','皮下埋植','','','','',NULL,'D',1,',21,,27,',1,''),(1167,3,'戈舍瑞林的给药方式所带来的弊端？\n','火柴杆大小的针头增加痛感和恐惧感；','需要专人操作及培训；\n。','注射时需要局麻（必要时）；','对于皮肤敏感者易引发感染影响美观','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1168,2,'抑那通®的通用名是？\n','醋酸戈舍瑞林缓释植入剂','注射用醋酸曲普瑞林','注射用曲普瑞林控释剂','注射用醋酸亮丙瑞林微球','','','','',NULL,'D',1,',21,,27,',1,''),(1169,2,'全球第一个通过FDA审批上市的长效GnRH类似物是？\n','抑那通®\n','诺雷德®\n','达菲林®','达必佳®','','','','',NULL,'A',1,',21,,27,',1,''),(1170,2,'醋酸亮丙瑞林与天然的GnRH的不同是：哪个位点的氨基酸取代了甘氨酸？\n','3-色氨酸\n','2-组氨酸\n','5-酪氨酸','6-D-亮氨酸','','','','',NULL,'D',1,',21,,27,',1,''),(1171,2,'抑那通®在中国的上市时间？\n','1990年','1991年\n','1992年\n','1993年','','','','',NULL,'C',1,',21,,27,',1,''),(1172,2,'抑那通®是高活性衍生物其活性与受体的结合能力是天然GnRH的多少倍？\n','50倍\n','80-100倍\n','100-150倍\n','150-200倍','','','','',NULL,'B',1,',21,,27,',1,''),(1173,2,'抑那通3.75里面的醋酸亮丙瑞林微球平均直径？\n','19微米\n','50微米\n','100微米','5微米','','','','',NULL,'A',1,',21,,27,',1,''),(1174,2,'FDA根据药物对动物和人类所具有不同程度的致畸危险将其分为5类称为药物的妊娠分类抑那通®属于其中的哪类？\n\n','A类\n','B类\n','C类\n','X类','','','','',NULL,'D',1,',21,,27,',1,''),(1175,2,'抑那通®的有效期？\n','1年','2年','3年','5年','','','','',NULL,'C',1,',21,,27,',1,''),(1176,2,'抑那通®的储藏温度是？\n','2-8℃避光储藏','8℃以下\n','室温（10-30℃）\n','高温储藏','','','','',NULL,'C',1,',21,,27,',1,''),(1177,3,'EM、子宫肌瘤的患者使用抑那通®时的禁忌症?\n','对本制剂成分、合成的LH-RH或LH-RH衍生物有过敏史者','孕妇或有可能怀孕的妇女或哺乳期妇女（见孕妇及哺乳期妇女用药）\n','有性质不明的异常的阴道出血者（有可能为恶性疾病）\n','有腹痛者。','','','','',NULL,'ABC',1,',21,,27,',1,''),(1178,3,'抑那通®在皮下注射时注意事项?。\n','注射部位应选择上臂腹部或臀部的皮下；','注射部位应每次变更不得在同一部位注射；\n','检查注射针头不得扎入血管内；','嘱咐患者不得按摩注射部位','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1179,3,'谈谈抑那通®独创的微球缓释技术在治疗EM上的特点和优势？\n','使用更细6号针头减少患者注射时的痛感和恐惧感。\n','不影响皮肤美观也减少了感染的风险。\n','不易堵针避免注射操作带来的不必要的纠纷\n','无需麻醉护士操作简单无需特殊培训','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1180,2,'对于因EM引发的不孕的患者经过3-6个月抑那通®治疗怀孕的几率可增加多少倍？\n','1倍','2倍','3倍','4倍','','','','',NULL,'D',1,',21,,27,',1,''),(1181,2,'抑那通®可改善生育评分达？\n','23%\n\n','34%\n','43%\n','0.6','','','','',NULL,'C',1,',21,,27,',1,''),(1182,2,'子宫内膜异位症的最后确诊有赖于\n','病史及妇科检查\n','B超声\n','CA125\n','剖腹或腹腔镜检查\n','以上都是','','','',NULL,'E',1,',21,,27,',1,''),(1183,2,'GnRH-a治疗中反向添加治疗的目的是\n\n','抑制异位子宫内膜\n','减轻副作用\n','提高受孕率\n','抑制卵巢\n','抑制垂体','','','',NULL,'B',1,',21,,27,',1,''),(1184,2,'关于子宫内膜异位症临床表现错误的是\n','子宫内膜异位的部位不同症状差别大\n','异位的子宫内膜面积大则症状明显\n','痛经的特点为继发性和进行性加重\n','不育因盆腔粘连子宫后倾卵巢功能失调及性交疼痛\n','体征随病变部位不同而改变','','','',NULL,'B',1,',21,,27,',1,''),(1185,2,'诊断子宫内膜异位症的最佳方法之一\n','B型超声检查','CA125测定','腹腔镜检查','盆腔检查','以上都不是','','','',NULL,'C',1,',21,,27,',1,''),(1186,2,'子宫内膜异位的痛经主要表现为\n','原发性痛经\n','继发性痛经进行性加重\n','运动性痛经\n','偶发痛经\n','以上都不是','','','',NULL,'B',1,',21,,27,',1,''),(1187,2,'关于子宫内膜异位症的治疗下列哪项是错误的','孕激素治疗\n\n','假孕治疗\n','放射治疗\n','假绝经治疗\n','根治性/半根治性手术','','','',NULL,'C',1,',21,,27,',1,''),(1188,3,'抑那通®注射部位？\n\n','上臂\n','臀部\n','腹部\n','大腿','','','','',NULL,'ABC',1,',21,,27,',1,''),(1189,3,'抑那通®目前在国内销售的规格有？','1.88mg/支\n\n','3.6mg/支','3.75mg/支','11.25mg/支','','','','',NULL,'ACD',1,',21,,27,',1,''),(1190,3,'ESHRE指南中有关GnRH激动剂的治疗正确的是？','未确诊时可行经验性治疗；。\n','治疗已确诊的内异症相关疼痛；','术后治疗；','内异症患者辅助生殖','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1191,2,'抑那通®最后一次给药停药后女性月经恢复的时间是?\n\n','4~6周左右\n','8~12周左右\n','16周左右\n','24周左右','','','','',NULL,'B',1,',21,,27,',1,''),(1192,2,'抑那通®最后一次给药停药后女性排卵恢复的时间是?\n','2~4周左右\n','4~6周左右\n','8~12周左右','24周左右','','','','',NULL,'C',1,',21,,27,',1,''),(1193,3,'抑那通®在EM患者的临床应用？\n','未确诊时的经验性治疗；','已确诊的治疗相关疼痛；','术后治疗延缓复发时间；','内异症患者辅助生殖。','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1194,2,'研究显示百分之多少的EM疼痛患者在使用抑那通®后疼痛得以缓解？\n','25%\n','50%\n','75%\n','85-100%','','','','',NULL,'D',1,',21,,27,',1,''),(1195,3,'抑那通®临床研究中出现的不良反应包括？','潮热头痛情绪紊乱','性欲减退\n\n','痤疮肌痛乳房变小阴道干燥\n','短期治疗后可逆转的骨质流失','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1196,2,'关于子宫内膜异位症下述哪项是错误的\n','子宫腺肌病是子宫内膜异位症\n','常发生在生育年龄\n','最常发生的部位是卵巢\n','妊娠后症状可以缓解甚至消失\n','很少发生恶变','','','',NULL,'A',1,',21,,27,',1,''),(1197,3,'子宫内膜异位症药物治疗的目的是\n','减灭和消除病灶\n','缓解并解除疼痛\n','减少和避免复发\n','改善和促进生育\n','避免并减少手术','','','',NULL,'ABCD',1,',21,,27,',1,''),(1198,2,'子宫内膜异位症的典型体征\n','子宫增大\n','附件区压痛\n\n','宫颈举痛\n','直肠子宫陷凹触痛结节\n','子宫压痛','','','',NULL,'D',1,',21,,27,',1,''),(1199,3,'关于子宫的说法，下面正确的是：','子宫位于输卵管和阴道之间，呈倒置的梨形','大小类似于鸡蛋','子宫的横向左右各有1个卵巢','子宫从解剖学上可分为子宫体、子宫颈、子宫阴道接合处几部分','子宫内膜腺能分泌糖类和粘液，帮助早期胚胎发育。','','','',NULL,'ABCDE',1,',21,,27,',1,''),(1200,3,'有关子宫内膜异位症，下面说法正确的是：','子宫内膜在子宫腔之外的其他部位生长的疾病','子宫内膜异位症基本上是指子宫的内膜和类似组织在子宫内腔和子宫体肌层之外的盆腔部位生长的疾病，育龄女性的发病率在5～10％',' 子宫内膜异位症可以根据发生部位分类，通常所说的子宫内膜异位症是指盆腔内发生的盆腔子宫内膜异位',' 多发部位包括卵巢、子宫浆膜面、子宫直肠陷凹、子宫骶韧带、直肠阴道膈、直肠、膀胱等，除此之外还可能会发生在生殖器、S状结肠、阑尾、输尿管、肺、胃、肝、皮肤、手术瘢痕等处，也有全身发病的情况',' 子宫内膜异位症是雌激素依赖性疾病，大部分都不会危及生命，但其主要症状疼痛和生育力降低会严重影响女性的生活质量','','','',NULL,'ABCDE',1,',21,,27,',1,''),(1201,3,'子宫内膜异位症的症状：','经期疼痛','月经过多','性交痛','排便痛','经期外下腹部疼痛','不孕','','',NULL,'ABCDEF',1,',21,,27,',1,''),(1202,3,'子宫内膜异位症的治疗目标主要是针对什么：','疼痛','不孕','卵巢巧克力囊肿','','','','','',NULL,'ABC',1,',21,,27,',1,''),(1203,2,'决定子宫内膜异位症治疗方针的最大因素是什么？','是否想要孩子','病情严重程度','粘连程度','囊肿大小','','','','',NULL,'A',1,',21,,27,',1,''),(1204,2,'子宫内膜异位症的发生部位中发生率最高的在哪里？','子宫浆膜','子宫骶韧带','子宫直肠陷凹','卵巢','','','','',NULL,'D',1,',21,,27,',1,''),(1205,3,'子宫内膜异位症性疼痛的治疗分为：','对症疗法','内分泌疗法','手术疗法','','','','','',NULL,'ABC',1,',21,,27,',1,''),(1206,3,'子宫内膜异位症性疼痛的对症治疗中使用的是什么药物？','镇痛剂','中药','白三烯拮抗剂','口服避孕药','','','','',NULL,'ABC',1,',21,,27,',1,''),(1207,3,'目前子宫内膜异位症的内分泌疗法中主要应用的是什么药物？','达那唑','口服避孕药','雌激素','GnRH激动剂','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1208,3,'子宫内膜异位症的治疗中口服避孕药的缺点有哪些？','症状的改善略差一些','证据不足','中高剂量用药会增加体重','有血栓形成和肝功能障碍的风险','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1209,3,'子宫内膜异位症的治疗中GNRH激动剂的优点有哪些？','疼痛症状的改善率较高','肝功能障碍，血栓形成的风险低','直接作用于子宫内膜病灶','可长期用药','','','','',NULL,'AB',1,',21,,27,',1,''),(1210,3,'子宫内膜异位症的治疗中GNRH激动剂的缺点有哪些？','低雌激素症状','不可长期用药（6个月以上）','男性化征兆','消化道症状','','','','',NULL,'AB',1,',21,,27,',1,''),(1211,3,'有关子宫肌瘤的说法正确的是？','子宫肌层内的平滑肌成分所发生良性肿瘤','从病理学上说属于平滑肌瘤',' 子宫肌瘤按发生部位分为子宫肌层内肌瘤，子宫粘膜下肌瘤和子宫浆膜下肌瘤','子宫肌瘤的症状不会因为肌瘤的部位和大小而不同','','','','',NULL,'ABC',1,',21,,27,',1,''),(1212,3,'子宫肌瘤的症状有哪些？','月经过多、不规则出血','下腹部有肿块感、','贫血、','膀胱压迫症状、','下腹部痛','','','',NULL,'ABCDE',1,',21,,27,',1,''),(1213,2,'子宫肌瘤的发病高峰是？','19岁以下','30至35岁','35至40岁','45至49岁','','','','',NULL,'D',1,',21,,27,',1,''),(1214,3,'GnRH激动剂在子宫肌瘤领域的适用范围是？','手术前给药，减少术中的出血量','手术前给药，缩小肌瘤以便能实施腹腔镜下肌瘤摘除术','停止月经以改善贫血症状','不开展手术，进行保守性管理','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1215,3,'子宫肌瘤的手术疗法大致分为哪两类？','子宫肌瘤摘除术','单纯全子宫切除术','子宫动脉栓塞术','聚焦超声疗法','','','','',NULL,'AB',1,',21,,27,',1,''),(1216,2,'LH是指？','促性腺激素','促黄体生成素','卵泡雌激素','促卵泡生成素','','','','',NULL,'B',1,',21,,27,',1,''),(1217,2,'FSH是指？','促性腺激素','促黄体生成素','卵泡刺激素','促卵泡生成素','','','','',NULL,'D',1,',21,,27,',1,''),(1218,2,'LH和FSH合称什么？','促性腺激素','促黄体生成素','卵泡雌激素','促卵泡生成素','','','','',NULL,'A',1,',21,,27,',1,''),(1219,2,'平均来说，月经周期是多少天居多？','26','27','28','35','','','','',NULL,'C',1,',21,,27,',1,''),(1220,2,'R-ASRM分期是什么？','修订版美国生育协会','美国生殖医学学会子宫内膜分期法','子宫内膜异位症临床分期','','','','','',NULL,'B',1,',21,,27,',1,''),(1221,2,'确诊子宫内膜异位症时必须进行什么检查？','子宫输卵管造影','开腹或者腹腔镜的直视检查','血清学诊断','影像学诊断','','','','',NULL,'B',1,',21,,27,',1,''),(1222,2,'子宫内膜异位症根据内诊所见的分期的名称是什么？','R-AFS分期','R-ASRM分期','Beecham分期','','','','','',NULL,'C',1,',21,,27,',1,''),(1223,2,'子宫内膜异位症的高发年龄为？','20-30岁','30-40岁','40-45岁','45-50岁','','','','',NULL,'B',1,',21,,27,',1,''),(1224,3,'有关假孕疗法，下面说法正确的是？','可以使子宫内膜异位症减轻','是使用雌激素和黄体酮人为制造长期妊娠状态治疗子宫内膜异位症的方法。','不存在血栓形成的问题','存在血栓形成的问题','','','','',NULL,'ABD',1,',21,,27,',1,''),(1225,3,'有关假绝经疗法，下面说法正确的是？','GnRH类似物通过抑制垂体分泌LH，FSH而抑制卵巢分泌雌激素。','制造不排卵，无月经的状态。','使子宫内膜病灶萎缩。','存在血栓形成的问题','','','','',NULL,'ABC',1,',21,,27,',1,''),(1226,3,'关于子宫内膜异位症，子宫肌瘤，子宫腺肌病，下面说法正确的是？','都容易发生在性成熟的女性中','绝经后不会发病','临床症状以不同程度的经期疼痛和月经过多为主','雌激素依赖性很强','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1227,3,'子宫内膜异位症想要孩子的患者可进行哪些治疗？','腹腔冲洗','辅助生殖医疗','腹腔镜手术','观察等待疗法','','','','',NULL,'ABCD',1,',21,,27,',1,''),(1228,2,'GnRH是由哪里分泌？','下丘脑','垂体','肾上腺','性腺','','','','',NULL,'A',1,',21,,34,',1,''),(1229,2,'GnRH作用于哪里？','下丘脑GnRH受体','垂体前叶GnRH受体','肾上腺','性腺','','','','',NULL,'B',1,',21,,34,',1,''),(1230,2,'GnRHa作用于哪里？','竞争结合下丘脑GnRH受体','竞争结合垂体前叶GnRH受体','肾上腺','性腺','','','','',NULL,'B',1,',21,,34,',1,''),(1231,2,'使用GnRHa药物后，在给药_____出现急性反应，引起FSH和LH分泌增加，持续______','2-3天，2周','2-3天，1周','3-5天，2周','3-5天，1周','','','','',NULL,'B',1,',21,,34,',1,''),(1232,2,'使用GnRHa药物后，给药______出现慢性作用，抑制LH和FSH的分泌，并进而抑制性激素的分泌，达到治疗性激素依赖疾病的作用','1-2周','2-4周','4周以后','6周以后','','','','',NULL,'B',1,',21,,34,',1,''),(1233,2,'以下哪项不是正常前列腺的生理功能？','分泌前列腺液','内含丰富的5-α还原酶，其使得睾酮转化成活性更高的双氢睾酮','与控制排尿与射精相关','生成并储存精子','','','','',NULL,'D',1,',21,,34,',1,''),(1234,2,'关于前列腺癌症状不正确的是？','早期前列腺癌常常症状隐匿','良性前列腺肥大与前列腺癌症状截然不同','前列腺癌发展到一定程度可能发生排尿障碍','晚期疾病可能发生骨转移，并有剧烈的疼痛','','','','',NULL,'B',1,',21,,34,',1,''),(1235,2,'关于前列腺癌的发生，以下哪些因素说法是不正确的','是内部因素（基因）和外部因素（环境）综合作用的结果','多吃水果蔬菜可能对预防前列腺癌有效','前列腺癌属于性传播疾病','当直系血亲中有前列腺癌患者时其前列腺癌发病率高于普通人群','','','','',NULL,'C',1,',21,,34,',1,''),(1236,2,'关于前列腺癌发病的流行病学数据不正确的是？','45岁以下患者少见','随着年龄增长累计发病率逐渐提高','最常见的发病年龄是45至50岁','很多因其他原因死亡的男性尸检发现前列腺癌细胞','','','','',NULL,'C',1,',21,,34,',1,''),(1237,2,'关于前列腺癌TNM分期不正确的是？','N分期描述淋巴结转移情况','Mx指的是不能确定是否发生远处转移','T3指的是肿瘤已经超过了前列腺包膜','N1指的是转移淋巴结个数超过10个','','','','',NULL,'D',1,',21,,34,',1,''),(1238,2,'关于Gleason评分不正确的是？','前列腺癌病理分级的常用系统','根据前列腺癌细胞的分化程度将前列腺癌分成5级','Gleason评分为2至10分','评分越低则预后越好','','','','',NULL,'D',1,',21,,34,',1,''),(1239,2,'局限性前列腺癌预后风险评估不正确的是？','低风险：T1–2a且Gleason评分<7且PSA<10ng/ml','中风险：T2b–c或Gleason评分=7或PSA:10至20ng/ml','高风险：T3–4或Gleason>7或PSA>20ng/ml','前列腺大小是最主要的评估预后风险指标','','','','',NULL,'D',1,',21,,34,',1,''),(1240,2,'关于PSA检查不正确的是？','良性前列腺肥大也可能出现PSA升高','前列腺癌经过系统治疗后PSA一定会回复到正常值','关于前列腺癌筛查的大规模进行目前有很多争议','PSA正常不能说前列腺一定没有问题','','','','',NULL,'B',1,',21,,34,',1,''),(1241,2,'男性特有的胡桃状大小的腺体是------','肾上腺','前列腺','a和b','都不是','','','','',NULL,'B',1,',21,,34,',1,''),(1242,2,'促黄体生成素释放激素（LHRH）也叫做-------','促性腺激素释放激素','卵泡刺激素','a和b','都不是','','','','',NULL,'A',1,',21,,34,',1,''),(1243,2,'LH刺激睾丸间质细胞使其分泌-------','睾酮','促性腺激素','卵泡刺激素','a和b','','','','',NULL,'A',1,',21,,34,',1,''),(1244,2,'已知能增加前列腺癌患病机率的因素是-----','年龄和家族遗传史','种族','a和b','都不是','','','','',NULL,'C',1,',21,,34,',1,''),(1245,2,'前列腺癌的早期症状是-------','尿频','局部前列腺癌经常是无症状的','排尿疼痛','以上都是','','','','',NULL,'D',1,',21,,34,',1,''),(1246,2,'前列腺癌的诊断检查手段主要有------','DRE和PSA血液测试，前列腺组织穿刺活检','PSA测试和钡餐，DRE','DRE和血液酸碱度检测，穿刺活检','以上都是','','','','',NULL,'A',1,',21,,34,',1,''),(1247,2,'RP是指：','放疗','激素治疗','根治性前列腺切除术','姑息治疗','','','','',NULL,'C',1,',21,,34,',1,''),(1248,2,'HT是指：','放疗','激素治疗','冷冻疗法','近距离放疗','','','','',NULL,'B',1,',21,,34,',1,''),(1249,2,'ADT是指:','雄激素剥夺治疗','放疗','二氢睾酮','最大雄激素阻断','','','','',NULL,'A',1,',21,,34,',1,''),(1250,2,'前列腺癌患者可使用醋酸亮丙瑞林进行治疗，每月注射______，或每3个月注射_____','4.75mg和12.25mg','3.75mg和11.25mg','2.75mg和10.25mg','6.75mg和12.25mg','','','','',NULL,'B',1,',21,,34,',1,''),(1251,2,'抑那通微球缓释技术的特点是：','缓慢释放药物维持有效浓度达28天','微球直径平均19µm','能使用6号针头注射,不堵针头','以上全部','','','','',NULL,'D',1,',21,,34,',1,''),(1252,2,'抑那通用于前列腺癌的禁忌症有:','对本药任一成份或亮丙瑞林及其衍生物的合成物过敏者','输尿管阻塞或脊髓受压患者','糖尿病患者','以上全部','','','','',NULL,'A',1,',21,,34,',1,''),(1253,2,'前列腺癌多发于什么部位？','中央带','外周带','移行带','都不是','','','','',NULL,'B',1,',21,,34,',1,''),(1254,2,'目前经直肠超声检查（transrectalultrasonography,TRUS）的最主要的作用是','协助肿瘤的临床分期','诊断前列腺癌最可靠的检查','引导进行前列腺的系统性穿刺活检','确定是否需要重复穿刺','','','','',NULL,'C',1,',21,,34,',1,''),(1255,2,'激素治疗治疗前列腺癌旨在','干扰睾酮的产生和/或作用','干扰黄体酮的产生和/或作用','完全切断睾酮和黄体酮的生成','切除产生睾酮和黄体酮的腺体','','','','',NULL,'A',1,',21,,34,',1,''),(1256,2,'将放射源直接植入前列腺的做法被称为','近距离放射治疗','三维适形放射治疗','根治性前列腺切除术','以上三项均是','','','','',NULL,'A',1,',21,,34,',1,''),(1257,2,'放射治疗的副作用包括','勃起功能障碍','泌尿与肠道功能改变','没有','a和b','','','','',NULL,'D',1,',21,,34,',1,''),(1258,2,'以下对于最大雄激素阻断治疗的描述，错误的是：','最大雄激素阻断不包括手术去势','去势＋口服抗雄药物＝最大雄激素阻断','最大雄激素阻断的英文缩写是MAB','','','','','',NULL,'A',1,',21,,34,',1,''),(1259,2,'内分泌治疗会带来患者的骨质疏松，以下那些治疗会造成患者骨密度下降？','手术去势','药物去势','口服抗雄药物','以上都会','','','','',NULL,'D',1,',21,,34,',1,''),(1260,2,'口服抗雄药物的治疗目的是：','去除肾上腺产生的睾酮','去除肾上腺产生的睾酮','去除睾丸和肾上腺产生的睾酮','直接杀死前列腺癌细胞','','','','',NULL,'A',1,',21,,34,',1,''),(1261,2,'通常来说，前列腺癌患者激素依赖的时间是：','约1年','约2年','约3年','约4年','','','','',NULL,'B',1,',21,,34,',1,''),(1262,2,'辅助激素治疗与___和_____联合使用以提高前列腺癌患者的存活率。','根治性前列腺切除术和放疗','观察等待和主动检测','放疗和观察等待','主动检测和根治性前列腺切除术','','','','',NULL,'A',1,',21,,34,',1,''),(1263,2,'一旦生化复发得到确认，额外检查方案可能包括','活检','局部（骨盆）成像','转移性疾病的成像','以上都是','','','','',NULL,'D',1,',21,,34,',1,''),(1264,2,'以下关于治愈性治疗血清PSA水平随访错误的是：','PSA持续升高说明体内有产生PSA的组织，即残留的前列腺癌病灶','成功的根治性前列腺切除术后能检测到最低值PSA','术后连续两次血清PSA水平超过0.2ng/ml提示前列腺癌生化复发','放疗后PSA最低值是生化治愈的标志，也是一个重要的预后判断因素','','','','',NULL,'B',1,',21,,34,',1,''),(1265,2,'亮丙瑞林适用于','局部晚期前列腺癌','甲状腺癌','直肠癌','脑肿瘤','','','','',NULL,'A',1,',21,,34,',1,''),(1266,2,'抑那通（亮丙瑞林）能长期抑制前列腺癌晚期患者的______','睾酮','催乳素','胰酶','a和c','','','','',NULL,'A',1,',21,,34,',1,''),(1267,2,'据报道，较之戈舍瑞林注射剂，患者更青睐于亮丙瑞林注射，这是因为它___','针头型号最细','不需要特殊针头','a和b','以上均不是','','','','',NULL,'C',1,',21,,34,',1,''),(1268,2,'抑那通的目标病人有:','转移的前列腺癌患者','高危前列腺癌患者','临床复发的前列腺癌患者','以上都是','','','','',NULL,'D',1,',21,,34,',1,''),(1269,2,'关于PC的分期，属于T3期的为：','肿瘤侵犯到除精囊外的临近结构：膀胱颈，直肠，提肛肌','肿瘤侵犯了前列腺的单叶','肿瘤侵犯到包膜内','肿瘤扩展到前列腺包膜外，并已侵犯到精囊','','','','',NULL,'D',1,',21,,34,',1,''),(1270,2,'前列腺增生与早期前列腺癌鉴别诊断最有价值的是下列哪一项检查','CT','前列腺癌穿刺活检','USG','X线平片','膀胱造影','','','',NULL,'B',1,',21,,34,',1,''),(1271,2,'目前国内外比较一致的观点是，当血清总PSA为＿＿＿，怀疑为PC','60-69岁PSA阈值〉=２.0ng/ml','60-69岁PSA阈值〉=3.0ng/ml','60-69岁PSA阈值〉=4.0ng/ml','60-69岁PSA阈值〉＝5.0ng/ml','','','','',NULL,'C',1,',21,,34,',1,''),(1272,2,'MAB（MaximalAndrogenBlockade）是指','雄激素剥夺治疗','根治性前列腺切除术','单一抗雄激素治疗','最大雄激素阻断','','','','',NULL,'D',1,',21,,34,',1,''),(1273,2,'前列腺癌患者采用GnRHa治疗应在___，给予抗雄激素药物至注射后2周，以对抗GnRHa的急性期作用导致的病情加剧','注射前2周','注射前1周','注射当天开始','注射后一周','','','','',NULL,'C',1,',21,,34,',1,''),(1274,3,'垂体分泌哪些激素？','GnRH','FSH','LH','雌二醇','睾酮','','','',NULL,'BC',1,',21,,34,',1,''),(1275,3,'人体调节雄性激素控制通路的关键器官是：','下丘脑','垂体','性腺','大脑皮质','','','','',NULL,'ABC',1,',21,,34,',1,''),(1276,3,'下述说法哪个（些）是正确的？','PSA是前列腺特异性抗原，通常检测的是尿液中PSA浓度','PSA是前列腺特异性抗原，通常的是血液中PSA浓度','PSA是前列腺特异性抗原，只有前列腺才产生PSA','PSA是前列腺特异性抗原，如果血液中PSA〉4ng/ml,说明患者可能患有良性前列腺增生，前列腺炎或前列腺癌','','','','',NULL,'BD',1,',21,,34,',1,''),(1277,3,'前列腺癌的高、中、低危依据哪些指标：','PSA','Gleason分级','TNM分期','','','','','',NULL,'ABC',1,',21,,34,',1,''),(1278,3,'下面哪个患者前列腺癌危险因素分析处于高危？','PSA<10ng/ml,Gleason评分为7，TNM临床分期处于2b期','PSA>20ng/ml,或Gleason评分为8或TNM临床分期处于T3-T4期','PSA10-20ng/ml,Gleason评分为7，TNM临床分期处于2b期','PSA<20ng/ml,Gleason评分为6，TNM临床分期处于2c期','','','','',NULL,'BD',1,',21,,34,',1,''),(1279,3,'内分泌治疗的方案包括：','单纯去势（手术或药物）','最大限度雄激素阻断','间歇内分泌治疗','根治性治疗前新辅助内分泌治疗','辅助内分泌治疗','','','',NULL,'ABCDE',1,',21,,34,',1,''),(1280,3,'有关抑那通的说法正确的有:','抑那通是GnRHa类药物,是激动剂','抑那通是GnRHa类药物,是拮抗剂','抑那通本质是十肽的激素衍生物,在6位以D-亮氨酸代替L-甘氨酸,其活性及其与受体的结合能力是天然GnRH的80-100倍','抑那通是1989年第一个通过FDA上市的长效GnRHa类药物','','','','',NULL,'ACD',1,',21,,34,',1,''),(1281,3,'对于高危前列腺癌患者,D’Amico研究证明放疗联合内分泌治疗可以:','放疗后使用6个月的抑那通可以提高总生存率','放疗后使用6个月的抑那通可以显著改善5年生存率','放疗后使用6个月的抑那通可以显著降低45%的5年死亡风险','放疗后使用6个月的抑那通可以延长生存时间,降低转移风险','','','','',NULL,'BCD',1,',21,,34,',1,''),(1282,3,'以下关于前列腺癌根治性手术治疗的描述哪项是正确的：','根治性前列腺切除术是指手术切除前列腺及精囊','根治术用于可能治愈的前列腺癌','根治术适应于年轻无其他重大疾病的预期寿命大于等于10年的患者','对于PSA>20或者Gleason评分≥8的局限性前列腺癌患者符合临床分期处于T1-T2c，预期寿命大于等于10年的，根治术后可给予其他辅助治疗','','','','',NULL,'ABCD',1,',21,,34,',1,''),(1283,3,'内分泌治疗包括哪些？','手术去势','药物去势','最大雄激素阻断治疗','','','','','',NULL,'ABC',1,',21,,34,',1,''),(1284,3,'以下关于内分泌治疗的适应证正确的是：','转移性前列腺癌','局限早期前列腺癌或局部进展前列腺癌，无法进行根治性前列腺切除术或放射治疗','新辅助内分泌治疗','配合放疗的辅助内分泌治疗','','','','',NULL,'ABCD',1,',21,,34,',1,''),(1285,3,'有关PSA检查时机，以下哪项是正确的？','对50岁以上有下尿路症状的男性进行常规PSA和DRE检查','对于有前列腺癌家族史的男性人群，应该从45岁开始定期检查随访','对DRE异常，有临床征象或影像学异常等的男性应进行PSA检查','PSA测试是检测尿液中PSA的水平','','','','',NULL,'ABC',1,',21,,34,',1,''),(1286,3,'前列腺癌治疗包括以下哪些治疗方式？','早期手术治疗','放射治疗','激素治疗','化疗','','','','',NULL,'ABCD',1,',21,,34,',1,''),(1287,3,'以下对于药物去势的描述中，正确的是：','药物去势在疗效上不可以替代手术去势','药物去势的主要方式是口服康士得、福至尔等药物','药物去势的主要方式是使用抑那通，诺雷得，达菲林等药物','对于有条件的患者药物去势要比手术去势能更好地提高生活质量','','','','',NULL,'CD',1,',21,,34,',1,''),(1288,3,'激素非依赖前列腺癌，患者需要接受的标准治疗是：','化疗','挽救性内分泌治疗','骨转移治疗','手术治疗','','','','',NULL,'ABC',1,',21,,34,',1,''),(1289,3,'以下关于生化复发错误的是：','根治术后生化复发是指血清PSA水平连续两次>2ng/ml','根治术后生化复发是指血清PSA水平连续两次>0.2ng/ml','放疗后生化复发是指放疗后PSA值高于最低点后连续3次增高。','放疗后生化复发是指放疗后PSA值高于最低点0.4ng/ml','','','','',NULL,'AD',1,',21,,34,',1,''),(1290,3,'抑那通的不良反应有:','常见的不良反应是低雄激素导致的潮红,热感','常见的不良反应是过敏,红肿','重要的不良反应有间质性肺炎,过敏,肝功能障碍,糖尿病症状,垂体卒中,抑郁等','重要的不良反应有尿道阻塞和脊髓压迫症状','','','','',NULL,'ACD',1,',21,,34,',1,''),(1291,3,'D’Amico研究的亮点在于:','这是2004年发表在JAMA杂志上的一个前瞻性,随机对照研究','结果支持高危前列腺癌患者放疗后联合抑那通治疗','绝大多数患者使用的是抑那通联合放疗(仅有10%患者用戈舍瑞林)','研究说明放疗后的高危前列腺癌患者使用抑那通比不用结果要好','','','','',NULL,'ABCD',1,',21,,34,',1,''),(1292,3,'判定激素抵抗性前列腺癌（CRPC，castration-resistantprostatecancer）须具备以下几个方面','血清睾酮达到去势水平＜50ng/dL或＜1.7nmol/L','间隔两周连续3次PSA升高','氟他胺抗雄撤退治疗至少4周和比卡鲁胺抗雄撤退治疗至少6周','二线内分泌治疗期间PSA进展','骨或软组织转移病变有进展','','','',NULL,'ABCDE',1,',21,,34,',1,''),(1293,3,'激素抵抗性前列腺癌（CRPC，castration-resistantprostatecancer）可以采用的治疗方法有','加减或替换抗雄药物','雌激素','孕激素','化疗','','','','',NULL,'ABCD',1,',21,,34,',1,''),(1294,3,'关于PC的分期，属于T２期的为：','肿瘤侵犯到除精囊外的临近结构：膀胱颈，直肠，提肛肌','肿瘤侵犯了前列腺的单叶','肿瘤侵犯到包膜，局限在包膜内','肿瘤扩展到前列腺包膜外，并已侵犯到精囊','','','','',NULL,'BC',1,',21,,34,',1,''),(1295,3,'以下哪些可以引发PSA增高','发热，炎症，感染','性生活（射精）','医源性操作（如导尿，肛门指诊，穿刺活检等）','前列腺癌','','','','',NULL,'ABCD',1,',21,,34,',1,''),(1296,3,'前列腺的结构分为','中央区','外周区','移行区','淋巴区','','','','',NULL,'ABC',1,',21,,34,',1,''),(1297,3,'对于高危的患者，癌细胞分化是非常差的，一般Gleason评分加起来是','7','8','9','10','','','','',NULL,'BCD',1,',21,,34,',1,''),(1298,3,'关于前列腺的位置描述正确的是','其上紧贴膀胱','位于盆骨下部','后面紧靠直肠','尿道从中间穿过','','','','',NULL,'ABCD',1,',21,,34,',1,''),(1299,3,'前列腺癌的辅助内分泌治疗目的是_______，提高长期存活率','治疗切缘残余病灶','治疗残余的阳性淋巴结','治疗微小转移病灶','治愈前列腺癌','','','','',NULL,'ABC',1,',21,,34,',1,''),(1300,2,'生化复发且有很高的临床广泛转移倾向的患者应尽早采用内分泌治疗是否正确：','是','否','','','','','','',NULL,'A',1,',21,,34,',1,''),(1301,2,'PSA是PC的特异性抗原，如果患者PSA增高，则一定是PC','对','错','','','','','','',NULL,'B',1,',21,,34,',1,''),(1302,2,'PSA是PC的特异性抗原，如果患者确诊为PC，则其PSA值一定高','对','错','','','','','','',NULL,'B',1,',21,,34,',1,''),(1303,2,'不能仅仅根据骨扫描来判断病人就是骨转移，因为骨扫描的特异性差：骨扫描认为是阳性的，假阳性率可占到67%','对','错','','','','','','',NULL,'A',1,',21,,34,',1,''),(1304,2,'Gleason评分系统被认为是癌症组织病理学进展分级的，最佳方法,包括5个等级（划分为1-5）：1代表侵袭性最高,肿瘤分化不佳','对','错','','','','','','',NULL,'B',1,',21,,34,',1,''),(1305,3,'关于恶性肿瘤，下面叙述正确的：','肿瘤是机体在各种致瘤因素作用下，局部组织的细胞在基因水平上失去对其生长的正常调控，导致异常增生而形成的新生物。','不侵袭周围组织，仅在局部发生','可自主增殖，浸润','可发生转移','','','','',NULL,'ACD',1,',21,',1,''),(1306,3,'有关癌症诊断，下面说法正确的是：','癌变初期大多都观察不到癌症的临床症状','很多症状并不是癌症所特有的，其他疾病也会出现','很难仅凭临床症状发现癌症','通常诊断癌症时需要进行筛查、确诊（病理诊断）、分期诊断等检查。','','','','',NULL,'ABCD',1,',21,',1,''),(1307,3,'下面说法正确的是：','筛查是指利用各种癌症的专属特点，为了检测是否存在癌症而进行各种检查的总称','癌症确诊基本上都是通过显微镜观察以检查或手术等方式采集的组织，实际确认癌细胞的存在（病理诊断）','病理诊断可以根据癌细胞的形状等获知该癌细胞具有何种特征，以选择疗法或预测疗程','分期诊断是表述癌症进展程度（分级，分期）的指标。','','','','',NULL,'ABCD',1,',21,',1,''),(1308,3,'关于癌症的治疗下面说法正确的是：','癌症的治疗方法大致可分为根治疗法和全身疗法，可根据癌细胞的类型和癌的分布范围进行选择。','根治疗法是指“以完全治愈为目的的治疗”，外科疗法和放射疗法都属于此类','全身疗法是指“使用药物等作用于全身的疗法”，抗癌药等属于此类','基本上来说，局部可切除癌症等情况选择根治疗法，晚期癌症等已扩散到全身的情况选择全身疗法','','','','',NULL,'ABCD',1,',21,',1,''),(1309,3,'关于外科疗法，说法正确的是：','扩展性手术可以提高癌症的根治性，但侵袭（创伤）较大，相反的缩小性手术能够在较低的侵袭下保留功能，但可能会存留癌细胞，可以说是难以两全。\n','癌症外科疗法（手术）的目的是以根治为指标完全切除肿瘤。','早期癌症等分期较低的病例为了提高根治性，会开展大范围切除肿瘤周边部位或淋巴结的扩大手术。','最近为了保留身体机能并减少侵袭，也逐渐开始开展尽量缩小切除部位的缩小手术','','','','',NULL,'ABCD',1,',21,',1,''),(1310,3,'放射疗法的实际应用包括：','以根治性治疗为目的的辐照','与手术联用','用以有效症状（姑息治疗）的辐照','温热疗法','','','','',NULL,'ABC',1,',21,',1,''),(1311,3,'化疗药物的特点，下面说法正确的是：','化疗药物主要通过阻断细胞分裂周期（细胞周期）来阻止细胞分裂，抑制癌细胞的增殖能力，从而杀灭癌细胞','化疗药物对正常细胞也有作用，故而具有不良反应。','造血系统及胃肠粘膜、口腔粘膜、毛发等正常细胞的细胞周期功能活跃、细胞分裂旺盛的器官，受化疗药物的影响也就更大，容易高发不良反应。','管理化疗药物诱发的不良反应是治疗成功的关键。','','','','',NULL,'ABCD',1,',21,',1,''),(1312,3,'关于分子靶向治疗药，说法正确的是：','作为新的抗癌药，分子靶向治疗药颇为引人注目。','分子靶向治疗药以参与癌细胞的增殖或转移等作用的特殊分子为靶向，仅选择性作用于该分子，从而抑制癌细胞的增殖或转移。','分子靶向治疗药具有良好的抗肿瘤效果，且对正常细胞作用较小，安全性也比较高，值得期待。','','','','','',NULL,'ABC',1,',21,',1,''),(1313,3,'关于乳腺癌的多药联合方案，下面说法正确的是：','CMF方案是治疗方案之一。','CAF方案是治疗方案之一。','CMF方案是：环磷酰胺＋多柔比星＋氟尿嘧啶','ＣＡＦ方案是：环磷酰胺＋甲氨蝶呤＋氟尿嘧啶','','','','',NULL,'AB',1,',21,',1,''),(1314,3,'对于癌症治疗的疗效评价，其中ＯＳ是什么：','有效率','总生存','无进展生存','中位生存期','','','','',NULL,'B',1,',21,',1,''),(1315,3,'对于癌症治疗的疗效评价，其中ＲＲ是什么：','有效率','总生存','无进展生存','中位生存期','','','','',NULL,'A',1,',21,',1,''),(1316,3,'对于癌症治疗的疗效评价，其中PFS是什么：','有效率','总生存','无进展生存','中位生存期','','','','',NULL,'C',1,',21,',1,''),(1317,3,'对于癌症治疗的疗效评价，其中ＭＳＴ是什么：','有效率','总生存','无进展生存','中位生存期','','','','',NULL,'D',1,',21,',1,''),(1318,3,'Leuplin1.88瓶装剂型的适应症是什么？','子宫内膜异位症','中枢性性早熟','前列腺癌','子宫肌瘤','','','','',NULL,'ABD',1,',21,',1,''),(1319,3,'Leuplin3.75瓶装剂型的适应症是什么','子宫内膜异位症','中枢性性早熟','前列腺癌','子宫肌瘤','绝经前乳腺癌','','','',NULL,'ABCDE',1,',21,',1,''),(1320,3,'Leuplin1.88DPS的适应症是什么','子宫内膜异位症','中枢性性早熟','前列腺癌','子宫肌瘤','绝经前乳腺癌','','','',NULL,'AD',1,',21,',1,''),(1321,3,'Leuplin3.75DPS的适应症是什么','子宫内膜异位症','中枢性性早熟','前列腺癌','子宫肌瘤','绝经前乳腺癌','','','',NULL,'ACDE',1,',21,',1,''),(1322,3,'Leuplin11.25DPS的适应症是什么','子宫内膜异位症','中枢性性早熟','前列腺癌','子宫肌瘤','绝经前乳腺癌','','','',NULL,'CE',1,',21,',1,''),(1323,3,'关于亮丙瑞林微球的说法正确的是？','并非体内埋植制剂','能够长期定量释放药物','微球的基质是高分子化合物，安全性高，释放药物后不会残留在给药部位。','是体内埋植制剂','','','','',NULL,'ABC',1,',21,',1,''),(1324,2,'亮丙瑞林1M剂型中微球的基质是：','PLGA','PLA','PGA','PAG','','','','',NULL,'A',1,',21,',1,''),(1325,2,'亮丙瑞林3M剂型中微球的基质是：','PLGA','PLA','PGA','PAG','','','','',NULL,'B',1,',21,',1,''),(1326,3,'关于亮丙瑞林的保存和使用期限，下面说法正确的是：','室温保存','使用期限是3年','室温1-30度','使用期限2年','','','','',NULL,'ABC',1,',21,',1,''),(1327,3,'Leuplin的作用机制，下面的说法正确的是','Leuplin能够强效而持久的刺激垂体表面的GnRH的受体。','Leuplin首次给药后立即强效刺激垂体，使LH，FSH的分泌一过性增加，并使睾酮的分泌一过性增加。','接着Leuplin强效持久的刺激垂体，降低垂体的反应性，抑制垂体的LH，FSH分泌，并抑制睾丸的睾酮分泌，从而使前列腺癌缩小。','因为Leuplin的这种作用，本类药物也被称作LH-RH激动剂。','','','','',NULL,'ABCD',1,',21,',1,''),(1328,2,'亮丙瑞林制剂的混悬溶剂的体积是多少毫升？','1ml','2ml','3ml','5ml','','','','',NULL,'A',1,',21,',1,''),(1329,3,'PC患者第一次施打抑那通，随着睾酮分泌的一过性升高，前列腺癌的症状暂时加重的现象有哪些？','肿瘤增大导致排尿困难的症状加重','肿瘤增大引起尿潴留','出现骨转移所致腰背痛加重','性欲减退','','','','',NULL,'ABC',1,',21,',1,''),(1330,3,'抑那通皮下注射时要注意以下几点？','注射部位应选择上臂、腹部或臀部的皮下。','每次给药均应变更注射部位，不得在同一部位重复注射。','\n确认注射针管没有刺入血管内。','嘱咐患者不得按摩注射部位','','','','',NULL,'ABCD',1,',21,',1,''),(1331,3,'抑那通注射的微球混悬液会在皮下凝集成块状，被细胞膜覆盖形成“肉芽肿”，将会：','形成肉芽肿后亮丙瑞林仍继续以恒定的速度释放，等到亮丙瑞林释放完毕后肉芽肿会在数周内自然消失','形成瘢痕组织','Leuplin的释放过程中形成肉芽肿，患者触碰到肉芽肿时可能会感觉到皮下有“硬块”','3M发生比例高于1M','','','','',NULL,'ACD',1,',21,',1,''),(1332,3,'抑那通释放过程中形成肉芽肿，很少情况下还可能会出现硬块尺寸较大、消失缓慢的情况，称为为“硬结”。','给药部位可能会出现“疼痛”或“形成脓肿、溃疡”等症状','影响抑那通药品释放','减少注射部位反应，建议不得在同一部位重复注射','不影响抑那通药品释放','','','','',NULL,'ACD',1,',21,',1,''),(1333,3,'抑那通急性作用：垂体-性腺系统功能促进作用，是基于以下那些原因发挥急性作用：','对垂体LH-RH受体的亲和性强','对机体内分解酶的耐受性高','\n促使垂体释放LH、FSH的作用强','提升血中睾酮浓度','','','','',NULL,'ABCD',1,',21,',1,''),(1334,2,'作用机制的基础研究中，亮丙瑞林对LH-RH受体的亲和性约为GnRH（LH-RH）的几倍？','5倍','9倍','100倍','150倍','','','','',NULL,'B',1,',21,',1,''),(1335,2,'作用机制的基础研究中，亮丙瑞林释放LH的作用约为天然LH-RH的几倍','5倍','9倍','100倍','150倍','','','','',NULL,'C',1,',21,',1,''),(1336,3,'抑那通慢性作用：垂体-性腺系统功能抑制作用\n本药基于以下原因发挥慢性作用：','减少垂体的LH-RH受体数（下调）、降低垂体的反应性（脱敏）','降低血中睾酮浓度','降低垂体中LH、FSH的浓度','抑制前列腺肿瘤细胞的增殖','','','','',NULL,'ABCD',1,',21,',1,''),(1337,3,'亮丙瑞林能强效且持久地刺激垂体，使垂体-性腺系统功能抑制作用的原因','使垂体的LH-RH受体数减少','使垂体的LH-RH受体数增加','使垂体-性腺系统功能反应性降低','使垂体-性腺系统功能反应性活跃','','','','',NULL,'AC',1,',21,',1,''),(1338,2,'临床研究中雄性大鼠单次皮下注射亮丙瑞林，经时测定血中睾酮浓度，结果几小时后血中睾酮的浓度达到峰值？','1小时','2小时','3小时','4小时','','','','',NULL,'B',1,',21,',1,''),(1339,2,'内分泌治疗与心血管疾病发作风险升高之间的关系，2010年FDA宣称','各别GnRHa增加心血管疾病发作风险不同','目前得出GnRHa会略微增加心血管疾病发作风险','目前尚未得出GnRHa会增加心血管疾病发作风险的结论','目前得出GnRHa会降低心血管疾病发作风险','','','','',NULL,'C',1,',21,',1,''),(1340,3,'内分泌治疗与心血管疾病发作风险升高之间的关系，2010年FDA建议','应警惕潜在问题，仔细权衡利弊','监测是否出现了心血管疾病','对心血管疾病的风险因素进行管理，如吸烟、血压、胆固醇、血糖值升高、体重增加等','除非得到医学专家的指示，否则患者不宜停止LH-RHa的治疗','','','','',NULL,'ABCD',1,',21,',1,''),(1341,2,'PC患者第一次施打抑那通，为避免点火效应，可以怎么做？','药品减量','给抑那通前先使用抗雄激素药物','不同部位施打','滴定注射','','','','',NULL,'B',1,',21,',1,''),(1342,2,'什么是PADT：PrimaryAndrogenDeprivationTherapy？','主要内分泌治疗','辅助内分泌治疗','新辅助内分泌治疗','首次雄激素剥夺治疗','','','','',NULL,'D',1,',21,',1,''),(1343,3,'常见PC治疗方案有哪些？','PADT','前列腺切除术','放射线治疗（外放疗）','放射线治疗（密封小放射源永久植入治疗）','','','','',NULL,'ABCD',1,',21,',1,''),(1344,2,'醋酸亮丙瑞林是哪家公司首先发现的？','武田','雅培','阿斯利康','辉凌','','','','',NULL,'A',1,',21,',1,''),(1345,3,'抑那通微球的基质主要由以下构成','乳酸-羟基乙酸共聚物“PLGA”','乳酸聚合物“PLA”','环糊精聚合物“CDA”','醋酸纤维素聚合物\"CAP\"','','','','',NULL,'AB',1,',21,',1,''),(1346,2,'醋酸亮丙瑞林是','E2的高活性衍生物','HER-2高活性衍生物','LHRH高活性衍生物','PSA高活性衍生物','','','','',NULL,'C',1,',21,',1,''),(1347,2,'注射用醋酸亮丙瑞林的严重不良反应报告有间质性肺炎、过敏样症状、肝功能障碍、黄疸、糖尿病发作或加重、抑郁、骨痛一过性加重、泌尿道梗阻、脊柱压迫。','对','错','','','','','','',NULL,'A',1,',21,',1,''),(1348,3,'中国大陆上市的抑那通剂型有','3.75mg','1.88mg','11.25mgDPS','3.75mgDPS','','','','',NULL,'ABC',1,',21,',1,''),(1349,2,'FPSA的中文名称是','饱和型前列腺特异抗原','游离型前列腺特异抗原','总前列腺特异抗原','结合型前列腺特异抗原','','','','',NULL,'B',1,',21,,34,',1,''),(1350,2,'TPSA的中文名称是','饱和型前列腺特异抗原','游离型前列腺特异抗原','总前列腺特异抗原','结合型前列腺特异抗原','','','','',NULL,'C',1,',21,,34,',1,''),(1351,2,'DRE的中文全称是','经直肠超声扫描','直肠指诊','骨闪烁扫描','前列腺活检','','','','',NULL,'B',1,',21,,34,',1,''),(1352,2,'TRUS的中文全称是','经直肠超声扫描','直肠指诊','骨闪烁扫描','前列腺活检','','','','',NULL,'A',1,',21,,34,',1,''),(1353,2,'以下哪些方法可以作为前列腺癌的确诊（病理诊断）手段？','PSA','DRE','TRUS','前列腺活检','','','','',NULL,'D',1,',21,,34,',1,''),(1354,2,'前列腺癌的诊断流程是','流行病学调查—病理诊断—分期诊断','血清PSA—前列腺活检—MRI','筛查（筛选检查）—确诊和病理诊断—分期诊断','DRE—TRUS—MRI/CT','','','','',NULL,'C',1,',21,,34,',1,''),(1355,2,'前列腺癌的易发部位是','前列腺外侧周围区','前列腺外侧中央区','前列腺内侧中央区','前列腺各部位','','','','',NULL,'A',1,',21,,34,',1,''),(1356,2,'PSA的检查是抽取哪个组织中的样本进行的？','前列腺液','血清','前列腺组织','尿液','','','','',NULL,'B',1,',21,,34,',1,''),(1357,2,'前列腺是男性特有的生殖器官,它的大小：','核桃大小','鸡蛋大小','桔子大小','','','','','',NULL,'A',1,',21,,34,',1,''),(1358,2,'前列腺癌有（）是发生在周围区的？','0.3','0.4','0.5','0.7','','','','',NULL,'D',1,',21,,34,',1,''),(1359,2,'移行区和中央区发病的比率加起来是？','0.3','0.4','0.5','0.7','','','','',NULL,'A',1,',21,,34,',1,''),(1360,2,'下丘脑产生的（）通过垂体门静脉运送到垂体前叶','ＬＨ','ＦＳＨ','ＬＨＲＨ','','','','','',NULL,'C',1,',21,,34,',1,''),(1361,2,'雄性激素约有95％是睾丸分泌的（）','睾酮','雄烯二酮','去氢表雄酮','','','','','',NULL,'A',1,',21,,34,',1,''),(1362,2,'以下属于T2a的是：\n','肿瘤扩散到包膜外（单侧或双侧）\n','浸润前列腺的双叶\n','浸润前列腺单叶的1/2以上，但未侵及双叶\n','浸润前列腺单叶的1/2或更少\n','肿瘤侵及精囊','','','',NULL,'D',1,',21,,34,',1,''),(1363,2,'以下属于T2b的是：\n\n','肿瘤扩散到包膜外（单侧或双侧）\n','浸润前列腺的双叶\n','浸润前列腺单叶的1/2以上，但未侵及双叶\n','浸润前列腺单叶的1/2或更少\n','肿瘤侵及精囊','','','',NULL,'C',1,',21,,34,',1,''),(1364,2,'以下属于T2c的是：','肿瘤扩散到包膜外（单侧或双侧）\n','浸润前列腺的双叶\n','浸润前列腺单叶的1/2以上，但未侵及双叶\n','浸润前列腺单叶的1/2或更少\n','肿瘤侵及精囊','','','',NULL,'B',1,',21,,34,',1,''),(1365,2,'以下属于T3a的是：','肿瘤扩散到包膜外（单侧或双侧）\n','浸润前列腺的双叶\n','浸润前列腺单叶的1/2以上，但未侵及双叶\n','浸润前列腺单叶的1/2或更少\n','肿瘤侵及精囊','','','',NULL,'A',1,',21,,34,',1,''),(1366,2,'以下属于T3b的是：','肿瘤扩散到包膜外（单侧或双侧）\n','浸润前列腺的双叶\n','浸润前列腺单叶的1/2以上，但未侵及双叶\n','浸润前列腺单叶的1/2或更少\n','肿瘤侵及精囊','','','',NULL,'E',1,',21,,34,',1,''),(1367,2,'以下属于T4的是\n','无法评价原发肿瘤\n','肿瘤浸润或固定于精囊腺外的临近组织（包括阔约肌/直肠/骨盆壁）','\n肿瘤局限于前列腺内\n','肿瘤穿破前列腺包膜向外扩散','','','','',NULL,'B',1,',21,,34,',1,''),(1368,2,'以下属于T3的是','无法评价原发肿瘤\n','肿瘤浸润或固定于精囊腺外的临近组织（包括阔约肌/直肠/骨盆壁）','\n肿瘤局限于前列腺内\n','肿瘤穿破前列腺包膜向外扩散','','','','',NULL,'D',1,',21,,34,',1,''),(1369,2,'以下属于T2的是','无法评价原发肿瘤\n','肿瘤浸润或固定于精囊腺外的临近组织（包括阔约肌/直肠/骨盆壁）','\n肿瘤局限于前列腺内\n','肿瘤穿破前列腺包膜向外扩散','','','','',NULL,'C',1,',21,,34,',1,''),(1370,2,'以下属于T1的是','无法评价原发肿瘤\n','肿瘤浸润或固定于精囊腺外的临近组织（包括阔约肌/直肠/骨盆壁）','\n肿瘤局限于前列腺内\n','肿瘤穿破前列腺包膜向外扩散','无法触知或无法通过影像诊断，临床上并不明显的肿瘤','','','',NULL,'E',1,',21,,34,',1,''),(1371,2,'以下属于T1a的是：','通过穿刺活检确认的肿瘤（例如导致PSA升高）\n\n','组织学检查中观测到偶发的肿瘤，比例超过切除组织的5%\n','\n组织学检查中观测到偶发的肿瘤，比例在切除组织的5%以下\n','未见原发肿瘤\n','无法评价原发肿留','','','',NULL,'C',1,',21,,34,',1,''),(1372,2,'关于Gleason评分，以下描述正确的是\n','该评分的数值越大，恶性程度就越高/预后就越差\n','该评分的数值越小，恶性程度就越高/预后就越差\n','评分为5-6，相当于高度恶性\n','评分为8-10，相当于低度恶性','','','','',NULL,'A',1,',21,,34,',1,''),(1373,2,'MAB疗法奏效的患者病情加重时仅停用抗雄激素药物即可再次改善的现象。其发生机制为即可再次改善的现象称为','抗雄激素撤退综合征','抗雄药物交替疗法','间歇性内分泌疗法','全雄激素阻断','','','','',NULL,'A',1,',21,,34,',1,''),(1374,2,'LH-RH类似物对垂体有强效而持续的刺激作用，能一过性地提升LH、FSH和睾酮浓度。结果就导致肿瘤暂时增大（急性效果）。','对','错','','','','','','',NULL,'A',1,',21,,34,',1,''),(1375,2,'LH-RH类似物可强效而持久地刺激LH-RH受体，降低垂体细胞表面GnRH受体的反应性，抑制垂体的LH、FSH分泌，进而抑制睾酮的分泌，降低血中睾酮的浓度，从而使肿瘤缩小（慢性效果）','对','错','','','','','','',NULL,'A',1,',21,,34,',1,''),(1376,2,'关于RP手术后前列腺癌复发的描述哪些是正确的','术后经过1个月以上PSA＜0.2ng/mL时判为PSA无复发','术后的病程中每隔2～4周测定PSA，连续2次≥0.2ng/mL即判定为PSA复发，首次变化日即为复发日。','若术后PSA从未降至＜0.2ng/mL，则判定为手术日之时复发','以上都对','','','','',NULL,'D',1,',21,,34,',1,''),(1377,3,'前列腺癌的筛查包括','PSA','DRE','TRUS','前列腺活检','','','','',NULL,'ABC',1,',21,,34,',1,''),(1378,3,'以下哪些方法可以作为前列腺癌的分期诊断手段？','PSA','MRI/CT','TRUS','骨闪烁扫描','','','','',NULL,'BD',1,',21,,34,',1,''),(1379,3,'前列腺癌的诊断包括以下哪些步骤？','流行病学调查','筛查（筛选检查）','确诊和病理诊断','分期诊断','','','','',NULL,'BCD',1,',21,,34,',1,''),(1380,3,'晚期前列腺癌随着骨转移可能会出现以下哪些症状？','腰背痛','血尿','凝血功能障碍','视觉障碍','','','','',NULL,'AB',1,',21,,34,',1,''),(1381,3,'前列腺在解剖学上分为；','中央区','移行区','周围区','浅表区','','','','',NULL,'ABC',1,',21,,34,',1,''),(1382,3,'垂体中产生的（）作用于性腺，提高性激素（睾酮或雌激素等）的分泌，作用于前列腺或子宫等。','ＬＨ','ＦＳＨ','ＬＨＲＨ','ＡＣＴＨ','','','','',NULL,'AB',1,',21,,34,',1,''),(1383,3,'雄性激素中约5％是肾上腺分泌的（）','睾酮','雄烯二酮','去氢表雄酮','','','','','',NULL,'BC',1,',21,,34,',1,''),(1384,3,'前列腺癌的风险因子中比较值得关注的包括：','人种','年龄','家族史','饮食生活','','','','',NULL,'ABCD',1,',21,,34,',1,''),(1385,3,'以下关于PSA正确的？\n\n','超过4.0ng/ml即判定为异常\n\n','PSA值升高时患癌的可能性提高','PSA对PC有特异性，但其不是癌症的特异性标志物\n','PSA可能会受多种行为的影响而出现假阳性','','','','',NULL,'ABCD',1,',21,,34,',1,''),(1386,3,'以下关于PSA正确的是哪几项？\n','是前列腺特异性抗原\n','是前列腺癌特异性抗原\n','PSA可做为PC的肿瘤标志物，通过血液学检查测定渗漏到血液中的PSA，可以筛查PC或检测治疗经过。\n','PSA增高时患PC的可能性增高','','','','',NULL,'ACD',1,',21,,34,',1,''),(1387,3,'以下关于直肠指诊描述正确的是？\n','缩写是DRE\n','是指从肛门伸入手指，从直肠前壁触知前列腺的检查方法。\n','其是PC诊疗中的必备手法\n','其缺点是对操作人员要求有一定的熟练度，并比较容易带入操作人员的主观判断\n','这种检查方法很难发现小的癌变和前列腺深处的癌变','','','',NULL,'ABCDE',1,',21,,34,',1,''),(1388,3,'关于恶性程度，以下说法正确的是：\n\n','高分化型癌细胞的恶性程度更低，预后良好\n','低分化型癌细胞的恶性程度较高，预后不良\n','PC基本都是用Gleason评分进行恶性程度评价\n','Gleason评分是预后评价的重要指标，临床实践中常用作确定治疗方针的因子','','','','',NULL,'ABCD',1,',21,,34,',1,''),(1389,3,'前列腺癌的治疗方法有哪些？','观察等待疗法','根治性前列腺切除术','放射疗法','内分泌疗法','化学疗法','','','',NULL,'ABCDE',1,',21,,34,',1,''),(1390,3,'以下哪些前列腺癌治疗属于根治性治疗？','观察等待疗法','根治性前列腺切除术','放射疗法','内分泌疗法','化学疗法','','','',NULL,'BC',1,',21,,34,',1,''),(1391,3,'以下哪些前列腺癌治疗属于全身性治疗？','观察等待疗法','根治性前列腺切除术','放射疗法','内分泌疗法','化学疗法','','','',NULL,'DE',1,',21,,34,',1,''),(1392,3,'前列腺癌放射疗法包括以下哪些？','根治性放疗','辅助放疗','挽救性放疗','姑息性放疗','','','','',NULL,'ABCD',1,',21,,34,',1,''),(1393,3,'以下哪些属于前列腺癌根治性外放疗','适形放射疗法','3D-CRT','IMRT','暂时性植入法','永久性植入法','','','',NULL,'ABC',1,',21,,34,',1,''),(1394,3,'前列腺癌近距离放疗包括','适形放射疗法','3D-CRT','IMRT','暂时性植入法','永久性植入法','','','',NULL,'DE',1,',21,,34,',1,''),(1395,3,'关于手术去势以下哪些是正确的？','也称作双侧睾丸切除术','因为去除了睾丸分泌的睾酮，故而能抑制肿瘤的增殖','这是费用较低且永久性的治疗方法','会给患者带来肉体和精神上的痛苦','是前列腺癌最好的治疗方法','','','',NULL,'ABCD',1,',21,,34,',1,''),(1396,3,'RP手术并发症以下哪些描述是正确的','主要的并发症包括尿失禁','主要的并发症包括勃起功能障碍','手术后几乎所有患者都会出现尿失禁的现象，12个月左右即可恢复','手术后几乎所有患者都会出现勃起功能障碍','','','','',NULL,'ABC',1,',21,,34,',1,''),(1397,3,'间歇性内分泌疗法的缺点有哪些？','需要密切监测','可能会导致病情进展','可能会导致治疗不充分','方法和疗效尚未达成一致','','','','',NULL,'ABCD',1,',21,,34,',1,''),(1398,3,'前列腺癌选择治疗方法的基本思路','临床病期T1、T2的局限性癌变以根治性疗法为主要治疗方案','T1期等肿瘤尺寸较小、恶性程度较低的病例也可选择PSA监测疗法，年龄较小等情况下还可选择积极的治疗','T3这种扩散癌变因为复发的可能性较高，所以就算要开展根治性治疗多数也要联合全身疗法（内分泌疗法）进行治疗','发生转移的情况下以内分泌疗法等全身疗法为主要治疗方案','','','','',NULL,'ABCD',1,',21,,34,',1,''),(1399,3,'内分泌治疗后判定病情进展要符合以下条件','隔4周以上测定的PSA比最低值升高25％','且升高幅度必须在2ng/mL以上','隔6周以上测定的PSA比最低值升高25％','且升高幅度必须在4ng/mL以上','','','','',NULL,'AB',1,',21,,34,',1,''),(1400,3,'以下关于PSA正确的是？\n','是前列腺特异性抗原\n','是前列腺癌特异性抗原\n','PSA可做为PC的肿瘤标志物，通过血液学检查测定渗漏到血液中的PSA，可以筛查PC或检测治疗经过。\n','PSA增高时患PC的可能性增高','','','','',NULL,'ACD',1,',21,,34,',1,''),(1401,2,'前列腺肥大和前列腺癌都会出现排尿困难（（排尿耗时较长、（排尿耗时较长、力道不足、尿失禁、尿不尽）和夜间尿频夜间尿频夜间尿频等症状。','对','错','','','','','','',NULL,'A',1,',21,,34,',1,''),(1402,2,'随着病情进展，前列腺肥大可能会发展成前列腺癌','对','错','','','','','','',NULL,'B',1,',21,,34,',1,''),(1403,2,'前列腺肥大是随着年龄的增长前列腺变得肥大的良性疾病，主要是靠近尿道的前列腺内侧中央区肥大','对','错','','','','','','',NULL,'A',1,',21,,34,',1,''),(1404,2,'卵泡刺激素是\n促性腺激素的一种。在男性体内可促进睾丸中精子的生成。在女性体内可促进卵泡的发育、促进卵泡激素的分泌。\n','对','错','','','','','','',NULL,'A',1,',21,,34,',1,''),(1405,2,'一般而言前列腺癌多发于50岁以上的人群，年龄越大患病率越高。','对','错','','','','','','',NULL,'A',1,',21,,34,',1,''),(1406,2,'若亲人中有前列腺癌患者，则本人发生前列腺癌的风险就会提\n高，因此家族史也是本病的风险因子之一。\n','对','错','','','','','','',NULL,'A',1,',21,,34,',1,''),(1407,2,'过度摄入动物性脂肪是前列腺癌的风险因子','对','错','','','','','','',NULL,'A',1,',21,,34,',1,''),(1408,2,'大豆（味增、纳豆、豆腐）、黄绿色蔬菜、马铃薯、绿茶等食物是前列腺癌的风险因子。','对','错','','','','','','',NULL,'B',1,',21,,34,',1,''),(1409,3,'以下有关开思亭的哪些论述是正确的?','开思亭是治疗慢性荨麻疹的一线用药','开思亭是治疗中重度变应性鼻炎的一线用药','开思亭强烈推荐用于以喷嚏与鼻痒为主诉的变应性鼻炎治疗首选','开思亭可以推荐用于2岁以下儿童患者','','','','',NULL,'AC',1,',23,,37,',1,''),(1410,2,'与常用的二代抗组胺药氯雷他定与西替利嗪相比较，开思亭的优势在于：','开思亭起效更快','开思亭在12岁以上儿童及成年过敏患者可推荐加倍剂量 ','开思亭更适合推荐儿童患者使用','开思亭的抗炎作用更强','','','','',NULL,'B',1,',23,,37,',1,''),(1411,2,'开思亭在皮肤科推广的产品定位是','加倍剂量，疗效更优','倍量强效更安全','倍量更强效 安全性依旧','20mg疗效更优','','','','',NULL,'C',1,',23,,37,',1,''),(1412,2,'开思亭的主要竞品之一皿治林的通用名是','西替利嗪','依匹斯汀','地氯雷他定','咪唑斯汀 ','','','','',NULL,'D',1,',23,,37,',1,''),(1413,3,'比较口服二代抗组胺药与鼻内激素治疗变应性鼻炎，以下哪些观点不正确：','口服二代抗组胺药不适合长期服用 ','鼻内激素起效慢','鼻内激素是治疗轻度变应性鼻炎的首选用药','开思亭可能产生潜在的嗜睡不良反应的风险','','','','',NULL,'ACD',1,',23,,37,',1,''),(1414,2,'根据开思亭说明书的描述，服药后成人嗜睡不良反应发生率为：','0.01','0.03','0.05','0.1','','','','',NULL,'B',1,',23,,37,',1,''),(1415,3,'亚宁定在主动脉夹层中的应用获得多方推荐，推荐的文献有：','主动脉夹层（内科）临床路径（2010年版）','盐酸乌拉地尔注射液临床应用专家共识组.','2010中国急诊高血压诊疗专家共识','B型主动脉夹层腔内治疗技术要点以及应避免的误区','','','','',NULL,'ABCD',1,',22,,37,',1,''),(1416,3,'主动脉夹层患者常需要把血压降低到较低水平，因此脏器灌注是临床需要考量的。研究显示下面哪些药物，能增加肾灌注血流？',' 硝普钠','尼卡地平','亚宁定  ','硝酸甘油','','','','',NULL,'BC',1,',22,,37,',1,''),(1417,2,'A型夹层行开胸手术后，在心外ICU常会出现低氧血症，其原因是因为_______,降压针剂中_______不加剧低氧血症？','麻醉药对肺功能抑制及炎性介质的释放，硝普钠。','患者长时间呼吸暂停，尼卡地平。','麻醉药对肺功能抑制及炎性介质的释放，亚宁定。','患者长时间呼吸暂停，亚宁定。','','','','',NULL,'C',1,',22,,37,',1,''),(1418,2,'最新研究显示，在AD患者术后统计中，尼卡地平组的______用量、______、________都比盐酸乌拉地尔组多，这是因为尼卡地平能引起明显的心率增快。','艾司络尔、降压药总花费、ICU停留时间。','艾司络尔、ICU总花费、ICU停留时间。','倍它乐可、降压药总花费、住院总天数。','倍它乐克、ICU总花费、住院总天数。','','','','',NULL,'B',1,',22,,37,',1,''),(1419,2,'AD择期手术患者B型患者和______患者，由于长期卧床且保持腹内压平稳，要求大便通畅。而药物_______有麻痹性肠梗阻的风险。','保守治疗的A型患者，尼卡地平。','立即手术的A型患者，硝普钠。\n','保守治疗的A型患者，硝普钠。','立即手术的A型患者，尼卡地平。','','','','',NULL,'A',1,',22,,37,',1,''),(1420,2,'Dp/Dt是主动脉夹层患者急性期严控的一个指标，是综合了心率和血压的指标。根据各大指南共识，AD患者需要在____时间内，把血压控制在______以内,心率控制在______以内.',' 30min,100-120,60-70.','30min,120-140,70-80.','15min,100-120,60-70','15min,120-140,70-80','','','','',NULL,'A',1,',22,,37,',1,''),(1421,3,'2015年亚宁定产品关键信息','双重机制，起效迅速','平稳降压，应用广泛','不影响心率、颅内压','双重降压、平稳可控','','','','',NULL,'ABC',1,',22,,37,',1,''),(1422,3,'以下哪些是2015年亚宁定A类科室','急症','ICU','神内外（NICU）','心胸血管外（CICU）','','','','',NULL,'ABCD',1,',22,,37,',1,''),(1423,3,'InteractII研究结果显示，根据不同血压变异性指数，以下哪些指标是最强的终点预测因素','超急性期的收缩压最大值','急性期的收缩压SD','超急性期的收缩压SD','急性期的收缩压最大值','','','','',NULL,'AB',1,',22,,37,',1,''),(1424,2,'InteractII研究结果显示，强化降压在横跨不同基线SBP水平的宽广的范围均表现有获益， 急性脑出血患者的目标SBP水平在什么区间可能提供最大的获益\n','110-119 mm Hg','120-129 mm Hg','130-139 mm Hg','140-149 mm Hg','','','','',NULL,'C',1,',22,,37,',1,''),(1425,2,'哪一句结论最能够将产品与INTERACTII研究联结起来','亚宁定是一个致力于卒中患者管理的产品','INTERACTII研究II是武田赞助的','无论在强化组，还是常规遵循指南组，亚宁定是应用最普遍的的静脉降压药物\n','亚宁定是急性高血压管理的最佳选择','','','','',NULL,'C',1,',22,,37,',1,''),(1426,3,'主动脉夹层可能分布在以下哪些科室？','急诊、血管外科','ICU 、心外ICU','心内科、心外科','CCU','','','','',NULL,'ABCD',1,',22,,37,',1,''),(1427,2,'亚宁定推注是高血压急症的快速降压用法，根据现有研究，单次推注10mg亚宁定原液，收缩压和舒张压分别降幅多少？','收缩压下降14.9%，舒张压下降13.5%','收缩压下降16.1%，舒张压下降15.6%','收缩压下降20.9%，舒张压下降13.7%','收缩压下降14.9%，舒张压下降15.8%','','','','',NULL,'A',1,',22,,37,',1,''),(1428,2,'亚宁定推注是高血压急症的快速降压用法，根据现有研究，单次推注20mg亚宁定原液，收缩压和舒张压分别降幅多少？','收缩压下降14.9%，舒张压下降13.5%','收缩压下降21.6%，舒张压下降19.6%','收缩压下降30.9%，舒张压下降13.8%','收缩压下降24.9%，舒张压下降15.9%','','','','',NULL,'B',1,',22,,37,',1,''),(1429,2,'亚宁定推注是高血压急症的快速降压用法，根据现有研究，单次推注40mg亚宁定原液，收缩压和舒张压分别降幅多少？','收缩压下降14.9%，舒张压下降13.7%','收缩压下降16.1%，舒张压下降15.8%','收缩压下降20.9%，舒张压下降13.9%','收缩压下降29.4%，舒张压下降29.4%','','','','',NULL,'D',1,',22,,37,',1,''),(1430,2,'INTERACT II研究病人分组中早期强化降压组目标收缩压','<170mmHg','<150mmHg','<140mmHg','<130mmHg','','','','',NULL,'C',1,',22,,40,',1,''),(1431,2,'INTERACT II研究两组病人使用乌拉地尔的比例分别是','强化降压组50%，标准降压组30%','强化降压组40%，标准降压组30%','强化降压组32.5%，标准降压组13.4%','强化降压组20%，标准降压组10%','','','','',NULL,'C',1,',22,,40,',1,''),(1432,2,'INTERACTII研究结果表明，强化降压组中治疗后1分到2分的残疾但尚可能独立生活病人比例_____，3分到5分的严重残疾病人比例_______，支持强化降压治疗对脑出血后生存者可获益。','增加，减少','增加，增加','减少，减少','减少，增加','','','','',NULL,'A',1,',22,,40,',1,''),(1433,2,'《盐酸乌拉地尔注射液临床应用专家共识》高血压脑病患者推荐维持剂量是多少','50-100μg/min','100-200μg/min','100-400μg/min','500-1000μg/min','','','','',NULL,'C',1,',22,,40,',1,''),(1434,2,'《盐酸乌拉地尔注射液临床应用专家共识》中脑出血患者的降压目标一般设定为平均动脉压降低到最大值的','5-10%','10-20%','20-25%','25-30%','','','','',NULL,'C',1,',22,,40,',1,''),(1435,2,'《盐酸乌拉地尔注射液临床应用专家共识》中高血压脑病患者在血压达标之前静推盐酸乌拉地尔注射液间隔是多久','1-5min','5-10min','10-15min','15-30min','','','','',NULL,'B',1,',22,,40,',1,''),(1436,2,'《盐酸乌拉地尔注射液临床应用专家共识》中针对主动脉夹层患者累计静推剂量不得超过','500mg','200mg','100mg','50mg','','','','',NULL,'C',1,',22,,40,',1,''),(1437,2,'50ml的输液微泵配8支亚宁定，输液速度为9ml/h，相当于给药速度','100μg/min','200μg/min','400μg/min','600μg/min','','','','',NULL,'D',1,',22,,40,',1,''),(1438,3,'以下有关INTERACT II研究患者入组数字哪些是正确的','共评估筛查28,829例  ','6411例完成筛选日志 ','2839例随机化 ','2829例纳入分析','','','','',NULL,'ABCD',1,',22,,40,',1,''),(1439,3,'以下哪些是INTERACT II研究的主要结论','早期强化降压治疗给广大ICH患者的治疗提供了有关安全性和有效性的证据','面对不同的患者和疾病特征，治疗效果无异质性 ','强化降压增加患者死亡率','指南降压组更安全','','','','',NULL,'AB',1,',22,,40,',1,''),(1440,3,'以下哪些是INTERACT II研究的关键信息','首次明确了急性脑出血处理时需要静脉药物治疗 ','无论在强化组，还是常规遵循指南组，亚宁定是应用最普遍的的静脉降压药物 ','亚宁定在强化组使用高达1/3，并不增加副作用，是安全有效的静脉降压药物 ','适用大多数患者并能较好地改善脑出血后生存者的功能恢复 ','','','','',NULL,'ABCD',1,',22,,40,',1,''),(1441,3,'《盐酸乌拉地尔注射液临床应用专家共识》中针对主动脉夹层患者有哪些给药方式推荐','持续泵注','反复静推','先推后泵','直推渐稳','','','','',NULL,'CD',1,',22,,40,',1,''),(1442,2,'依巴斯汀的主要代谢产物是？','卡瑞斯汀','沙格列汀','维格列汀','阿托伐他丁','','','','',NULL,'A',1,',23,',1,''),(1443,2,'依巴斯汀转换为主要活性产物的转化率为？','0.5','0.75','0.95','1','','','','',NULL,'D',1,',23,',1,''),(1444,2,'依巴斯汀及其代谢产物与人体血清蛋白亲和力为？','0.5','0.75','>95%','1','','','','',NULL,'C',1,',23,',1,''),(1445,2,'依巴斯汀的半衰期为？','2-4h','4-10h','11-15h','15-19h','','','','',NULL,'D',1,',23,',1,''),(1446,2,'依巴斯汀重复剂量会？','延长半衰期，产生蓄积','延长半衰期，无蓄积','不改变半衰期，产生蓄积','不改变半衰期，无蓄积','','','','',NULL,'D',1,',23,',1,''),(1447,2,'依巴斯汀停药几天后可维持稳态血药浓度？','1天','2天','3天','4天','','','','',NULL,'D',1,',23,',1,''),(1448,2,'单一剂量依巴斯汀的最大抗组胺效应出现在？','服药后30min','服药后1h','服药后2h','服药后4h','','','','',NULL,'D',1,',23,',1,''),(1449,2,'单一剂量依巴斯汀的最大抗组胺效应可以维持？','1天','2天','3天','4天','','','','',NULL,'A',1,',23,',1,''),(1450,2,'依巴斯汀抑制过敏原诱导的皮肤单刺试验和鼻激发试验可以持续？','12h','24h','36h','48h','','','','',NULL,'B',1,',23,',1,''),(1451,2,'广泛研究显示，推荐剂量的依巴斯汀对精神活动的影响是？','有轻微影响','无影响','影响显著','结论尚不明确','','','','',NULL,'B',1,',23,',1,''),(1452,2,'依巴斯汀10-40mg范围内，其代谢产物血浆浓度(Cmax)与剂量的关系是？','成正比','成反比','无相关性','结论尚不明确','','','','',NULL,'A',1,',23,',1,''),(1453,2,'依巴斯汀抗组胺效应与剂量的关系是？','剂量越大，抗组胺效应越强','剂量越小，抗组胺效应越强','剂量与抗组胺效应无关','视个体差异而定','','','','',NULL,'A',1,',23,',1,''),(1454,2,'在常用的第二代抗组胺药物中，能够调整剂量至20mg的是？','开思亭®','氯雷他定','西替利嗪','非索非那定','','','','',NULL,'A',1,',23,',1,''),(1455,2,'在季节性过敏性鼻炎的治疗中，依巴斯汀10mg/d与西替利嗪10mg/d以及氯雷他定10mg/d相比？','疗效更佳','疗效相当','疗效稍差','无法评定疗效','','','','',NULL,'A',1,',23,',1,''),(1456,2,'过敏性鼻炎治疗中，依巴斯汀20mg/d与西替利嗪以及氯雷他定相比，疗效更佳，尤其是对于？','老年患者','儿童患者','合并感染患者','症状更严重的患者','','','','',NULL,'D',1,',23,',1,''),(1457,2,'开思亭®10mg或者20mg总体不良事件发生率？','稍高于安慰剂','与安慰剂相似','显著低于安慰剂','结论尚不明确','','','','',NULL,'B',1,',23,',1,''),(1458,2,'依巴斯汀基本无镇静作用，主要是由于？','血浆浓度低','半衰期短','血脑屏障透过率低','以上都不对','','','','',NULL,'C',1,',23,',1,''),(1459,2,'过敏性鼻炎主要是由以下哪类反应引起的？','Ⅰ型过敏反应','Ⅱ型过敏反应','Ⅲ型过敏反应','Ⅳ型过敏反应','','','','',NULL,'A',1,',23,',1,''),(1460,2,'慢性荨麻疹的一线治疗药物是？','糖皮质激素','减充血剂','抗组胺药物','肥大细胞稳定剂','','','','',NULL,'C',1,',23,',1,''),(1461,2,'依巴斯汀对一下哪项过敏性鼻炎症状的疗效较其他药物显著？','流涕','喷嚏','鼻塞','以上都是','','','','',NULL,'D',1,',23,',1,''),(1462,2,'下列药物中，半衰期最长的是？','西替利嗪','左西替利嗪','氯雷他定','依巴斯汀','','','','',NULL,'D',1,',23,',1,''),(1463,2,'下列药物中，日治疗费用最低的是？','依巴斯汀','非索非那定','左西替利嗪','地氯雷他定','','','','',NULL,'A',1,',23,',1,''),(1464,2,'对于6-11岁的儿童，开思亭®的推荐剂量是？','20mgqd','10mgqd','5mgqd','2.5mgqd','','','','',NULL,'C',1,',23,',1,''),(1465,2,'对于2-5岁的儿童，开思亭®的推荐剂量是？','20mgqd','10mgqd','5mgqd','2.5mgqd','','','','',NULL,'D',1,',23,',1,''),(1466,2,'对于严重肝功能衰竭患者，开思亭®的用量？','严禁超过5mg/d','严禁超过10mg/d','严禁超过15mg/d','严禁超过20mg/d','','','','',NULL,'B',1,',23,',1,''),(1467,2,'过敏性鼻炎在以下哪种人群中发病率最高？','有心脏病家族史的人群中','有高血压家族史的人群中','有过敏性疾病家族史的人群中','有糖尿病家族史的人群中','','','','',NULL,'C',1,',23,',1,''),(1468,2,'拮抗H1受体的主要作用是？','减少胃酸分泌','抗过敏','促进大脑皮质活动','以上都不是','','','','',NULL,'B',1,',23,',1,''),(1469,2,'抗组胺药物与受体结合后？','不可逆的损坏受体','防止组胺与受体结合','与组胺结合功能更强','以上都不是','','','','',NULL,'B',1,',23,',1,''),(1470,2,'使用最广泛的控制过敏性鼻炎典型症状的方法是？','避免过敏原','患者教育','药物治疗','以上都不是','','','','',NULL,'C',1,',23,',1,''),(1471,2,'氯雷他定的常规使用剂量是？','10mg/d','20mg/d','30mg/d','40mg/d','','','','',NULL,'A',1,',23,',1,''),(1472,2,'西替利嗪的常规使用剂量是？','10mg/d','20mg/d','30mg/d','40mg/d','','','','',NULL,'A',1,',23,',1,''),(1473,2,'氯雷他定的商品名是？','皿治林','仙特敏','息斯敏','开瑞坦','','','','',NULL,'D',1,',23,',1,''),(1474,2,'西替利嗪的商品名是？','皿治林','仙特敏','息斯敏','开瑞坦','','','','',NULL,'B',1,',23,',1,''),(1475,2,'咪唑斯汀的商品名是？','皿治林','仙特敏','息斯敏','开瑞坦','','','','',NULL,'A',1,',23,',1,''),(1476,2,'阿司咪唑的商品名是？','皿治林','仙特敏','息斯敏','开瑞坦','','','','',NULL,'C',1,',23,',1,''),(1477,2,'以下需要空腹服用的是？','开瑞坦','开思亭','仙特敏','以上都不是','','','','',NULL,'A',1,',23,',1,''),(1478,2,'14项安慰剂对照，双盲研究，共纳入了多少名过敏性鼻炎患者，证明了开思亭®10mg与20mg均具有良好的安全性？','580','1081','1690','5059','','','','',NULL,'D',1,',23,',1,''),(1479,2,'研究显示，依巴斯汀达到以下何种剂量时会产生轻度镇静作用？','10mg','20mg','30mg','50mg','','','','',NULL,'D',1,',23,',1,''),(1480,2,'依巴斯汀能有效改善患者鼻塞症状，可能的主要原因是？','血脑屏障透过率低','代谢迅速','有效阻断组胺与H1受体结合','具有直接的抗炎作用','','','','',NULL,'D',1,',23,',1,''),(1481,2,'研究显示，以下哪项与QT间期变化显著相关？','依巴斯汀10mg','依巴斯汀20mg','依巴斯汀30mg','特非那定180mg','','','','',NULL,'D',1,',23,',1,''),(1482,2,'以下说法错误的是？','依巴斯汀以及其代谢产物与血清蛋白的结合力强','依巴斯汀的消除半衰期与给药剂量密切相关','依巴斯汀重复给药无蓄积','依巴斯汀无食物-药物相互作用','','','','',NULL,'B',1,',23,',1,''),(1483,2,'在临床试验中，依巴斯汀发生的不良反应主要是？','与安慰剂无差异的轻、中度不良反应','与安慰剂无差异的中、重度不良反应','与安慰剂有差异的轻、中度不良反应','与安慰剂有差异的中、重度不良反应','','','','',NULL,'A',1,',23,',1,''),(1484,2,'一般情况下，应尽量避免依巴斯汀与下列哪项合用？','大环内脂类抗生素','酒精','食物','茶碱','','','','',NULL,'A',1,',23,',1,''),(1485,2,'以下哪项不是过敏性鼻炎的早期症状？','鼻痒','流泪','流涕','持续性鼻塞','','','','',NULL,'D',1,',23,',1,''),(1486,2,'所谓慢性荨麻疹持续至少几周？','1周','2周','4周','6周','','','','',NULL,'D',1,',23,',1,''),(1487,2,'在过敏性鼻炎与荨麻疹的治疗中，免疫治疗的目的主要是？','减少受体','产生抗体','收缩血管','减少炎症介质释放','','','','',NULL,'B',1,',23,',1,''),(1488,2,'SAR指的是？','常年性过敏性鼻炎','慢性荨麻疹','季节性过敏性鼻炎','以上都不对','','','','',NULL,'C',1,',23,',1,''),(1489,2,'在临床研究中，依巴斯汀被报道的发生率最高的不良反应是？','头痛，与安慰剂无差异','腹痛，与安慰剂无差异','腹泻，与安慰剂无差异','嗜睡，与安慰剂无差异','','','','',NULL,'A',1,',23,',1,''),(1490,2,'开思亭®的包装是？','5片/板','8片/板','10片/板','12片/板','','','','',NULL,'C',1,',23,',1,''),(1491,2,'第一代抗组胺药物因其抗胆碱能活性，会导致？','口干','便秘','尿潴留','以上都是','','','','',NULL,'D',1,',23,',1,''),(1492,2,'依巴斯汀主要选择的组胺受体是？','中枢H1受体','周围H1受体','H2受体','H3受体','','','','',NULL,'B',1,',23,',1,''),(1493,3,'以下哪些药物与依巴斯汀无相互作用？','酒精','地西泮','华法林','茶碱','','','','',NULL,'ABCD',1,',23,',1,''),(1494,3,'第一代抗组胺药物的主要缺点包括？','镇静作用','胃肠道反应','与酒精和其他药物的相互作用','抗胆碱作用','','','','',NULL,'ABCD',1,',23,',1,''),(1495,3,'以下哪些是第二代抗组胺药物？','依巴斯汀','非索非那定','西替利嗪','特非那定','','','','',NULL,'ABCD',1,',23,',1,''),(1496,3,'在过敏性鼻炎中，组胺的释放会导致？','血管舒张','毛细血管通透性降低','刺激神经末梢','血管收缩','','','','',NULL,'AC',1,',23,',1,''),(1497,3,'在过敏性鼻炎中，组胺的释放导致下列哪些症状？','流涕','鼻痒','喷嚏','流泪','','','','',NULL,'ABCD',1,',23,',1,''),(1498,3,'在荨麻疹中，组胺的释放会导致？','血管收缩，导致红斑','血管舒张，导致红斑','局部毛细血管通透性减少，导致肿胀','局部毛细血管通透性增加，导致肿胀','','','','',NULL,'BD',1,',23,',1,''),(1499,3,'过敏性鼻炎与荨麻疹治疗中的可选方案包括？','避免过敏原','糖皮质激素','抗组胺药物','化学治疗','','','','',NULL,'ABC',1,',23,',1,''),(1500,3,'依巴斯汀的化学结构使其？','作用持续时间长','对中枢H1受体活性低','不可逆的阻断组胺与H1受体结合','转化率低','','','','',NULL,'AB',1,',23,',1,''),(1501,3,'抗组胺药物能够缓解下列哪些过敏性鼻炎症状？','流涕','鼻痒','喷嚏','眼部症状','','','','',NULL,'ABCD',1,',23,',1,''),(1502,3,'以下哪些是依巴斯汀的药代动力学特点？','同时服用食物会导致代谢产物Cmax和AUC发生显著改变','重复剂量不改变半衰期，但会产生蓄积','停药4天后仍为稳态血药浓度','快速转化为代谢产物','','','','',NULL,'CD',1,',23,',1,''),(1503,3,'在缓解皮肤反应方面，依巴斯汀20mg/d的疗效强于以下哪些药物？','西替利嗪','氯雷他定','左西替利嗪','非索非那定','','','','',NULL,'ABCD',1,',23,',1,''),(1504,3,'以下哪些是研究表明依巴斯汀20mg具有的特点？','显著改善蚊虫叮咬伤口大小与瘙痒','显著抑制皮肤风团反应','抗组胺效应显著优于依巴斯汀10mg与西替利嗪','唯一可使用20mg剂量的非镇静抗组胺药','','','','',NULL,'ABCD',1,',23,',1,''),(1505,3,'以下哪些可以引起过敏性鼻炎？','花粉','尘螨','动物','昆虫','','','','',NULL,'ABCD',1,',23,',1,''),(1506,3,'下列哪些可以引起荨麻疹？','水杨酸药物','消炎药','狗的毛发或唾液','食品中的柠檬黄染料','','','','',NULL,'ABCD',1,',23,',1,''),(1507,3,'以下哪些药物是ARIA指南中推荐的过敏性鼻炎治疗药物？','口服抗组胺药','鼻内抗组胺药','鼻内减充血剂','异丙托溴铵','','','','',NULL,'ABCD',1,',23,',1,''),(1508,3,'依巴斯汀在推荐剂量下不影响？','驾驶和操作技能','QT间期','精神活动','风团面积','','','','',NULL,'ABC',1,',23,',1,''),(1509,3,'依巴斯汀的作用包括？','抗组胺作用','抗过敏作用','抗炎作用','抗心律失常作用','','','','',NULL,'ABC',1,',23,',1,''),(1510,3,'依巴斯汀在哪些方面具有显著的疗效？','间歇性过敏性鼻炎','常年性过敏性鼻炎','荨麻疹','蚊虫叮咬引起的皮肤反应','','','','',NULL,'ABCD',1,',23,',1,''),(1511,3,'过敏性鼻炎的管理包括以下哪些？','避免过敏原','药物治疗','免疫治疗','患者教育','','','','',NULL,'ABCD',1,',23,',1,''),(1512,3,'依巴斯汀安全性体现在以下哪些方面？','总体安全性和耐受性高','无认知或精神运动受损','无镇静作用','心脏安全性高','','','','',NULL,'ABCD',1,',23,',1,''),(1513,3,'以下对于开思亭®的描述，正确的是？','疗效持久','缓解所有过敏症状','无镇静作用','轻度增加QT间期','','','','',NULL,'ABC',1,',23,',1,''),(1514,3,'过敏性鼻炎治疗共识中，过敏性鼻炎的症状包括？','鼻塞','鼻腔分泌物','哮喘','嗅觉障碍','','','','',NULL,'ABCD',1,',23,',1,''),(1515,3,'利兹睡眠评估问卷显示，以下哪项不会影响睡眠？','依巴斯汀10mg','依巴斯汀20mg','依巴斯汀30mg','曲普利啶10mg','','','','',NULL,'AB',1,',23,',1,''),(1516,3,'依巴斯汀20mg显著优于西替利嗪10mg与氯雷他定10mg，体现在？','更高的组胺诱导风团的阈值浓度','更有效的改善过敏性鼻炎患者症状评分','更高的风团及瘙痒缓解率','更大的QT间期改变值','','','','',NULL,'ABC',1,',23,',1,''),(1517,3,'依巴斯汀20mg与依巴斯汀10mg相比？','对于症状更严重的过敏性鼻炎患者疗效更佳','更有效的缓解荨麻疹患者皮肤症状','不良反应发生率显著升高','对PAR患者疗效显著优于氯雷他定','','','','',NULL,'ABD',1,',23,',1,''),(1518,3,'依巴斯汀的适应症是？','间歇性过敏性鼻炎','常年性过敏性鼻炎','特发性慢性荨麻疹','支气管哮喘','','','','',NULL,'ABC',1,',23,',1,''),(1519,3,'以下哪些患者在使用依巴斯汀时需要慎重？','特发性慢性荨麻疹患者','长QT间期综合症患者','低钾血症患者','在使用大环内脂类抗生素的患者','','','','',NULL,'BCD',1,',23,',1,''),(1520,3,'依巴斯汀的禁忌症是？','已知对依巴斯汀或对药物任何成分过敏的病人','合并过敏性结膜炎的过敏性鼻炎病人','严重肝损伤病人','慢性肾衰病人','','','','',NULL,'AC',1,',23,',1,''),(1521,3,'依巴斯汀剂量范围在1-30mg/d的研究显示？','与安慰剂比较QT间期改变无差异','QT间期改变与年龄、体重无关','QT间期改变与种族有关','QT间期改变与性别有关','','','','',NULL,'AB',1,',23,',1,''),(1522,3,'关于依巴斯汀安全性的描述，正确的是？','依巴斯汀具有有剂量可变性和宽泛的治疗安全边界','10mg和20mg依巴斯汀在不良反应发生率方面不存在剂量联系','依巴斯汀心脏安全性良好','依巴斯汀与特非那定相比显著延长QT间期','','','','',NULL,'ABC',1,',23,',1,''),(1523,3,'荨麻疹的特点包括以下哪些？','鼻塞','局部肿胀','风团','瘙痒','','','','',NULL,'BCD',1,',23,',1,''),(1524,3,'关于第一代抗组胺药物，描述正确的是？','能够快速缓解症状','具有明显的镇静作用','抗胆碱能活性明显','一般都来自于烷基胺','','','','',NULL,'ABCD',1,',23,',1,''),(1525,3,'组胺的三大受体是？','H1','H2','H3','H4','','','','',NULL,'ABC',1,',23,',1,''),(1526,3,'以下哪些是第一代抗组胺药物？','苯海拉明','曲普利啶','咪唑斯汀','阿司咪唑','','','','',NULL,'AB',1,',23,',1,''),(1527,2,'符合中国高血压防治指南对于高血压急症的定义的是？','血压明显升高并需要紧急处理的临床症状；','血压严重升高(＞180/120mmHg）并伴发进行性靶器官功能不全的表现','血压严重升高(＞180/110mmHg)并伴发进行性靶器官功能不全的表现','血压严重升高但不伴靶器官损害','','','','',NULL,'B',1,',22,',1,''),(1528,2,'以下哪种是高血压急症的临床表现？','主动脉夹层分离','急性左心衰伴肺水肿','嗜铬细胞瘤危象','以上都是','','','','',NULL,'D',1,',22,',1,''),(1529,2,'围手术期高血压最容易发生意外的器官是？','心','脑','肾','肝','','','','',NULL,'A',1,',22,',1,''),(1530,2,'围手术期发生高血压的原因有？','术前有原发性高血压,术前的紧张焦虑等精神因素','术中的手术刺激及应激反应','麻醉方式和麻醉过程中某些药物的使用','以上都是','','','','',NULL,'D',1,',22,',1,''),(1531,2,'血管扩张剂在治疗急性左心衰的主要作用是？','降低心脏前后负荷','改善心脏功能，降低心肌耗氧','减轻心脏负荷，增加心输出量','以上都是','','','','',NULL,'D',1,',22,',1,''),(1532,2,'以下哪种不是常用的静脉抗高血压用药？','硝普钠','乌拉地尔','硫酸镁','尼卡地平','','','','',NULL,'C',1,',22,',1,''),(1533,2,'理想的静脉注射抗高血压药物的具备的特性是？','降低血压的同时不减少重要器官的血流供应','没有急性耐受性反应，减少交感神经兴奋作用','安全,无毒性代谢物','以上都是','','','','',NULL,'D',1,',22,',1,''),(1534,2,'围手术期高血压处理的基本原则是？','起效迅速,平稳降压不反跳','不减少重要器官的血流供应','适度降压,安全可控','以上都是','','','','',NULL,'D',1,',22,',1,''),(1535,2,'亚急症高血压指需要在多长时间内降到安全水平的高血压？','2h内','12-24h','24-48h','1个月','','','','',NULL,'C',1,',22,',1,''),(1536,2,'高血压急症的治疗需要关注？','应考虑2种或以上药物联合应用，如β受体阻滞剂、ACEI加利尿剂，β受体阻滞剂加钙拮抗剂','应注意由于血压降低过快而出现新的症状','掌握快速降压的力度应该是个体化的，了解病人此次高血压亚急症出现以前即平时的血压状况，是否有脑血管病，是否有冠心病、肾病等均对此时的降压治疗有所帮助','以上都是','','','','',NULL,'D',1,',22,',1,''),(1537,2,'以下哪种说法最符合对围手术期高血压的认识？','主要是基础高血压疾病的反映，不用特殊处理','在疾病、麻醉、手术刺激等因素下表现出的器官存在潜在危险的信号','除非出现血压急性升高，不主张将血压降至低于平时水平','围手术期的高血压治疗更主要是针对靶器官的治疗','','','','',NULL,'D',1,',22,',1,''),(1538,2,'以下哪种说法最符合对围手术期高血压用药安全性的认识？','术前应注重降压治疗对麻醉药的作用','术中应注重麻醉下对降压药的作用','针对不同术前血压状态的患者选用不同的降压药','以上都是','','','','',NULL,'D',1,',22,',1,''),(1539,2,'以下哪种不是围术期高血压发生的原因？','焦虑与紧张引起的高血压','麻醉引起的高血压','妊娠高血压','手术操作引起的高血压','','','','',NULL,'C',1,',22,',1,''),(1540,2,'中国高血压防治指南对于高血压急症的定义正确的是?','血压明显升高并需要紧急处理的临床症状','血压严重升高(＞180/120mmHg）并伴发进行性靶器官功能不全的表现','血压严重升高(＞180/110mmHg)并伴发进行性靶器官功能不全的表现','血压严重升高但不伴靶器官损害','','','','',NULL,'B',1,',22,',1,''),(1541,2,'乌拉地尔是属于哪一类静脉抗高血压药物？','β受体阻滞剂','α受体阻滞剂','钙离子拮抗剂','ACEI类','','','','',NULL,'B',1,',22,',1,''),(1542,2,'亚宁定与其它静脉用抗高血压制剂的优势是？','起效迅速,降压平稳不反跳','禁忌症少,使用范围宽泛','保障靶器官的血流灌注','以上都是','','','','',NULL,'D',1,',22,',1,''),(1543,2,'亚宁定的作用机制是？','通过中枢和外周两个途径降压','仅作用于外周血管的a1受体阻滞剂','仅作用于中枢5HT-1A受体而发挥中枢降压作用','具有选择性的β1受体阻滞剂','','','','',NULL,'A',1,',22,',1,''),(1544,2,'以下哪个是亚宁定的作用特点？','与硝普钠疗效相当，低血压发生率少','降压平稳，可控性好','不升高颅内压,不影响心率','以上都是','','','','',NULL,'D',1,',22,',1,''),(1545,2,'以下哪个不是亚宁定的关键信息？','高血压危象的一线治疗药物','不影响心率和颅内压','起效快，作用时间短','更简便和安全的治疗选择','','','','',NULL,'C',1,',22,',1,''),(1546,2,'亚宁定（乌拉地尔）的适用范围包括？','脑卒中的血压控制','急性心衰伴肺水肿的血管扩张药物选择','急性肾衰和急性心梗的血压控制','以上都是','','','','',NULL,'D',1,',22,',1,''),(1547,2,'亚宁定运用于围手术期降压的优势是？','独特的双重作用机制是','适度降压,安全可控','不影响心率和颅内压','以上都是','','','','',NULL,'D',1,',22,',1,''),(1548,2,'乌拉地尔适合在以下哪种情形的患者？','收缩压〉100mmHg,并伴有肺淤血的急性左心衰的患者','缺血性心肌病引起的左心衰，扩张性心肌病引起的左心衰','可用于CO↓，PCWP>18mmHg的心衰患者','以上都是','','','','',NULL,'A',1,',22,',1,''),(1549,2,'以下哪个血管活性药物在2010中国急性心力衰竭诊断和治疗指南里获得IIa的推荐？','尼卡地平','地尔硫卓','乌拉地尔','硝苯地平','','','','',NULL,'C',1,',22,',1,''),(1550,2,'亚宁定静脉首剂给药25mg后多久起效？','立即','3-5min','30min','30-50min','','','','',NULL,'B',1,',22,',1,''),(1551,2,'亚宁定静脉给药半衰期为？','1-1.2h','2-4.8h','3-4.5h','5-6.8h','','','','',NULL,'B',1,',22,',1,''),(1552,2,'平稳降压时亚宁定需以多少速度静脉滴注？','1－4ug/min','10－40ug/min','100－400ug/min','1000－4000ug/min','','','','',NULL,'C',1,',22,',1,''),(1553,2,'快速降压时亚宁定泵入速度为？','10ug/min速度泵入','100ug/min速度泵入','250ug/min速度泵入','1000ug/min速度泵入','','','','',NULL,'D',1,',22,',1,''),(1554,2,'平稳降压时亚宁定泵入速度为？','10－40ug/min的速度泵入','100－400ug/min的速度泵入','1000－4000ug/min的速度泵入','1－4ug/min的速度泵入','','','','',NULL,'B',1,',22,',1,''),(1555,2,'亚宁定每支含多少ml？','1','5','10','20','','','','',NULL,'B',1,',22,',1,''),(1556,2,'硝普钠的副作用包括？','代谢为氰化物和硫氰酸盐,长期蓄积有致命毒性','严重的低血压反应','肝肾功能损害','以上都是','','','','',NULL,'D',1,',22,',1,''),(1557,3,'高血压急症的治疗原则是？','立即有效降低血压','10min-2hMAP降低35%','10min-1hMAP降低25%','2-6h降至160/100mmHg','','','','',NULL,'ACD',1,',22,',1,''),(1558,3,'亚宁定的主要的代谢产物（羟化乌拉地尔）？','有生物活性','有毒副作用','无生物活性','无毒副作用','','','','',NULL,'CD',1,',22,',1,''),(1559,3,'以下描述属于亚宁定优势的有？','亚宁定被列入较多指南和专家建议','亚宁定通过独特的双重作用扩张血管,中枢和外周机制协同作用的结果保证了降压效果迅速、有力','亚宁定安全可靠,不损伤肾功能','亚宁定比硝普钠使用更简便','','','','',NULL,'ABCD',1,',22,',1,''),(1560,3,'为什么说亚宁定操作简便？','无需临时配液','输液时无避光的苛刻要求','无心动过速，针对不同的降压需求可采用灵活的给药方案：静脉推注，持续静脉点滴或使用输液泵','应用输液泵剂量恒定，可不监测血压','','','','',NULL,'ABC',1,',22,',1,''),(1561,3,'亚宁定的适应症包括？','高血压危象（如血压急剧升高）','重度和极重度高血压','难治性高血压','围手术期高血压','','','','',NULL,'ABCD',1,',22,',1,''),(1562,2,'关于推广信息的标准，下列描述哪项是错误的：','药品信息推广应与中国药品主管部门批准的药品信息相一致','广信息清楚、易理解、准确、全面、公正、客观、且达到足以使相对人能就有关药品的治疗价值形成自己观点的完整程度','药品推广信息以对所有相关证据所作的最新评估为依据并清楚地反映出相关证据事实','销售人员可以自行收集整理推广信息并印刷成册向HCP发放','','','','',NULL,'D',1,',41,',1,''),(1563,2,'关于医疗卫生专业人士的随行客人（陪同人员），下列描述哪项是正确的：','对被邀请的医疗卫生专业人士的配偶可以支付费用','对被邀请的医疗卫生专业人士的未成年子女可以支付费用','若该陪同人员也是医疗卫生专业人士，则可以支付费用','对这类人员不能支付任何费用','','','','',NULL,'D',1,',41,',1,''),(1564,2,'下列关于各省级常委、委员讲课费的支付标准正确的是：','单次报酬小于等于5000元','单次报酬小于等于3000元','单次报酬小于等于2000元','单次报酬小于等于1500元','','','','',NULL,'C',1,',41,',1,''),(1565,2,'下列物品中，公司不允许赠送的医用物品有：','购书券','医学书籍','解剖模型','听诊器','','','','',NULL,'A',1,',41,',1,''),(1566,2,'在武田中国，可以赠送给医疗卫生专业人士的物品有：','精装视频、绘画作品、娱乐项目入场券等个人礼品','  “非贵重”的风俗礼品（如元旦、春节、端午、中秋、国庆）','每件价值在人民币100元以内的、与医疗专业服务相关的推广辅助用品','现金或现金等价物','','','','',NULL,'C',1,',41,',1,''),(1567,2,'关于推广活动的地点选择，公司允许的有：','KTV包房','高尔夫中心','医院会议室','洗浴中心','','','','',NULL,'C',1,',41,',1,''),(1568,2,'关于武田赞助医疗卫生专业人士出席互动交流活动应满足的条件，下列描述哪项是错误的：','互动交流活动符合公司关于招待活动的规定','对医疗卫生专业人士赞助应限于对差旅行、餐费、住宿及会议注册费的支付','因医疗卫生专业人士离开其工作出席会议而支付其一笔费用作为补偿','对医疗卫生专业人士提供赞助不得以其对某药品的处方、推荐或推广等义务为条件','','','','',NULL,'C',1,',41,',1,''),(1569,2,'关于赞助医疗卫生专业人士出席学术活动，公司不允许承担的费用有：','会议相关的餐费','房费中包含的洗衣费及酒吧花销','会议的注册费','参加会议所必须的机票和出租车费','','','','',NULL,'B',1,',41,',1,''),(1570,2,'下列关于选择商务舱的描述正确的是：','连续飞行超过6小时可以选择商务舱','只要客户要求就可以选择商务舱','只要是赞助HCP参加海外会议就可以选择商务舱','全国常委，全国委员以上级别的HCP可以选择商务舱','','','','',NULL,'A',1,',41,',1,''),(1571,2,'在推广活动中以下哪些行为是公司所允许的：','组织“幸运抽奖”类的活动','提供附属于活动的茶歇和餐饮','向与会者提供娱乐活动的入场券','会后组织周边景区观光','','','','',NULL,'B',1,',41,',1,''),(1572,3,'以下人员中属于医疗卫生专业人士的有：','医生','药剂师','药品采购人员','护士','','','','',NULL,'ABCD',1,',41,',1,''),(1573,3,'关于公司邀请医疗专业人士提供服务时，必须满足：','在开始提供服务前签订有关服务内容和服务费计费依据的书面协议','开始提供服务前必须确定并记录需要有关服务的正当理由','相关医疗专业人士的聘请标准需与上述正当理由直接相关，且所确定的人选具备必要的资质','不得以聘用医疗专业人士提供相关服务作为诱导其开具处方、推荐、采购、供应和或使用任何药品的条件','','','','',NULL,'ABCD',1,',41,',1,''),(1574,3,'出于善意，武田药品员工发现任何可能违反全球政策、相关本地政策或适用法律时可以报告给以下哪些人员：','他们的经理','所在地的其他管理性员工','法务或合规人员','本地的合规热线','','','','',NULL,'ABCD',1,',41,',1,''),(1575,3,'武田只可在有充分理由的情况下方可组织或赞助医疗卫生专业人士赴中国境外参加活动，所谓充分理由的情况是指：','有关活动所邀请的大部分医疗卫生专业人士都来自境外，且出于会议安排及安全的考虑，在他国举办该活动更为合理','HCP可以拜访其海外亲戚','作为有关活动主题的相关资源或专家均在中国境外','获得一个了解文化的经历','','','','',NULL,'AC',1,',41,',1,''),(1576,3,'关于武田推广材料及电子版推广材料的描述正确的是：','不得有尚未在中国获得审批上市的药品内容','不得有超出适应症的使用宣传','需经医学部审核确认','在药品获得上市许可前，可以不经公司医学人员监督，直接进行推广','','','','',NULL,'ABC',1,',41,',1,'');
/*!40000 ALTER TABLE `problems` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `users`
--

DROP TABLE IF EXISTS `users`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `users` (
  `UserId` int(11) NOT NULL AUTO_INCREMENT,
  `UserName` varchar(100) NOT NULL,
  `Email` varchar(100) NOT NULL,
  `DeptId` int(11) DEFAULT '0',
  `Status` int(11) NOT NULL DEFAULT '1',
  `CanApprove` int(11) NOT NULL DEFAULT '0',
  `JobGrade` int(11) DEFAULT NULL,
  `CreatedUser` int(11) DEFAULT NULL,
  `CreatedTime` datetime DEFAULT NULL,
  `EditUser` int(11) DEFAULT NULL,
  `EditTime` datetime DEFAULT NULL,
  `EmployeeId` varchar(20) NOT NULL,
  `UserWId` varchar(100) DEFAULT NULL,
  `UserArea` varchar(100) DEFAULT NULL,
  `UserPosition` varchar(100) DEFAULT NULL,
  `UserProduct` varchar(100) DEFAULT NULL,
  `UserParent` varchar(100) DEFAULT NULL,
  `UserParentId` varchar(100) DEFAULT NULL,
  `DeptCode` varchar(100) DEFAULT NULL,
  `CanApprovestr` varchar(100) DEFAULT NULL,
  PRIMARY KEY (`UserId`),
  UNIQUE KEY `EmployeeId` (`EmployeeId`)
) ENGINE=InnoDB AUTO_INCREMENT=1427 DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `users`
--

LOCK TABLES `users` WRITE;
/*!40000 ALTER TABLE `users` DISABLE KEYS */;
INSERT INTO `users` VALUES (1,'卢安邦','Pony.Lu@takeda.com',227,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00001','rf3035','President Office','President','','野口晓','E02947','','是'),(2,'王卫','frank.wang@takeda.com',65,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01821','ck2795','GBU','VP, Commercial Operations','','卢安邦','E00001','','是'),(3,'崔一','Ethan.Cui@takeda.com',65,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00114','sh1278','CBU','Head of CBU','','王卫','E01821','CNGBUD0001','是'),(4,'左明星','mingxing.zuo@takeda.com',5,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02494','id3304','CBU','NSD','Mix','崔一','E00114','CNCBUD0001','是'),(5,'陈云飞','Yunfei-1.Chen@takeda.com',6,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02062','lk6824','CBU-BJ','MR','Mix','高光吉','E03001','CNCDSM0001','否'),(6,'董剑','jian.dong@takeda.com',6,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02704','op1570','CBU-BJ','MR','Mix','高光吉','E03001','CNCDSM0001','否'),(7,'刘慧鑫','Huixin.Liu@takeda.com',6,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03009','ah0601','CBU-BJ','MR','Mix','高光吉','E03001','CNCDSM0001','否'),(8,'黄日生','Risheng.Huang@takeda.com',6,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03157','cl5907','CBU-BJ','MR','Mix','高光吉','E03001','CNCDSM0001','否'),(9,'陈波','bo.chen@takeda.com',6,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00575','qm1317','CBU-BJ','SMR','Mix','高光吉','E03001','CNCDSM0001','否'),(10,'陶金','Jin.Tao@takeda.com',6,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03007','rz2448','CBU-BJ','SMR','Mix','高光吉','E03001','CNCDSM0001','否'),(11,'姜忠莉','zhongli.jiang@takeda.com',6,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03012','jw8351','CBU-BJ','SMR','Mix','高光吉','E03001','CNCDSM0001','否'),(12,'李良','Liang.Li2@takeda.com',9,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02611','st2254','CBU-BJ','MR','Mix','韩娜','E02735','CNCDSM0004','否'),(13,'邢佳伟','Jiawei.Xing@takeda.com',9,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02777','sc0375','CBU-BJ','MR','Mix','韩娜','E02735','CNCDSM0004','否'),(14,'孙元庆','yuanqing.sun@takeda.com',9,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02787','lf7405','CBU-BJ','MR','Mix','韩娜','E02735','CNCDSM0004','否'),(15,'高玉丹','Yudan.Gao@takeda.com',9,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02782','aj0899','CBU-BJ','MR','Mix','韩娜','E02735','CNCDSM0004','否'),(16,'赵孟娜','Mengna.Zhao@takeda.com',9,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02828','ov0633','CBU-BJ','MR','Mix','韩娜','E02735','CNCDSM0004','否'),(17,'杨永福','Yongfu.Yang@takeda.com',9,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03095','ik8711','CBU-BJ','MR','Mix','韩娜','E02735','CNCDSM0004','否'),(18,'杨沫','mo.yang@takeda.com',10,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00736','au3356','CBU-BJ','MR','CV','空缺','','CNCDSM0005','否'),(19,'王晶晶','Jingjing.Wang@takeda.com',10,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02574','da8402','CBU-BJ','MR','Mix','空缺','','CNCDSM0005','否'),(20,'马永娟','Yongjuan.Ma@takeda.com',10,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02571','ow0787','CBU-BJ','MR','Mix','空缺','','CNCDSM0005','否'),(21,'王江涛','Jiangtao.Wang@takeda.com',10,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02655','bg2341','CBU-BJ','MR','Mix','空缺','','CNCDSM0005','否'),(22,'李俊卿','junqing.li@takeda.com',10,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00709','qf4642','CBU-BJ','SMR','Mix','空缺','','CNCDSM0005','否'),(23,'袁峰','feng.yuan@takeda.com',10,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00712','xd4059','CBU-BJ','SMR','Mix','空缺','','CNCDSM0005','否'),(24,'张娟','juan.zhang@takeda.com',10,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02573','cd4707','CBU-BJ','SMR','Mix','空缺','','CNCDSM0005','否'),(25,'郭建平','jianping.guo@takeda.com',11,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00388','ky5609','CBU-BJ','Hospital Specialist','Mix','梁蓉','E00381','CNCDSM0006','否'),(26,'刘静','jing.liu2@takeda.com',11,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00793','gw8379','CBU-BJ','MR','Mix','梁蓉','E00381','CNCDSM0006','否'),(27,'赵国宇','Guoyu.Zhao@takeda.com',11,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02837','gs6487','CBU-BJ','MR','Mix','梁蓉','E00381','CNCDSM0006','否'),(28,'郭浩','hao.guo@takeda.com',11,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02874','wb9544','CBU-BJ','MR','Mix','梁蓉','E00381','CNCDSM0006','否'),(29,'姚燕云','yanyun.yao@takeda.com',11,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00382','gn5732','CBU-BJ','SMR','Mix','梁蓉','E00381','CNCDSM0006','否'),(30,'梁蓉','Rong.Liang@takeda.com',58,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00381','db6136','CBU-BJ','DSM','Mix','林桂福','E00541','CNCRSM0001','是'),(31,'唐虎','Hu.Tang@takeda.com',58,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02620','iz2245','CBU-BJ','DSM','Mix','林桂福','E00541','CNCRSM0001','是'),(32,'韩娜','na.han@takeda.com',58,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02735','tz4290','CBU-BJ','DSM','Mix','林桂福','E00541','CNCRSM0001','是'),(33,'赵杰','jie.zhao@takeda.com',0,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02784','ad1481','CBU-BJ','RPM','','林桂福','E00541','','否'),(34,'闵苒','Ran.Min@takeda.com',58,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03058','bi1742','CBU-BJ','RPM','','林桂福','E00541','CNCRSM0001','否'),(35,'徐君','Jun.Xu@takeda.com',58,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02621','ej6734','CBU-BJ','SDSM','Mix','林桂福','E00541','CNCRSM0001','是'),(36,'高光吉','guangji.gao@takeda.com',58,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03001','ir2227','CBU-BJ','SDSM','Mix','林桂福','E00541','CNCRSM0001','是'),(37,'郭楠','nan.guo@takeda.com',7,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00711','kg8444','CBU-BJ','MR','Mix','唐虎','E02620','CNCDSM0002','否'),(38,'王伟佳','weijia.wang@takeda.com',7,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00775','hr1367','CBU-BJ','MR','Mix','唐虎','E02620','CNCDSM0002','否'),(39,'勾晓冬','xiaodong.gou@takeda.com',7,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01720','ef8342','CBU-BJ','MR','Mix','唐虎','E02620','CNCDSM0002','否'),(40,'卢振','zhen.lu@takeda.com',7,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02690','ng7894','CBU-BJ','MR','Mix','唐虎','E02620','CNCDSM0002','否'),(41,'董鹏','Peng.Dong@takeda.com',7,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02719','tz3724','CBU-BJ','MR','Mix','唐虎','E02620','CNCDSM0002','否'),(42,'陈满堂','mantang.chen@takeda.com',7,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02785','sl8458','CBU-BJ','SMR','Mix','唐虎','E02620','CNCDSM0002','否'),(43,'史娜','Na.Shi@takeda.com',8,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02758','hx0896','CBU-BJ','Hospital Specialist','Mix','徐君','E02621','CNCDSM0003','否'),(44,'刘亚博','yabo.liu@takeda.com',8,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00728','zp3387','CBU-BJ','MR','Mix','徐君','E02621','CNCDSM0003','否'),(45,'蔡旭','Xu1.Cai@takeda.com',8,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02570','oq4848','CBU-BJ','MR','Mix','徐君','E02621','CNCDSM0003','否'),(46,'周荣','Rong.Zhou@takeda.com',8,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02778','pu1457','CBU-BJ','MR','Mix','徐君','E02621','CNCDSM0003','否'),(47,'关元全','Yuanquan.Guan@takeda.com',8,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02966','nf2963','CBU-BJ','MR','Mix','徐君','E02621','CNCDSM0003','否'),(48,'彭鹏','peng.peng@takeda.com',8,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03010','sf4718','CBU-BJ','MR','Mix','徐君','E02621','CNCDSM0003','否'),(49,'王俊','jun.wang5@takeda.com',8,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01998','va1961','CBU-BJ','SMR','Mix','徐君','E02621','CNCDSM0003','否'),(50,'王晶','jing1.wang@takeda.com',8,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02771','mg2789','CBU-BJ','SMR','Mix','徐君','E02621','CNCDSM0003','否'),(51,'龙敏','Min.Long@takeda.com',8,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02829','mz2264','CBU-BJ','SMR','Mix','徐君','E02621','CNCDSM0003','否'),(52,'林桂福','Guifu.Lin@takeda.com',57,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00541','pf6620','CBU-BJ','RSM','Mix','左明星','E02494','CNCNSD0001','是'),(53,'杨丽','Li-1.Yang@takeda.com',20,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00939','cn1288','CBU-GD','Executive Hospital Specialist','Mix','陈帅','E01652','CNCDSM0015','否'),(54,'刘旭莉','xuli.liu@takeda.com',20,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02859','mq5395','CBU-GD','Executive Hospital Specialist','Mix','陈帅','E01652','CNCDSM0015','否'),(55,'陈再生','zaisheng.chen@takeda.com',20,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01882','hf4512','CBU-GD','Hospital Specialist','Mix','陈帅','E01652','CNCDSM0015','否'),(56,'胡柏信','Boxin.Hu@takeda.com',20,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02255','av6799','CBU-GD','Hospital Specialist','Mix','陈帅','E01652','CNCDSM0015','否'),(57,'李雪梅','xuemei.li@takeda.com',20,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01254','nt6668','CBU-GD','MR','Mix','陈帅','E01652','CNCDSM0015','否'),(58,'彭伊娜','yina.peng@takeda.com',20,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01816','zw6317','CBU-GD','MR','Mix','陈帅','E01652','CNCDSM0015','否'),(59,'吴棉俊','Mianjun.Wu@takeda.com',20,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02526','hh8844','CBU-GD','SMR','Mix','陈帅','E01652','CNCDSM0015','否'),(60,'王少俏','Shaoqiao.Wang@takeda.com',20,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02562','cn3926','CBU-GD','SMR','Mix','陈帅','E01652','CNCDSM0015','否'),(61,'陆莹','ying.lu@takeda.com',12,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00455','ob7535','CBU-GD','Hospital Specialist','Mix','高艳芬','E02819','CNCDSM0007','否'),(62,'江巧云','qiaoyun.jiang@takeda.com',12,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02036','yp4847','CBU-GD','Hospital Specialist','Mix','高艳芬','E02819','CNCDSM0007','否'),(63,'陈艺明','yiming.chen@takeda.com',12,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01735','qr0067','CBU-GD','MR','Mix','高艳芬','E02819','CNCDSM0007','否'),(64,'黄昭润','zhaorun.huang@takeda.com',12,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02116','ib6686','CBU-GD','MR','Mix','高艳芬','E02819','CNCDSM0007','否'),(65,'吴圣奇','shengqi.wu@takeda.com',12,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02139','bi2351','CBU-GD','MR','Mix','高艳芬','E02819','CNCDSM0007','否'),(66,'李淑玲','Shuling1.Li@takeda.com',12,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02305','vp6202','CBU-GD','MR','Mix','高艳芬','E02819','CNCDSM0007','否'),(67,'王婷婷','tingting1.wang@takeda.com',12,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03138','vw5409','CBU-GD','MR','Mix','高艳芬','E02819','CNCDSM0007','否'),(68,'许启文','Qiwen.Xu@takeda.com',59,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00542','mw8256','CBU-GD','DSM','Mix','焦阳','E00929','CNCRSM0002','是'),(69,'徐黎','lib.xu@takeda.com',59,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00856','pz2877','CBU-GD','DSM','Mix','焦阳','E00929','CNCRSM0002','是'),(70,'谢冬梅','dongmei.xie@takeda.com',59,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00892','zw2450','CBU-GD','DSM','Mix','焦阳','E00929','CNCRSM0002','是'),(71,'陈帅','shuai.chen@takeda.com',59,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01652','ma1949','CBU-GD','DSM','Mix','焦阳','E00929','CNCRSM0002','是'),(72,'王光武','guangwu.wang@takeda.com',59,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01736','vd9588','CBU-GD','DSM','Mix','焦阳','E00929','CNCRSM0002','是'),(73,'曾黎','li.zeng@takeda.com',59,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01737','zg4036','CBU-GD','RPM','','焦阳','E00929','CNCRSM0002','否'),(74,'刘翠春','cuichun.liu@takeda.com',59,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00754','mk0270','CBU-GD','SDSM','Mix','焦阳','E00929','CNCRSM0002','是'),(75,'欧林','lin.ou@takeda.com',59,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00966','zu0961','CBU-GD','SDSM','Mix','焦阳','E00929','CNCRSM0002','是'),(76,'肖烨','ye.xiao@takeda.com',59,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01696','ql3069','CBU-GD','SDSM','Mix','焦阳','E00929','CNCRSM0002','是'),(77,'高艳芬','Yanfen.Gao@takeda.com',59,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02819','ga6563','CBU-GD','SDSM','Mix','焦阳','E00929','CNCRSM0002','是'),(78,'林俊伟','Junwei.Lin@takeda.com',59,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02844','tb0628','CBU-GD','SDSM','Mix','焦阳','E00929','CNCRSM0002','是'),(79,'李志新','zhixin.li@takeda.com',59,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00783','mk7420','CBU-GD','SRPM','','焦阳','E00929','CNCRSM0002','否'),(80,'程千','qian.cheng@takeda.com',18,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00369','cr2592','CBU-GD','Hospital Specialist','CV','林俊伟','E02844','CNCDSM0013','否'),(81,'茹琴','qin.ru@takeda.com',18,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00447','vz3306','CBU-GD','Hospital Specialist','Mix','林俊伟','E02844','CNCDSM0013','否'),(82,'崔彬彬','binbin.cui@takeda.com',18,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00678','gc5458','CBU-GD','Hospital Specialist','CV','林俊伟','E02844','CNCDSM0013','否'),(83,'黄桂春','guichun.huang@takeda.com',18,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00739','kl4612','CBU-GD','Hospital Specialist','Mix','林俊伟','E02844','CNCDSM0013','否'),(84,'朱志开','Zhikai.Zhu@takeda.com',18,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03036','bo6469','CBU-GD','Hospital Specialist','CV','林俊伟','E02844','CNCDSM0013','否'),(85,'郑英平','Yingping.Zheng@takeda.com',18,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02722','wl0998','CBU-GD','MR','CV','林俊伟','E02844','CNCDSM0013','否'),(86,'左海燕','haiyan.zuo@takeda.com',18,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00844','lw3621','CBU-GD','SMR','CV','林俊伟','E02844','CNCDSM0013','否'),(87,'黄亮','Liang.Huang@takeda.com',18,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02796','uv0781','CBU-GD','SMR','Mix','林俊伟','E02844','CNCDSM0013','否'),(88,'李森','Sen.Li@takeda.com',18,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03035','gw5691','CBU-GD','SMR','CV','林俊伟','E02844','CNCDSM0013','否'),(89,'曹丽丹','Lidan.Cao@takeda.com',15,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03117','aq0791','CBU-GD','Executive Hospital Specialist','Mix','刘翠春','E00754','CNCDSM0010','否'),(90,'费少华','shaohua.fei@takeda.com',15,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00484','ls9428','CBU-GD','Hospital Specialist','Mix','刘翠春','E00754','CNCDSM0010','否'),(91,'马玉梅','Yumei.Ma@takeda.com',15,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02561','bn6827','CBU-GD','Hospital Specialist','Mix','刘翠春','E00754','CNCDSM0010','否'),(92,'任甲子','Jiazi.Ren@takeda.com',15,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02190','dl1817','CBU-GD','SMR','Endo','刘翠春','E00754','CNCDSM0010','否'),(93,'黄倩','qian.huang@takeda.com',15,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02131','wf0696','CBU-GD','SMR','Endo','刘翠春','E00754','CNCDSM0010','否'),(94,'谢永斌','Yongbin.Xie@takeda.com',15,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02475','cb7516','CBU-GD','SMR','Mix','刘翠春','E00754','CNCDSM0010','否'),(95,'吴亨通','Hengtong.Wu@takeda.com',19,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02870','ae7417','CBU-GD','Executive Hospital Specialist','Endo','欧林','E00966','CNCDSM0014','否'),(96,'刘琳','Lin.Liu1@takeda.com',19,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02130','zz3727','CBU-GD','Hospital Specialist','Endo','欧林','E00966','CNCDSM0014','否'),(97,'陈巧燕','qiaoyan.chen@takeda.com',19,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00683','co2035','CBU-GD','MR','CV','欧林','E00966','CNCDSM0014','否'),(98,'郭伟伟','weiwei.guo@takeda.com',19,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01795','vx6848','CBU-GD','MR','Endo','欧林','E00966','CNCDSM0014','否'),(99,'苏小莲','Xiaolian.Su@takeda.com',19,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02420','ot6950','CBU-GD','MR','Endo','欧林','E00966','CNCDSM0014','否'),(100,'陈世雄','shixiong.chen@takeda.com',19,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00876','rg5676','CBU-GD','SMR','Endo','欧林','E00966','CNCDSM0014','否'),(101,'曹官林','guanlin.cao@takeda.com',19,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02709','vz9398','CBU-GD','SMR','Endo','欧林','E00966','CNCDSM0014','否'),(102,'吴志强','zhiqiang.wu@takeda.com',16,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00350','eq1745','CBU-GD','Executive Hospital Specialist','Endo','王光武','E01736','CNCDSM0011','否'),(103,'李磊','Lei2.Li@takeda.com',16,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02229','rl0951','CBU-GD','Hospital Specialist','Mix','王光武','E01736','CNCDSM0011','否'),(104,'曾祥铭','Xiangming.Zeng@takeda.com',16,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02356','to1596','CBU-GD','MR','Mix','王光武','E01736','CNCDSM0011','否'),(105,'符燕','yan.fu@takeda.com',16,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02723','vr6584','CBU-GD','MR','Mix','王光武','E01736','CNCDSM0011','否'),(106,'彭练','Lian.Peng@takeda.com',16,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02935','rh3586','CBU-GD','MR','Mix','王光武','E01736','CNCDSM0011','否'),(107,'陈永梅','yongmei.chen@takeda.com',16,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02324','mt3657','CBU-GD','SMR','Mix','王光武','E01736','CNCDSM0011','否'),(108,'马伟协','weixie.ma@takeda.com',17,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00351','wj5858','CBU-GD','Hospital Specialist','CV','肖烨','E01696','CNCDSM0012','否'),(109,'张芳','fang.zhang@takeda.com',17,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02237','mf3769','CBU-GD','Hospital Specialist','Mix','肖烨','E01696','CNCDSM0012','否'),(110,'钟姗杏','shanxing.zhong@takeda.com',17,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00356','ev4213','CBU-GD','SMR','CV','肖烨','E01696','CNCDSM0012',''),(111,'刘畅','chang.liu@takeda.com',17,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01675','ga4414','CBU-GD','SMR','CV','肖烨','E01696','CNCDSM0012',''),(112,'仲丽萍','Lipin.Zhong@takeda.com',17,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02169','dq7495','CBU-GD','SMR','Mix','肖烨','E01696','CNCDSM0012',''),(113,'李正华','zhenghua.li@takeda.com',17,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02265','we3638','CBU-GD','SMR','CV','肖烨','E01696','CNCDSM0012',''),(114,'吴磊','Lei1.Wu@takeda.com',17,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03064','oa3477','CBU-GD','SMR','Mix','肖烨','E01696','CNCDSM0012',''),(115,'苏明锋','mingfeng.su@takeda.com',13,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01682','qa2680','CBU-GD','MR','Mix','谢冬梅','E00892','CNCDSM0008','否'),(116,'徐丽2','lic.xu@takeda.com',13,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01734','nz3200','CBU-GD','MR','Mix','谢冬梅','E00892','CNCDSM0008','否'),(117,'王爱琴','Aiqin.Wang@takeda.com',13,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01759','yr0071','CBU-GD','MR','Bas','谢冬梅','E00892','CNCDSM0008','否'),(118,'潘颖','ying.pan2@takeda.com',13,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01905','st3866','CBU-GD','MR','Mix','谢冬梅','E00892','CNCDSM0008','否'),(119,'姚惠江','huijiang.yao@takeda.com',13,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00368','qr6286','CBU-GD','SMR','Mix','谢冬梅','E00892','CNCDSM0008',''),(120,'吴晓燕','xiaoyan.wu@takeda.com',13,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00545','ue0378','CBU-GD','SMR','CV','谢冬梅','E00892','CNCDSM0008',''),(121,'高俊杰','junjie.gao@takeda.com',13,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00969','gz2978','CBU-GD','SMR','Mix','谢冬梅','E00892','CNCDSM0008',''),(122,'蔡颖','Ying.Cai@takeda.com',13,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02427','tp8421','CBU-GD','SMR','Mix','谢冬梅','E00892','CNCDSM0008',''),(123,'潘亮','liang.pan@takeda.com',14,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00454','fp2008','CBU-GD','Hospital Specialist','CV','徐黎','E00856','CNCDSM0009','否'),(124,'魏锦春','jinchun.wei@takeda.com',14,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02424','ej3266','CBU-GD','Hospital Specialist','Mix','徐黎','E00856','CNCDSM0009','否'),(125,'王晓琳','xiaolin.wang@takeda.com',14,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00840','mu6320','CBU-GD','SMR','Mix','徐黎','E00856','CNCDSM0009',''),(126,'黄春梅','Chunmei.Huang@takeda.com',14,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02476','gj0642','CBU-GD','SMR','Mix','徐黎','E00856','CNCDSM0009',''),(127,'吴国亮','Guoliang.Wu@takeda.com',14,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02388','jq8613','CBU-GD','SMR','Mix','徐黎','E00856','CNCDSM0009',''),(128,'谢辉','Hui.Xie2@takeda.com',14,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01598','ud7975','CBU-GD','SMR','Act','徐黎','E00856','CNCDSM0009',''),(129,'陈佳云','Jiayun.Chen@takeda.com',14,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02531','dq1805','CBU-GD','SMR','Mix','徐黎','E00856','CNCDSM0009',''),(130,'唐小棠','xiaotang.tang@takeda.com',21,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01683','rn6575','CBU-GD','Executive Hospital Specialist','Mix','许启文','E00542','CNCDSM0016','否'),(131,'邹传玮','chuanwei.zou@takeda.com',21,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01709','bz6128','CBU-GD','MR','Mix','许启文','E00542','CNCDSM0016','否'),(132,'欧阳飞','fei.ouyang@takeda.com',21,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00543','UQ7638','CBU-GD','SMR','Mix','许启文','E00542','CNCDSM0016',''),(133,'吴炎','yan.wu@takeda.com',21,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01670','dm4913','CBU-GD','SMR','Mix','许启文','E00542','CNCDSM0016',''),(134,'颜雯','Wen.Yan@takeda.com',21,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02959','ga6431','CBU-GD','SMR','Mix','许启文','E00542','CNCDSM0016',''),(135,'焦阳','yang.jiao@takeda.com',57,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00929','oh4267','CBU-GD','SRSM','Mix','左明星','E02494','CNCNSD0001','是'),(136,'刘彪','Biao.Liu@takeda.com',27,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02710','qn2422','CBU-HB','MR','Act','郭东方','E02900','CNCDSM0022','否'),(137,'王华明','huaming.Wang@takeda.com',27,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03069','cv7650','CBU-HB','MR','Mix','郭东方','E02900','CNCDSM0022','否'),(138,'韩蜀','Shu1.Han@takeda.com',27,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02675','nw5411','CBU-HB','SMR','Mix','郭东方','E02900','CNCDSM0022','否'),(139,'石峰','feng.shi@takeda.com',60,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02449','ij9597','CBU-HB','DSM','Mix','林洁','E02342','CNCRSM0003','是'),(140,'刘锋','Feng.Liu@takeda.com',60,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02872','wj9716','CBU-HB','DSM','Mix','林洁','E02342','CNCRSM0003','是'),(141,'郭东方','Dongfang.Guo@takeda.com',60,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02900','wj1438','CBU-HB','DSM','Mix','林洁','E02342','CNCRSM0003','是'),(142,'任战国','Zhanguo.Ren@takeda.com',60,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02929','nj3454','CBU-HB','DSM','Mix','林洁','E02342','CNCRSM0003','是'),(143,'张美玲','Meiling.Zhang@takeda.com',60,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02972','cs8964','CBU-HB','DSM','Mix','林洁','E02342','CNCRSM0003','是'),(144,'严鹏','Peng.Yan@takeda.com',60,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02276','fc6939','CBU-HB','SDSM','Mix','林洁','E02342','CNCRSM0003','是'),(145,'何菡菡','hanhan.he@takeda.com',22,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00843','wq1825','CBU-HB','MR','Mix','刘锋','E02872','CNCDSM0017','否'),(146,'刘永红','Yonghong2.Liu@takeda.com',22,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02538','bo4583','CBU-HB','MR','Mix','刘锋','E02872','CNCDSM0017','否'),(147,'刘雪贞','xuezhen.liu@takeda.com',22,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03090','pr6569','CBU-HB','MR','Mix','刘锋','E02872','CNCDSM0017','否'),(148,'汪浩','Hao.Wang@takeda.com',22,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02598','vs0201','CBU-HB','SMR','Mix','刘锋','E02872','CNCDSM0017','否'),(149,'晏霞','xia.yan@takeda.com',24,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02093','ku2241','CBU-HB','Executive Hospital Specialist','CV','任战国','E02929','CNCDSM0019','否'),(150,'李晶晶','Jingjing.Li@takeda.com',24,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02811','lb5532','CBU-HB','Hospital Specialist','Mix','任战国','E02929','CNCDSM0019','否'),(151,'陈洁','jie.chen@takeda.com',24,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02039','ar8666','CBU-HB','MR','Mix','任战国','E02929','CNCDSM0019','否'),(152,'吴保珍','baozhen.wu@takeda.com',24,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02218','ap0619','CBU-HB','MR','Mix','任战国','E02929','CNCDSM0019','否'),(153,'王馨','xin3.wang@takeda.com',24,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03002','rc3618','CBU-HB','MR','Mix','任战国','E02929','CNCDSM0019','否'),(154,'周海姣','haijiao.zhou@takeda.com',24,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00621','kk6525','CBU-HB','SMR','Mix','任战国','E02929','CNCDSM0019','否'),(155,'张振国','待定',23,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03113','eb2774','CBU-HB','Hospital Specialist','Mix','石峰','E02449','CNCDSM0018','否'),(156,'周贵裕','guiyu.zhou@takeda.com',23,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00970','fv1808','CBU-HB','MR','Mix','石峰','E02449','CNCDSM0018','否'),(157,'罗五利','Wuli.Luo@takeda.com',23,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02261','yn4447','CBU-HB','MR','Endo','石峰','E02449','CNCDSM0018','否'),(158,'张鹏','Peng2.Zhang@takeda.com',23,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02600','sx6217','CBU-HB','MR','Mix','石峰','E02449','CNCDSM0018','否'),(159,'孙凌云','Lingyun.Sun@takeda.com',23,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02636','wk8750','CBU-HB','MR','Mix','石峰','E02449','CNCDSM0018','否'),(160,'张媛','Yuan1.Zhang@takeda.com',23,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02831','th1825','CBU-HB','MR','Mix','石峰','E02449','CNCDSM0018','否'),(161,'王婷','Ting1.Wang@takeda.com',23,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03110','rx1499','CBU-HB','MR','Mix','石峰','E02449','CNCDSM0018','否'),(162,'彭叶荣','yerong.peng@takeda.com',26,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01752','eo9949','CBU-HB','MR','Mix','严鹏','E02276','CNCDSM0021','否'),(163,'陈宇哲','yuzhe.chen@takeda.com',26,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02164','qx0907','CBU-HB','MR','Mix','严鹏','E02276','CNCDSM0021','否'),(164,'陈静','Jing3.Chen@takeda.com',26,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02444','rv9507','CBU-HB','MR','Mix','严鹏','E02276','CNCDSM0021','否'),(165,'李虹云','hongyun.li@takeda.com',26,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00424','md7638','CBU-HB','SMR','Mix','严鹏','E02276','CNCDSM0021','否'),(166,'杨玲芳','lingfang.yang@takeda.com',25,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00859','sc2829','CBU-HB','MR','Mix','张美玲','E02972','CNCDSM0020','否'),(167,'刘芬','Fen1.Liu@takeda.com',25,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02517','pw3698','CBU-HB','MR','Mix','张美玲','E02972','CNCDSM0020','否'),(168,'闫欣博','xinbo.yan@takeda.com',25,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03018','yt5528','CBU-HB','MR','Mix','张美玲','E02972','CNCDSM0020','否'),(169,'林洁','Jie.Lin@takeda.com',57,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02342','wz2303','CBU-HB','RSM','Mix','左明星','E02494','CNCNSD0001','是'),(170,'马馨','cynthia.ma@takeda.com',5,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00616','vw7028','CBU-MKT','Portfolio Strategy Manager','','崔一','E00114','CNCBUD0001','否'),(171,'李国元','Greg.Li@takeda.com',5,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02967','tc9229','CBU-MKT','Senior Marketing Manager','','崔一','E00114','CNCBUD0001','否'),(172,'张东文','dongwen.zhang@takeda.com',4,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00634','ko3991','CBU-MKT','Sr. Product Manager','','李国元','E02967','CBU-MM-03','否'),(173,'罗萍','Ping.Luo@takeda.com',2,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00357','vq4634','CBU-MKT','Sr. Product Manager','','李国元','E02967','CBU-MM-01','否'),(174,'张晓元','cindy.zhang@takeda.com',2,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01885','ls2639','CBU-MKT','Sr. Product Manager','','李国元','E02967','CBU-MM-01','否'),(175,'石琳','Lin.Shi@takeda.com',3,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02650','gc4358','CBU-MKT','Product Manager','','马馨','E00616','CBU-MM-02','否'),(176,'疏桐','Tong.Shu@takeda.com',0,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02285','pt2428','CBU-MKT','APM','','熊鹰','E02118','','否'),(177,'周鸿鑫','hongxin.zhou@takeda.com',0,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00927','yz2121','CBU-MKT','Project Supervisor','','张东文','E00634','','否'),(178,'吴俊杰','junjie.wu@takeda.com.cn',0,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00977','td7062','CBU-MKT','Project Specialist','','张晓元','E01885','','否'),(179,'李文军','wenjun.li@takeda.com',55,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00397','ul7751','CBU-Nesina','Hospital Specialist','Nesina','尔漫','E00400','CNCDSM0050','否'),(180,'金雪','xue.jin@takeda.com',55,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00406','xh1102','CBU-Nesina','Hospital Specialist','Nesina','尔漫','E00400','CNCDSM0050','否'),(181,'边孝华','xiaohua.bian@takeda.com',55,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00416','ze9754','CBU-Nesina','Hospital Specialist','Nesina','尔漫','E00400','CNCDSM0050','否'),(182,'朱希男','xinan.zhu@takeda.com',55,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00418','zr6263','CBU-Nesina','SMR','Nesina','尔漫','E00400','CNCDSM0050','否'),(183,'包澍岩','shuyan.bao@takeda.com',55,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00496','al5278','CBU-Nesina','SMR','Nesina','尔漫','E00400','CNCDSM0050','否'),(184,'陈婧','jinga.chen@takeda.com',55,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00554','hz2916','CBU-Nesina','SMR','Nesina','尔漫','E00400','CNCDSM0050','否'),(185,'李宏旭','hongxu.li@takeda.com',55,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00951','kt9662','CBU-Nesina','SMR','Nesina','尔漫','E00400','CNCDSM0050','否'),(186,'曾志','Zhi.Zeng@takeda.com',53,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03188','yy9517','CBU-Nesina','MR','Nesina','空缺','','CNCDSM0048','否'),(187,'徐添添','Tiantian.Xu@takeda.com',56,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02687','td8944','CBU-Nesina','MR','Nesina','李其兵','E02816','CNCDSM0051','否'),(188,'冯景龙','Jinglong.Feng@takeda.com',56,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03127','ds5960','CBU-Nesina','MR','Nesina','李其兵','E02816','CNCDSM0051','否'),(189,'陈伟','Wei1.chen@takeda.com',56,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03141','wz6235','CBU-Nesina','SMR','Nesina','李其兵','E02816','CNCDSM0051','否'),(190,'周晓丹','Xiaodan.Zhou@takeda.com',54,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02497','dd2808','CBU-Nesina','MR','Nesina','李伟平','E00820','CNCDSM0049','否'),(191,'张泽禄','zelu.zhang@takeda.com',54,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00638','vm8381','CBU-Nesina','SMR','','李伟平','E00820','CNCDSM0049','否'),(192,'王洛超','luochao.wang@takeda.com',54,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00857','xj3295','CBU-Nesina','SMR','Nesina','李伟平','E00820','CNCDSM0049','否'),(193,'李伟平','weiping.li@takeda.com',64,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00820','vp6718','CBU-Nesina','DSM','Nesina','张云涌','E00399','CNCRSM0007','是'),(194,'李其兵','Qibing.Li@takeda.com',64,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02816','un9684','CBU-Nesina','DSM','Nesina','张云涌','E00399','CNCRSM0007','是'),(195,'邱怡','yi.qiu@takeda.com',64,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03014','is6210','CBU-Nesina','RPM','','张云涌','E00399','CNCRSM0007','否'),(196,'尔漫','Man.Er@takeda.com',64,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00400','lz1663','CBU-Nesina','SDSM','Nesina','张云涌','E00399','CNCRSM0007','是'),(197,'周日超','Richao.Zhou@takeda.com',64,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03057','qr3371','CBU-Nesina','SDSM','Nesina','张云涌','E00399','CNCRSM0007','是'),(198,'孙燕华','yanhua.sun@takeda.com',52,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00669','nb0306','CBU-Nesina','SMR','Nesina','周日超','E03057','CNCDSM0047','否'),(199,'张云涌','Yunyong.Zhang@takeda.com',57,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00399','pe2441','CBU-Nesina','NSM','Nesina','左明星','E02494','CNCNSD0001','是'),(200,'李彤','Tong.Li@takeda.com',31,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02885','rp9616','CBU-SH','Executive Hospital Specialist','Mix','陈迪','','CNCDSM0026','否'),(201,'张超','Chao.Zhang@takeda.com',31,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02971','qz4262','CBU-SH','Hospital Specialist','Mix','陈迪','','CNCDSM0026','否'),(202,'沈聪聪','congcong.shen@takeda.com',0,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00791','qo7035','CBU-SH','MR','','陈迪','','','否'),(203,'李烨','ye.li@takeda.com',31,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00847','cp7094','CBU-SH','MR','Mix','陈迪','','CNCDSM0026','否'),(204,'顾梅','mei.gu@takeda.com',31,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01777','ef7871','CBU-SH','MR','Mix','陈迪','','CNCDSM0026','否'),(205,'袁佳敏','jiamin.yuan@takeda.com',31,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02244','qs1707','CBU-SH','MR','Mix','陈迪','','CNCDSM0026','否'),(206,'闫威名','weiming.yan@takeda.com',31,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02894','rc0823','CBU-SH','MR','Mix','陈迪','','CNCDSM0026','否'),(207,'孙嘉文','jiawen.sun@takeda.com',31,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00280','tt4874','CBU-SH','SMR','Mix','陈迪','','CNCDSM0026','否'),(208,'王卿','Qing1.Wang@takeda.com',29,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02743','ou3357','CBU-SH','Hospital Specialist','CV','崔建华','E01690','CNCDSM0024','否'),(209,'李靖','Jing2.Li@takeda.com',29,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02210','br5606','CBU-SH','MR','Mix','崔建华','E01690','CNCDSM0024','否'),(210,'蒋美君','meijun.jiang@takeda.com',29,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02247','tb2899','CBU-SH','MR','CV','崔建华','E01690','CNCDSM0024','否'),(211,'张黎俊','Lijun1.Zhang@takeda.com',29,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02970','jo9843','CBU-SH','MR','Mix','崔建华','E01690','CNCDSM0024','否'),(212,'林美芳','meifang.lin@takeda.com',29,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00279','lt1488','CBU-SH','SMR','CV','崔建华','E01690','CNCDSM0024','否'),(213,'刘奕','yi.liu@takeda.com',29,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00855','jv6861','CBU-SH','SMR','Mix','崔建华','E01690','CNCDSM0024','否'),(214,'袁晓维','xiaowei.yuan@takeda.com',29,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01955','um9557','CBU-SH','SMR','CV','崔建华','E01690','CNCDSM0024','否'),(215,'张嘉','jia.zhang@takeda.com',30,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01687','wl5863','CBU-SH','Executive Hospital Specialist','CV','丁羚','E02246','CNCDSM0025','否'),(216,'宫尚勇','shangyong.gong@takeda.com',30,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02267','ip5891','CBU-SH','Executive Hospital Specialist','Mix','丁羚','E02246','CNCDSM0025','否'),(217,'王海滨','Haibin.Wang@takeda.com',30,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02485','sy9341','CBU-SH','Hospital Specialist','CV','丁羚','E02246','CNCDSM0025','否'),(218,'侯黎凤','Lifeng.Hou@takeda.com',30,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02523','em6273','CBU-SH','MR','CV','丁羚','E02246','CNCDSM0025','否'),(219,'龚晏','Yan.Gong@takeda.com',30,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02632','ln0754','CBU-SH','MR','Mix','丁羚','E02246','CNCDSM0025','否'),(220,'张玮','Wei1.Zhang2@takeda.com',30,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02937','he7601','CBU-SH','MR','Mix','丁羚','E02246','CNCDSM0025','否'),(221,'杨丽','Li1.Yang@takeda.com',33,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02884','cq8658','CBU-SH','Executive Hospital Specialist','Mix','祁丽亚','E02239','CNCDSM0028','否'),(222,'张毅','Yi1.Zhang@takeda.com',33,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02918','tb6707','CBU-SH','Hospital Specialist','Endo','祁丽亚','E02239','CNCDSM0028','否'),(223,'黄小丹','xiaodan.huang@takeda.com',33,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00981','hg8315','CBU-SH','MR','Endo','祁丽亚','E02239','CNCDSM0028','否'),(224,'伍虹霞','Hongxia.Wu@takeda.com',33,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02349','vq9487','CBU-SH','MR','Endo','祁丽亚','E02239','CNCDSM0028','否'),(225,'王文文','Wenwen.Wang@takeda.com',33,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02693','xw9250','CBU-SH','MR','Mix','祁丽亚','E02239','CNCDSM0028','否'),(226,'余浩','Hao.Yu@takeda.com',33,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03128','tc7307','CBU-SH','MR','Mix','祁丽亚','E02239','CNCDSM0028','否'),(227,'谢慧','Hui1.Xie@takeda.com',33,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03056','dh1835','CBU-SH','SMR','Endo','祁丽亚','E02239','CNCDSM0028','否'),(228,'郭婉婷','wanting.guo@takeda.com',32,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01994','QE0766','CBU-SH','MR','Act','万灵雁','E00777','CNCDSM0027','否'),(229,'金晓欣','Xiaoxin.Jin@takeda.com',32,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02963','ja7234','CBU-SH','MR','Endo','万灵雁','E00777','CNCDSM0027','否'),(230,'李俊','Jun.Li@takeda.com',32,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00592','gg3771','CBU-SH','SMR','Endo','万灵雁','E00777','CNCDSM0027','否'),(231,'丁璐','lu.ding@takeda.com',32,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02334','vj4703','CBU-SH','SMR','Endo','万灵雁','E00777','CNCDSM0027','否'),(232,'万灵雁','lingyan.wan@takeda.com',61,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00777','yv1081','CBU-SH','DSM','Mix','熊鹰','E02118','CNCRSM0004','是'),(233,'崔建华','jianhua.cui@takeda.com',61,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01690','pm0948','CBU-SH','DSM','Mix','熊鹰','E02118','CNCRSM0004','是'),(234,'丁羚','Ling.Ding@takeda.com',61,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02246','qc1701','CBU-SH','DSM','Mix','熊鹰','E02118','CNCRSM0004','是'),(235,'张曼莉','Manli.Zhang@takeda.com',61,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02868','mi1340','CBU-SH','DSM','Mix','熊鹰','E02118','CNCRSM0004','是'),(236,'吴璎璎','Yingying2.Wu@takeda.com',61,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02286','vy9862','CBU-SH','RPM','','熊鹰','E02118','CNCRSM0004','否'),(237,'周公波','gongbo.zhou@takeda.com',61,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02058','lw8398','CBU-SH','SDSM','Mix','熊鹰','E02118','CNCRSM0004','是'),(238,'祁丽亚','Liya.Qi@takeda.com',61,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02239','lh0257','CBU-SH','SDSM','Mix','熊鹰','E02118','CNCRSM0004','是'),(239,'岳辉','Hui.Yue@takeda.com',61,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02450','sf5671','CBU-SH','SDSM','Mix','熊鹰','E02118','CNCRSM0004','是'),(240,'薛锦鑫','jinxin.xue@takeda.com',34,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02515','xo6690','CBU-SH','Hospital Specialist','Mix','岳辉','E02450','CNCDSM0029','否'),(241,'陆金伟','jinwei.lu@takeda.com',34,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02835','jy1529','CBU-SH','Hospital Specialist','Mix','岳辉','E02450','CNCDSM0029','否'),(242,'李亚辉','yahui.li@takeda.com',34,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02000','bt1628','CBU-SH','MR','Mix','岳辉','E02450','CNCDSM0029','否'),(243,'茅天雯','tianwen.mao@takeda.com',34,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00738','of3884','CBU-SH','MR','Mix','岳辉','E02450','CNCDSM0029','否'),(244,'宋爱华','Aihua.Song@takeda.com',34,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02922','zh6526','CBU-SH','MR','Mix','岳辉','E02450','CNCDSM0029','否'),(245,'吕娟','Juan.Lv@takeda.com.cn',35,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00973','oc7866','CBU-SH','MR','Mix','张曼莉','E02868','CNCDSM0030','否'),(246,'张晶','Jing1.Zhang@takeda.com',35,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02713','ge1222','CBU-SH','MR','Mix','张曼莉','E02868','CNCDSM0030','否'),(247,'李洋','yang.li@takeda.com',35,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02214','nc1788','CBU-SH','SMR','Mix','张曼莉','E02868','CNCDSM0030','否'),(248,'姚晓娟','xiaojuan.Yao@takeda.com',28,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02726','ef4326','CBU-SH','Executive Hospital Specialist','Mix','周公波','E02058','CNCDSM0023','否'),(249,'赵倩','qian.zhao@takeda.com',0,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00391','aa2999','CBU-SH','MR','','周公波','E02058','','否'),(250,'李艳','Yan-1.Li@takeda.com',28,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01689','pb0521','CBU-SH','MR','Mix','周公波','E02058','CNCDSM0023','否'),(251,'戚胜杰','shengjie.Qi@takeda.com',28,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03149','tr4575','CBU-SH','MR','CV','周公波','E02058','CNCDSM0023','否'),(252,'张爱珠','aizhu.zhang@takeda.com',28,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00321','pl3821','CBU-SH','SMR','Act','周公波','E02058','CNCDSM0023','否'),(253,'周捷','jie.zhou@takeda.com',28,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00986','ne3311','CBU-SH','SMR','Mix','周公波','E02058','CNCDSM0023','否'),(254,'姜陆月','luyue.jiang@takeda.com',28,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02346','gu9629','CBU-SH','SMR','Mix','周公波','E02058','CNCDSM0023','否'),(255,'熊鹰','Ying.Xiong2@takeda.com',57,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02118','rs9594','CBU-SH','RSM','Mix','左明星','E02494','CNCNSD0001','是'),(256,'康晨曦','Kang.Xichen@takeda.com',36,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01713','mu5216','CBU-TJ','MR','Mix','肇伟','E03131','CNCDSM0031','否'),(257,'周贺','He.Zhou@takeda.com',36,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02436','cl5324','CBU-TJ','MR','Mix','肇伟','E03131','CNCDSM0031','否'),(258,'吴海峰','haifeng.wu@takeda.com',36,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01910','kp1420','CBU-TJ','SMR','Mix','肇伟','E03131','CNCDSM0031','否'),(259,'梅永纯','Yongchun.Mei@takeda.com',36,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02372','tp7896','CBU-TJ','SMR','Mix','肇伟','E03131','CNCDSM0031','否'),(260,'李振山','Zhenshan.Li@takeda.com',62,1,1,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03132','eq8735','CBU-TJ','DSM','Mix','张亮亮','E03082','CNCRSM0005','是'),(261,'张伟伟','weiwei1.zhang@takeda.com',39,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03136','hw4602','CBU-TJ','MR','Endo','空缺','','CNCDSM0034','否'),(262,'宋东波','Dongbo.Song@takeda.com',39,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03130','fd7444','CBU-TJ','Hospital Specialist','Mix','李振山','E03132','CNCDSM0034','否'),(263,'潘秋杰','qiujie.pan@takeda.com',39,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00497','lp4254','CBU-TJ','MR','Mix','李振山','E03132','CNCDSM0034','否'),(264,'关珊','shan.Guan@takeda.com',39,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03135','iv8256','CBU-TJ','MR','Act','李振山','E03132','CNCDSM0034','否'),(265,'李彬','bin.li@takeda.com',39,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00551','qt7660','CBU-TJ','SMR','Mix','李振山','E03132','CNCDSM0034','否'),(266,'梅耀军','Yaojun.Mei@takeda.com',39,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02404','se7813','CBU-TJ','SMR','Mix','李振山','E03132','CNCDSM0034','否'),(267,'李萌','Meng1.Li@takeda.com',40,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02025','cn4457','CBU-TJ','MR','Mix','马丽娅','E00403','CNCDSM0035','否'),(268,'杨鑫琪','xinqi.yang@takeda.com',40,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02204','td3998','CBU-TJ','MR','Mix','马丽娅','E00403','CNCDSM0035','否'),(269,'刘彦雪','yanxue.liu@takeda.com',40,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02679','ji2955','CBU-TJ','MR','Mix','马丽娅','E00403','CNCDSM0035','否'),(270,'张苏萌','sumeng.zhang@takeda.com',40,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00552','yo6363','CBU-TJ','SMR','Mix','马丽娅','E00403','CNCDSM0035','否'),(271,'铁瑛','ying.tie@takeda.com',40,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01693','gs5137','CBU-TJ','SMR','Mix','马丽娅','E00403','CNCDSM0035','否'),(272,'刘宁','ning.liu@takeda.com',41,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01766','ed3721','CBU-TJ','MR','Mix','倪仲维','E00405','CNCDSM0036','否'),(273,'秦昊','hao.qin@takeda.com',41,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02990','zh6954','CBU-TJ','MR','Endo','倪仲维','E00405','CNCDSM0036','否'),(274,'何其彬','qibin.he@takeda.com',41,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00498','rx3178','CBU-TJ','SMR','Endo','倪仲维','E00405','CNCDSM0036','否'),(275,'郝芸','yun.hao@takeda.com',41,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00076','pb9315','CBU-TJ','SMR','Mix','倪仲维','E00405','CNCDSM0036','否'),(276,'王宽宽','kuankuan.wang@takeda.com',37,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E01970','HV8502','CBU-TJ','MR','Bas','皮轶光','E00412','CNCDSM0032','否'),(277,'王洋','Yang2.Wang@takeda.com',37,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02462','hr5464','CBU-TJ','MR','Endo','皮轶光','E00412','CNCDSM0032','否'),(278,'丁浩墨','haomo.ding@takeda.com',37,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02569','ck6988','CBU-TJ','MR','Bas','皮轶光','E00412','CNCDSM0032','否'),(279,'李垚佶','yaoji.li@takeda.com',37,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02750','yp3211','CBU-TJ','MR','Endo','皮轶光','E00412','CNCDSM0032','否'),(280,'赵晓静','xiaojing.zhao@takeda.com',37,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03027','zd3380','CBU-TJ','MR','Bas','皮轶光','E00412','CNCDSM0032','否'),(281,'马铎','duo.ma@takeda.com',42,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E00996','bk5538','CBU-TJ','MR','Mix','宋利明','E00401','CNCDSM0037','否'),(282,'吴晓雷','xiaolei.wu@takeda.com',42,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02051','ze5597','CBU-TJ','MR','Mix','宋利明','E00401','CNCDSM0037','否'),(283,'陈靖宇','jingyu.chen@takeda.com',42,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E02437','du9753','CBU-TJ','MR','Mix','宋利明','E00401','CNCDSM0037','否'),(284,'李树征','Shuzheng.Li@takeda.com',42,1,0,0,1,'2015-06-06 18:25:34',1,'2015-06-06 18:25:34','E03133','rl5645','CBU-TJ','MR','Mix','宋利明','E00401','CNCDSM0037','否'),(285,'杨雪莲','xuelian.yang@takeda.com',42,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00801','kr3757','CBU-TJ','SMR','Mix','宋利明','E00401','CNCDSM0037','否'),(286,'陈亮','liang.chen@takeda.com',42,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00954','we3528','CBU-TJ','SMR','Mix','宋利明','E00401','CNCDSM0037','否'),(287,'武肃','su.wu@takeda.com',43,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00998','ke7624','CBU-TJ','MR','CV','宋雨箬','E00411','CNCDSM0038','否'),(288,'齐跃','yue.qi@takeda.com',43,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01684','zi7542','CBU-TJ','MR','CV','宋雨箬','E00411','CNCDSM0038','否'),(289,'张耕','Geng.Zhang@takeda.com',43,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02368','ok8784','CBU-TJ','MR','CV','宋雨箬','E00411','CNCDSM0038','否'),(290,'邸欣','xin.di@takeda.com',43,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01532','fo9959','CBU-TJ','MR','CV','宋雨箬','E00411','CNCDSM0038','否'),(291,'陈磊','Lei1.Chen@takeda.com',44,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02800','oy8651','CBU-TJ','SMR','Mix','宋雨箬','E00411','CNCDSM0039','否'),(292,'崔柳','liu.cui@takeda.com',38,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00993','ng0603','CBU-TJ','MR','CV','姚媁','E00398','CNCDSM0033','否'),(293,'初露','Lu.Chu@takeda.com',38,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02461','tu5321','CBU-TJ','MR','CV','姚媁','E00398','CNCDSM0033','否'),(294,'谢红霞','Hongxia.Xie@takeda.com',38,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02470','nz6226','CBU-TJ','MR','CV','姚媁','E00398','CNCDSM0033','否'),(295,'刘忠平','zhongping.liu@takeda.com',38,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02697','bq8832','CBU-TJ','MR','CV','姚媁','E00398','CNCDSM0033','否'),(296,'李娆','Rao.Li@takeda.com',38,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02860','hm8682','CBU-TJ','MR','CV','姚媁','E00398','CNCDSM0033','否'),(297,'李冬菊','dongju.li@takeda.com',38,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02910','hc9798','CBU-TJ','MR','Mix','姚媁','E00398','CNCDSM0033','否'),(298,'朱双双','Shuangshuang.Zhu@takeda.com',38,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02903','vu1895','CBU-TJ','MR','Mix','姚媁','E00398','CNCDSM0033','否'),(299,'姚媁','wei.yao@takeda.com',62,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00398','kn5996','CBU-TJ','DSM','Mix','张亮亮','E03082','CNCRSM0005','是'),(300,'宋利明','liming.song@takeda.com',62,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00401','od5832','CBU-TJ','DSM','Mix','张亮亮','E03082','CNCRSM0005','是'),(301,'倪仲维','zhongwei.ni@takeda.com',62,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00405','ww0785','CBU-TJ','DSM','Mix','张亮亮','E03082','CNCRSM0005','是'),(302,'宋雨箬','yuruo.song@takeda.com',62,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00411','ld5900','CBU-TJ','DSM','CV','张亮亮','E03082','CNCRSM0005','是'),(303,'皮轶光','Yiguang.Pi@takeda.com',62,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00412','rm5913','CBU-TJ','DSM','Endo','张亮亮','E03082','CNCRSM0005','是'),(304,'付强','qiang.fu@takeda.com',0,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00423','je9688','CBU-TJ','DSM','','张亮亮','E03082','','是'),(305,'肇伟','Wei1.Zhao@takeda.com',62,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03131','tf2812','CBU-TJ','DSM','Mix','张亮亮','E03082','CNCRSM0005','是'),(306,'辛强','qiang.xin@takeda.com',62,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00410','ns8350','CBU-TJ','RPM','','张亮亮','E03082','CNCRSM0005','否'),(307,'李锐','Rui.Li@takeda.com',62,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03150','yq9338','CBU-TJ','RPM','','张亮亮','E03082','CNCRSM0005','否'),(308,'张业魁','Yekui.Zhang@takeda.com',62,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00402','ba1152','CBU-TJ','SDSM','Mix','张亮亮','E03082','CNCRSM0005','是'),(309,'马丽娅','Liya.Ma@takeda.com',62,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00403','vf3284','CBU-TJ','SDSM','Mix','张亮亮','E03082','CNCRSM0005','是'),(310,'贾莹','ying1.jia@takeda.com',44,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02371','um1479','CBU-TJ','Hospital Specialist','Endo','张业魁','E00402','CNCDSM0039','否'),(311,'王英杰','yingjie.wang@takeda.com',44,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01692','uz2627','CBU-TJ','MR','CV','张业魁','E00402','CNCDSM0039','否'),(312,'邢雪洁','xuejie.xing@takeda.com',44,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01950','wq6707','CBU-TJ','MR','Mix','张业魁','E00402','CNCDSM0039','否'),(313,'刘晓旭','Xiaoxu.Liu@takeda.com',44,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01985','ls2963','CBU-TJ','MR','Mix','张业魁','E00402','CNCDSM0039','否'),(314,'李伟','Wei-1.Li@takeda.com',44,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00419','kv4259','CBU-TJ','SMR','Mix','张业魁','E00402','CNCDSM0039','否'),(315,'高磊','lei.gao@takeda.com',44,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00715','rj4510','CBU-TJ','SMR','Mix','张业魁','E00402','CNCDSM0039','否'),(316,'戚晓国','xiaoguo.qi@takeda.com',44,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00959','BW3923','CBU-TJ','SMR','Mix','张业魁','E00402','CNCDSM0039','否'),(317,'张亮亮','Liangliang.Zhang@takeda.com',57,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03082','cg7714','CBU-TJ','RSM','Mix','左明星','E02494','CNCNSD0001','是'),(318,'李凯3','Kaia.Li@takeda.com',45,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01694','pa7462','CBU-ZJ','Executive Hospital Specialist','Mix','郭群','E00818','CNCDSM0040','否'),(319,'朱张军','zhangjun.zhu@takeda.com',45,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00325','ha3165','CBU-ZJ','Hospital Specialist','Mix','郭群','E00818','CNCDSM0040','否'),(320,'顾晓峰','Xiaofeng.Gu@takeda.com',45,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02958','oc2852','CBU-ZJ','Hospital Specialist','Mix','郭群','E00818','CNCDSM0040','否'),(321,'高鹏','peng.gao@takeda.com',45,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02199','pa8707','CBU-ZJ','MR','Mix','郭群','E00818','CNCDSM0040','否'),(322,'王燕','Yan2.Wang@takeda.com',45,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02297','vi1492','CBU-ZJ','MR','Mix','郭群','E00818','CNCDSM0040','否'),(323,'张欣','xin2.zhang@takeda.com',45,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02353','pn7457','CBU-ZJ','MR','Mix','郭群','E00818','CNCDSM0040','否'),(324,'刘飞','fei1.liu@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02838','gn1276','CBU-ZJ','MR','','郭群','E00818','','否'),(325,'王一涵','Yihan.Wang@takeda.com',45,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03087','yx1726','CBU-ZJ','MR','Mix','郭群','E00818','CNCDSM0040','否'),(326,'张秋实','Qiushi.Zhang@takeda.com',45,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03075','np8406','CBU-ZJ','MR','Mix','郭群','E00818','CNCDSM0040','否'),(327,'施强','qiang.shi@takeda.com',45,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00305','sx7621','CBU-ZJ','SMR','Mix','郭群','E00818','CNCDSM0040','否'),(328,'胡霖','Lin.Hu@takeda.com',45,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03099','we3935','CBU-ZJ','SMR','CV','郭群','E00818','CNCDSM0040','否'),(329,'秦秀芬','xiufen.qin@takeda.com',51,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00336','rg9873','CBU-ZJ','MR','Mix','刘瑜','E00911','CNCDSM0046','否'),(330,'金跃初','yuechy.jin@takeda.com',51,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01749','vf7866','CBU-ZJ','MR','Mix','刘瑜','E00911','CNCDSM0046','否'),(331,'徐晨','chen.xu@takeda.com',51,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02068','hw9638','CBU-ZJ','MR','Mix','刘瑜','E00911','CNCDSM0046','否'),(332,'黄小勇','xiaoyong.huang@takeda.com',51,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02185','tt7394','CBU-ZJ','MR','Mix','刘瑜','E00911','CNCDSM0046','否'),(333,'刘发印','fayin.liu@takeda.com',51,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02649','ct8559','CBU-ZJ','MR','Mix','刘瑜','E00911','CNCDSM0046','否'),(334,'朱玲仙','lingxian.zhu@takeda.com',51,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00982','qw6512','CBU-ZJ','SMR','Mix','刘瑜','E00911','CNCDSM0046','否'),(335,'马发良','faliang.ma@takeda.com',51,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00987','zf9527','CBU-ZJ','SMR','Mix','刘瑜','E00911','CNCDSM0046','否'),(336,'杨俊勇','junyong.yang@takeda.com',51,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01685','xp6684','CBU-ZJ','SMR','Mix','刘瑜','E00911','CNCDSM0046','否'),(337,'杨中平','Zhongping.Yang@takeda.com',49,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02296','pt6901','CBU-ZJ','MR','Mix','曲芳','E02783','CNCDSM0044','否'),(338,'刘光明','Guangming.Liu@takeda.com',49,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02862','he3574','CBU-ZJ','MR','Mix','曲芳','E02783','CNCDSM0044','否'),(339,'仇正刚','Zhenggang.Qiu@takeda.com',49,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02913','ss4337','CBU-ZJ','MR','Mix','曲芳','E02783','CNCDSM0044','否'),(340,'张微微','Weiwei2.Zhang@takeda.com',49,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03168','qn9696','CBU-ZJ','MR','Mix','曲芳','E02783','CNCDSM0044','否'),(341,'熊华伟','huawei.xiong@takeda.com',48,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00375','rv6245','CBU-ZJ','Hospital Specialist','Mix','王云霞','E03154','CNCDSM0043','否'),(342,'马红梅','Hongmei.Ma@takeda.com',48,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02944','ks2404','CBU-ZJ','Hospital Specialist','Mix','王云霞','E03154','CNCDSM0043','否'),(343,'张红珍','hongzhen.zhang@takeda.com',48,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03174','ib6961','CBU-ZJ','Hospital Specialist','Mix','王云霞','E03154','CNCDSM0043','否'),(344,'赵鲁峰','lufeng.zhao@takeda.com',48,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00965','gs5352','CBU-ZJ','MR','Mix','王云霞','E03154','CNCDSM0043','否'),(345,'王亚军','yajun.wang@takeda.com',48,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00765','ae5155','CBU-ZJ','SMR','Mix','王云霞','E03154','CNCDSM0043','否'),(346,'冯现伟','xianwei.feng@takeda.com.cn',48,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00948','qs3611','CBU-ZJ','SMR','Mix','王云霞','E03154','CNCDSM0043','否'),(347,'张杰','jie.zhang@takeda.com',50,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01975','to6575','CBU-ZJ','MR','Mix','袁海英','E02322','CNCDSM0045','否'),(348,'王乾','qian2.wang@takeda.com',50,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02467','oq0348','CBU-ZJ','MR','Mix','袁海英','E02322','CNCDSM0045','否'),(349,'吴佳凤','Jiafeng.Wu@takeda.com',50,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02407','yo4533','CBU-ZJ','MR','Mix','袁海英','E02322','CNCDSM0045','否'),(350,'曾红','Hong.Zeng@takeda.com',50,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03123','va4721','CBU-ZJ','MR','Mix','袁海英','E02322','CNCDSM0045','否'),(351,'杨小杰','xiaojie.yang@takeda.com',50,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00304','en2978','CBU-ZJ','SMR','Mix','袁海英','E02322','CNCDSM0045','否'),(352,'徐伟','wei1.xu@takeda.com',50,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02354','qt3559','CBU-ZJ','SMR','Mix','袁海英','E02322','CNCDSM0045','否'),(353,'鲍芸燕','Yunyan.Bao@takeda.com',46,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02613','xu0262','CBU-ZJ','MR','Mix','张佳宇','E00829','CNCDSM0041','否'),(354,'董佳敏','Jiamin.Dong@takeda.com',46,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02848','cc5409','CBU-ZJ','MR','Mix','张佳宇','E00829','CNCDSM0041','否'),(355,'施芳芳','Fangfang.Shi@takeda.com',46,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03124','hi8747','CBU-ZJ','MR','Mix','张佳宇','E00829','CNCDSM0041','否'),(356,'吴书浩','shuhao.wu@takeda.com',46,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03158','ml2852','CBU-ZJ','MR','Mix','张佳宇','E00829','CNCDSM0041','否'),(357,'吴江东','jiangdong.wu@takeda.com',46,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00988','gi5616','CBU-ZJ','SMR','Mix','张佳宇','E00829','CNCDSM0041','否'),(358,'张笑赫','Xiaohe.Zhang@takeda.com',46,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02403','hx2921','CBU-ZJ','SMR','Mix','张佳宇','E00829','CNCDSM0041','否'),(359,'陈立鸿','Lihong1.Chen@takeda.com',46,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03039','fg1443','CBU-ZJ','SMR','Mix','张佳宇','E00829','CNCDSM0041','否'),(360,'贺小容','Xiaorong.He@takeda.com',47,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02406','im2571','CBU-ZJ','MR','Mix','张玮','E00306','CNCDSM0042','否'),(361,'吴文','Wen.Wu@takeda.com',47,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02810','sp0251','CBU-ZJ','MR','Mix','张玮','E00306','CNCDSM0042','否'),(362,'邓凌峰','Lingfeng.Deng@takeda.com',47,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02823','qe2403','CBU-ZJ','MR','Mix','张玮','E00306','CNCDSM0042','否'),(363,'谭飞','Fei.Tan@takeda.com',47,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02825','ay3878','CBU-ZJ','MR','Mix','张玮','E00306','CNCDSM0042','否'),(364,'楼菲菲','feifei.lou@takeda.com',47,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02906','md9543','CBU-ZJ','MR','Mix','张玮','E00306','CNCDSM0042','否'),(365,'张玮','wei.zhang@takeda.com',63,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00306','mi7149','CBU-ZJ','DSM','Mix','章玺','E00299','CNCRSM0006','是'),(366,'郭群','qun.guo@takeda.com',63,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00818','om1223','CBU-ZJ','DSM','Mix','章玺','E00299','CNCRSM0006','是'),(367,'刘瑜','yu.liu@takeda.com',63,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00911','em2567','CBU-ZJ','DSM','Mix','章玺','E00299','CNCRSM0006','是'),(368,'袁海英','Haiying.Yuan@takeda.com',63,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02322','py6843','CBU-ZJ','DSM','Mix','章玺','E00299','CNCRSM0006','是'),(369,'曲芳','fang.qu@takeda.com',63,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02783','mn6823','CBU-ZJ','DSM','Mix','章玺','E00299','CNCRSM0006','是'),(370,'张佳宇','jiayu.zhang@takeda.com',0,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00829','oc3553','CBU-ZJ','DSM(Acting)','Mix','章玺','E00299','','是'),(371,'翁丽慧','lihui.weng@takeda.com',63,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00312','vm9260','CBU-ZJ','RPM','','章玺','E00299','CNCRSM0006','否'),(372,'王云霞','Yunxia1.Wang@takeda.com',63,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03154','yz7962','CBU-ZJ','SDSM','Mix','章玺','E00299','CNCRSM0006','是'),(373,'章玺','Xi.Zhang@takeda.com',57,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00299','pd7581','CBU-ZJ','RSM','Mix','左明星','E02494','CNCNSD0001','是'),(374,'李飞','fei.li@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00613','oz7848','COE-MSFE','Sales Data Analyst','','刘婷','E00089','','否'),(375,'丁焱雯','Even.Ding@takeda.com',241,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01072','db4483','COE-MSFE','Sales Data Analyst','','刘婷','E00089','SFE-HO-0004','否'),(376,'吕扬','tiffany.lv@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01578','rk6369','COE-MSFE','Sales Data Analyst','','刘婷','E00089','','否'),(377,'张颖','yingsfe.zhang@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00471','mi6403','COE-MSFE','Sr. SFE Analysis Supervisor','','刘婷','E00089','','否'),(378,'周婷婷','tingting.zhou@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00931','pp9462','COE-MSFE','COE Business Assistant','','卢安邦','E00001','','否'),(379,'虞娟娟','Kitty.Yu@takeda.com',242,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00067','nm4228','COE-MSFE','Sr. Marketing Effectiveness Manager','','卢安邦','E00001','SFE-HO-0011','是'),(380,'杨勍','Qing.Yang@takeda.com',242,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00092','fa6401','COE-MSFE','Sr. SFE & Sales System Execution Manager','','卢安邦','E00001','SFE-HO-0011','是'),(381,'刘婷','Ting.Liu@takeda.com',242,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00089','bv5614','COE-MSFE','Sr. SFE Manager','','卢安邦','E00001','SFE-HO-0011','是'),(382,'王伟','Shally.Wang@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00516','un4717','COE-MSFE','Project Supervisor','','杨勍','E00092','','否'),(383,'鲍文洁','wenjie.bao@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02191','ga7981','COE-MSFE','Sr. Sales System Analyst','','杨勍','E00092','','否'),(384,'赵璨','can.zhao@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03025','er3437','COE-MSFE','Market Research Analyst','','虞娟娟','E00067','','否'),(385,'姚远','Yuan.Yao@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02853','aw5423','COE-MSFE','Market Research Manager','','虞娟娟','E00067','','否'),(386,'王蕾','leia.wang@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01666','sm8882','COE-MSFE','New Product Planning Analyst','','虞娟娟','E00067','','否'),(387,'贾茹','ru.jia@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02801','ek4835','COE-MSFE','New Product Planning Associate Manager','','虞娟娟','E00067','','否'),(388,'崔建华','grace.cui@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02091','aa2793','COE-MSFE','Sr. Market Data Analyst','','虞娟娟','E00067','','否'),(389,'曹晓丹','xiaodan.Cao@takeda.com',65,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03020','di1949','COE-Sales Training','Associate Sales Training Manager','','黄登原','E00091','CNGBUD0001','否'),(390,'姚青','teresa.yao@takeda.com',149,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00805','id3847','COE-Sales Training','Associate Training Manager','','黄登原','E00091','CNOBUD0001','否'),(391,'涂煌初','Huangchu.Tu@takeda.com',149,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00980','jy8770','COE-Sales Training','Sales Training Manager','','黄登原','E00091','CNOBUD0001','否'),(392,'王川','Cherry.Wang@takeda.com',149,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00094','mu5189','COE-Sales Training','Sales Training Manager','','黄登原','E00091','CNOBUD0001','否'),(393,'莫烨','ye.mo@takeda.com',65,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02183','qf7214','COE-Sales Training','Sales Training Manager','','黄登原','E00091','CNGBUD0001','否'),(394,'石银燕','yinyan.shi@takeda.com',65,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00639','as4763','COE-Sales Training','Sales Training Manager','','黄登原','E00091','CNGBUD0001','否'),(395,'杨融','rong.yang@takeda.com',149,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03060','pu0473','COE-Sales Training','Sales Training Manager','','黄登原','E00091','CNOBUD0001','否'),(396,'韩达','Da.Han@takeda.com',65,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02883','ll5664','COE-Sales Training','Sr. Training Consultant','','黄登原','E00091','CNGBUD0001','否'),(397,'朱元东','Andy.Zhu1@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03044','my0642','COE-Sales Training','Associate Sales Training Manager','','贾艳杰','E02764','','否'),(398,'董春玲','chunling.dong@takeda.com',149,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00751','wg4373','COE-Sales Training','Associate Training Manager','','贾艳杰','E02764','CNOBUD0001','否'),(399,'杨晶晶','jingjing.yang@takeda.com',189,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00921','yf7772','COE-Sales Training','Sales Training Manager','','贾艳杰','E02764','CNRBUD0001','否'),(400,'杜伟涛','weitao.du@takeda.com',5,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01967','fz4026','COE-Sales Training','Sales Training Manager','','贾艳杰','E02764','CNCBUD0001','否'),(401,'冯雨','yu.feng@takeda.com',5,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02217','rw6501','COE-Sales Training','Sales Training Manager','','贾艳杰','E02764','CNCBUD0001','否'),(402,'吴刘军','Liujun.Wu@takeda.com',5,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02347','ui0333','COE-Sales Training','Sales Training Manager','','贾艳杰','E02764','CNCBUD0001','否'),(403,'贾艳杰','Yanjie.Jia@takeda.com',5,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02764','ff1522','COE-Sales Training','Sr. Sales Training Manager','','卢安邦','E00001','CNCBUD0001','是'),(404,'朱莉','Li.Zhu@takeda.com',242,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02763','mt1207','COE-Sales Training','Sr. Sales Training Manager','','卢安邦','E00001','SFE-HO-0011','是'),(405,'黄登原','Samuel.Huang@takeda.com',149,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00091','es3322','COE-Sales Training','Sr. Sales Training Manager(OBU)','','卢安邦','E00001','CNOBUD0001','是'),(406,'郭建昕','待定',242,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03037','ia0374','COE-Sales Training','Sales Training Manager','','朱莉','E02763','SFE-HO-0011','否'),(407,'李子木','Lily.Li@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00036','gc7339','COE-Sales Training','Training Assistant','','朱莉','E02763','','否'),(408,'张宁','Ning.Zhang@takeda.com',65,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00352','sw0745','GBU','NSD','','王卫','E01821','CNGBUD0001','是'),(409,'张凯军','Kaijun.Zhang@takeda.com',65,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00250','tr3880','GBU','RSD','','王卫','E01821','CNGBUD0001','是'),(410,'潘海风','haifeng.pan@takeda.com',65,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01577','ng9982','GBU','RSD','','王卫','E01821','CNGBUD0001','是'),(411,'马琪','qi.ma@takeda.com',87,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00265','ha4688','GBU-BJ','Hospital Specialist','Panto IV','程相楠','E02412','CNGDSM0022','否'),(412,'佟铃','ling.tong@takeda.com',87,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01527','qn3982','GBU-BJ','MR','Panto IV','程相楠','E02412','CNGDSM0022','否'),(413,'徐延峰','yanfeng.xu@takeda.com',87,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02685','au1671','GBU-BJ','MR','Panto IV','程相楠','E02412','CNGDSM0022','否'),(414,'杜真','zhen.du@takeda.com',87,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01363','lv5363','GBU-BJ','SMR','Panto IV','程相楠','E02412','CNGDSM0022','否'),(415,'裴嘉宁','jianing.pei@takeda.com',87,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01389','ra8468','GBU-BJ','SMR','Panto IV','程相楠','E02412','CNGDSM0022','否'),(416,'杭艳','yan.hang@takeda.com',87,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01972','xk0214','GBU-BJ','SMR','Panto IV','程相楠','E02412','CNGDSM0022','否'),(417,'陈丽','Li3.Chen@takeda.com',88,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03003','rf6640','GBU-BJ','Hospital Specialist','Lansoprazole','丁香','E02008','CNGDSM0023','否'),(418,'于红苗','hongmiao.yu@takeda.com',88,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02591','my5670','GBU-BJ','MR','Lansoprazole','丁香','E02008','CNGDSM0023','否'),(419,'李杨','yang1.li@takeda.com',88,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02747','wo5967','GBU-BJ','MR','Lansoprazole','丁香','E02008','CNGDSM0023','否'),(420,'张蕾','Lei1.Zhang@takeda.com',88,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02756','kd1595','GBU-BJ','MR','Lansoprazole','丁香','E02008','CNGDSM0023','否'),(421,'齐亭亭','Tingting.Qi@takeda.com',88,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02890','cp6369','GBU-BJ','MR','Lansoprazole','丁香','E02008','CNGDSM0023','否'),(422,'王逢逢','fengfeng.wang@takeda.com',88,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03011','ll3673','GBU-BJ','MR','Lansoprazole','丁香','E02008','CNGDSM0023','否'),(423,'谭婧','Jing.Tan@takeda.com',89,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02815','cw5772','GBU-BJ','MR','Lansoprazole','高永杰','E02102','CNGDSM0024','否'),(424,'张兵','Bing.Zhang@takeda.com',89,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02878','wn0672','GBU-BJ','MR','Lansoprazole','高永杰','E02102','CNGDSM0024','否'),(425,'崔静桥','Jingqiao.Cui@takeda.com',89,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02233','cr0892','GBU-BJ','SMR','Panto IV + Oral Mix','高永杰','E02102','CNGDSM0024','否'),(426,'赵至谦','Zhiqian.Zhao@takeda.com',89,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02232','rf3804','GBU-BJ','SMR','Panto IV + Oral Mix','高永杰','E02102','CNGDSM0024','否'),(427,'张秀婷','xiuting.zhang@takeda.com',90,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02337','sr5913','GBU-BJ','MR','Lansoprazole','姜蕊','E02671','CNGDSM0025','否'),(428,'高爽月','Shuangyue.Gao@takeda.com',90,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02812','mv0923','GBU-BJ','MR','Lansoprazole','姜蕊','E02671','CNGDSM0025','否'),(429,'仇飞','Fei.Qiu@takeda.com',90,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02952','an0980','GBU-BJ','MR','Lansoprazole','姜蕊','E02671','CNGDSM0025','否'),(430,'丁啓玲','Qiling.Ding@takeda.com',90,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02961','fu6885','GBU-BJ','MR','Lansoprazole','姜蕊','E02671','CNGDSM0025','否'),(431,'李薇','wei1.li@takeda.com',90,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02824','xi6810','GBU-BJ','SMR','Lansoprazole','姜蕊','E02671','CNGDSM0025','否'),(432,'石秀琴','Xiuqin.Shi@takeda.com',91,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02446','jd8217','GBU-BJ','MR','Panto IV','李丽','E01219','CNGDSM0026','否'),(433,'洪秋娟','qiujuan.hong@takeda.com',91,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01446','bi4772','GBU-BJ','SMR','Panto IV','李丽','E01219','CNGDSM0026','否'),(434,'陈爱莲','ailian.chen@takeda.com',91,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01454','ae7772','GBU-BJ','SMR','Panto IV','李丽','E01219','CNGDSM0026','否'),(435,'单冶','ye.shan@takeda.com',91,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01474','pk3664','GBU-BJ','SMR','Panto IV','李丽','E01219','CNGDSM0026','否'),(436,'宁帅','shuai.ning@takeda.com',91,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01489','be6658','GBU-BJ','SMR','Panto IV','李丽','E01219','CNGDSM0026','否'),(437,'倪波波','bobo.ni@takeda.com',91,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02016','dw8648','GBU-BJ','SMR','Panto IV','李丽','E01219','CNGDSM0026','否'),(438,'刘玲','Ling-1.Liu@takeda.com',91,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02057','ax7753','GBU-BJ','SMR','Panto IV','李丽','E01219','CNGDSM0026','否'),(439,'吴明军','Mingjun.Wu@takeda.com',92,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02536','mr1552','GBU-BJ','MR','Panto IV','李雪艳','E01345','CNGDSM0027','否'),(440,'王昀','kiki.wang@takeda.com',92,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01194','ny4713','GBU-BJ','SMR','Panto IV','李雪艳','E01345','CNGDSM0027','否'),(441,'张丽丽','lili.zhang@takeda.com',92,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01424','xb3944','GBU-BJ','SMR','Panto IV','李雪艳','E01345','CNGDSM0027','否'),(442,'李建新','jianxin.li@takeda.com',92,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01632','ab7808','GBU-BJ','SMR','Panto IV','李雪艳','E01345','CNGDSM0027','否'),(443,'陈思阳','Siyang.Chen@takeda.com',92,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02435','sr6741','GBU-BJ','SMR','Panto IV','李雪艳','E01345','CNGDSM0027','否'),(444,'哈敬强','Jingqiang.Ha@takeda.com',92,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03016','mm0469','GBU-BJ','SMR','Panto IV','李雪艳','E01345','CNGDSM0027','否'),(445,'付静男','jingnan.fu@takeda.com',93,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02010','ve7554','GBU-BJ','MR','Panto Oral','张驰','E00247','CNGDSM0028','否'),(446,'刘宁宁','Ningning.Liu@takeda.com',93,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02414','vd9424','GBU-BJ','MR','Panto Oral','张驰','E00247','CNGDSM0028','否'),(447,'郭领群','lingqun.guo@takeda.com',93,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01177','ks1576','GBU-BJ','SMR','Panto Oral','张驰','E00247','CNGDSM0028','否'),(448,'何云飞','yunfei.he@takeda.com',93,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01225','wi7942','GBU-BJ','SMR','Panto Oral','张驰','E00247','CNGDSM0028','否'),(449,'张小伟','Xiaowei.Zhang@takeda.com',93,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01613','xn0882','GBU-BJ','SMR','Panto Oral','张驰','E00247','CNGDSM0028','否'),(450,'张茉','mo.zhang@takeda.com',0,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01827','oj7946','GBU-BJ','SMR','','张驰','E00247','','否'),(451,'张珊珊','Shanshan.Zhang@takeda.com',135,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00473','oj4319','GBU-BJ','RSM','','张凯军','E00250','CNGRSD0002','是'),(452,'张驰','chi.zhang@takeda.com',141,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00247','qk4590','GBU-BJ','DSM','Panto Oral','张珊珊','E00473','CNGRSM0005','是'),(453,'丁香','xiang.ding@takeda.com',141,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02008','bv5861','GBU-BJ','DSM','Lansoprazole','张珊珊','E00473','CNGRSM0005','是'),(454,'高永杰','yongjie.gao@takeda.com',141,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02102','tj2380','GBU-BJ','DSM','Panto IV + Oral Mix','张珊珊','E00473','CNGRSM0005','是'),(455,'程相楠','Xiangnan.Cheng@takeda.com',141,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02412','lk5715','GBU-BJ','DSM','Panto IV','张珊珊','E00473','CNGRSM0005','是'),(456,'姜蕊','Rui.Jiang@takeda.com',141,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02671','xd0267','GBU-BJ','DSM','Lansoprazole','张珊珊','E00473','CNGRSM0005','是'),(457,'李丽','lilly.li@takeda.com',141,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01219','af0435','GBU-BJ','SDSM','Panto IV','张珊珊','E00473','CNGRSM0005','是'),(458,'李雪艳','xueyan.li@takeda.com',141,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01345','fv2719','GBU-BJ','SDSM','Panto IV','张珊珊','E00473','CNGRSM0005','是'),(459,'李冬严','Dongyan.Li@takeda.com',141,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00258','qa4637','GBU-BJ','SRPM','','张珊珊','E00473','CNGRSM0005','否'),(460,'姜清香','qingxiang.jiang@takeda.com',108,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01139','dj1636','GBU-FJ','Executive Hospital Specialist','Panto IV','蔡定健','E01138','CNGDSM0043','否'),(461,'周欣婷','xinting.zhou@takeda.com',108,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01140','us1680','GBU-FJ','Executive Hospital Specialist','Panto IV','蔡定健','E01138','CNGDSM0043','否'),(462,'郭炜','wei.guo@takeda.com',108,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01141','gr1351','GBU-FJ','Executive Hospital Specialist','Panto IV','蔡定健','E01138','CNGDSM0043','否'),(463,'吴云辉','yunhui.wu@takeda.com',108,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01846','tp1886','GBU-FJ','MR','Panto IV','蔡定健','E01138','CNGDSM0043','否'),(464,'陈林花','Linhua.Chen@takeda.com',108,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02899','sm0458','GBU-FJ','MR','Panto IV','蔡定健','E01138','CNGDSM0043','否'),(465,'张百忍','baireng.zhang@takeda.com',109,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01622','co3935','GBU-FJ','MR','Panto IV','陈茂林','E01290','CNGDSM0044','否'),(466,'缪少丽','shaoli.miao@takeda.com',109,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02749','pi8794','GBU-FJ','MR','Panto IV','陈茂林','E01290','CNGDSM0044','否'),(467,'曾丹','dan.zeng@takeda.com',109,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01620','qf6556','GBU-FJ','SMR','Panto IV','陈茂林','E01290','CNGDSM0044','否'),(468,'耿安霞','Anxia.Geng@takeda.com',109,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01621','nq4484','GBU-FJ','SMR','Panto IV','陈茂林','E01290','CNGDSM0044','否'),(469,'宋斌','bin.song@takeda.com',109,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02178','pu4213','GBU-FJ','SMR','Panto IV','陈茂林','E01290','CNGDSM0044','否'),(470,'苏尚丽','shangli.su@takeda.com',110,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00338','dy8114','GBU-FJ','Hospital Specialist','Lansoprazole','谌娟娟','E00624','CNGDSM0045','否'),(471,'蒋锦旺','jinwang.jiang@takeda.com',110,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00784','jb0087','GBU-FJ','Hospital Specialist','Lansoprazole','谌娟娟','E00624','CNGDSM0045','否'),(472,'秦静','jing.qin@takeda.com',110,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01895','le4815','GBU-FJ','Hospital Specialist','Lansoprazole','谌娟娟','E00624','CNGDSM0045','否'),(473,'陈涵','Han.Chen@takeda.com',110,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02806','xi9361','GBU-FJ','MR','Lansoprazole','谌娟娟','E00624','CNGDSM0045','否'),(474,'许良菊','liangju.xu@takeda.com',110,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00599','jd9259','GBU-FJ','SMR','Lansoprazole','谌娟娟','E00624','CNGDSM0045','否'),(475,'宋健伟','jianwei.song@takeda.com',110,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01966','tj0626','GBU-FJ','SMR','Lansoprazole','谌娟娟','E00624','CNGDSM0045','否'),(476,'许晶','Jing3.Xu@takeda.com',112,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01292','zc6875','GBU-FJ','Hospital Specialist','Panto IV','方毅贤','E00773','CNGDSM0047','否'),(477,'吴文明','wenming.wu@takeda.com',112,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01982','jr1251','GBU-FJ','Hospital Specialist','Panto IV','方毅贤','E00773','CNGDSM0047','否'),(478,'陈自敏','zimin.chen@takeda.com',112,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01259','eb8511','GBU-FJ','MR','Panto IV','方毅贤','E00773','CNGDSM0047','否'),(479,'赖瑞兰','ruilan.lai@takeda.com',112,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01770','la0760','GBU-FJ','MR','Panto IV','方毅贤','E00773','CNGDSM0047','否'),(480,'叶剑华','jianhua.ye@takeda.com',112,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01897','tb8863','GBU-FJ','MR','Panto IV','方毅贤','E00773','CNGDSM0047','否'),(481,'冯德草','decao.feng@takeda.com',112,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01142','xa4335','GBU-FJ','SMR','Panto IV','方毅贤','E00773','CNGDSM0047','否'),(482,'魏晓琴','xiaoqin.wei@takeda.com',112,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01357','bx8834','GBU-FJ','SMR','Panto IV','方毅贤','E00773','CNGDSM0047','否'),(483,'陈茂林','maolin.chen@takeda.com',145,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01290','ij6264','GBU-FJ','DSM','Panto IV','黄加福','E00363','CNGRSM0009','是'),(484,'薛锴华','kaihua.xue@takeda.com',145,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00598','fj5755','GBU-FJ','DSM','Panto IV','黄加福','E00363','CNGRSM0009','是'),(485,'潘晓荣','xiaorong.pan@takeda.com',145,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00367','zn7651','GBU-FJ','DSM','Panto Oral','黄加福','E00363','CNGRSM0009','是'),(486,'黄毅琳','yilin.huang@takeda.com',145,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00452','dj5389','GBU-FJ','DSM','Panto IV + Oral Mix','黄加福','E00363','CNGRSM0009','是'),(487,'方毅贤','yixian.fang@takeda.com',145,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00773','zv7570','GBU-FJ','DSM','Panto IV','黄加福','E00363','CNGRSM0009','是'),(488,'杨娇','jiao.yang2@takeda.com',145,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02044','nt8884','GBU-FJ','RPM','','黄加福','E00363','CNGRSM0009','否'),(489,'潘清','qing.pan@takeda.com',145,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02331','pj6450','GBU-FJ','RPM','','黄加福','E00363','CNGRSM0009','否'),(490,'蔡定健','dingjian.cai@takeda.com',145,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01138','pq7573','GBU-FJ','SDSM','Panto IV','黄加福','E00363','CNGRSM0009','是'),(491,'颜虹','Hong.Yan@takeda.com',145,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00359','fg3143','GBU-FJ','SDSM','Panto IV','黄加福','E00363','CNGRSM0009','是'),(492,'谌娟娟','juanjuan.chen@takeda.com',145,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00624','ff7964','GBU-FJ','SDSM','Lansoprazole','黄加福','E00363','CNGRSM0009','是'),(493,'孙爱慧','aihui.sun@takeda.com',113,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01727','fs8211','GBU-FJ','MR','Panto Oral','黄毅琳','E00452','CNGDSM0048','否'),(494,'杨超阳','chaoyang.yang@takeda.com',113,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01880','zx5615','GBU-FJ','MR','Panto Oral','黄毅琳','E00452','CNGDSM0048','否'),(495,'刘钊','zhao.liu@takeda.com',113,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01309','ew2433','GBU-FJ','SMR','Panto Oral','黄毅琳','E00452','CNGDSM0048','否'),(496,'陈景龙','jinglong.chen@takeda.com',113,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01773','fa1858','GBU-FJ','SMR','Panto IV + Oral Mix','黄毅琳','E00452','CNGDSM0048','否'),(497,'邓程伟','chengwei.deng@takeda.com',111,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00346','fj1934','GBU-FJ','Executive Hospital Specialist','Lansoprazole','空缺','','CNGDSM0046','否'),(498,'叶小兰','xiaolan.ye@takeda.com',111,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01853','cf1379','GBU-FJ','MR','Lansoprazole','空缺','','CNGDSM0046','否'),(499,'曾水琴','Shuiqin.Zeng@takeda.com',111,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02664','yv7733','GBU-FJ','MR','Lansoprazole','空缺','','CNGDSM0046','否'),(500,'张晓江','xiaojiang.zhang@takeda.com',111,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01811','rh1313','GBU-FJ','SMR','Lansoprazole','空缺','','CNGDSM0046','否'),(501,'洪志雄','Zhixiong.Hong@takeda.com',111,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02201','vg1711','GBU-FJ','SMR','Lansoprazole','空缺','','CNGDSM0046','否'),(502,'戴少容','shaorong.dai@takeda.com',114,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01355','oc8711','GBU-FJ','MR','Panto Oral','潘晓荣','E00367','CNGDSM0049','否'),(503,'虞发炳','fabing.yu@takeda.com',114,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01849','xd8421','GBU-FJ','MR','Panto Oral','潘晓荣','E00367','CNGDSM0049','否'),(504,'高达宇','dayu.gao@takeda.com',114,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02192','wm0404','GBU-FJ','MR','Panto Oral','潘晓荣','E00367','CNGDSM0049','否'),(505,'陈巧媚','Qiaomei.Chen@takeda.com',114,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02318','fb4844','GBU-FJ','MR','Panto Oral','潘晓荣','E00367','CNGDSM0049','否'),(506,'王宝生','Baosheng.Wang@takeda.com',114,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03120','cx7896','GBU-FJ','MR','Panto Oral','潘晓荣','E00367','CNGDSM0049','否'),(507,'谢通','tong.xie@takeda.com',114,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01782','xg2842','GBU-FJ','SMR','Panto Oral','潘晓荣','E00367','CNGDSM0049','否'),(508,'彭丽燕','liyan.peng@takeda.com',115,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01285','rb1872','GBU-FJ','Hospital Specialist','Panto IV','薛锴华','E00598','CNGDSM0050','否'),(509,'汪桂芳','Guifang.Wang@takeda.com',115,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01479','lk8288','GBU-FJ','Hospital Specialist','Panto IV','薛锴华','E00598','CNGDSM0050','否'),(510,'沈俊艺','junyi.shen@takeda.com',115,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02387','ts6442','GBU-FJ','Hospital Specialist','Panto IV','薛锴华','E00598','CNGDSM0050','否'),(511,'陈明英','mingying.chen@takeda.com',115,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02383','zw1605','GBU-FJ','Hospital Specialist','Panto IV','薛锴华','E00598','CNGDSM0050','否'),(512,'杨阳1','Yang.Yang@takeda.com',115,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01342','qb5589','GBU-FJ','MR','Panto IV','薛锴华','E00598','CNGDSM0050','否'),(513,'金军伟','junwei.jin@takeda.com',115,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01300','uy2465','GBU-FJ','SMR','Panto IV','薛锴华','E00598','CNGDSM0050','否'),(514,'马锦东','jindong.ma@takeda.com',115,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01399','as5786','GBU-FJ','SMR','Panto IV','薛锴华','E00598','CNGDSM0050','否'),(515,'赵晋方','Jinfang.Zhao@takeda.com',116,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02677','ye5572','GBU-FJ','Executive Hospital Specialist','Panto IV','颜虹','E00359','CNGDSM0051','否'),(516,'李学文','xuewen.li@takeda.com',116,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01625','zs3652','GBU-FJ','MR','Panto IV','颜虹','E00359','CNGDSM0051','否'),(517,'叶琴','qin.ye@takeda.com',116,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01825','wu5319','GBU-FJ','MR','Panto IV','颜虹','E00359','CNGDSM0051','否'),(518,'陈建旗','jianqi.chen@takeda.com',116,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01925','pf5254','GBU-FJ','MR','Panto IV','颜虹','E00359','CNGDSM0051','否'),(519,'何燕霞','Yanxia.He@takeda.com',116,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02576','on0782','GBU-FJ','MR','Panto IV','颜虹','E00359','CNGDSM0051','否'),(520,'张莹','Ying3.Zhang@takeda.com',116,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02916','bt1261','GBU-FJ','MR','Panto IV','颜虹','E00359','CNGDSM0051','否'),(521,'陈恩张','Enzhang.Chen@takeda.com',116,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01604','ai7766','GBU-FJ','SMR','Panto IV','颜虹','E00359','CNGDSM0051','否'),(522,'黄加福','Jiafu.Huang@takeda.com',136,1,1,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E00363','gb7029','GBU-FJ','RSM','','张宁','E00352','CNGRSD0003','是'),(523,'陈烁冰','Shuobing.Chen@takeda.com',117,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02464','zt7537','GBU-GZ','MR','Panto Oral','邓丽军','E00366','CNGDSM0052','否'),(524,'陈星茹','Xingru.Chen@takeda.com',117,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02560','ve0558','GBU-GZ','MR','Oral Mix','邓丽军','E00366','CNGDSM0052','否'),(525,'张虹','Hong.Zhang@takeda.com',117,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02572','gd0376','GBU-GZ','MR','Panto Oral','邓丽军','E00366','CNGDSM0052','否'),(526,'黄腾达','Tengda.Huang@takeda.com',117,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E02939','hz6371','GBU-GZ','MR','Panto Oral','邓丽军','E00366','CNGDSM0052','否'),(527,'黄露敏','lumin.huang@takeda.com',117,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E03140','us8550','GBU-GZ','MR','Oral Mix','邓丽军','E00366','CNGDSM0052','否'),(528,'刘殷玉','Yinyu.Liu@takeda.com',117,1,0,0,1,'2015-06-06 18:25:35',1,'2015-06-06 18:25:35','E01348','oz1602','GBU-GZ','SMR','Oral Mix','邓丽军','E00366','CNGDSM0052','否'),(529,'王国懿','Guoyi.Wang@takeda.com',119,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02518','rj9753','GBU-GZ','Hospital Specialist','Panto IV','何廷隆','E02004','CNGDSM0054','否'),(530,'黄家胤','jiayin.huang@takeda.com',119,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02208','se7611','GBU-GZ','MR','Panto IV + Oral Mix','何廷隆','E02004','CNGDSM0054','否'),(531,'陈华妹','huamei.chen@takeda.com',119,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02212','jr3845','GBU-GZ','MR','Panto IV + Oral Mix','何廷隆','E02004','CNGDSM0054','否'),(532,'邓宏杰','Hongjie.Deng@takeda.com',119,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02304','li0327','GBU-GZ','MR','Panto IV + Oral Mix','何廷隆','E02004','CNGDSM0054','否'),(533,'杨威','wei1.yang@takeda.com',119,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02856','zp1204','GBU-GZ','MR','Panto IV','何廷隆','E02004','CNGDSM0054','否'),(534,'周婷','Ting.Zhou2@takeda.com',119,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01818','ft5398','GBU-GZ','SMR','Panto IV','何廷隆','E02004','CNGDSM0054','否'),(535,'黄泽建','zejian.huang@takeda.com',119,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02854','tb0923','GBU-GZ','SMR','Panto IV','何廷隆','E02004','CNGDSM0054','否'),(536,'张传强','Chuanqiang.Zhang@takeda.com',119,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03067','hm5634','GBU-GZ','SMR','Panto IV','何廷隆','E02004','CNGDSM0054','否'),(537,'吴浩荣','haorong.wu@takeda.com',118,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01315','of9968','GBU-GZ','Hospital Specialist','Panto IV','空缺','','CNGDSM0053','否'),(538,'张昌泉','changquan.zhang@takeda.com',118,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E00727','pz0851','GBU-GZ','MR','Panto IV','空缺','','CNGDSM0053','否'),(539,'陈玓','Di1.Chen@takeda.com',118,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02558','at0206','GBU-GZ','MR','Panto IV','空缺','','CNGDSM0053','否'),(540,'刘丽娟','Lijuan.Liu@takeda.com',118,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02660','xg0312','GBU-GZ','MR','Panto IV + Oral Mix','空缺','','CNGDSM0053','否'),(541,'徐晓辉','xiaohui.xu@takeda.com',118,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01605','pz1673','GBU-GZ','SMR','Panto IV','空缺','','CNGDSM0053','否'),(542,'刘灵','Ling.Liu@takeda.com',146,1,1,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01214','be1915','GBU-GZ','DSM','Oral Mix','刘建华','E00354','CNGRSM0010','是'),(543,'邓丽军','Lijun.Deng@takeda.com',146,1,1,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E00366','wf3321','GBU-GZ','DSM','Oral Mix','刘建华','E00354','CNGRSM0010','是'),(544,'周文刚','wengang.zhou@takeda.com',146,1,1,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E00451','dh1619','GBU-GZ','DSM','Panto IV + Oral Mix','刘建华','E00354','CNGRSM0010','是'),(545,'游琼河','Qionghe.You@takeda.com',146,1,1,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E00365','nn4335','GBU-GZ','DSM','Panto IV','刘建华','E00354','CNGRSM0010','是'),(546,'祝丽清','Liqing.Zhu@takeda.com',146,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02425','xz1760','GBU-GZ','RPM','','刘建华','E00354','CNGRSM0010','否'),(547,'杨亿','yi.yang@takeda.com',146,1,1,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01571','wk9495','GBU-GZ','SDSM','Panto IV + Oral Mix','刘建华','E00354','CNGRSM0010','是'),(548,'何廷隆','tinglong.he@takeda.com',146,1,1,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02004','wo8592','GBU-GZ','SDSM','Panto IV + Oral Mix','刘建华','E00354','CNGRSM0010','是'),(549,'陈思明','siming.Chen@takeda.com',146,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03081','gl2369','GBU-GZ','SRPM','','刘建华','E00354','CNGRSM0010','否'),(550,'孙云青','yunqing.sun@takeda.com',120,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01186','gc0277','GBU-GZ','MR','Panto Oral','刘灵','E01214','CNGDSM0055','否'),(551,'陈锦松','jinsong.chen@takeda.com',120,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01273','rj6852','GBU-GZ','MR','Panto Oral','刘灵','E01214','CNGDSM0055','否'),(552,'李琴琴','qinqin.li@takeda.com',120,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01519','rn9343','GBU-GZ','MR','Oral Mix','刘灵','E01214','CNGDSM0055','否'),(553,'林伦盛','Lunsheng.Lin@takeda.com',120,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02357','pn5492','GBU-GZ','MR','Panto Oral','刘灵','E01214','CNGDSM0055','否'),(554,'陈少江','shaojiang.chen@takeda.com',120,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02717','ed0299','GBU-GZ','MR','Panto Oral','刘灵','E01214','CNGDSM0055','否'),(555,'周伯达','boda.zhou@takeda.com',121,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01269','ao2542','GBU-GZ','Hospital Specialist','Panto IV','杨亿','E01571','CNGDSM0056','否'),(556,'胡敏','min.hu@takeda.com',121,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01844','ix5444','GBU-GZ','Hospital Specialist','Panto IV','杨亿','E01571','CNGDSM0056','否'),(557,'严恒','heng.yan@takeda.com',121,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01628','qg9824','GBU-GZ','SMR','Panto IV','杨亿','E01571','CNGDSM0056','否'),(558,'刘杰','jie.liu@takeda.com',121,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01786','gi1608','GBU-GZ','SMR','Panto IV','杨亿','E01571','CNGDSM0056','否'),(559,'吴霖霖','linlin.wu@takeda.com',121,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02186','ol3346','GBU-GZ','SMR','Panto IV','杨亿','E01571','CNGDSM0056','否'),(560,'姚明川','mingchuan.yao@takeda.com',121,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03034','wc8566','GBU-GZ','SMR','Panto IV + Oral Mix','杨亿','E01571','CNGDSM0056','否'),(561,'于涛','tao.yu@takeda.com',122,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01576','rk0973','GBU-GZ','Hospital Specialist','Panto IV','游琼河','E00365','CNGDSM0057','否'),(562,'杨军','Jun.Yang@takeda.com',122,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02409','az1285','GBU-GZ','MR','Panto IV','游琼河','E00365','CNGDSM0057','否'),(563,'罗彦','Yan.Luo@takeda.com',122,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02458','ot4335','GBU-GZ','MR','Panto IV','游琼河','E00365','CNGDSM0057','否'),(564,'梁亮','Liang.Liang@takeda.com',122,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02428','gc1772','GBU-GZ','MR','Panto IV','游琼河','E00365','CNGDSM0057','否'),(565,'陈红','hong.chen@takeda.com',122,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E00763','nl7818','GBU-GZ','SMR','Panto IV','游琼河','E00365','CNGDSM0057','否'),(566,'刘建华','Jianhua.Liu@takeda.com',136,1,1,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E00354','ix4869','GBU-GZ','SRSM','','张宁','E00352','CNGRSD0003','是'),(567,'陈冬梅','dongmei.chen@takeda.com',123,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01334','cr9318','GBU-GZ','MR','Lansoprazole','周文刚','E00451','CNGDSM0058','否'),(568,'李海涛','Haitao.Li@takeda.com',123,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02419','qj4848','GBU-GZ','MR','Panto IV + Oral Mix','周文刚','E00451','CNGDSM0058','否'),(569,'陈鹏','Peng.Chen@takeda.com',123,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02616','fl4804','GBU-GZ','MR','Lansoprazole','周文刚','E00451','CNGDSM0058','否'),(570,'邓高东','gaodong.deng@takeda.com',123,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02772','og8663','GBU-GZ','MR','Panto IV + Oral Mix','周文刚','E00451','CNGDSM0058','否'),(571,'邱云','Yun.Qiu@takeda.com',123,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02976','uj6345','GBU-GZ','MR','Lansoprazole','周文刚','E00451','CNGDSM0058','否'),(572,'冯志明','Zhiming.Feng@takeda.com',123,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03139','ga0480','GBU-GZ','MR','Panto IV + Oral Mix','周文刚','E00451','CNGDSM0058','否'),(573,'祝敬美','Jingmei.Zhu@takeda.com',0,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01583','dz7270','GBU-HB','Hospital Specialist','','空缺','','','否'),(574,'陈景涛','Jingtao.Chen@takeda.com',128,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03073','oa8338','GBU-HB','Hospital Specialist','Panto IV','空缺','','CNGDSM0063','否'),(575,'曹勇','Yong1.Cao@takeda.com',128,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03072','ka6325','GBU-HB','MR','Panto IV','空缺','','CNGDSM0063','否'),(576,'柯琴','Qin.Ke@takeda.com',128,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03096','sz2927','GBU-HB','MR','Panto IV','空缺','','CNGDSM0063','否'),(577,'汪友龙','youlong.wang@takeda.com',128,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01514','jb1638','GBU-HB','SMR','Panto IV','空缺','','CNGDSM0063','否'),(578,'金河来','helai.jin@takeda.com',124,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E00438','nr8690','GBU-HB','Hospital Specialist','Lansoprazole','李林','E00735','CNGDSM0059','否'),(579,'蓝云峰','yunfeng.lan@takeda.com',124,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02188','cy8742','GBU-HB','MR','Panto Oral','李林','E00735','CNGDSM0059','否'),(580,'李光明','guangming.li@takeda.com',124,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01375','vu1648','GBU-HB','SMR','Panto IV + Oral Mix','李林','E00735','CNGDSM0059','否'),(581,'郭勇','yong.guo2@takeda.com',0,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01726','fo7490','GBU-HB','SMR','Panto IV + Oral Mix','李林','E00735','','否'),(582,'太平','ping.tai@takeda.com',124,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02019','it5376','GBU-HB','SMR','Panto IV + Oral Mix','李林','E00735','CNGDSM0059','否'),(583,'何利荣','Lirong.He@takeda.com',124,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02473','sv5786','GBU-HB','SMR','Panto IV','李林','E00735','CNGDSM0059','否'),(584,'印昌龙','Changlong.Yin@takeda.com',124,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02957','tk8607','GBU-HB','SMR','Lansoprazole','李林','E00735','CNGDSM0059','否'),(585,'朱兴亮','xingliang.zhu@takeda.com',125,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01861','fy1750','GBU-HB','Hospital Specialist','Panto IV + Oral Mix','梅运华','E01837','CNGDSM0060','否'),(586,'陈露','Lu.Chen2@takeda.com',125,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01932','gw6803','GBU-HB','MR','Panto IV + Oral Mix','梅运华','E01837','CNGDSM0060','否'),(587,'龙顺银','shunyin.long@takeda.com',125,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02168','zk0560','GBU-HB','MR','Panto IV + Oral Mix','梅运华','E01837','CNGDSM0060','否'),(588,'李华栋','Huadong.Li@takeda.com',125,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03000','zg8337','GBU-HB','MR','Panto IV + Oral Mix','梅运华','E01837','CNGDSM0060','否'),(589,'赵莉','li.zhao@takeda.com',125,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01221','ye6662','GBU-HB','SMR','Panto IV + Oral Mix','梅运华','E01837','CNGDSM0060','否'),(590,'高昌猛','changmeng.gao@takeda.com',125,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01436','mm3636','GBU-HB','SMR','Panto IV + Oral Mix','梅运华','E01837','CNGDSM0060','否'),(591,'林春霞','chunxia.lin@takeda.com',125,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02472','ft9527','GBU-HB','SMR','Panto IV + Oral Mix','梅运华','E01837','CNGDSM0060','否'),(592,'王秀珍','Xiuzhen.Wang@takeda.com',125,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03045','xs6324','GBU-HB','SMR','Panto IV + Oral Mix','梅运华','E01837','CNGDSM0060','否'),(593,'杨云','yun.yang@takeda.com',147,1,1,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01490','uv3525','GBU-HB','DSM','Panto IV + Oral Mix','王琛','E00468','CNGRSM0011','是'),(594,'王静','Jing4.Wang@takeda.com',147,1,1,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02546','jy0894','GBU-HB','DSM','Oral Mix','王琛','E00468','CNGRSM0011','是'),(595,'王薇','Wei1.Wang@takeda.com',147,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02686','ka6502','GBU-HB','RPM','','王琛','E00468','CNGRSM0011','否'),(596,'李林','lin.li@takeda.com',147,1,1,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E00735','fe0534','GBU-HB','SDSM','Panto IV + Oral Mix','王琛','E00468','CNGRSM0011','是'),(597,'吴艳芳','yanfang.wu@takeda.com',147,1,1,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E00822','hp2714','GBU-HB','SDSM','Panto IV','王琛','E00468','CNGRSM0011','是'),(598,'梅运华','yunhua.mei@takeda.com',147,1,1,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01837','yy2823','GBU-HB','SDSM','Panto IV + Oral Mix','王琛','E00468','CNGRSM0011','是'),(599,'武琳','Lin-1.Wu@takeda.com',126,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E00679','vt8317','GBU-HB','Hospital Specialist','Lansoprazole','王静','E02546','CNGDSM0061','否'),(600,'韩冬','Dong.Han@takeda.com',126,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02385','yx2318','GBU-HB','MR','Lansoprazole','王静','E02546','CNGDSM0061','否'),(601,'向阳','Yang.Xiang@takeda.com',126,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02520','bj5885','GBU-HB','MR','Panto Oral','王静','E02546','CNGDSM0061','否'),(602,'刘霞','Xia.Liu@takeda.com',126,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02736','ql6903','GBU-HB','MR','Panto Oral','王静','E02546','CNGDSM0061','否'),(603,'段欢琴','Huanqin.Duan@takeda.com',126,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02923','ff9441','GBU-HB','MR','Panto Oral','王静','E02546','CNGDSM0061','否'),(604,'李一川','yichuan.Li@takeda.com',126,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03004','xu3730','GBU-HB','MR','Lansoprazole','王静','E02546','CNGDSM0061','否'),(605,'明艳','Yan.Ming@takeda.com',126,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01603','oa7902','GBU-HB','SMR','Lansoprazole','王静','E02546','CNGDSM0061','否'),(606,'王锐波','ruibo.wang@takeda.com',127,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01481','im8672','GBU-HB','Hospital Specialist','Panto IV','吴艳芳','E00822','CNGDSM0062','否'),(607,'张美容','meirong.zhang@takeda.com',127,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02769','dk2356','GBU-HB','Hospital Specialist','Panto IV','吴艳芳','E00822','CNGDSM0062','否'),(608,'廖彬彬','Binbin.Liao@takeda.com',127,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03191','iv1959','GBU-HB','Hospital Specialist','Panto IV','吴艳芳','E00822','CNGDSM0062','否'),(609,'熊焱','Yan1.Xiong@takeda.com',127,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02440','un0376','GBU-HB','MR','Panto IV','吴艳芳','E00822','CNGDSM0062','否'),(610,'潘列非','Liefei.Pan@takeda.com',127,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03074','kv3953','GBU-HB','MR','Panto IV','吴艳芳','E00822','CNGDSM0062','否'),(611,'张勇','Yong1.Zhang@takeda.com',128,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03077','cl0323','GBU-HB','MR','Panto IV','吴艳芳','E00822','CNGDSM0063','否'),(612,'李秋华','coco.li@takeda.com',127,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01271','gn6620','GBU-HB','SMR','Panto IV','吴艳芳','E00822','CNGDSM0062','否'),(613,'熊乐乐','lele.xiong@takeda.com',127,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01930','km6592','GBU-HB','SMR','Panto IV','吴艳芳','E00822','CNGDSM0062','否'),(614,'徐语轩','yuxuan.xu@takeda.com',129,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01568','za2951','GBU-HB','MR','Panto IV + Oral Mix','杨云','E01490','CNGDSM0064','否'),(615,'李欣宸','Xinchen.Li@takeda.com',129,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02500','dg3634','GBU-HB','MR','Panto IV + Oral Mix','杨云','E01490','CNGDSM0064','否'),(616,'董团','tuan.dong@takeda.com',129,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01535','yh0384','GBU-HB','SMR','Panto IV + Oral Mix','杨云','E01490','CNGDSM0064','否'),(617,'卜金','jin.pu@takeda.com',129,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02144','iy9846','GBU-HB','SMR','Panto IV + Oral Mix','杨云','E01490','CNGDSM0064','否'),(618,'戚继承','Jicheng.Qi@takeda.com',129,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02642','cj5251','GBU-HB','SMR','Panto IV + Oral Mix','杨云','E01490','CNGDSM0064','否'),(619,'王甜','待定',129,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03030','待定','GBU-HB','SMR','Panto IV + Oral Mix','杨云','E01490','CNGDSM0064','否'),(620,'王琛','chen-1.wang@takeda.com',136,1,1,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E00468','rf5076','GBU-HB','SRSM','','张宁','E00352','CNGRSD0003','是'),(621,'顾佳贇','Jiayun.Gu@takeda.com',67,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02871','lg5285','GBU-HZ','MR','Panto IV','贾佳','E01586','CNGDSM0002','否'),(622,'阎娜','Na.Yan@takeda.com',67,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E03112','bj1221','GBU-HZ','MR','Panto IV','贾佳','E01586','CNGDSM0002','否'),(623,'王晓彬','Xiaobin.Wang@takeda.com',67,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01587','fp7943','GBU-HZ','SMR','Panto IV','贾佳','E01586','CNGDSM0002','否'),(624,'周亚平','yaping.zhou@takeda.com',67,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E01633','wn5591','GBU-HZ','SMR','Panto IV','贾佳','E01586','CNGDSM0002','否'),(625,'宁淋淋','Linlin.Ning@takeda.com',0,1,0,0,1,'2015-06-06 18:25:36',1,'2015-06-06 18:25:36','E02138','az9984','GBU-HZ','SMR','Panto IV','贾佳','E01586','','否'),(626,'高婷','Ting.Gao@takeda.com',67,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02401','it4893','GBU-HZ','SMR','Panto IV','贾佳','E01586','CNGDSM0002','否'),(627,'翁月娟','yuejuan.weng@takeda.com',0,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00699','kv5172','GBU-HZ','MR','','空缺','','','否'),(628,'来叶挺','yeting.lai@takeda.com',68,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01852','fj9659','GBU-HZ','Hospital Specialist','Panto IV + Oral Mix','吕炜','E01753','CNGDSM0003','否'),(629,'周小雄','Xiaoxiong.Zhou@takeda.com',68,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02360','ek0473','GBU-HZ','Hospital Specialist','Oral Mix','吕炜','E01753','CNGDSM0003','否'),(630,'陈吴峰','wufeng.chen@takeda.com',68,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01934','ig8714','GBU-HZ','MR','Oral Mix','吕炜','E01753','CNGDSM0003','否'),(631,'沈志芳','Zhifang.Shen@takeda.com',68,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02519','wl8627','GBU-HZ','MR','Oral Mix','吕炜','E01753','CNGDSM0003','否'),(632,'林裕久','yujiu.lin@takeda.com',68,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02907','av9508','GBU-HZ','MR','Panto Oral','吕炜','E01753','CNGDSM0003','否'),(633,'胡秀华','xiuhua.Hu@takeda.com',68,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03080','dc3794','GBU-HZ','MR','Panto Oral','吕炜','E01753','CNGDSM0003','否'),(634,'朱祥婷','Xiangting.Zhu@takeda.com',134,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00160','ah3656','GBU-HZ','RSM','','潘海风','E01577','CNGRSD0001','是'),(635,'徐少英','Shaoyin.Xu@takeda.com',69,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01800','bp0703','GBU-HZ','Hospital Specialist','Panto IV','瞿亚娟','E01278','CNGDSM0004','否'),(636,'王玉洁','Yujie.Wang@takeda.com',69,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02491','af8735','GBU-HZ','MR','Panto IV','瞿亚娟','E01278','CNGDSM0004','否'),(637,'章敏','Min.Zhang@takeda.com',69,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03041','ot7585','GBU-HZ','MR','Panto IV','瞿亚娟','E01278','CNGDSM0004','否'),(638,'俞磊','lei.yu@takeda.com',69,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01302','kh5674','GBU-HZ','SMR','Panto IV','瞿亚娟','E01278','CNGDSM0004','否'),(639,'傅强锋','qiangfeng.fu@takeda.com',69,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01428','px0522','GBU-HZ','SMR','Panto IV','瞿亚娟','E01278','CNGDSM0004','否'),(640,'郑浙龙','zhelong.zheng@takeda.com',69,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01453','ph8860','GBU-HZ','SMR','Panto IV','瞿亚娟','E01278','CNGDSM0004','否'),(641,'陈烨','Ye.Chen@takeda.com',69,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02111','pm9975','GBU-HZ','SMR','Panto IV','瞿亚娟','E01278','CNGDSM0004','否'),(642,'金强','qiang.jin@takeda.com',66,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02088','sw8959','GBU-HZ','MR','Panto IV + Oral Mix','沈占强','E02327','CNGDSM0001','否'),(643,'宣超','Chao.Xuan@takeda.com',66,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02136','gd5833','GBU-HZ','MR','Lansoprazole','沈占强','E02327','CNGDSM0001','否'),(644,'楼杰聪','Jiecong.Lou@takeda.com',66,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02402','ll5479','GBU-HZ','MR','Panto IV + Oral Mix','沈占强','E02327','CNGDSM0001','否'),(645,'陈晓风','xiaofeng2.chen@takeda.com',66,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03159','vx5361','GBU-HZ','MR','Panto IV + Oral Mix','沈占强','E02327','CNGDSM0001','否'),(646,'王小晋','xiaojin.wang@takeda.com',66,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01154','gw0604','GBU-HZ','SMR','Panto IV','沈占强','E02327','CNGDSM0001','否'),(647,'陈茹','Ru.Chen@takeda.com',70,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02624','zb2432','GBU-HZ','Hospital Specialist','Panto Oral','汪毓佩','E02648','CNGDSM0005','否'),(648,'楼芳','fang.lou@takeda.com',70,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00864','zq6536','GBU-HZ','MR','Oral Mix','汪毓佩','E02648','CNGDSM0005','否'),(649,'张会','Hui1.Zhang@takeda.com',70,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02311','ow6681','GBU-HZ','MR','Oral Mix','汪毓佩','E02648','CNGDSM0005','否'),(650,'尚方龙','Fanglong.Shang@takeda.com',70,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02898','be5710','GBU-HZ','MR','Panto Oral','汪毓佩','E02648','CNGDSM0005','否'),(651,'夏清玄','Qingxuan.Xia@takeda.com',70,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02945','ai0368','GBU-HZ','MR','Oral Mix','汪毓佩','E02648','CNGDSM0005','否'),(652,'李琴','qin.li@takeda.com',70,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00825','fr3394','GBU-HZ','SMR','Oral Mix','汪毓佩','E02648','CNGDSM0005','否'),(653,'杨兵','bing.yang@takeda.com',70,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01996','ba8949','GBU-HZ','SMR','Oral Mix','汪毓佩','E02648','CNGDSM0005','否'),(654,'方祥','Xiang.Fang@takeda.com',71,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02495','xe1408','GBU-HZ','MR','Oral Mix','王桦','E02338','CNGDSM0006','否'),(655,'邴巍','Wei.Bing@takeda.com',71,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02522','zl8554','GBU-HZ','MR','Panto Oral','王桦','E02338','CNGDSM0006','否'),(656,'陈小凤','xiaofeng.chen@takeda.com',71,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02663','zf8522','GBU-HZ','MR','Oral Mix','王桦','E02338','CNGDSM0006','否'),(657,'樊新丽','xinli.fan@takeda.com',71,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01754','ka4972','GBU-HZ','SMR','Oral Mix','王桦','E02338','CNGDSM0006','否'),(658,'魏东丽','dongli.wei@takeda.com',71,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01954','yy3666','GBU-HZ','SMR','Panto Oral','王桦','E02338','CNGDSM0006','否'),(659,'瞿卿','Qing.Qu@takeda.com',71,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02451','wa4436','GBU-HZ','SMR','Oral Mix','王桦','E02338','CNGDSM0006','否'),(660,'沈占强','Zhanqiang.Shen@takeda.com',0,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02327','od7927','GBU-HZ','DSM','Panto IV + Oral Mix','朱祥婷','E00160','','是'),(661,'王桦','hua.wang@takeda.com',137,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02338','km7874','GBU-HZ','DSM','Oral Mix','朱祥婷','E00160','CNGRSM0001','是'),(662,'汪毓佩','yupei.Wang@takeda.com',137,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02648','vi9359','GBU-HZ','DSM','Oral Mix','朱祥婷','E00160','CNGRSM0001','是'),(663,'乐静','jing.le@takeda.com',137,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01824','vm7997','GBU-HZ','RPM','','朱祥婷','E00160','CNGRSM0001','否'),(664,'瞿亚娟','yajuan.qu@takeda.com',137,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01278','er2358','GBU-HZ','SDSM','Panto IV','朱祥婷','E00160','CNGRSM0001','是'),(665,'贾佳','tony.jia@takeda.com',137,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01586','if7310','GBU-HZ','SDSM','Panto IV','朱祥婷','E00160','CNGRSM0001','是'),(666,'吕炜','wei.lv@takeda.com',137,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01753','ea2429','GBU-HZ','SDSM','Panto IV + Oral Mix','朱祥婷','E00160','CNGRSM0001','是'),(667,'张龙','Long.Zhang@takeda.com',72,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02602','bo2853','GBU-JS','MR','Panto IV + Oral Mix','陈月红','E02397','CNGDSM0007','否'),(668,'孙雅君','Yajun.Sun@takeda.com',72,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02599','oj9927','GBU-JS','MR','Panto IV + Oral Mix','陈月红','E02397','CNGDSM0007','否'),(669,'张欢欢','huanhuan.zhang@takeda.com',72,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02911','ga8470','GBU-JS','MR','Panto IV + Oral Mix','陈月红','E02397','CNGDSM0007','否'),(670,'刘兴泉','xingquan.liu@takeda.com',72,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01508','tz0826','GBU-JS','SMR','Panto IV + Oral Mix','陈月红','E02397','CNGDSM0007','否'),(671,'杨立明','liming.yang@takeda.com',73,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01394','xo6693','GBU-JS','MR','Panto IV + Oral Mix','费杳','E02646','CNGDSM0008','否'),(672,'顾大一','dayi.gu@takeda.com',73,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02739','be7550','GBU-JS','MR','Panto IV + Oral Mix','费杳','E02646','CNGDSM0008','否'),(673,'钮高强','Gaoqiang.Niu@takeda.com',73,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02744','tr4767','GBU-JS','MR','Panto IV + Oral Mix','费杳','E02646','CNGDSM0008','否'),(674,'李书玲','shuling.li@takeda.com',74,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01965','qr0210','GBU-JS','Hospital Specialist','Panto IV + Oral Mix','空缺','','CNGDSM0009','否'),(675,'谢晓燕','Xiaoyan.Xie@takeda.com',74,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02146','tx0858','GBU-JS','Hospital Specialist','Panto IV + Oral Mix','空缺','','CNGDSM0009','否'),(676,'王文波','wenbo.wang@takeda.com',74,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01829','tp1233','GBU-JS','MR','Panto IV + Oral Mix','空缺','','CNGDSM0009','否'),(677,'袁方','fang.yuan@takeda.com',74,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02085','za1773','GBU-JS','MR','Panto IV + Oral Mix','空缺','','CNGDSM0009','否'),(678,'曹洪云','hongyun.cao@takeda.com',74,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02893','fz0225','GBU-JS','MR','Panto IV + Oral Mix','空缺','','CNGDSM0009','否'),(679,'陈月红','Yuehong.Chen@takeda.com',138,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02397','yu7712','GBU-JS','DSM','Panto IV + Oral Mix','谢智琼','E02487','CNGRSM0002','是'),(680,'费杳','Yao.Fei@takeda.com',138,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02646','vr7781','GBU-JS','DSM','Panto IV + Oral Mix','谢智琼','E02487','CNGRSM0002','是'),(681,'李大庆','Daqing.Li@takeda.com',224,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00073','lp0489','GBU-MKT','Marketing Manager','','刘伟','E02761','GBU-MM-01','否'),(682,'孙源','yuan.sun@takeda.com',225,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02198','nf7426','GBU-MKT','Product Manager','','刘伟','E02761','GBU-PM-03','否'),(683,'周振','Zhen3.Zhou@takeda.com',0,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02830','hh9311','GBU-MKT','Product Manager','','刘伟','E02761','','否'),(684,'吕琪','Qi.Lv@takeda.com',224,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02077','hn6532','GBU-MKT','Sr. Product Manager','','刘伟','E02761','GBU-MM-01','否'),(685,'何茹','Ru.He@takeda.com',65,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02912','cv4605','GBU-MKT','Sr. Product Manager','','刘伟','E02761','CNGBUD0001','否'),(686,'杜明丽','mingli.Du@takeda.com',0,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03144','ji3457','GBU-MKT','Sr. Project Supervisor','','刘伟','E02761','','否'),(687,'李颖异','Yingyi.Li@takeda.com',0,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02980','kg0970','GBU-MKT','APM','','吕琪','E02077','','否'),(688,'刘伟','David3.Liu@takeda.com',0,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02761','xn0581','GBU-MKT','Marketing Director','','王卫','E01821','','是'),(689,'赵兰兰','lanlan.zhao@takeda.com',94,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01166','pa7843','GBU-SD','Hospital Specialist','Panto IV','雷波','E02656','CNGDSM0029','否'),(690,'苏堪振','kanzhen.su@takeda.com',94,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01810','pi2759','GBU-SD','MR','Panto IV + Oral Mix','雷波','E02656','CNGDSM0029','否'),(691,'訾庆霖','qinglin.zi@takeda.com',94,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02554','kb6820','GBU-SD','MR','Panto IV + Oral Mix','雷波','E02656','CNGDSM0029','否'),(692,'孙书豪','Shuhao.Sun@takeda.com',94,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02699','ss4719','GBU-SD','MR','Panto IV + Oral Mix','雷波','E02656','CNGDSM0029','否'),(693,'李阳','Yang5.Li@takeda.com',94,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02965','kn4306','GBU-SD','MR','Panto IV + Oral Mix','雷波','E02656','CNGDSM0029','否'),(694,'陈旭辉','xuhui.chen@takeda.com',94,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02891','bt0473','GBU-SD','MR','Panto IV + Oral Mix','雷波','E02656','CNGDSM0029','否'),(695,'崔绪瑞','Xurui.Cui@takeda.com',94,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03078','rg6879','GBU-SD','MR','Panto IV + Oral Mix','雷波','E02656','CNGDSM0029','否'),(696,'董鑫爱','xinai.dong@takeda.com',95,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00378','ub3194','GBU-SD','Hospital Specialist','Panto IV + Oral Mix','李秉强','E00377','CNGDSM0030','否'),(697,'毛俊','jun.mao@takeda.com',95,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00379','rj0807','GBU-SD','Hospital Specialist','Panto IV + Oral Mix','李秉强','E00377','CNGDSM0030','否'),(698,'朱艺博','yibo.zhu@takeda.com',95,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00380','fz2352','GBU-SD','MR','Panto IV + Oral Mix','李秉强','E00377','CNGDSM0030','否'),(699,'沙雪丹','xuedan.sha@takeda.com',95,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01769','ws4663','GBU-SD','MR','Panto IV + Oral Mix','李秉强','E00377','CNGDSM0030','否'),(700,'黄祖明','Zuming.Huang@takeda.com',95,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02417','lk6219','GBU-SD','MR','Panto IV + Oral Mix','李秉强','E00377','CNGDSM0030','否'),(701,'邢琳','Lin.XING@takeda.com',95,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02418','wm6377','GBU-SD','MR','Panto IV + Oral Mix','李秉强','E00377','CNGDSM0030','否'),(702,'徐斐斐','FeiFei.Xu@takeda.com',95,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02733','un8900','GBU-SD','MR','Panto IV + Oral Mix','李秉强','E00377','CNGDSM0030','否'),(703,'李荣菊','rongju.li@takeda.com',96,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01202','rx5353','GBU-SD','Hospital Specialist','Panto IV + Oral Mix','刘国','E02364','CNGDSM0031','否'),(704,'张艳华','yanhua.zhang@takeda.com',96,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01441','nl7983','GBU-SD','Hospital Specialist','Panto IV + Oral Mix','刘国','E02364','CNGDSM0031','否'),(705,'潘爱霞','aixia.pan@takeda.com',96,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03029','xu3419','GBU-SD','Hospital Specialist','Panto IV + Oral Mix','刘国','E02364','CNGDSM0031','否'),(706,'刘云','yun.liu@takeda.com',96,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01544','ji0661','GBU-SD','SMR','Panto IV','刘国','E02364','CNGDSM0031','否'),(707,'刘斐','Fei3.Liu@takeda.com',96,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03079','dt1690','GBU-SD','SMR','Panto IV + Oral Mix','刘国','E02364','CNGDSM0031','否'),(708,'刘国','Guo.Liu@takeda.com',142,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02364','kk6900','GBU-SD','DSM','Panto IV + Oral Mix','吴大胜','E00370','CNGRSM0006','是'),(709,'吴树文','Shuwen.Wu@takeda.com',142,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02376','fd3251','GBU-SD','DSM','Panto IV + Oral Mix','吴大胜','E00370','CNGRSM0006','是'),(710,'雷波','bo.lei@takeda.com',142,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02656','lu5269','GBU-SD','DSM','Panto IV + Oral Mix','吴大胜','E00370','CNGRSM0006','是'),(711,'李秉强','Bingqiang.Li@takeda.com',142,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00377','ny3250','GBU-SD','SDSM','Panto IV + Oral Mix','吴大胜','E00370','CNGRSM0006','是'),(712,'张泽亮','Zeliang.Zhang@takeda.com',142,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00384','ug2823','GBU-SD','SDSM','Panto IV + Oral Mix','吴大胜','E00370','CNGRSM0006','是'),(713,'苑素敏','Sumin.Yuan@takeda.com',142,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00371','jb7012','GBU-SD','SRPM','','吴大胜','E00370','CNGRSM0006','否'),(714,'李星华','xinghua.li@takeda.com',97,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01826','qc0879','GBU-SD','MR','Panto IV + Oral Mix','吴树文','E02376','CNGDSM0032','否'),(715,'田继顺','jishun.tian@takeda.com',97,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01963','jw4354','GBU-SD','MR','Panto IV + Oral Mix','吴树文','E02376','CNGDSM0032','否'),(716,'张秋光','qiuguang.zhang@takeda.com',97,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02235','on7949','GBU-SD','MR','Panto IV','吴树文','E02376','CNGDSM0032','否'),(717,'李颍红','yinghong.li@takeda.com',97,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02200','pd9810','GBU-SD','MR','Panto IV','吴树文','E02376','CNGDSM0032','否'),(718,'朱清','Qing-1.Zhu@takeda.com',97,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02315','rc4702','GBU-SD','MR','Panto IV + Oral Mix','吴树文','E02376','CNGDSM0032','否'),(719,'段卫星','weixing.duan@takeda.com',97,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03019','fk8853','GBU-SD','MR','Panto IV + Oral Mix','吴树文','E02376','CNGDSM0032','否'),(720,'彭凤梅','Fengmei.Peng@takeda.com',97,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03106','dy1292','GBU-SD','MR','Panto Oral','吴树文','E02376','CNGDSM0032','否'),(721,'史旭东','Xudong.Shi@takeda.com',97,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02555','re9528','GBU-SD','SMR','Panto IV + Oral Mix','吴树文','E02376','CNGDSM0032','否'),(722,'韩治会','zhihui.han@takeda.com',97,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03151','ez6746','GBU-SD','SMR','Panto IV + Oral Mix','吴树文','E02376','CNGDSM0032','否'),(723,'吴大胜','Dasheng.Wu@takeda.com',135,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00370','nc5100','GBU-SD','SRSM','','张凯军','E00250','CNGRSD0002','是'),(724,'唐浩','Hao.Tang@takeda.com',98,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02253','ml0538','GBU-SD','MR','Panto IV + Oral Mix','张泽亮','E00384','CNGDSM0033','否'),(725,'吴琳','Lin.Wu@takeda.com',98,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01470','xt2977','GBU-SD','MR','Panto IV + Oral Mix','张泽亮','E00384','CNGDSM0033','否'),(726,'翟璟','Jing.Zhai@takeda.com',98,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02521','yv6297','GBU-SD','MR','Lansoprazole','张泽亮','E00384','CNGDSM0033','否'),(727,'张小英','Xiaoying.Zhang@takeda.com',98,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03043','no1282','GBU-SD','MR','Panto IV + Oral Mix','张泽亮','E00384','CNGDSM0033','否'),(728,'施洁','jie.shi@takeda.com',98,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01263','vv7617','GBU-SD','SMR','Panto IV','张泽亮','E00384','CNGDSM0033','否'),(729,'孙海宏','haihong.sun@takeda.com',98,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01486','tt7865','GBU-SD','SMR','Panto IV + Oral Mix','张泽亮','E00384','CNGDSM0033','否'),(730,'宁晓宇','xiaoyu.ning@takeda.com',98,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00385','vt6715','GBU-SD','SMR','Panto IV + Oral Mix','张泽亮','E00384','CNGDSM0033','否'),(731,'李娴','Xian.Li@takeda.com',75,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02727','vs5262','GBU-SH','Executive Hospital Specialist','Panto IV','陈亮','E02126','CNGDSM0010','否'),(732,'孔祥娟','Xiangjuan.Kong@takeda.com',75,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02539','ii1204','GBU-SH','Hospital Specialist','Panto IV','陈亮','E02126','CNGDSM0010','否'),(733,'徐晋','Jin.Xu2@takeda.com',75,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02166','iz9730','GBU-SH','MR','Panto IV','陈亮','E02126','CNGDSM0010','否'),(734,'王婷','amy.wang6@takeda.com',75,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01165','qu6217','GBU-SH','SMR','Panto IV','陈亮','E02126','CNGDSM0010','否'),(735,'赵维敛','william.zhao@takeda.com',75,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01502','rb7505','GBU-SH','SMR','Panto IV','陈亮','E02126','CNGDSM0010','否'),(736,'朱一镜','yijing.zhu@takeda.com',75,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01832','cy7371','GBU-SH','SMR','Panto IV','陈亮','E02126','CNGDSM0010','否'),(737,'朱鑫伟','Xinwei.Zhu@takeda.com',75,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02738','tb1992','GBU-SH','SMR','Panto IV + Oral Mix','陈亮','E02126','CNGDSM0010','否'),(738,'叶超','Chao.Ye@takeda.com',75,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02716','pj4473','GBU-SH','SMR','Panto IV','陈亮','E02126','CNGDSM0010','否'),(739,'王碧珺','Bijun.Wang@takeda.com',75,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03059','su0996','GBU-SH','SMR','Panto IV','陈亮','E02126','CNGDSM0010','否'),(740,'李长巍','changwei.li@takeda.com',73,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02987','bz5447','GBU-SH','MR','Panto IV + Oral Mix','费杳','E02646','CNGDSM0008','否'),(741,'吴亚亮','yaliang.wu@takeda.com',76,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01836','cm1503','GBU-SH','Hospital Specialist','Oral Mix','李良华','E01198','CNGDSM0011','否'),(742,'毛灵波','lingbo.mao@takeda.com',76,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01858','nq8490','GBU-SH','Hospital Specialist','Panto Oral','李良华','E01198','CNGDSM0011','否'),(743,'李晖','Hui-2.Li@takeda.com',76,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00845','pi9486','GBU-SH','MR','Oral Mix','李良华','E01198','CNGDSM0011','否'),(744,'陈剑龙','Jianlong.Chen@takeda.com',76,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02580','aw8932','GBU-SH','MR','Panto IV + Oral Mix','李良华','E01198','CNGDSM0011','否'),(745,'吴学圣','Xuesheng.Wu@takeda.com',76,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02479','om1358','GBU-SH','SMR','Panto Oral','李良华','E01198','CNGDSM0011','否'),(746,'卢松贺','songhe.lu@takeda.com',77,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01857','in3847','GBU-SH','Hospital Specialist','Panto IV','李元强','E01404','CNGDSM0012','否'),(747,'贾荟','hui.jia@takeda.com',77,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01512','hr0923','GBU-SH','MR','Panto IV','李元强','E01404','CNGDSM0012','否'),(748,'康荣华','Ronghua.Kang@takeda.com',77,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01590','lg3686','GBU-SH','MR','Panto IV + Oral Mix','李元强','E01404','CNGDSM0012','否'),(749,'徐莉莉','Lili.Xu@takeda.com',77,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02524','fg7896','GBU-SH','MR','Panto IV','李元强','E01404','CNGDSM0012','否'),(750,'周瑜','yu.zhou@takeda.com',77,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01518','ln9901','GBU-SH','SMR','Panto IV','李元强','E01404','CNGDSM0012','否'),(751,'卢兴盛','Xingsheng.Lu@takeda.com',77,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02165','nn8943','GBU-SH','SMR','Panto IV','李元强','E01404','CNGDSM0012','否'),(752,'孟浩','hao.meng@takeda.com',81,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01400','zu5320','GBU-SH','Hospital Specialist','Panto IV + Oral Mix','罗造极','E01305','CNGDSM0016','否'),(753,'刘璟','Jing.Liu3@takeda.com',81,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02059','em1615','GBU-SH','Hospital Specialist','Oral Mix','罗造极','E01305','CNGDSM0016','否'),(754,'杨鹏飞','Pengfei.Yang@takeda.com',81,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02393','qy7753','GBU-SH','MR','Oral Mix','罗造极','E01305','CNGDSM0016','否'),(755,'蒋海燕','haiyan.jiang@takeda.com',81,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01443','xm9457','GBU-SH','SMR','Panto IV + Oral Mix','罗造极','E01305','CNGDSM0016','否'),(756,'刘炜','Wei.Liu@takeda.com',81,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02645','al3652','GBU-SH','SMR','Panto IV + Oral Mix','罗造极','E01305','CNGDSM0016','否'),(757,'沈庆','qing.shen@takeda.com',78,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00790','pz2914','GBU-SH','MR','Oral Mix','马俊杰','E00288','CNGDSM0013','否'),(758,'何娴','Xian.He@takeda.com',78,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02983','cs9537','GBU-SH','MR','Oral Mix','马俊杰','E00288','CNGDSM0013','否'),(759,'赵亦扬','yiyang.zhao@takeda.com',78,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03148','cv1432','GBU-SH','MR','Panto IV + Oral Mix','马俊杰','E00288','CNGDSM0013','否'),(760,'朱文博','wenbo.zhu@takeda.com',78,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00285','bj2407','GBU-SH','SMR','Panto IV + Oral Mix','马俊杰','E00288','CNGDSM0013','否'),(761,'赵岚','lan.zhao@takeda.com',78,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00290','ja1953','GBU-SH','SMR','Panto IV + Oral Mix','马俊杰','E00288','CNGDSM0013','否'),(762,'张吉','ji.zhang@takeda.com',78,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00481','zc3000','GBU-SH','SMR','Panto IV + Oral Mix','马俊杰','E00288','CNGDSM0013','否'),(763,'施晓蕾','xiaolei.shi@takeda.com',78,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00863','zb7816','GBU-SH','SMR','Panto IV + Oral Mix','马俊杰','E00288','CNGDSM0013','否'),(764,'何灵通','Lingtong.He@takeda.com',78,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02123','ic0762','GBU-SH','SMR','Panto IV + Oral Mix','马俊杰','E00288','CNGDSM0013','否'),(765,'谢智琼','Zhiqiong.Xie@takeda.com',134,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02487','ux6786','GBU-SH','RSM','','潘海风','E01577','CNGRSD0001','是'),(766,'朱蓉','Rong.Zhu1@takeda.com',79,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02124','pg3586','GBU-SH','MR','Panto IV','王震模','E02514','CNGDSM0014','否'),(767,'龚艳红','Yanhong.Gong@takeda.com',79,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02802','pn6968','GBU-SH','MR','Panto IV + Oral Mix','王震模','E02514','CNGDSM0014','否'),(768,'陈莉','Li2.Chen@takeda.com',79,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02480','sb5506','GBU-SH','SMR','Panto IV','王震模','E02514','CNGDSM0014','否'),(769,'张喆','Zhe.Zhang@takeda.com',79,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02601','lt8667','GBU-SH','SMR','Panto IV + Oral Mix','王震模','E02514','CNGDSM0014','否'),(770,'黄华良','Hualiang.Huang@takeda.com',79,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02711','mx4631','GBU-SH','SMR','Panto IV + Oral Mix','王震模','E02514','CNGDSM0014','否'),(771,'李良华','lianghua.li@takeda.com',139,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01198','pt4768','GBU-SH','DSM','Panto IV + Oral Mix','谢智琼','E02487','CNGRSM0003','是'),(772,'罗造极','zaoji.luo@takeda.com',81,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01305','bo3743','GBU-SH','DSM','Panto IV + Oral Mix','谢智琼','E02487','CNGDSM0016','是'),(773,'李元强','yuanqiang.li@takeda.com',139,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01404','uu4788','GBU-SH','DSM','Panto IV + Oral Mix','谢智琼','E02487','CNGRSM0003','是'),(774,'马俊杰','junjie.ma@takeda.com',139,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00288','ub4768','GBU-SH','DSM','Panto IV + Oral Mix','谢智琼','E02487','CNGRSM0003','是'),(775,'王震模','zhenmo.wang@takeda.com',139,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02514','ar7913','GBU-SH','DSM','Panto IV + Oral Mix','谢智琼','E02487','CNGRSM0003','是'),(776,'刘艳2','lilly.liu@takeda.com',139,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01847','pr4399','GBU-SH','RPM','','谢智琼','E02487','CNGRSM0003','否'),(777,'徐淼','miao.xu@takeda.com',139,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01377','bd0343','GBU-SH','SDSM','Panto IV + Oral Mix','谢智琼','E02487','CNGRSM0003','是'),(778,'陈亮','Liang2.Chen@takeda.com',139,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02126','vl8954','GBU-SH','SDSM','Panto IV + Oral Mix','谢智琼','E02487','CNGRSM0003','是'),(779,'刘广成','guangchen.liu@takeda.com',80,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01403','dx3429','GBU-SH','Hospital Specialist','Panto IV + Oral Mix','徐淼','E01377','CNGDSM0015','否'),(780,'丁丹丹','Dandan.Ding@takeda.com',80,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02551','xz0507','GBU-SH','MR','Panto IV','徐淼','E01377','CNGDSM0015','否'),(781,'贺轶骅','yihua.he@takeda.com',80,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01393','tv3401','GBU-SH','SMR','Panto IV','徐淼','E01377','CNGDSM0015','否'),(782,'陈琛','chen.chen3@takeda.com',80,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01501','yt3427','GBU-SH','SMR','Panto IV','徐淼','E01377','CNGDSM0015','否'),(783,'黄洁','Jie.Huang6@takeda.com',80,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01572','xa0615','GBU-SH','SMR','Panto IV','徐淼','E01377','CNGDSM0015','否'),(784,'周小英','Xiaoying.Zhou@takeda.com',80,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01585','qk9348','GBU-SH','SMR','Panto IV','徐淼','E01377','CNGDSM0015','否'),(785,'范左臣','Zuochen.Fan@takeda.com',80,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01602','fe3459','GBU-SH','SMR','Panto IV','徐淼','E01377','CNGDSM0015','否'),(786,'谌丽娟','Lijuan.Chen@takeda.com',80,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02095','mt1920','GBU-SH','SMR','Panto IV','徐淼','E01377','CNGDSM0015','否'),(787,'潘豪兴','Haoxing.Pan@takeda.com',130,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02842','xb9257','GBU-SZ','MR','Panto IV + Oral Mix','段焕光','E00355','CNGDSM0065','否'),(788,'鲁颂楠','songnan.lu@takeda.com',130,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01311','wu4726','GBU-SZ','SMR','Panto IV + Oral Mix','段焕光','E00355','CNGDSM0065','否'),(789,'吴康利','kangli.wu@takeda.com',130,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01431','ma0433','GBU-SZ','SMR','Panto Oral','段焕光','E00355','CNGDSM0065','否'),(790,'官广平','guangping.guan@takeda.com',130,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01467','oe5683','GBU-SZ','SMR','Panto IV + Oral Mix','段焕光','E00355','CNGDSM0065','否'),(791,'刘辉','hui.liu2@takeda.com',130,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01793','tl9750','GBU-SZ','SMR','Panto IV + Oral Mix','段焕光','E00355','CNGDSM0065','否'),(792,'罗文捷','Wenjie1.Luo@takeda.com',130,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02992','nu5325','GBU-SZ','SMR','Panto IV + Oral Mix','段焕光','E00355','CNGDSM0065','否'),(793,'朱光萍','guangping.zhu@takeda.com',131,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01129','dw7473','GBU-SZ','Hospital Specialist','Panto IV + Oral Mix','刘洪华','E01133','CNGDSM0066','否'),(794,'李秋芹','qiuqin.li@takeda.com',131,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00733','xw3857','GBU-SZ','MR','Panto IV + Oral Mix','刘洪华','E01133','CNGDSM0066','否'),(795,'陈静','jing.chen2@takeda.com',131,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01787','vk6254','GBU-SZ','MR','Panto Oral','刘洪华','E01133','CNGDSM0066','否'),(796,'罗欣','xin.luo@takeda.com',131,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01318','ix5352','GBU-SZ','SMR','Panto IV + Oral Mix','刘洪华','E01133','CNGDSM0066','否'),(797,'蔡林衡','linheng.cai@takeda.com',131,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01413','ja8660','GBU-SZ','SMR','Panto IV + Oral Mix','刘洪华','E01133','CNGDSM0066','否'),(798,'黎华龙','hualong.li@takeda.com',131,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01433','pj6294','GBU-SZ','SMR','Panto IV + Oral Mix','刘洪华','E01133','CNGDSM0066','否'),(799,'杨永锋','Yongfeng.Yang@takeda.com',131,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02559','ka4651','GBU-SZ','SMR','Panto IV + Oral Mix','刘洪华','E01133','CNGDSM0066','否'),(800,'王恭辉','gonghui.wang@takeda.com',132,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00337','so7951','GBU-SZ','Executive Hospital Specialist','Panto IV + Oral Mix','刘鑫','E01274','CNGDSM0067','否'),(801,'黄宏华','honghua.huang@takeda.com',132,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01234','np4677','GBU-SZ','Hospital Specialist','Panto IV + Oral Mix','刘鑫','E01274','CNGDSM0067','否'),(802,'张永焕','yonghuan.zhang@takeda.com',132,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01347','bc0274','GBU-SZ','Hospital Specialist','Panto IV + Oral Mix','刘鑫','E01274','CNGDSM0067','否'),(803,'银兴叶','xingye.yin@takeda.com',132,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01396','bm1513','GBU-SZ','Hospital Specialist','Panto IV + Oral Mix','刘鑫','E01274','CNGDSM0067','否'),(804,'华忠','zhong.hua@takeda.com',132,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00353','uj5118','GBU-SZ','Hospital Specialist','Panto IV + Oral Mix','刘鑫','E01274','CNGDSM0067','否'),(805,'罗月琴','yueqin.luo@takeda.com',132,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01478','zx0216','GBU-SZ','SMR','Panto IV + Oral Mix','刘鑫','E01274','CNGDSM0067','否'),(806,'刘成','cheng1.liu@takeda.com',132,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02588','za2741','GBU-SZ','SMR','Panto IV + Oral Mix','刘鑫','E01274','CNGDSM0067','否'),(807,'刘鑫','xin.liu3@takeda.com',148,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01274','fa6802','GBU-SZ','DSM','Panto IV + Oral Mix','谢志丹','E02618','CNGRSM0012','是'),(808,'刘洪华','honghua.liu@takeda.com',148,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01133','dg4727','GBU-SZ','SDSM','Panto IV + Oral Mix','谢志丹','E02618','CNGRSM0012','是'),(809,'段焕光','Huanguang.Duan@takeda.com',148,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00355','cj5272','GBU-SZ','SDSM','Panto IV + Oral Mix','谢志丹','E02618','CNGRSM0012','是'),(810,'许夏婷','Xiating.Xu@takeda.com',148,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02790','hp9774','GBU-SZ','SDSM','Panto IV + Oral Mix','谢志丹','E02618','CNGRSM0012','是'),(811,'焦鹏','peng.jiao@takeda.com',133,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01757','ir4620','GBU-SZ','MR','Panto IV + Oral Mix','许夏婷','E02790','CNGDSM0068','否'),(812,'陈文清','wenqing.chen@takeda.com',133,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01884','ft1660','GBU-SZ','MR','Panto IV + Oral Mix','许夏婷','E02790','CNGDSM0068','否'),(813,'唐敏敏','minmin.tang@takeda.com',133,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02881','jr0826','GBU-SZ','MR','Panto IV','许夏婷','E02790','CNGDSM0068','否'),(814,'袁小虎','Xiaohu.Yuan@takeda.com',133,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01373','fw5491','GBU-SZ','SMR','Panto IV + Oral Mix','许夏婷','E02790','CNGDSM0068','否'),(815,'周玲霞','lingxia.zhou@takeda.com',133,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00342','vh9716','GBU-SZ','SMR','Panto IV + Oral Mix','许夏婷','E02790','CNGDSM0068','否'),(816,'郝培涛','Peitao.Hao@takeda.com',133,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02843','hb2507','GBU-SZ','SMR','Panto IV + Oral Mix','许夏婷','E02790','CNGDSM0068','否'),(817,'谢志丹','Zhidan.Xie@takeda.com',136,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02618','yw4885','GBU-SZ','RSM','','张宁','E00352','CNGRSD0003','是'),(818,'付春磊','chunlei.fu@takeda.com',99,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01557','fd3571','GBU-TJ','MR','Panto IV','关洪雨','E01146','CNGDSM0034','否'),(819,'王威','wei.wang3@takeda.com',99,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01560','ge5711','GBU-TJ','MR','Panto IV','关洪雨','E01146','CNGDSM0034','否'),(820,'刘博文','bowen.liu@takeda.com',99,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01813','xp6821','GBU-TJ','MR','Panto IV','关洪雨','E01146','CNGDSM0034','否'),(821,'张建欣','jianxin.zhang@takeda.com',99,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01761','lc2933','GBU-TJ','MR','Panto IV','关洪雨','E01146','CNGDSM0034','否'),(822,'肖颖阳','Yingyang.Xiao@takeda.com',99,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03085','yo3476','GBU-TJ','MR','Oral Mix','关洪雨','E01146','CNGDSM0034','否'),(823,'吕英丽','yingli.lv@takeda.com',99,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01416','ag5403','GBU-TJ','SMR','Panto IV + Oral Mix','关洪雨','E01146','CNGDSM0034','否'),(824,'关洪雨','hongyu.guan@takeda.com',143,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01146','fg4604','GBU-TJ','DSM','Panto IV + Oral Mix','刘宇明','E01127','CNGRSM0007','是'),(825,'张亚楠','yanan.zhang@takeda.com',143,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00404','ad7304','GBU-TJ','DSM','Lansoprazole','刘宇明','E01127','CNGRSM0007','是'),(826,'王媛媛','yuanyuan.wang@takeda.com',143,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02040','vi5452','GBU-TJ','DSM','Panto IV + Oral Mix','刘宇明','E01127','CNGRSM0007','是'),(827,'孙剑飞','jianfei.sun@takeda.com',143,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02174','oy4763','GBU-TJ','DSM','Panto IV + Oral Mix','刘宇明','E01127','CNGRSM0007','是'),(828,'尚玥馨','yuexin.shang@takeda.com',143,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01137','rk1977','GBU-TJ','RPM','','刘宇明','E01127','CNGRSM0007','否'),(829,'王忠雪','zhongxue.wang@takeda.com',0,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01329','hc0652','GBU-TJ','RPM','','刘宇明','E01127','','否'),(830,'卢振江','Zhenjiang.Lu@takeda.com',143,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00407','ev7702','GBU-TJ','SDSM','Panto IV + Oral Mix','刘宇明','E01127','CNGRSM0007','是'),(831,'赵耀','Yao.Zhao@takeda.com',143,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03028','yu8534','GBU-TJ','SDSM','Panto IV + Oral Mix','刘宇明','E01127','CNGRSM0007','是'),(832,'刘芳','Fang.Liu2@takeda.com',100,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01537','od5862','GBU-TJ','MR','Panto IV','卢振江','E00407','CNGDSM0035','否'),(833,'柴翠云','cuiyun.chai@takeda.com',100,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00839','yc1719','GBU-TJ','MR','Panto IV','卢振江','E00407','CNGDSM0035','否'),(834,'金钊','zhao.jin@takeda.com',100,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01831','ft2935','GBU-TJ','MR','Panto IV','卢振江','E00407','CNGDSM0035','否'),(835,'李若晦','ruohui.li@takeda.com',100,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02501','rb8989','GBU-TJ','MR','Panto Oral','卢振江','E00407','CNGDSM0035','否'),(836,'谷迎秋','yingqiu.gu@takeda.com',100,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02658','ny7671','GBU-TJ','MR','Panto IV','卢振江','E00407','CNGDSM0035','否'),(837,'王金伶','jinling.wang@takeda.com',100,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01631','pa6965','GBU-TJ','SMR','Panto IV','卢振江','E00407','CNGDSM0035','否'),(838,'龚海侠','haixia.gong@takeda.com',100,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01946','ac0496','GBU-TJ','SMR','Panto Oral','卢振江','E00407','CNGDSM0035','否'),(839,'周峰','Feng1.Zhou@takeda.com',100,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02951','ex9595','GBU-TJ','SMR','Panto IV','卢振江','E00407','CNGDSM0035','否'),(840,'张志华','Zhihua.Zhang@takeda.com',102,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02307','eo7407','GBU-TJ','Hospital Specialist','Panto IV','孙剑飞','E02174','CNGDSM0037','否'),(841,'马丽娜','marina.ma@takeda.com',0,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01136','xf4431','GBU-TJ','MR','','孙剑飞','E02174','','否'),(842,'文翠华','cuihua.wen@takeda.com',102,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01370','uc8304','GBU-TJ','MR','Panto IV + Oral Mix','孙剑飞','E02174','CNGDSM0037','否'),(843,'王曦萌','Ximeng.Wang@takeda.com',102,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02920','gb5959','GBU-TJ','MR','Panto IV + Oral Mix','孙剑飞','E02174','CNGDSM0037','否'),(844,'孙晓蕾','Xiaolei.Sun@takeda.com',102,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E03026','fh3216','GBU-TJ','MR','Panto Oral','孙剑飞','E02174','CNGDSM0037','否'),(845,'沈利','Li.Shen@takeda.com',102,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02644','wv3907','GBU-TJ','SMR','Panto IV','孙剑飞','E02174','CNGDSM0037','否'),(846,'孟玲新','Lingxin.Meng@takeda.com',102,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02948','cy5395','GBU-TJ','SMR','Panto IV + Oral Mix','孙剑飞','E02174','CNGDSM0037','否'),(847,'王静1','Jing.Wang@takeda.com',103,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01558','el8789','GBU-TJ','MR','Oral Mix','王媛媛','E02040','CNGDSM0038','否'),(848,'刘新新','xinxin.liu@takeda.com',103,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01899','yi8703','GBU-TJ','MR','Panto IV','王媛媛','E02040','CNGDSM0038','否'),(849,'左媛媛','yuanyuan.zuo@takeda.com',103,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01147','xb7213','GBU-TJ','SMR','Panto IV','王媛媛','E02040','CNGDSM0038','否'),(850,'罗铁樑','tieliang.luo@takeda.com',103,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01293','jn4332','GBU-TJ','SMR','Panto IV','王媛媛','E02040','CNGDSM0038','否'),(851,'姜涛1','Tao.Jiang2@takeda.com',103,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01409','df1715','GBU-TJ','SMR','Oral Mix','王媛媛','E02040','CNGDSM0038','否'),(852,'王然','Ran.Wang@takeda.com',103,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01469','mh0442','GBU-TJ','SMR','Panto IV + Oral Mix','王媛媛','E02040','CNGDSM0038','否'),(853,'刘宇明','yuming.liu@takeda.com',135,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01127','tx7758','GBU-TJ','RSM','','张凯军','E00250','CNGRSD0002','是'),(854,'毕毅洁','yijie.bi@takeda.com',104,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00130','zr0845','GBU-TJ','MR','Lansoprazole','张亚楠','E00404','CNGDSM0039','否'),(855,'孙培','pei.sun@takeda.com',104,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02142','wa5899','GBU-TJ','MR','Lansoprazole','张亚楠','E00404','CNGDSM0039','否'),(856,'陈超','Chao.Chen@takeda.com',104,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02398','uz0592','GBU-TJ','MR','Lansoprazole','张亚楠','E00404','CNGDSM0039','否'),(857,'张洁','Jie1.Zhang@takeda.com',104,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02532','jq9436','GBU-TJ','MR','Lansoprazole','张亚楠','E00404','CNGDSM0039','否'),(858,'王传东','chuandong.wang@takeda.com',104,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02995','wg2529','GBU-TJ','MR','Lansoprazole','张亚楠','E00404','CNGDSM0039','否'),(859,'赵多','duo.zhao@takeda.com',104,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01938','ii8941','GBU-TJ','SMR','Lansoprazole','张亚楠','E00404','CNGDSM0039','否'),(860,'姚德生','frank.yao@takeda.com',101,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01327','av0779','GBU-TJ','MR','Panto IV','赵耀','E03028','CNGDSM0036','否'),(861,'赵晓峰','xiaofeng.zhao@takeda.com',101,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01496','lj6434','GBU-TJ','MR','Panto Oral','赵耀','E03028','CNGDSM0036','否'),(862,'曲东','dong.qu@takeda.com',101,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01533','vb0394','GBU-TJ','MR','Panto IV + Oral Mix','赵耀','E03028','CNGDSM0036','否'),(863,'辛光利','guangli.xin@takeda.com',101,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00395','tf0562','GBU-TJ','MR','Lansoprazole','赵耀','E03028','CNGDSM0036','否'),(864,'薛昕','xin.xue@takeda.com',101,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02715','vb7746','GBU-TJ','MR','Panto IV + Oral Mix','赵耀','E03028','CNGDSM0036','否'),(865,'李威','Wei.Li4@takeda.com',101,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01217','ep4280','GBU-TJ','SMR','Panto Oral','赵耀','E03028','CNGDSM0036','否'),(866,'李冬冬','dongdong.li@takeda.com',82,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01407','vc2243','GBU-WZ','Hospital Specialist','Panto IV + Oral Mix','丁伟莉','E02098','CNGDSM0017','否'),(867,'邵建海','jianhai.shao@takeda.com',82,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01890','jt3423','GBU-WZ','MR','Oral Mix','丁伟莉','E02098','CNGDSM0017','否'),(868,'黄君兴','junxing.huang@takeda.com',82,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02069','ae6766','GBU-WZ','MR','Panto IV + Oral Mix','丁伟莉','E02098','CNGDSM0017','否'),(869,'何章伟','Zhangwei.He@takeda.com',82,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02434','av0710','GBU-WZ','MR','Panto IV + Oral Mix','丁伟莉','E02098','CNGDSM0017','否'),(870,'薛纪彬','Jibin.Xue@takeda.com',82,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02488','tj0252','GBU-WZ','MR','Panto IV','丁伟莉','E02098','CNGDSM0017','否'),(871,'赵碎楼','Suilou.Zhao@takeda.com',82,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02469','bn2442','GBU-WZ','SMR','Panto IV + Oral Mix','丁伟莉','E02098','CNGDSM0017','否'),(872,'潘鲁孝','luxiao.pan@takeda.com',82,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02678','xp4720','GBU-WZ','SMR','Panto IV + Oral Mix','丁伟莉','E02098','CNGDSM0017','否'),(873,'唐彬','bin.tang@takeda.com',134,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01819','wx5622','GBU-WZ','RSM','','潘海风','E01577','CNGRSD0001','是'),(874,'刘明磊','minglei.liu@takeda.com',83,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00646','hr7377','GBU-WZ','MR','Panto IV + Oral Mix','汤祎','E01187','CNGDSM0018','否'),(875,'王莹','yinga.wang@takeda.com',83,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E00887','rc4597','GBU-WZ','MR','Panto IV + Oral Mix','汤祎','E01187','CNGDSM0018','否'),(876,'何日艳','riyan.he@takeda.com',83,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02042','jb8729','GBU-WZ','MR','Panto IV + Oral Mix','汤祎','E01187','CNGDSM0018','否'),(877,'朱娈','Luan.Zhu@takeda.com',83,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02329','ph7334','GBU-WZ','MR','Panto IV + Oral Mix','汤祎','E01187','CNGDSM0018','否'),(878,'楼雁苏','yansu.lou@takeda.com',83,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01376','gt0471','GBU-WZ','SMR','Panto IV + Oral Mix','汤祎','E01187','CNGDSM0018','否'),(879,'周博杰','bojie.zhou@takeda.com',83,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01634','th1297','GBU-WZ','SMR','Panto Oral','汤祎','E01187','CNGDSM0018','否'),(880,'汤祎','yi.tang@takeda.com',140,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01187','kb0550','GBU-WZ','DSM','Panto IV + Oral Mix','唐彬','E01819','CNGRSM0004','是'),(881,'杨波','bo.yang@takeda.com',140,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01801','rg7979','GBU-WZ','DSM','Panto IV + Oral Mix','唐彬','E01819','CNGRSM0004','是'),(882,'张玮','Wei3.Zhang@takeda.com',140,1,0,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E02956','wo4339','GBU-WZ','RPM','','唐彬','E01819','CNGRSM0004','否'),(883,'姚映霞','yingxia.yao@takeda.com',140,1,1,0,1,'2015-06-06 18:25:37',1,'2015-06-06 18:25:37','E01163','do2951','GBU-WZ','SDSM','Panto IV + Oral Mix','唐彬','E01819','CNGRSM0004','是'),(884,'丁伟莉','weili.ding@takeda.com',140,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02098','ly9961','GBU-WZ','SDSM','Panto IV + Oral Mix','唐彬','E01819','CNGRSM0004','是'),(885,'颜志浪','Zhilang.Yan@takeda.com',84,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02745','zc7457','GBU-WZ','Hospital Specialist','Panto IV + Oral Mix','杨波','E01801','CNGDSM0019','否'),(886,'娄雯','Wen.Lou@takeda.com',84,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02242','ag0885','GBU-WZ','MR','Panto IV','杨波','E01801','CNGDSM0019','否'),(887,'谢作胜','Zuosheng-1.Xie@takeda.com',84,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02258','fw3775','GBU-WZ','MR','Panto IV + Oral Mix','杨波','E01801','CNGDSM0019','否'),(888,'李晓健','Xiaojian.Li@takeda.com',84,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03103','ge9404','GBU-WZ','MR','Panto IV + Oral Mix','杨波','E01801','CNGDSM0019','否'),(889,'孙林','lin.sun@takeda.com',84,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01995','rb5945','GBU-WZ','SMR','Panto IV','杨波','E01801','CNGDSM0019','否'),(890,'郑胜强','shengqiang.zheng@takeda.com',85,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01314','ou6346','GBU-WZ','Executive Hospital Specialist','Panto IV + Oral Mix','姚映霞','E01163','CNGDSM0020','否'),(891,'陈立华','lihua.chen@takeda.com',85,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01321','uw4947','GBU-WZ','Hospital Specialist','Panto IV + Oral Mix','姚映霞','E01163','CNGDSM0020','否'),(892,'鲁鹏','peng.lu@takeda.com',85,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01833','tn8630','GBU-WZ','Hospital Specialist','Panto IV + Oral Mix','姚映霞','E01163','CNGDSM0020','否'),(893,'赵辉辉','huihui.zhao@takeda.com',85,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01510','jf5391','GBU-WZ','MR','Panto IV + Oral Mix','姚映霞','E01163','CNGDSM0020','否'),(894,'张静','jing.zhang3@takeda.com',85,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01805','cj2775','GBU-WZ','SMR','Panto IV + Oral Mix','姚映霞','E01163','CNGDSM0020','否'),(895,'张慧','hui.zhang@takeda.com',86,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00316','du0037','GBU-WZ','Hospital Specialist','Oral Mix','郑武','','CNGDSM0021','否'),(896,'程德辉','dehui.cheng@takeda.com',86,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01641','ar2387','GBU-WZ','MR','Oral Mix','郑武','','CNGDSM0021','否'),(897,'林旭克','Xuke.Lin@takeda.com',86,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02400','ab6332','GBU-WZ','MR','Panto Oral','郑武','','CNGDSM0021','否'),(898,'温灵枝','lingzhi.wen@takeda.com',86,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02454','tw1852','GBU-WZ','MR','Oral Mix','郑武','','CNGDSM0021','否'),(899,'张瑞利','Ruili.Zhang@takeda.com',86,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02380','fi1797','GBU-WZ','SMR','Oral Mix','郑武','','CNGDSM0021','否'),(900,'王莉娜','lina.wang@takeda.com',0,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01172','wl1964','GBU-XJ','DSM','','陈青莲','E01411','','是'),(901,'潘帅','shuai.pan@takeda.com',144,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01546','mx2224','GBU-XJ','DSM','Panto IV + Oral Mix','陈青莲','E01411','CNGRSM0008','是'),(902,'穆轲','Ke.Mu@takeda.com',144,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02456','fb9298','GBU-XJ','DSM','Panto IV + Oral Mix','陈青莲','E01411','CNGRSM0008','是'),(903,'庄军','Jun.Zhuang@takeda.com',144,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02930','sc0657','GBU-XJ','DSM','Panto IV + Oral Mix','陈青莲','E01411','CNGRSM0008','是'),(904,'张梅静','Meijing.Zhang@takeda.com',144,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02325','ee2692','GBU-XJ','RPM','','陈青莲','E01411','CNGRSM0008','否'),(905,'张馨','xin3.zhang@takeda.com',105,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02363','gf5448','GBU-XJ','Hospital Specialist','Panto IV + Oral Mix','穆轲','E02456','CNGDSM0040','否'),(906,'成彩虹','Caihong.Cheng@takeda.com',105,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01240','ll2317','GBU-XJ','MR','Panto Oral','穆轲','E02456','CNGDSM0040','否'),(907,'刘菊梅','jumei.liu@takeda.com',105,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00698','qr1089','GBU-XJ','MR','Panto IV','穆轲','E02456','CNGDSM0040','否'),(908,'刘晓琨','Xiaokun.Liu@takeda.com',105,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02359','mu7688','GBU-XJ','MR','Lansoprazole','穆轲','E02456','CNGDSM0040','否'),(909,'曹岩清','Yanqing.Cao@takeda.com',105,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02507','hv6518','GBU-XJ','MR','Panto IV + Oral Mix','穆轲','E02456','CNGDSM0040','否'),(910,'王惠娟','Huijuan.Wang@takeda.com',105,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02534','xx0804','GBU-XJ','MR','Panto IV + Oral Mix','穆轲','E02456','CNGDSM0040','否'),(911,'蒙婕','jie.meng@takeda.com',106,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01482','ot6585','GBU-XJ','MR','Panto IV + Oral Mix','潘帅','E01546','CNGDSM0041','否'),(912,'张千业','qianye.zhang@takeda.com',106,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02826','ed9807','GBU-XJ','MR','Panto IV + Oral Mix','潘帅','E01546','CNGDSM0041','否'),(913,'宋佳','Jia.Song@takeda.com',106,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02968','tb1977','GBU-XJ','MR','Panto IV + Oral Mix','潘帅','E01546','CNGDSM0041','否'),(914,'马顺波','Shunbo.Ma@takeda.com',106,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03102','ij4798','GBU-XJ','MR','Panto IV + Oral Mix','潘帅','E01546','CNGDSM0041','否'),(915,'康紫龙','zilong.kang@takeda.com',106,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03038','cy3788','GBU-XJ','MR','Panto IV + Oral Mix','潘帅','E01546','CNGDSM0041','否'),(916,'曹子龙','zilong.cao@takeda.com',106,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01344','oo7506','GBU-XJ','SMR','Panto IV','潘帅','E01546','CNGDSM0041','否'),(917,'徐良','liang.xu@takeda.com',106,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01545','gz0937','GBU-XJ','SMR','Panto IV','潘帅','E01546','CNGDSM0041','否'),(918,'辛玉萍','Yuping.Xin@takeda.com',106,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02330','nm6451','GBU-XJ','SMR','Panto IV + Oral Mix','潘帅','E01546','CNGDSM0041','否'),(919,'陈青莲','qinglian.chen@takeda.com',135,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01411','hv8954','GBU-XJ','RSM(Acting)','','张凯军','E00250','CNGRSD0002','是'),(920,'田瑜','yu.tian@takeda.com',107,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01889','qg1651','GBU-XJ','Hospital Specialist','Panto IV','庄军','E02930','CNGDSM0042','否'),(921,'袁子翔','zixiang.yuan@takeda.com',107,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03024','ve5716','GBU-XJ','Hospital Specialist','Panto IV + Oral Mix','庄军','E02930','CNGDSM0042','否'),(922,'张仍','Reng.Zhang@takeda.com',107,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02326','km4611','GBU-XJ','MR','Panto IV + Oral Mix','庄军','E02930','CNGDSM0042','否'),(923,'江磊','lei.jiang@takeda.com',107,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02510','fd4215','GBU-XJ','MR','Panto IV + Oral Mix','庄军','E02930','CNGDSM0042','否'),(924,'杨毅','Yi1.Yang@takeda.com',107,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02902','ib4274','GBU-XJ','MR','Panto Oral','庄军','E02930','CNGDSM0042','否'),(925,'杨静','Jing1.Yang@takeda.com',107,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03046','xg2571','GBU-XJ','MR','Lansoprazole','庄军','E02930','CNGDSM0042','否'),(926,'赵进庆','jinqing.zhao@takeda.com',107,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02905','vd8388','GBU-XJ','SMR','Panto IV','庄军','E02930','CNGDSM0042','否'),(927,'曲耀斌','yaobin.qu@takeda.com',227,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00920','gw2675','KA','KA Head','','王卫','E01821','GM-01','是'),(928,'顾子丹','zidan.gu@takeda.com',230,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01867','aj7679','KA','District Project Manager','','胡桂明','E00277','KA0003','否'),(929,'张华俊','huajun.zhang@takeda.com',230,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00595','ul1716','KA','KA Manager','','胡桂明','E00277','KA0003','否'),(930,'曲健','jian.qu@takeda.com',230,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01123','tk8919','KA','KA Manager','','胡桂明','E00277','KA0003','否'),(931,'陈慧','hui.chen@takeda.com',230,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01739','ws5354','KA','KA Manager','','胡桂明','E00277','KA0003','否'),(932,'赵元茜','Yuanqian.Zhao@takeda.com',230,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00311','bh7038','KA','KA Manager','','胡桂明','E00277','KA0003','否'),(933,'刘志坚','Zhijian.Liu@takeda.com',230,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00386','ix6943','KA','Sr. KA Manager','','胡桂明','E00277','KA0003','否'),(934,'吴桂平','guiping.wu@takeda.com',230,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01124','qh9434','KA','Sr. KA Manager','','胡桂明','E00277','KA0003','否'),(935,'江明赛','mingsai.jiang@takeda.com',230,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01893','gk8553','KA','Sr. KA Manager','','胡桂明','E00277','KA0003','否'),(936,'付钰','Yu.Fu@takeda.com',232,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00274','ht4020','KA','KA Manager','','李凯2','E01661','KA0014','否'),(937,'常可新','kexin.chang@takeda.com',232,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01120','jh1761','KA','KA Manager','','李凯2','E01661','KA0014','否'),(938,'杨艳娇','yanjiao.yang@takeda.com',232,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01718','ik8217','KA','KA Manager','','李凯2','E01661','KA0014','否'),(939,'黄威','Wei.Huang@takeda.com',232,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00526','om2548','KA','KA Manager','','李凯2','E01661','KA0014','否'),(940,'施正中','zhengzhong.shi@takeda.com',232,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02021','te1918','KA','KA Manager','','李凯2','E01661','KA0014','否'),(941,'牛倩','qian.niu@takeda.com',232,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01701','wg5672','KA','Sr. KA Manager','','李凯2','E01661','KA0014','否'),(942,'欧洁灵','jieling.ou@takeda.com',231,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01865','ir7251','KA','District Project Manager','','龙迎梅','E01662','KA0011','否'),(943,'朱燕清','judy.zhu@takeda.com',231,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01900','pw2795','KA','KA Manager','','龙迎梅','E01662','KA0011','否'),(944,'胡荣','Rong.Hu@takeda.com',231,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02249','lr6987','KA','KA Manager','','龙迎梅','E01662','KA0011','否'),(945,'漆安定','anding.qi@takeda.com',231,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01702','ju0574','KA','Sr. KA Manager','','龙迎梅','E01662','KA0011','否'),(946,'游晓','Pitt.you@takeda.com',231,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01936','cg1987','KA','Sr. KA Manager','','龙迎梅','E01662','KA0011','否'),(947,'贺童','Jessy.He@takeda.com',229,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00029','ig2603','KA','KA Development Manager','','曲耀斌','E00920','KA0002','否'),(948,'刘春娇','chunjiao.liu@takeda.com',229,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01868','cb8584','KA','National Project Manager','','曲耀斌','E00920','KA0002','否'),(949,'王檬','meng.wang@takeda.com',229,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00933','ww5129','KA','Project Supervisor','','曲耀斌','E00920','KA0002','否'),(950,'胡桂明','Guiming.Hu@takeda.com',229,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00277','nx5781','KA','Regional KA Director_East','','曲耀斌','E00920','KA0002','否'),(951,'龙迎梅','yingmei.long@takeda.com',229,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01662','xf9167','KA','Regional KA Manager_South','','曲耀斌','E00920','KA0002','否'),(952,'李凯','Kai-8.Li@takeda.com',229,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01661','ot5619','KA','Sr. Regional KA Manager_North','','曲耀斌','E00920','KA0002','否'),(953,'吴非','Fei1.Wu@takeda.com',237,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02537','ig7770','Medical Affairs','Medical Advisor','','李磊','E00815','ONCO-MAM-01','否'),(954,'杨瑶瑶','wendy.yang@takeda.com',0,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01706','dx4993','Medical Affairs','Sr. MSL','','李磊','E00815','','否'),(955,'刘鸣明','mingming.liu@takeda.com',1,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00992','zu9579','Medical Affairs','Medical Advisor','','谢晓宇','E01086','AMD-01','否'),(956,'马传荣','Maria.Ma@takeda.com',223,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02942','ms7731','Medical Affairs','MSL','','谢晓宇','E01086','CVM-MSLM-01','否'),(957,'周璇和','Joe.Zhou@takeda.com',228,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02943','ap4424','Medical Affairs','MSL','','谢晓宇','E01086','GM-MA-01','否'),(958,'金鑫','xin.jin@takeda.com',223,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01764','bf1992','Medical Affairs','Sr. MSL','','谢晓宇','E01086','CVM-MSLM-01','否'),(959,'袁丁','Ding.Yuan@takeda.com',238,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02308','ft8582','Medical Affairs','MSL','','张冀宁','E00814','ONCO-MSLM-01','否'),(960,'夏冰','Bing.Xia@takeda.com',238,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02979','gy2483','Medical Affairs','MSL','','张冀宁','E00814','ONCO-MSLM-01','否'),(961,'张清睿','qingrui.zhang@takeda.com',0,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03170','ki7591','Medical Affairs','MSL','','张冀宁','E00814','','否'),(962,'王杉','Shan.Wang@takeda.com',0,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03017','pz0791','Medical Affairs','Medical Information Supervisor','','张婷艳','E02817','','否'),(963,'罗璐','Lu.Luo@takeda.com',0,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00105','hz1847','Medical Affairs','Sr. Clinical Research Associate','','张婷艳','E02817','','否'),(964,'刘燕','Yan.Liu@takeda.com',234,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02291','jd8940','Medical Affairs','Sr. MI Officer','','张婷艳','E02817','MI&PVM-01','否'),(965,'张英楠','Yingnan.Zhang@takeda.com',234,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02603','xq3797','Medical Affairs','Sr. MI Specialist','','张婷艳','E02817','MI&PVM-01','否'),(966,'赵增荣','zengrong.zhao@takeda.com',0,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02556','mr7421','Medical Affairs','Sr. PV Specialist','','张婷艳','E02817','','否'),(967,'祝笠','Li3.Zhu@takeda.com',0,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02954','zm8322','Medical Affairs','CV TA Lead','','张英民','E02361','','否'),(968,'曹明君','mingjun.cao@takeda.com',1,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00571','og4358','Medical Affairs','Medical Advisor','','张英民','E02361','AMD-01','否'),(969,'毕培轩','peixuan.bi@takeda.com',1,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03008','rp6854','Medical Affairs','MSL','','张英民','E02361','AMD-01','否'),(970,'陈明','Ming-1.Chen@takeda.com',1,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02274','ev4373','Medical Affairs','Sr. Medical Advisor','','张英民','E02361','AMD-01','否'),(971,'张英民','Yingmin.Zhang@takeda.com',233,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02361','tv8890','Medical Affairs','Associate TA Director-CVM','','张云','E01097','MD-01','否'),(972,'谢晓宇','justin.xie@takeda.com',222,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01086','oi9688','Medical Affairs','Associate TA Manager-GM','','张云','E01097','CVM&GM-MAM-01','否'),(973,'张婷艳','Tingyan.Zhang@takeda.com',234,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02817','xt3480','Medical Affairs','Sr. Medical Operation Manager','','张云','E01097','MI&PVM-01','否'),(974,'朱芳','Niki.Zhu@takeda.com',233,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00100','yh7981','Medical Affairs','Sr. TA Manager-GI','','张云','E01097','MD-01','否'),(975,'张冀宁','cathy.zhang@takeda.com',233,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00814','ph8342','Medical Affairs','TA Manager-Non Onco','','张云','E01097','MD-01','否'),(976,'李磊','lei-1.li@takeda.com',233,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00815','ou0980','Medical Affairs','TA Manager-Onco','','张云','E01097','MD-01','否'),(977,'郭璇','Xuan.Guo@takeda.com',226,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02240','rv4685','Medical Affairs','Medical Advisor','','朱芳','E00100','GI&RE-MAM-01','否'),(978,'张琳','Lin.Zhang@takeda.com',226,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02230','vt2261','Medical Affairs','Medical Advisor','','朱芳','E00100','GI&RE-MAM-01','否'),(979,'范晓思','xiaosi.fan@takeda.com',240,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00695','br4340','Medical Affairs','MSL','','朱芳','E00100','RE&GI-MSLM-01','否'),(980,'冯晓飞','eric.feng@takeda.com',223,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01707','xg8795','Medical Affairs','MSL','','祝笠','E02954','CVM-MSLM-01','否'),(981,'张晓东','Peter.Zhang@takeda.com',149,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00074','tg7703','OBU','Head of OBU','Enantone','王卫','E01821','','是'),(982,'吴文凯','Wenkai.Wu@takeda.com',149,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00559','tg3946','OBU','NSD','Enantone','崔一','E00114','CNOBUD0001','是'),(983,'霍晶','jing.huo@takeda.com',151,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00928','ij0424','OBU-BJ','Hospital Specialist','Enantone','苏文奇','E02788','CNODSM0002','否'),(984,'姜淑娟','Shujuan.Jiang@takeda.com',151,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02548','fa0200','OBU-BJ','Hospital Specialist','Enantone','苏文奇','E02788','CNODSM0002','否'),(985,'王晓静','xiaojing.wang@takeda.com',151,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02634','nt8670','OBU-BJ','Hospital Specialist','Enantone','苏文奇','E02788','CNODSM0002','否'),(986,'王冲','Chong.Wang@takeda.com',151,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02499','sl0388','OBU-BJ','MR','Enantone','苏文奇','E02788','CNODSM0002','否'),(987,'陈立宏','Lihong.Chen@takeda.com',151,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02927','zl6910','OBU-BJ','MR','Enantone','苏文奇','E02788','CNODSM0002','否'),(988,'张涛','Tao-1.Zhang@takeda.com',151,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00862','di8483','OBU-BJ','SMR','Enantone','苏文奇','E02788','CNODSM0002','否'),(989,'熊汉成','Hancheng.Xiong@takeda.com',180,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02850','jh8692','OBU-BJ','MR','Enantone','苏小燕','E03108','CNODSM0031','否'),(990,'邹玥','yue.zou@takeda.com',155,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00129','sm9538','OBU-BJ','Hospital Specialist','Enantone','王欣','E00128','CNODSM0006','否'),(991,'李倩','qian.li@takeda.com',155,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00132','xn9025','OBU-BJ','MR','Enantone','王欣','E00128','CNODSM0006','否'),(992,'朱俊杰','junjie.zhu@takeda.com',155,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00140','lo2452','OBU-BJ','MR','Enantone','王欣','E00128','CNODSM0006','否'),(993,'张晶晶','jingjing.zhang@takeda.com',182,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00647','pz6770','OBU-BJ','RSM','Enantone','吴文凯','E00559','CNONSD0001','是'),(994,'王雨','yu.wang@takeda.com',156,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00848','ws8127','OBU-BJ','Hospital Specialist','Enantone','于辉','E02282','CNODSM0007','否'),(995,'吴琼','qiong1.wu@takeda.com',156,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02698','mt3664','OBU-BJ','Hospital Specialist','Enantone','于辉','E02282','CNODSM0007','否'),(996,'李玲玲','lingling.li@takeda.com',156,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01704','hf8517','OBU-BJ','MR','Enantone','于辉','E02282','CNODSM0007','否'),(997,'陈亚雪','yaxue.chen@takeda.com',156,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01974','FZ1454','OBU-BJ','MR','Enantone','于辉','E02282','CNODSM0007','否'),(998,'洪波','bo.hong@takeda.com',156,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00131','ab0555','OBU-BJ','SMR','Enantone','于辉','E02282','CNODSM0007','否'),(999,'高文笑','Wenxiao.Gao@takeda.com',156,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02652','em6452','OBU-BJ','SMR','Enantone','于辉','E02282','CNODSM0007','否'),(1000,'刘堃','Kun-1.Liu@takeda.com',154,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00700','bc7515','OBU-BJ','MR','Enantone','袁刚毅','E00643','CNODSM0005','否'),(1001,'李军','Jun-1.Li@takeda.com',154,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00949','ze7439','OBU-BJ','MR','Enantone','袁刚毅','E00643','CNODSM0005','否'),(1002,'闫萍','ping.yan@takeda.com',154,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01909','ij4471','OBU-BJ','MR','Enantone','袁刚毅','E00643','CNODSM0005','否'),(1003,'陈静','jing2.chen@takeda.com',154,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02320','nd7976','OBU-BJ','MR','Enantone','袁刚毅','E00643','CNODSM0005','否'),(1004,'刘士魁','Shikui.Liu@takeda.com',154,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03005','qq9255','OBU-BJ','MR','Enantone','袁刚毅','E00643','CNODSM0005','否'),(1005,'吴金宝','jinbao.wu@takeda.com',154,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00706','rc4931','OBU-BJ','SMR','Enantone','袁刚毅','E00643','CNODSM0005','否'),(1006,'陈立国','liguo.chen@takeda.com',154,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00950','ei7065','OBU-BJ','SMR','Enantone','袁刚毅','E00643','CNODSM0005','否'),(1007,'苗智博','zhibo.Miao@takeda.com',154,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03066','md3478','OBU-BJ','SMR','Enantone','袁刚毅','E00643','CNODSM0005','否'),(1008,'赵思思','sisi.zhao@takeda.com',183,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00122','bp7995','OBU-BJ','DSM','Enantone','张晶晶','E00647','CNORSM0001','是'),(1009,'王欣','Xin.Wang@takeda.com',183,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00128','tn0858','OBU-BJ','DSM','Enantone','张晶晶','E00647','CNORSM0001','是'),(1010,'袁刚毅','gangyi.yuan@takeda.com',183,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00643','kh1751','OBU-BJ','DSM','Enantone','张晶晶','E00647','CNORSM0001','是'),(1011,'于辉','Hui.Yu@takeda.com',183,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02282','wk3935','OBU-BJ','DSM','Enantone','张晶晶','E00647','CNORSM0001','是'),(1012,'苏文奇','Wenqi.Su@takeda.com',183,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02788','dx6522','OBU-BJ','DSM','Enantone','张晶晶','E00647','CNORSM0001','是'),(1013,'邹广华','Guanghua.Zou@takeda.com',183,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03109','uo6713','OBU-BJ','DSM','Enantone','张晶晶','E00647','CNORSM0001','是'),(1014,'尚丽颖','Liying.Shang@takeda.com',183,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02734','ty7611','OBU-BJ','RPM','','张晶晶','E00647','CNORSM0001','否'),(1015,'苏小燕','Xiaoyan.Su@takeda.com',183,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03108','ry5989','OBU-BJ','SDSM','Enantone','张晶晶','E00647','CNORSM0001','是'),(1016,'高多佳','Duojia.Gao@takeda.com',152,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02431','tk3830','OBU-BJ','MR','Enantone','赵思思','E00122','CNODSM0003','否'),(1017,'支丹','dan.zhi@takeda.com',152,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02586','fc5698','OBU-BJ','MR','Enantone','赵思思','E00122','CNODSM0003','否'),(1018,'刘丹','dan.liu@takeda.com',152,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00117','hz6641','OBU-BJ','SMR','Enantone','赵思思','E00122','CNODSM0003','否'),(1019,'孙晓雪','xiaoxue.sun@takeda.com',152,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01430','au1276','OBU-BJ','SMR','Enantone','赵思思','E00122','CNODSM0003','否'),(1020,'郝国平','Guoping.Hao@takeda.com',152,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02505','xb5841','OBU-BJ','SMR','Enantone','赵思思','E00122','CNODSM0003','否'),(1021,'程春','Chun.Cheng@takeda.com',152,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02633','fn1206','OBU-BJ','SMR','Enantone','赵思思','E00122','CNODSM0003','否'),(1022,'江思颖','siying.jiang@takeda.com',152,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02892','ko0914','OBU-BJ','SMR','Enantone','赵思思','E00122','CNODSM0003','否'),(1023,'朱航宇','hangyu.zhu@takeda.com',150,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00680','ut2333','OBU-BJ','MR','Enantone','邹广华','E03109','CNODSM0001','否'),(1024,'王璐','lu.wang@takeda.com',0,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01719','ss6247','OBU-BJ','MR','Enantone','邹广华','E03109','','否'),(1025,'吴成','cheng.wu@takeda.com',150,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00737','rr0018','OBU-BJ','SMR','Enantone','邹广华','E03109','CNODSM0001','否'),(1026,'黄华','hua.huang@takeda.com',150,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00821','bi2226','OBU-BJ','SMR','Enantone','邹广华','E03109','CNODSM0001','否'),(1027,'初宇卓','yuzhuo.chu@takeda.com',150,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01873','qh9992','OBU-BJ','SMR','Enantone','邹广华','E03109','CNODSM0001','否'),(1028,'尹重阳','Chongyang.Yin@takeda.com',150,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03047','wj3647','OBU-BJ','SMR','Enantone','邹广华','E03109','CNODSM0001','否'),(1029,'易栋','dong.yi@takeda.com',161,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00221','te1980','OBU-GD','Hospital Specialist','Enantone','蔡伟信','E00220','CNODSM0012','否'),(1030,'戴文标','Wenbiao.Dai@takeda.com',161,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02529','ju3868','OBU-GD','MR','Enantone','蔡伟信','E00220','CNODSM0012','否'),(1031,'邱俊东','Jundong.Qiu@takeda.com',161,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03070','vx4819','OBU-GD','MR','Enantone','蔡伟信','E00220','CNODSM0012','否'),(1032,'陈晴','qing.chen@takeda.com',161,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00222','nl5883','OBU-GD','SMR','Enantone','蔡伟信','E00220','CNODSM0012','否'),(1033,'谢雷','lei.xie@takeda.com',161,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E01679','ym2347','OBU-GD','SMR','Enantone','蔡伟信','E00220','CNODSM0012','否'),(1034,'潘茵琳','Yinlin.Pan@takeda.com',161,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02270','sh4367','OBU-GD','SMR','Enantone','蔡伟信','E00220','CNODSM0012','否'),(1035,'黄庆标','Qingbiao.Huang@takeda.com',161,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02457','rp6510','OBU-GD','SMR','Enantone','蔡伟信','E00220','CNODSM0012','否'),(1036,'谢泳雪','yongxue.xie@takeda.com',159,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00657','qy2152','OBU-GD','MR','Enantone','江文泰','E00823','CNODSM0010','否'),(1037,'林家辉','Jiahui.Lin@takeda.com',159,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02567','px3540','OBU-GD','MR','Enantone','江文泰','E00823','CNODSM0010','否'),(1038,'杨敏','min.yang@takeda.com',159,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02789','xo6428','OBU-GD','MR','Enantone','江文泰','E00823','CNODSM0010','否'),(1039,'臧珊','Shan.Zang@takeda.com',159,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02757','xg5996','OBU-GD','MR','Enantone','江文泰','E00823','CNODSM0010','否'),(1040,'房宏雄','hongxiong.fang@takeda.com',159,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00231','ls5369','OBU-GD','SMR','Enantone','江文泰','E00823','CNODSM0010','否'),(1041,'宁春婵','chunchan.ning@takeda.com',159,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02292','tj6695','OBU-GD','SMR','Enantone','江文泰','E00823','CNODSM0010','否'),(1042,'谢添','Tian1.Xie@takeda.com',159,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02863','gq1430','OBU-GD','SMR','Enantone','江文泰','E00823','CNODSM0010','否'),(1043,'夏跃兰','Yuelan.Xia@takeda.com',184,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00212','nl3729','OBU-GD','DSM','Enantone','王佑伟','E00875','CNORSM0002','是'),(1044,'江文泰','wentai.jiang@takeda.com',184,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00823','pj4159','OBU-GD','DSM','Enantone','王佑伟','E00875','CNORSM0002','是'),(1045,'周文洁','wenjie.zhou@takeda.com',184,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00979','ii5000','OBU-GD','DSM','Enantone','王佑伟','E00875','CNORSM0002','是'),(1046,'许伟庆','Weiqing.Xu@takeda.com',184,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02264','fl4819','OBU-GD','DSM','Enantone','王佑伟','E00875','CNORSM0002','是'),(1047,'赵发','Fa.Zhao@takeda.com',184,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02466','im4878','OBU-GD','DSM','Enantone','王佑伟','E00875','CNORSM0002','是'),(1048,'蔡伟信','Weixin.Cai@takeda.com',184,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00220','ow0066','OBU-GD','SDSM','Enantone','王佑伟','E00875','CNORSM0002','是'),(1049,'叶金淑','jinshu.ye@takeda.com',184,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00619','qv0248','OBU-GD','SRPM','','王佑伟','E00875','CNORSM0002','否'),(1050,'王佑伟','youwei.wang@takeda.com',182,1,1,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00875','qx6617','OBU-GD','RSM','Enantone','吴文凯','E00559','CNONSD0001','是'),(1051,'欧阳启良','qiliang.ouyang@takeda.com',162,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00228','jm8160','OBU-GD','Hospital Specialist','Enantone','夏跃兰','E00212','CNODSM0013','否'),(1052,'龚洪霞','Hongxia.Gong@takeda.com',162,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02585','og6376','OBU-GD','Hospital Specialist','Enantone','夏跃兰','E00212','CNODSM0013','否'),(1053,'刘琰玲','yanling.liu@takeda.com',162,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00772','qw6468','OBU-GD','MR','Enantone','夏跃兰','E00212','CNODSM0013','否'),(1054,'吴谦','Qian.Wu@takeda.com',162,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02293','if8226','OBU-GD','MR','Enantone','夏跃兰','E00212','CNODSM0013','否'),(1055,'朱银林','Yinlin.Zhu@takeda.com',162,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02527','gy2647','OBU-GD','MR','Enantone','夏跃兰','E00212','CNODSM0013','否'),(1056,'汪新燕','xinyan.wang@takeda.com',162,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00232','bp2142','OBU-GD','SMR','Enantone','夏跃兰','E00212','CNODSM0013','否'),(1057,'袁明波','mingbo.yuan@takeda.com',158,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03147','qd5320','OBU-GD','Hospital Specialist','Enantone','许伟庆','E02264','CNODSM0009','否'),(1058,'冼秋宜','qiuyi.xian@takeda.com',158,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00956','pi4977','OBU-GD','MR','Enantone','许伟庆','E02264','CNODSM0009','否'),(1059,'查东虎','donghu.zha@takeda.com',158,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00991','qy3813','OBU-GD','MR','Enantone','许伟庆','E02264','CNODSM0009','否'),(1060,'曹武卫','wuwei.cao@takeda.com',158,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02839','dq1813','OBU-GD','MR','Enantone','许伟庆','E02264','CNODSM0009','否'),(1061,'王飞','fei.wang@takeda.com',158,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E00215','il0803','OBU-GD','SMR','Enantone','许伟庆','E02264','CNODSM0009','否'),(1062,'吴娟','Juan.Wu@takeda.com',158,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02390','zm4565','OBU-GD','SMR','Enantone','许伟庆','E02264','CNODSM0009','否'),(1063,'洪祺琼','Qiqiong.Hong@takeda.com',158,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E02477','ha2630','OBU-GD','SMR','Enantone','许伟庆','E02264','CNODSM0009','否'),(1064,'林培立','Peili.Lin@takeda.com',157,1,0,0,1,'2015-06-06 18:25:38',1,'2015-06-06 18:25:38','E03118','yy4512','OBU-GD','MR','Enantone','赵发','E02466','CNODSM0008','否'),(1065,'潘燕萍','yanping.pan@takeda.com',157,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00214','cg9506','OBU-GD','SMR','Enantone','赵发','E02466','CNODSM0008','否'),(1066,'冯道远','Daoyuan.Feng@takeda.com',157,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02530','md0371','OBU-GD','SMR','Enantone','赵发','E02466','CNODSM0008','否'),(1067,'柯雄斌','Xiongbin.Ke@takeda.com',157,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02563','ps4341','OBU-GD','SMR','Enantone','赵发','E02466','CNODSM0008','否'),(1068,'陈慎填','Shentian.Chen@takeda.com',157,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03068','wo9940','OBU-GD','SMR','Enantone','赵发','E02466','CNODSM0008','否'),(1069,'陆叶','ye.lu@takeda.com',160,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01678','bz2877','OBU-GD','MR','Enantone','周文洁','E00979','CNODSM0011','否'),(1070,'王国媛','guoyuan.wang@takeda.com',160,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02196','oe4393','OBU-GD','MR','Enantone','周文洁','E00979','CNODSM0011','否'),(1071,'焦楠','Nan.Jiao@takeda.com',160,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02422','jd9691','OBU-GD','MR','Enantone','周文洁','E00979','CNODSM0011','否'),(1072,'郑良艳','liangyan.zheng@takeda.com',160,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03071','so3542','OBU-GD','MR','Enantone','周文洁','E00979','CNODSM0011','否'),(1073,'韩艳','yan.han@takeda.com',160,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02153','ls2565','OBU-GD','SMR','Enantone','周文洁','E00979','CNODSM0011','否'),(1074,'张金娥','jine.zhang@takeda.com',185,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00224','yy1196','OBU-HB','DSM','Enantone','杜鹏飞','E00225','CNORSM0003','是'),(1075,'赵芸','yun.zhao@takeda.com',185,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00655','sk5396','OBU-HB','DSM','Enantone','杜鹏飞','E00225','CNORSM0003','是'),(1076,'郭竹琴','Zhuqin.Guo@takeda.com',185,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00135','gj1752','OBU-HB','DSM','Enantone','杜鹏飞','E00225','CNORSM0003','是'),(1077,'李金芳','jinfang.li@takeda.com',185,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01654','ze7718','OBU-HB','RPM','','杜鹏飞','E00225','CNORSM0003','否'),(1078,'黄桂斌','guibin.huang@takeda.com',185,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02248','tm6362','OBU-HB','SDSM','Enantone','杜鹏飞','E00225','CNORSM0003','是'),(1079,'荆玉辉','yuhui.jing@takeda.com',166,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00151','af2302','OBU-HB','MR','Enantone','郭竹琴','E00135','CNODSM0017','否'),(1080,'望丽','Li-2.Wang@takeda.com',166,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00502','vx9117','OBU-HB','MR','Enantone','郭竹琴','E00135','CNODSM0017','否'),(1081,'邵光俊','guangjun.shao@takeda.com',166,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00670','ye5040','OBU-HB','MR','Enantone','郭竹琴','E00135','CNODSM0017','否'),(1082,'王营','Ying1.Wang@takeda.com',166,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02542','tw3574','OBU-HB','MR','Enantone','郭竹琴','E00135','CNODSM0017','否'),(1083,'刘珍','Zhen1.Liu@takeda.com',166,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02746','es7718','OBU-HB','MR','Enantone','郭竹琴','E00135','CNODSM0017','否'),(1084,'彭晶','jing.peng@takeda.com',165,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00957','yy2274','OBU-HB','MR','Enantone','黄桂斌','E02248','CNODSM0016','否'),(1085,'屈孝凤','Xiaofeng.Qu@takeda.com',165,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02597','kf3243','OBU-HB','MR','Enantone','黄桂斌','E02248','CNODSM0016','否'),(1086,'刘蕾','Lei3.Liu@takeda.com',165,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02752','le8616','OBU-HB','MR','Enantone','黄桂斌','E02248','CNODSM0016','否'),(1087,'陆丁','Ding.Lu@takeda.com',165,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02780','ee5800','OBU-HB','MR','Enantone','黄桂斌','E02248','CNODSM0016','否'),(1088,'屈洋','Yang.Qu@takeda.com',165,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03094','sz9637','OBU-HB','MR','Enantone','黄桂斌','E02248','CNODSM0016','否'),(1089,'徐浩','hao.xu@takeda.com',165,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00605','rf2016','OBU-HB','SMR','Enantone','黄桂斌','E02248','CNODSM0016','否'),(1090,'杜鹏飞','Pengfei.Du@takeda.com',182,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00225','jg8301','OBU-HB','RSM','Enantone','吴文凯','E00559','CNONSD0001','是'),(1091,'傅秋明','qiuming.fu@takeda.com',164,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01980','iw5972','OBU-HB','MR','Enantone','张金娥','E00224','CNODSM0015','否'),(1092,'朱启敏','Qimin.Zhu@takeda.com',164,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02474','bq3645','OBU-HB','MR','Enantone','张金娥','E00224','CNODSM0015','否'),(1093,'王晗','han.wang@takeda.com',164,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02543','ut4947','OBU-HB','MR','Enantone','张金娥','E00224','CNODSM0015','否'),(1094,'谢艳萍','yanping.xie@takeda.com',164,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00229','dt2963','OBU-HB','SMR','Enantone','张金娥','E00224','CNODSM0015','否'),(1095,'谢俊','jun.xie@takeda.com',164,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00510','wg9808','OBU-HB','SMR','Enantone','张金娥','E00224','CNODSM0015','否'),(1096,'周芬雪','fenxue.zhou@takeda.com',164,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00645','ds4818','OBU-HB','SMR','Enantone','张金娥','E00224','CNODSM0015','否'),(1097,'余船','chuan.yu@takeda.com',163,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00995','sw4662','OBU-HB','MR','Enantone','赵芸','E00655','CNODSM0014','否'),(1098,'让兴敏','Xingmin.Rang@takeda.com',163,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03105','hw2372','OBU-HB','MR','Enantone','赵芸','E00655','CNODSM0014','否'),(1099,'钟启平','qiping.zhong@takeda.com',163,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02901','ex3724','OBU-HB','SMR','Enantone','赵芸','E00655','CNODSM0014','否'),(1100,'耿嘉美','jiamei.geng@takeda.com',181,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00832','jv6504','OBU-JS','MR','Enantone','空缺','','CNODSM0032','否'),(1101,'章观保','guanbao.zhang@takeda.com',167,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02997','su1388','OBU-JS','MR','Enantone','林莉','E00653','CNODSM0018','否'),(1102,'缪吴泷','wulong.miao@takeda.com',167,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03155','ir0907','OBU-JS','MR','Enantone','林莉','E00653','CNODSM0018','否'),(1103,'戚宇','yu.qi@takeda.com',167,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00176','vv7310','OBU-JS','SMR','Enantone','林莉','E00653','CNODSM0018','否'),(1104,'周晓兰','Xiaolan.Zhou@takeda.com',171,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03129','va4882','OBU-JS','Hospital Specialist','Enantone','潘健明','E02545','CNODSM0022','否'),(1105,'王刘','liu.wang@takeda.com',171,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00866','qo1046','OBU-JS','MR','Enantone','潘健明','E02545','CNODSM0022','否'),(1106,'陈红宝','Hongbao.Chen@takeda.com',171,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03126','is0944','OBU-JS','MR','Enantone','潘健明','E02545','CNODSM0022','否'),(1107,'王冬霞','dongxia.wang@takeda.com',171,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00156','bl9591','OBU-JS','SMR','Enantone','潘健明','E02545','CNODSM0022','否'),(1108,'衡朵','duo.heng@takeda.com',171,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00817','ei7696','OBU-JS','SMR','Enantone','潘健明','E02545','CNODSM0022','否'),(1109,'黄燕','Yan.Huang@takeda.com',172,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02836','kv5623','OBU-JS','Executive Hospital Specialist','Enantone','秦卫平','E02925','CNODSM0023','否'),(1110,'罗林群','Linqun.Luo@takeda.com',172,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02928','dg2950','OBU-JS','MR','Enantone','秦卫平','E02925','CNODSM0023','否'),(1111,'杨霞','Xia.Yang@takeda.com',172,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02985','dv1535','OBU-JS','MR','Enantone','秦卫平','E02925','CNODSM0023','否'),(1112,'李如榕','rurong.li@takeda.com',172,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00196','zq3698','OBU-JS','SMR','Enantone','秦卫平','E02925','CNODSM0023','否'),(1113,'陈义','Yi.Chen@takeda.com',172,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02676','cu5212','OBU-JS','SMR','Enantone','秦卫平','E02925','CNODSM0023','否'),(1114,'林莉','Li.Lin@takeda.com',188,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00653','po3433','OBU-JS','DSM','Enantone','汪小飞','E02768','CNORSM0006','是'),(1115,'秦卫平','weiping.qin@takeda.com',188,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02925','xg4538','OBU-JS','DSM','Enantone','汪小飞','E02768','CNORSM0006','是'),(1116,'潘健明','Jianming.Pan@takeda.com',188,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02545','wj1622','OBU-JS','DSM(Acting)','Enantone','汪小飞','E02768','CNORSM0006','是'),(1117,'徐健健','Jianjian.Xu@takeda.com',188,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02294','fz1846','OBU-JS','RPM','','汪小飞','E02768','CNORSM0006','否'),(1118,'张雯','Wen1.Zhang@takeda.com',188,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02438','lt8678','OBU-JS','SDSM','Enantone','汪小飞','E02768','CNORSM0006','是'),(1119,'汪小飞','Xiaofei.Wang@takeda.com',182,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02768','nf0349','OBU-JS','SRSM','Enantone','吴文凯','E00559','CNONSD0001','是'),(1120,'张志刚','zhigang.zhang@takeda.com',153,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00124','if4753','OBU-JS','Executive Hospital Specialist','Enantone','张雯','E02438','CNODSM0004','否'),(1121,'周云梅','yunmei.zhou@takeda.com',153,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00148','rl1335','OBU-JS','MR','Enantone','张雯','E02438','CNODSM0004','否'),(1122,'牛同庆','tongqing.niu@takeda.com',153,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01656','mw0255','OBU-JS','MR','Enantone','张雯','E02438','CNODSM0004','否'),(1123,'袁琳琳','linlin.yuan@takeda.com',153,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01741','zh8363','OBU-JS','MR','Enantone','张雯','E02438','CNODSM0004','否'),(1124,'曲岩岩','yanyan.qu@takeda.com',153,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01999','nt4348','OBU-JS','SMR','Enantone','张雯','E02438','CNODSM0004','否'),(1125,'胡建国','Jianguo.Hu@takeda.com',153,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02128','fo9999','OBU-JS','SMR','Enantone','张雯','E02438','CNODSM0004','否'),(1126,'李光俊','Guangjun.Li@takeda.com',153,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02666','bm5968','OBU-JS','SMR','Enantone','张雯','E02438','CNODSM0004','否'),(1127,'陈腾飞','Tengfei.Chen@takeda.com',153,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02921','fb8997','OBU-JS','SMR','Enantone','张雯','E02438','CNODSM0004','否'),(1128,'王彬','Bin1.Wang@takeda.com',153,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03050','sh3919','OBU-JS','SMR','Enantone','张雯','E02438','CNODSM0004','否'),(1129,'杨楠','Richard.Yang@takeda.com',149,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00115','dc4075','OBU-MKT','Marketing Manager','','崔一','E00114','CNOBUD0001','否'),(1130,'崔华薇','Vicky.Cui@takeda.com',235,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00060','bi4771','OBU-MKT','Product Manager','','杨楠','E00115','OBU-MM-01','否'),(1131,'王磊','allen.wang@takeda.com',236,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00781','ft6986','OBU-MKT','Product Manager','','杨楠','E00115','OBU-PM-03','否'),(1132,'尹玲','Ling.Yin@takeda.com',235,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02865','vg3556','OBU-MKT','Product Manager','','杨楠','E00115','OBU-MM-01','否'),(1133,'吴奇伟','qiwei.wu@takeda.com',0,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01658','mk1865','OBU-MKT','Product Manager','','杨楠','E00115','','否'),(1134,'王昕馨','vivian.wang@takeda.com',0,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02583','dy0633','OBU-MKT','Project Supervisor','','杨楠','E00115','','否'),(1135,'张莉','lola.zhang@takeda.com',235,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01919','xq1624','OBU-MKT','Sr. Product Manager','','杨楠','E00115','OBU-MM-01','否'),(1136,'陈菁','jing.chen@takeda.com',170,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00184','gp2745','OBU-SH','MR','Enantone','曹毅','E02873','CNODSM0021','否'),(1137,'马英','ying.ma@takeda.com',170,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01714','ri2944','OBU-SH','MR','Enantone','曹毅','E02873','CNODSM0021','否'),(1138,'周燕','Yan.Zhou@takeda.com',170,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02973','oq0308','OBU-SH','MR','Enantone','曹毅','E02873','CNODSM0021','否'),(1139,'周亮','liang.zhou@takeda.com',170,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01669','vn1527','OBU-SH','SMR','Enantone','曹毅','E02873','CNODSM0021','否'),(1140,'马哈雷','Halei.Ma@takeda.com',170,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03048','yi7242','OBU-SH','SMR','Enantone','曹毅','E02873','CNODSM0021','否'),(1141,'王丽','Li-1.Wang@takeda.com',186,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00191','in5559','OBU-SH','DSM','Enantone','李娜','E00185','CNORSM0004','是'),(1142,'曹毅','Yi.Cao@takeda.com',186,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02873','vb3811','OBU-SH','DSM','Enantone','李娜','E00185','CNORSM0004','是'),(1143,'赵妍','yan.zhao@takeda.com',186,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00194','op6200','OBU-SH','DSM(Acting)','Enantone','李娜','E00185','CNORSM0004','是'),(1144,'谢国芳','Guofang.Xie@takeda.com',186,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02949','ik6856','OBU-SH','RPM','','李娜','E00185','CNORSM0004','否'),(1145,'王梦珏','Mengjue.Wang@takeda.com',169,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02774','ko4679','OBU-SH','MR','Enantone','王丽','E00191','CNODSM0020','否'),(1146,'蒋珏','Jue.Jiang@takeda.com',169,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02924','uz5472','OBU-SH','MR','Enantone','王丽','E00191','CNODSM0020','否'),(1147,'梅小艳','xiaoyan.Mei@takeda.com',169,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03021','rt3527','OBU-SH','MR','Enantone','王丽','E00191','CNODSM0020','否'),(1148,'曹伟樑','weiliang.cao@takeda.com',169,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00186','ph1444','OBU-SH','SMR','Enantone','王丽','E00191','CNODSM0020','否'),(1149,'徐敏','Min.Xu@takeda.com.cn',169,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00189','nd6734','OBU-SH','SMR','Enantone','王丽','E00191','CNODSM0020','否'),(1150,'杨紊斌','Wenbin.Yang@takeda.com',169,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02770','gp2752','OBU-SH','SMR','Enantone','王丽','E00191','CNODSM0020','否'),(1151,'李娜','Na.Li@takeda.com',182,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00185','lo5071','OBU-SH','RSM','Enantone','吴文凯','E00559','CNONSD0001','是'),(1152,'秦爱梅','aimei.qin@takeda.com',168,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00188','jm8016','OBU-SH','Hospital Specialist','Enantone','赵妍','E00194','CNODSM0019','否'),(1153,'刘梦怡','mengyi.liu@takeda.com',168,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00682','eh8655','OBU-SH','Hospital Specialist','Enantone','赵妍','E00194','CNODSM0019','否'),(1154,'胡飞燕','feiyan.hu@takeda.com',168,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00831','jb1916','OBU-SH','MR','Enantone','赵妍','E00194','CNODSM0019','否'),(1155,'向丽','li.xiang@takeda.com',168,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02706','mp1552','OBU-SH','MR','Enantone','赵妍','E00194','CNODSM0019','否'),(1156,'程超','chao1.cheng@takeda.com',168,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02759','gw2266','OBU-SH','MR','Enantone','赵妍','E00194','CNODSM0019','否'),(1157,'李超','Chao1.Li@takeda.com',168,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03040','zm7797','OBU-SH','MR','Enantone','赵妍','E00194','CNODSM0019','否'),(1158,'吴方君','fangjun.Wu@takeda.com',168,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03142','lr0330','OBU-SH','MR','Enantone','赵妍','E00194','CNODSM0019','否'),(1159,'朱瑞','Rui.Zhu@takeda.com',0,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02792','ty9816','OBU-SH','SMR','Enantone','赵妍','E00194','','否'),(1160,'李娜','Na1.Li@takeda.com',176,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02640','wt8560','OBU-ZJ','MR','Enantone','崔亮田','E00165','CNODSM0027','否'),(1161,'陶野','Ye.Tao@takeda.com',176,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02794','bc5551','OBU-ZJ','MR','Enantone','崔亮田','E00165','CNODSM0027','否'),(1162,'许燕','yan.xu@takeda.com',176,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00720','qf8101','OBU-ZJ','SMR','Enantone','崔亮田','E00165','CNODSM0027','否'),(1163,'张婷婷','tingting.zhang@takeda.com',176,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00830','dk4997','OBU-ZJ','SMR','Enantone','崔亮田','E00165','CNODSM0027','否'),(1164,'周越烽','yuefeng.zhou@takeda.com',176,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02946','rv2788','OBU-ZJ','SMR','Enantone','崔亮田','E00165','CNODSM0027','否'),(1165,'麻仕薇','shiwei.ma@takeda.com',175,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02742','ug4797','OBU-ZJ','Executive Hospital Specialist','Enantone','段珂丽','E00989','CNODSM0026','否'),(1166,'陈燕云','Yanyun.Chen@takeda.com',175,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02502','eq9401','OBU-ZJ','MR','Enantone','段珂丽','E00989','CNODSM0026','否'),(1167,'余本雄','benxiong.yu@takeda.com',175,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00181','qs8442','OBU-ZJ','SMR','Enantone','段珂丽','E00989','CNODSM0026','否'),(1168,'李荣科','rongke.li@takeda.com',175,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00809','te3944','OBU-ZJ','SMR','Enantone','段珂丽','E00989','CNODSM0026','否'),(1169,'赵慧','hui.zhao@takeda.com',175,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02038','vc9331','OBU-ZJ','SMR','Enantone','段珂丽','E00989','CNODSM0026','否'),(1170,'陈少姿','shaozi.chen@takeda.com',175,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02024','jk9700','OBU-ZJ','SMR','Enantone','段珂丽','E00989','CNODSM0026','否'),(1171,'赖琴琴','qinqin.lai@takeda.com',175,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02033','wz4948','OBU-ZJ','SMR','Enantone','段珂丽','E00989','CNODSM0026','否'),(1172,'刘秋月','qiuyue.liu@takeda.com',178,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00240','zj6055','OBU-ZJ','Hospital Specialist','Enantone','洪小红','E00714','CNODSM0029','否'),(1173,'赖巧玲','qiaoling.lai@takeda.com',178,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01686','vt9703','OBU-ZJ','MR','Enantone','洪小红','E00714','CNODSM0029','否'),(1174,'何雪斌','Xuebin.He@takeda.com',178,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02623','wv3829','OBU-ZJ','MR','Enantone','洪小红','E00714','CNODSM0029','否'),(1175,'黄燕铃','yanling.huang@takeda.com',178,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00503','yy3286','OBU-ZJ','SMR','Enantone','洪小红','E00714','CNODSM0029','否'),(1176,'李燕燕','yanyan.li@takeda.com',178,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00770','gg8261','OBU-ZJ','SMR','Enantone','洪小红','E00714','CNODSM0029','否'),(1177,'皮伟红','weihong.pi@takeda.com',178,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01748','rj4697','OBU-ZJ','SMR','Enantone','洪小红','E00714','CNODSM0029','否'),(1178,'张燕维','yanwei.zhang@takeda.com',178,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00330','hw1677','OBU-ZJ','SMR','Enantone','洪小红','E00714','CNODSM0029','否'),(1179,'陈黎雄','lixiong.chen@takeda.com',178,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02452','xq0594','OBU-ZJ','SMR','Enantone','洪小红','E00714','CNODSM0029','否'),(1180,'郭玲','ling.guo@takeda.com',177,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02137','rn9971','OBU-ZJ','MR','Enantone','空缺','','CNODSM0028','否'),(1181,'朱静静','jingjing.zhu@takeda.com',177,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02135','yh4518','OBU-ZJ','MR','Enantone','空缺','','CNODSM0028','否'),(1182,'张傲峰','aofeng.zhang@takeda.com',177,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02681','rp5354','OBU-ZJ','MR','Enantone','空缺','','CNODSM0028','否'),(1183,'李启','Qi.Li@takeda.com',177,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02489','oy3950','OBU-ZJ','SMR','Enantone','空缺','','CNODSM0028','否'),(1184,'张翔','xiang.zhang@takeda.com',173,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00664','gz1288','OBU-ZJ','Hospital Specialist','Enantone','王学鼎','E00659','CNODSM0024','否'),(1185,'任碧英','biying.ren@takeda.com',173,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02149','th7750','OBU-ZJ','MR','Enantone','王学鼎','E00659','CNODSM0024','否'),(1186,'郑珍珍','Zhenzhen.Zheng@takeda.com',173,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02589','dx2760','OBU-ZJ','MR','Enantone','王学鼎','E00659','CNODSM0024','否'),(1187,'林莞城','guancheng.lin@takeda.com',173,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00676','rp3613','OBU-ZJ','SMR','Enantone','王学鼎','E00659','CNODSM0024','否'),(1188,'熊艳','yan.xiong@takeda.com',173,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00936','ox7730','OBU-ZJ','SMR','Enantone','王学鼎','E00659','CNODSM0024','否'),(1189,'陈国煌','Guohuang.Chen@takeda.com',173,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00938','ax3956','OBU-ZJ','SMR','Enantone','王学鼎','E00659','CNODSM0024','否'),(1190,'林滨','Bin.Lin@takeda.com',173,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02682','xk8796','OBU-ZJ','SMR','Enantone','王学鼎','E00659','CNODSM0024','否'),(1191,'吴晓星','xiaoxing.wu@takeda.com',182,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00753','ze4448','OBU-ZJ','RSM','Enantone','吴文凯','E00559','CNONSD0001','是'),(1192,'洪小红','xiaohong.hong@takeda.com',187,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00714','jz0906','OBU-ZJ','DSM','Enantone','吴晓星','E00753','CNORSM0005','是'),(1193,'郑文旭','wenxu.zheng@takeda.com',187,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00888','bl4777','OBU-ZJ','DSM','Enantone','吴晓星','E00753','CNORSM0005','是'),(1194,'崔亮田','liangtian.cui@takeda.com',187,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00165','nu8478','OBU-ZJ','DSM','Enantone','吴晓星','E00753','CNORSM0005','是'),(1195,'储云月','yunyue.chu@takeda.com',187,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00162','ik3353','OBU-ZJ','RPM','','吴晓星','E00753','CNORSM0005','否'),(1196,'王学鼎','xueding.wang@takeda.com',187,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00659','vl3120','OBU-ZJ','SDSM','Enantone','吴晓星','E00753','CNORSM0005','是'),(1197,'段珂丽','keli.duan@takeda.com',187,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00989','aj8974','OBU-ZJ','SDSM','Enantone','吴晓星','E00753','CNORSM0005','是'),(1198,'周雨奇','yuqi.zhou@takeda.com',187,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01891','hi7371','OBU-ZJ','SDSM','Enantone','吴晓星','E00753','CNORSM0005','是'),(1199,'龚海波','haibo.gong@takeda.com',179,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00197','zj5188','OBU-ZJ','Hospital Specialist','Enantone','郑文旭','E00888','CNODSM0030','否'),(1200,'吕创伟','chuangwei.lv@takeda.com',179,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01776','hu6950','OBU-ZJ','MR','Enantone','郑文旭','E00888','CNODSM0030','否'),(1201,'林健','jian.lin@takeda.com',179,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02089','zd2914','OBU-ZJ','MR','Enantone','郑文旭','E00888','CNODSM0030','否'),(1202,'方琼','Qiong.Fang@takeda.com',179,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02641','yx0998','OBU-ZJ','MR','Enantone','郑文旭','E00888','CNODSM0030','否'),(1203,'关艳敏','Yanmin.Guan@takeda.com',179,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02718','ps4411','OBU-ZJ','MR','Enantone','郑文旭','E00888','CNODSM0030','否'),(1204,'张忠山','zhongshan.zhang@takeda.com',179,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02760','ug4400','OBU-ZJ','MR','Enantone','郑文旭','E00888','CNODSM0030','否'),(1205,'黄素依','suyi.huang@takeda.com',179,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01750','my1970','OBU-ZJ','SMR','Enantone','郑文旭','E00888','CNODSM0030','否'),(1206,'梁燕','yan.liang@takeda.com',174,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00161','ei3942','OBU-ZJ','Hospital Specialist','Enantone','周雨奇','E01891','CNODSM0025','否'),(1207,'何小玲','xiaoling.he@takeda.com',174,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00167','hv3520','OBU-ZJ','Hospital Specialist','Enantone','周雨奇','E01891','CNODSM0025','否'),(1208,'曾烟娥','yane.zeng@takeda.com',174,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00810','yv5628','OBU-ZJ','MR','Enantone','周雨奇','E01891','CNODSM0025','否'),(1209,'马晓欣','Xiaoxin.Ma@takeda.com',174,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02503','av9336','OBU-ZJ','MR','Enantone','周雨奇','E01891','CNODSM0025','否'),(1210,'漆英','ying.qi@takeda.com',174,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E00218','bz3455','OBU-ZJ','SMR','Enantone','周雨奇','E01891','CNODSM0025','否'),(1211,'唐蕊','rui.tang@takeda.com',174,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01744','qf4729','OBU-ZJ','SMR','Enantone','周雨奇','E01891','CNODSM0025','否'),(1212,'吴万','Wan.Wu@takeda.com',174,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02377','ep0877','OBU-ZJ','SMR','Enantone','周雨奇','E01891','CNODSM0025','否'),(1213,'张伟','wilbur.zhang@takeda.com',189,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01050','ro0254','RBU','Head of RBU','','王卫','E01821','','是'),(1214,'贺馨','cynthia.he@takeda.com',191,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01313','or8881','RBU-BJ','MR','Kestine','仓萍萍','E01362','CNRDSM0002','否'),(1215,'曾敏慧','minhui.zeng@takeda.com',191,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02009','ra1396','RBU-BJ','MR','Ebrantil','仓萍萍','E01362','CNRDSM0002','否'),(1216,'胡晓乐','xiaole.hu@takeda.com',191,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02578','wj9436','RBU-BJ','MR','Ebrantil','仓萍萍','E01362','CNRDSM0002','否'),(1217,'怀皓','Hao.Huai@takeda.com',191,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02797','ty6333','RBU-BJ','MR','Ebrantil','仓萍萍','E01362','CNRDSM0002','否'),(1218,'张惠','hui2.zhang@takeda.com',191,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02889','km2688','RBU-BJ','MR','Ebrantil','仓萍萍','E01362','CNRDSM0002','否'),(1219,'姜硕','Shuo.Jiang@takeda.com',191,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02926','bq6970','RBU-BJ','MR','Ebrantil','仓萍萍','E01362','CNRDSM0002','否'),(1220,'孙研','yan1.sun@takeda.com',0,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02981','su1772','RBU-BJ','MR','Ebrantil','仓萍萍','E01362','','否'),(1221,'陈振','zhen.chen@takeda.com',191,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01822','jh1360','RBU-BJ','SMR','Ebrantil','仓萍萍','E01362','CNRDSM0002','否'),(1222,'武青','qing.wu@takeda.com',219,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01361','vs1849','RBU-BJ','DSM','Ebrantil','崔魁荣','E01341','CNRRSM0001','是'),(1223,'韩晓燕','xiaoyan.han@takeda.com',219,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01548','er0442','RBU-BJ','DSM','Ebrantil','崔魁荣','E01341','CNRRSM0001','是'),(1224,'闫晓雪','xiaoxue.yan@takeda.com',0,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01174','qn2814','RBU-BJ','DSM','','崔魁荣','E01341','','是'),(1225,'仓萍萍','pingping.cang@takeda.com',219,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01362','zk0918','RBU-BJ','DSM','Ebrantil,Kestine','崔魁荣','E01341','CNRRSM0001','是'),(1226,'井维印','weiyin.jing@takeda.com',219,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02160','xu9426','RBU-BJ','DSM','Ebrantil,Kestine','崔魁荣','E01341','CNRRSM0001','是'),(1227,'张伟涛','Weitao.Zhang@takeda.com',219,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01211','sc4256','RBU-BJ','DSM(Acting)','Ebrantil,Kestine','崔魁荣','E01341','CNRRSM0001','是'),(1228,'黄力','li.Huang@takeda.com',0,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01597','nn7828','RBU-BJ','DSM(Acting)','Ebrantil,Kestine','崔魁荣','E01341','','是'),(1229,'石萍','ping.shi@takeda.com',219,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01182','wd0540','RBU-BJ','DSM(Acting)','Ebrantil','崔魁荣','E01341','CNRRSM0001','是'),(1230,'刘静洁','jingjie.liu@takeda.com',219,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01412','ep2965','RBU-BJ','RPM','','崔魁荣','E01341','CNRRSM0001','否'),(1231,'赫鑫','xin.he@takeda.com',0,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02041','ve0860','RBU-BJ','RPM','','崔魁荣','E01341','','否'),(1232,'王丽','carolyn.wang@takeda.com',219,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01289','mr6303','RBU-BJ','SDSM','Ebrantil','崔魁荣','E01341','CNRRSM0001','是'),(1233,'唐亮','liang.tang@takeda.com',219,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01374','ds7995','RBU-BJ','SDSM','Kestine','崔魁荣','E01341','CNRRSM0001','是'),(1234,'孙书平','shuping.sun@takeda.com',215,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01551','eb1803','RBU-BJ','MR','Ebrantil','韩晓燕','E01548','CNRDSM0028','否'),(1235,'于洪敏','hongmin.yu@takeda.com',215,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01523','ax7621','RBU-BJ','SMR','Ebrantil','韩晓燕','E01548','CNRDSM0028','否'),(1236,'刘爱','Ai.Liu@takeda.com',216,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02332','ou3294','RBU-BJ','Hospital Specialist','Ebrantil,Kestine','黄力','E01597','CNRDSM0029','否'),(1237,'侯有英','Youying.Hou@takeda.com',216,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02615','et5514','RBU-BJ','Hospital Specialist','Ebrantil','黄力','E01597','CNRDSM0029','否'),(1238,'韩德娣','dedi.han@takeda.com',216,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02820','ra1867','RBU-BJ','MR','Ebrantil,Kestine','黄力','E01597','CNRDSM0029','否'),(1239,'于颖颖','yingying.yu@takeda.com',204,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01562','qd0225','RBU-BJ','MR','Ebrantil,Kestine','井维印','E02160','CNRDSM0016','否'),(1240,'师潇旋','Xiaoxuan.Shi@takeda.com',204,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02222','dh8562','RBU-BJ','MR','Ebrantil','井维印','E02160','CNRDSM0016','否'),(1241,'郭贤亮','xianliang.guo@takeda.com',204,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02904','sr3789','RBU-BJ','MR','Ebrantil,Kestine','井维印','E02160','CNRDSM0016','否'),(1242,'巩洪梅','hongmei.gong@takeda.com',204,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01248','yz4834','RBU-BJ','SMR','Ebrantil','井维印','E02160','CNRDSM0016','否'),(1243,'闫秀丽','Xiuli.Yan@takeda.com',204,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02328','ve4381','RBU-BJ','SMR','Ebrantil,Kestine','井维印','E02160','CNRDSM0016','否'),(1244,'孔小令','Xiaoling.Kong@takeda.com',195,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02411','ao5226','RBU-BJ','DSM','Ebrantil,Kestine','空缺','','CNRDSM0006',''),(1245,'吴琼','qiong.wu@takeda.com',0,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01206','al2406','RBU-BJ','MR','','空缺','','','否'),(1246,'关兴波','xingbo.guan@takeda.com',195,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01385','me1361','RBU-BJ','MR','Kestine','空缺','','CNRDSM0006','否'),(1247,'程宝琦','Baoqi.Cheng@takeda.com',195,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02254','ap3307','RBU-BJ','MR','Ebrantil,Kestine','空缺','','CNRDSM0006','否'),(1248,'张淼','miao.zhang@takeda.com',195,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02814','ii0546','RBU-BJ','MR','Ebrantil,Kestine','空缺','','CNRDSM0006','否'),(1249,'张锡玉','xiyu.zhang@takeda.com',195,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03162','ix6555','RBU-BJ','MR','Ebrantil,Kestine','空缺','','CNRDSM0006','否'),(1250,'田艺','yi.tian@takeda.com',195,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01475','xw3352','RBU-BJ','SMR','Ebrantil,Kestine','空缺','','CNRDSM0006','否'),(1251,'翟传英','chuanying.zhai@takeda.com',197,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02056','dp3594','RBU-BJ','MR','Ebrantil','石萍','E01182','CNRDSM0008','否'),(1252,'孙静','jing1.sun@takeda.com',197,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02365','kc9390','RBU-BJ','MR','Ebrantil,Kestine','石萍','E01182','CNRDSM0008','否'),(1253,'徐敏','Min2.Xu@takeda.com',197,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02643','kt0761','RBU-BJ','MR','Ebrantil,Kestine','石萍','E01182','CNRDSM0008','否'),(1254,'蒋荣','Rong.Jiang@takeda.com',197,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02793','nt3616','RBU-BJ','MR','Ebrantil,Kestine','石萍','E01182','CNRDSM0008','否'),(1255,'田虎','Hu.Tian@takeda.com',197,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02876','yw5893','RBU-BJ','MR','Ebrantil,Kestine','石萍','E01182','CNRDSM0008','否'),(1256,'王彩莲','Cailian.Wang@takeda.com',197,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03091','ym0798','RBU-BJ','MR','Ebrantil,Kestine','石萍','E01182','CNRDSM0008','否'),(1257,'邢进','Jin.Xing@takeda.com',190,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02262','av8234','RBU-BJ','MR','Kestine','唐亮','E01374','CNRDSM0001','否'),(1258,'李静蕊','Jingrui.Li@takeda.com',190,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02399','rn7514','RBU-BJ','MR','Kestine','唐亮','E01374','CNRDSM0001','否'),(1259,'单文明','待定',129,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03022','待定','RBU-BJ','MR','Kestine','唐亮','E01374','CNGDSM0064','否'),(1260,'于华清','待定',129,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03088','待定','RBU-BJ','MR','Kestine','唐亮','E01374','CNGDSM0064','否'),(1261,'陈秀辉','Xiuhui.Chen@takeda.com',190,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03173','af6220','RBU-BJ','MR','Kestine','唐亮','E01374','CNRDSM0001','否'),(1262,'贾运芳','yunfang.jia@takeda.com',190,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01367','xb6499','RBU-BJ','SMR','Kestine','唐亮','E01374','CNRDSM0001','否'),(1263,'李凯1','Kai.Li@takeda.com',190,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01485','ss9443','RBU-BJ','SMR','Kestine','唐亮','E01374','CNRDSM0001','否'),(1264,'贾丹丹','dandan.jia@takeda.com',192,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02054','sp9945','RBU-BJ','MR','Ebrantil','王丽','E01289','CNRDSM0003','否'),(1265,'李艳','Yan.Li@takeda.com',192,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02303','ys2827','RBU-BJ','MR','Ebrantil','王丽','E01289','CNRDSM0003','否'),(1266,'牛洁','Jie.Niu@takeda.com',192,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02512','oe4837','RBU-BJ','MR','Ebrantil','王丽','E01289','CNRDSM0003','否'),(1267,'杨白冰','Baibing.Yang@takeda.com',192,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02541','dq2910','RBU-BJ','MR','Ebrantil','王丽','E01289','CNRDSM0003','否'),(1268,'吕丽颖','Liying.Lv@takeda.com',192,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02781','hp8326','RBU-BJ','MR','Ebrantil','王丽','E01289','CNRDSM0003','否'),(1269,'王玲','Ling-1.Wang@takeda.com',192,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02055','wy6717','RBU-BJ','SMR','Ebrantil','王丽','E01289','CNRDSM0003','否'),(1270,'徐璟','Jing.Xu@takeda.com',193,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02030','yb2233','RBU-BJ','MR','Ebrantil','武青','E01361','CNRDSM0004','否'),(1271,'任晓航','Xiaohang.Ren@takeda.com',193,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02822','uf2391','RBU-BJ','MR','Ebrantil','武青','E01361','CNRDSM0004','否'),(1272,'刘娟','Juan.Liu@takeda.com',193,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02999','sd9576','RBU-BJ','MR','Ebrantil','武青','E01361','CNRDSM0004','否'),(1273,'张挺','Ting1.Zhang@takeda.com',193,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03104','tj0961','RBU-BJ','MR','Ebrantil','武青','E01361','CNRDSM0004','否'),(1274,'李少龙','shaolong.li@takeda.com',193,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01210','my0913','RBU-BJ','SMR','Ebrantil','武青','E01361','CNRDSM0004','否'),(1275,'郭金华','jinhua.guo@takeda.com',196,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01159','ai3712','RBU-BJ','Executive Hospital Specialist','Ebrantil','闫晓雪','E01174','CNRDSM0007','否'),(1276,'冀媛','yuan.ji@takeda.com',196,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01167','qx7802','RBU-BJ','Executive Hospital Specialist','Ebrantil','闫晓雪','E01174','CNRDSM0007','否'),(1277,'许立柳','liliu.xu@takeda.com',196,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01195','ka0462','RBU-BJ','Hospital Specialist','Ebrantil','闫晓雪','E01174','CNRDSM0007','否'),(1278,'朱健健','jianjian.zhu@takeda.com',196,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01559','po5377','RBU-BJ','MR','Ebrantil','闫晓雪','E01174','CNRDSM0007','否'),(1279,'杜盼先','panxian.du@takeda.com',196,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02114','ii4222','RBU-BJ','MR','Ebrantil','闫晓雪','E01174','CNRDSM0007','否'),(1280,'张建帅','Jianshuai.Zhang@takeda.com',196,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02724','wi1678','RBU-BJ','MR','Ebrantil','闫晓雪','E01174','CNRDSM0007','否'),(1281,'杨亚丽','yali.yang@takeda.com',196,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01268','ju8220','RBU-BJ','SMR','Kestine','闫晓雪','E01174','CNRDSM0007','否'),(1282,'田娜','marry.tian@takeda.com',196,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01281','gr0255','RBU-BJ','SMR','Kestine','闫晓雪','E01174','CNRDSM0007','否'),(1283,'马帅帅','shuaishuai.ma@takeda.com',196,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01461','lv1433','RBU-BJ','SMR','Ebrantil','闫晓雪','E01174','CNRDSM0007','否'),(1284,'崔魁荣','kuirong.cui@takeda.com',189,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01341','uq4383','RBU-BJ','RSM','','张伟','E01050','CNRBUD0001','是'),(1285,'宋乐菊','leju.song@takeda.com',194,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02877','fz7348','RBU-BJ','MR','Ebrantil,Kestine','张伟涛','E01211','CNRDSM0005','否'),(1286,'梁晨','Chen.Liang@takeda.com',194,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02888','lm2974','RBU-BJ','MR','Ebrantil,Kestine','张伟涛','E01211','CNRDSM0005','否'),(1287,'邓云凤','yunfeng.deng@takeda.com',194,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02879','dc2303','RBU-BJ','MR','Ebrantil,Kestine','张伟涛','E01211','CNRDSM0005','否'),(1288,'李鹏','Peng.Li@takeda.com',0,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02977','rp8748','RBU-BJ','MR','Ebrantil','张伟涛','E01211','','否'),(1289,'陈建新','jianxin.chen@takeda.com',198,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02152','ys6515','RBU-GD','Executive Hospital Specialist','Kestine','陈黎芳','E01296','CNRDSM0009','否'),(1290,'陈汀','ting.chen@takeda.com',198,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01176','mv7555','RBU-GD','Hospital Specialist','Ebrantil','陈黎芳','E01296','CNRDSM0009','否'),(1291,'李兴国','xingguo.li@takeda.com.cn',198,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01601','ct3925','RBU-GD','MR','Kestine','陈黎芳','E01296','CNRDSM0009','否'),(1292,'苏秋云','qiuyun.su@takeda.com',198,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02064','oz1682','RBU-GD','MR','Kestine','陈黎芳','E01296','CNRDSM0009','否'),(1293,'祝玉栋','yudong.zhu@takeda.com',198,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01262','zh1882','RBU-GD','SMR','Ebrantil','陈黎芳','E01296','CNRDSM0009','否'),(1294,'林鹤','he.lin@takeda.com',0,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01178','si0578','RBU-GD','DSM','','梁英','E01319','','是'),(1295,'林冬奎','dongkui.lin@takeda.com',220,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01328','fu4257','RBU-GD','DSM','Ebrantil,Kestine','梁英','E01319','CNRRSM0002','是'),(1296,'柳晓楠','xiaonan.liu@takeda.com',220,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01456','ln1841','RBU-GD','DSM','Ebrantil','梁英','E01319','CNRRSM0002','是'),(1297,'肖东升','Dongsheng.Xiao@takeda.com',220,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03061','wf0639','RBU-GD','DSM','Ebrantil,Kestine','梁英','E01319','CNRRSM0002','是'),(1298,'张娟','Juan3.Zhang@takeda.com',220,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03111','kl9655','RBU-GD','DSM','Ebrantil','梁英','E01319','CNRRSM0002','是'),(1299,'张华根','huagen.zhang@takeda.com',220,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01317','vg2772','RBU-GD','DSM(Acting)','Ebrantil','梁英','E01319','CNRRSM0002','是'),(1300,'魏林平','linping.wei@takeda.com',220,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01143','rn0651','RBU-GD','RPM','','梁英','E01319','CNRRSM0002','否'),(1301,'郭永辉','yonghui.guo@takeda.com',220,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02708','uz9748','RBU-GD','RPM','','梁英','E01319','CNRRSM0002','否'),(1302,'陈黎芳','lifang.chen@takeda.com',220,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01296','wz4453','RBU-GD','SDSM','Ebrantil,Kestine','梁英','E01319','CNRRSM0002','是'),(1303,'詹恩权','enquan.zhan@takeda.com',220,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01378','pw9952','RBU-GD','SDSM','Kestine','梁英','E01319','CNRRSM0002','是'),(1304,'谭胜','sheng.tan@takeda.com',220,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01563','ym1298','RBU-GD','SDSM','Ebrantil','梁英','E01319','CNRRSM0002','是'),(1305,'陈玙芳','judy.chen@takeda.com',199,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01303','fc4750','RBU-GD','MR','Ebrantil,Kestine','林冬奎','E01328','CNRDSM0011','否'),(1306,'林惠超','huichao.lin@takeda.com',199,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02170','jr1810','RBU-GD','MR','Kestine','林冬奎','E01328','CNRDSM0011','否'),(1307,'王建生','jiansheng.wang@takeda.com',199,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02896','tt9411','RBU-GD','MR','Kestine','林冬奎','E01328','CNRDSM0011','否'),(1308,'申玉勇','Yuyong.Shen@takeda.com',199,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02931','yx2487','RBU-GD','MR','Ebrantil,Kestine','林冬奎','E01328','CNRDSM0011','否'),(1309,'郭伯应','boying.guo@takeda.com',199,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02065','fo6559','RBU-GD','SMR','Kestine','林冬奎','E01328','CNRDSM0011','否'),(1310,'熊小峰','Xiaofeng.Xiong@takeda.com',199,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03063','nl8898','RBU-GD','SMR','Ebrantil','林冬奎','E01328','CNRDSM0011','否'),(1311,'杨汉光','hanguang.yang@takeda.com',202,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01541','mh7529','RBU-GD','Hospital Specialist','Ebrantil','柳晓楠','E01456','CNRDSM0014','否'),(1312,'汪媛斌','yuanbin.wang@takeda.com',202,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01427','zx2338','RBU-GD','MR','Ebrantil','柳晓楠','E01456','CNRDSM0014','否'),(1313,'黄慧芳','huifang.huang@takeda.com',202,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02171','lk4904','RBU-GD','MR','Ebrantil','柳晓楠','E01456','CNRDSM0014','否'),(1314,'罗志聪','zhicong.luo@takeda.com',202,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02647','us3830','RBU-GD','MR','Ebrantil','柳晓楠','E01456','CNRDSM0014','否'),(1315,'马敏儿','miner.ma@takeda.com',202,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01455','vr1690','RBU-GD','SMR','Ebrantil','柳晓楠','E01456','CNRDSM0014','否'),(1316,'翁庆泉','Qingquan.Weng@takeda.com',202,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02423','da7979','RBU-GD','SMR','Ebrantil','柳晓楠','E01456','CNRDSM0014','否'),(1317,'朱荣','Rong.Zhu@takeda.com',205,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01244','ez5923','RBU-GD','Executive Hospital Specialist','Ebrantil,Kestine','谭胜','E01563','CNRDSM0017','否'),(1318,'桂明','Ming.Gui@takeda.com',205,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02272','rf6962','RBU-GD','Executive Hospital Specialist','Ebrantil','谭胜','E01563','CNRDSM0017','否'),(1319,'桂敏','min.gui@takeda.com',205,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02177','tc6354','RBU-GD','MR','Ebrantil','谭胜','E01563','CNRDSM0017','否'),(1320,'李慧群','huiqun.li@takeda.com',205,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03062','fl4788','RBU-GD','MR','Ebrantil','谭胜','E01563','CNRDSM0017','否'),(1321,'余露','lu.yu@takeda.com',205,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03033','nc8844','RBU-GD','MR','Ebrantil','谭胜','E01563','CNRDSM0017','否'),(1322,'赵明月','mingyue.zhao@takeda.com',205,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03032','xh3761','RBU-GD','MR','Ebrantil','谭胜','E01563','CNRDSM0017','否'),(1323,'许红丹','judy.xu@takeda.com',0,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01253','lq0216','RBU-GD','SMR','','谭胜','E01563','','否'),(1324,'王平','Ping.Wang2@takeda.com',217,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01477','mq3569','RBU-GD','MR','Ebrantil','肖东升','E03061','CNRDSM0030','否'),(1325,'韦祖吟','zuyin.wei@takeda.com',217,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02211','kj2960','RBU-GD','MR','Ebrantil,Kestine','肖东升','E03061','CNRDSM0030','否'),(1326,'蒋事文','shiwen.jiang@takeda.com',217,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02897','sm8331','RBU-GD','MR','Ebrantil,Kestine','肖东升','E03061','CNRDSM0030','否'),(1327,'徐广根','Guanggen.Xu@takeda.com',217,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03137','hq8267','RBU-GD','SMR','Ebrantil,Kestine','肖东升','E03061','CNRDSM0030','否'),(1328,'喻向前','xiangqian.Yu@takeda.com',217,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03114','Xiangqian Yu','RBU-GD','SMR','Ebrantil','肖东升','E03061','CNRDSM0030','否'),(1329,'李志超','zhichao.li@takeda.com',200,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01627','bz1711','RBU-GD','MR','Kestine','詹恩权','E01378','CNRDSM0012','否'),(1330,'肖娴','xian.xiao@takeda.com',200,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02115','lu0450','RBU-GD','MR','Kestine','詹恩权','E01378','CNRDSM0012','否'),(1331,'范思梅','simei.fan@takeda.com',200,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01275','uc0957','RBU-GD','SMR','Ebrantil,Kestine','詹恩权','E01378','CNRDSM0012','否'),(1332,'温代雄','daixiong.wen@takeda.com',200,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01384','hd3859','RBU-GD','SMR','Kestine','詹恩权','E01378','CNRDSM0012','否'),(1333,'黄燕红','yanhong.huang@takeda.com',200,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01419','hi4895','RBU-GD','SMR','Kestine','詹恩权','E01378','CNRDSM0012','否'),(1334,'卢细细','xixi.lu@takeda.com',200,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01943','br0337','RBU-GD','SMR','Kestine','詹恩权','E01378','CNRDSM0012','否'),(1335,'黄秋雄','Qiuxiong.Huang@takeda.com',200,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02795','rf8557','RBU-GD','SMR','Kestine','詹恩权','E01378','CNRDSM0012','否'),(1336,'罗书明','Shuming.Luo@takeda.com',200,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02960','qn3975','RBU-GD','SMR','Kestine','詹恩权','E01378','CNRDSM0012','否'),(1337,'蔡宝明','baoming.cai@takeda.com',201,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01128','nq1367','RBU-GD','Hospital Specialist','Ebrantil','张华根','E01317','CNRDSM0013','否'),(1338,'伍瑞娴','angel.wu@takeda.com',201,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01156','tb1448','RBU-GD','Hospital Specialist','Ebrantil','张华根','E01317','CNRDSM0013','否'),(1339,'李栋','Dong.Li@takeda.com',201,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03031','ub8715','RBU-GD','Hospital Specialist','Ebrantil,Kestine','张华根','E01317','CNRDSM0013','否'),(1340,'许珊燕','shanyan.xu@takeda.com',0,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01504','qn2549','RBU-GD','MR','','张华根','E01317','','否'),(1341,'蔡美娟','meijuan.cai@takeda.com',0,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01567','ko1793','RBU-GD','MR','','张华根','E01317','','否'),(1342,'陈志贤','zhixian.chen@takeda.com',201,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01907','bx0246','RBU-GD','MR','Ebrantil','张华根','E01317','CNRDSM0013','否'),(1343,'林优亨','youheng.lin@takeda.com',201,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02882','tp9600','RBU-GD','MR','Ebrantil','张华根','E01317','CNRDSM0013','否'),(1344,'翁伟嘉','weijia.weng@takeda.com',201,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01272','su8321','RBU-GD','SMR','Ebrantil','张华根','E01317','CNRDSM0013','否'),(1345,'杨筱秋','xiaoqiu.yang@takeda.com',207,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01249','hd1965','RBU-GD','Hospital Specialist','Ebrantil','张娟','E02766','CNRDSM0019','否'),(1346,'艾静','jing.ai@takeda.com',207,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01729','zc3775','RBU-GD','MR','Ebrantil','张娟','E02766','CNRDSM0019','否'),(1347,'魏智炜','Zhiwei.Wei@takeda.com',207,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02895','ze3265','RBU-GD','MR','Ebrantil','张娟','E02766','CNRDSM0019','否'),(1348,'郭琼','qiong.guo@takeda.com',207,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03163','nl9882','RBU-GD','MR','Ebrantil,Kestine','张娟','E02766','CNRDSM0019','否'),(1349,'梁英','ying.liang2@takeda.com',189,1,1,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01319','wd4601','RBU-GD','RSM','','张伟','E01050','CNRBUD0001','是'),(1350,'陆乾烨','qianye.lu@takeda.com',239,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01061','ch8988','RBU-MKT','Product Manager','','龚华峰','E01052','RBU-PM-01','否'),(1351,'骆颖妍','amy.luo@takeda.com',0,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01057','jw7287','RBU-MKT','Project Specialist','','龚华峰','E01052','','否'),(1352,'刘佳','angela.liu@takeda.com',0,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01054','jq5877','RBU-MKT','Project Supervisor','','龚华峰','E01052','','否'),(1353,'王吉','justin.wang@takeda.com',189,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01058','ji6568','RBU-MKT','SPM','','龚华峰','E01052','CNRBUD0001','否'),(1354,'高瞻','zhan.gao@takeda.com',239,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01987','wz8714','RBU-MKT','SPM','','龚华峰','E01052','RBU-PM-01','否'),(1355,'龚华峰','wolfen.gong@takeda.com',189,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01052','xd5255','RBU-MKT','Sr. Marketing Manager','','张伟','E01050','CNRBUD0001','否'),(1356,'戴云祥','xunxiang.dai@takeda.com',212,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01283','bo2742','RBU-SH','Hospital Specialist','Ebrantil','党晶','E01232','CNRDSM0025','否'),(1357,'陶景','jing.tao@takeda.com',212,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01515','ou1477','RBU-SH','Hospital Specialist','Ebrantil','党晶','E01232','CNRDSM0025','否'),(1358,'梁军','Jun.Liang@takeda.com',212,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02481','cj3610','RBU-SH','MR','Ebrantil','党晶','E01232','CNRDSM0025','否'),(1359,'刘玉祥','yuxiang.liu@takeda.com',212,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01306','us9985','RBU-SH','SMR','Ebrantil','党晶','E01232','CNRDSM0025','否'),(1360,'祝文苗','wenmiao.zhu@takeda.com',212,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01574','pq9414','RBU-SH','SMR','Ebrantil','党晶','E01232','CNRDSM0025','否'),(1361,'陈光传','Guangchuan.Chen@takeda.com',212,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02310','pa0345','RBU-SH','SMR','Ebrantil','党晶','E01232','CNRDSM0025','否'),(1362,'许勇','Yong.Xu@takeda.com',212,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02674','yr5583','RBU-SH','SMR','Ebrantil','党晶','E01232','CNRDSM0025','否'),(1363,'曾婷婷','tingting.zeng@takeda.com',208,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02869','pf3416','RBU-SH','MR','Ebrantil','空缺','','CNRDSM0021','否'),(1364,'孙宗平','Zongping.Sun@takeda.com',208,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02630','ew1755','RBU-SH','SMR','Ebrantil','空缺','','CNRDSM0021','否'),(1365,'徐光健','Guangjian.Xu@takeda.com',210,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02382','jo4992','RBU-SH','Hospital Specialist','Ebrantil','雷廷明','E01286','CNRDSM0023','否'),(1366,'贾光艳','guangyan.jia@takeda.com',210,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02209','yi7275','RBU-SH','MR','Ebrantil','雷廷明','E01286','CNRDSM0023','否'),(1367,'王云霞','yunxia.wang@takeda.com',210,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01181','gy3863','RBU-SH','SMR','Ebrantil','雷廷明','E01286','CNRDSM0023','否'),(1368,'陆洋','yang.lu@takeda.com',210,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E01188','dw6833','RBU-SH','SMR','Ebrantil','雷廷明','E01286','CNRDSM0023','否'),(1369,'张伟庆','Weiqing.Zhang@takeda.com',210,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02482','pn3653','RBU-SH','SMR','Ebrantil,Kestine','雷廷明','E01286','CNRDSM0023','否'),(1370,'马兢怡','Jingyi1.Ma@takeda.com',210,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02936','gk1717','RBU-SH','SMR','Ebrantil','雷廷明','E01286','CNRDSM0023','否'),(1371,'余倩芬','Qianfen.Yu@takeda.com',218,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02832','jz7290','RBU-SH','MR','Ebrantil','李玲','E01196','CNRDSM0031','否'),(1372,'柳华栋','huadong.liu@takeda.com',218,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02834','sa5311','RBU-SH','MR','Ebrantil','李玲','E01196','CNRDSM0031','否'),(1373,'唐孝波','Xiaobo.Tang@takeda.com',218,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E02982','xb6942','RBU-SH','MR','Ebrantil','李玲','E01196','CNRDSM0031','否'),(1374,'戴莉红','Lihong.Dai@takeda.com',218,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03049','aj8392','RBU-SH','SMR','Ebrantil','李玲','E01196','CNRDSM0031','否'),(1375,'李富春','Fuchun.Li@takeda.com',218,1,0,0,1,'2015-06-06 18:25:39',1,'2015-06-06 18:25:39','E03053','gi3560','RBU-SH','SMR','Ebrantil','李玲','E01196','CNRDSM0031','否'),(1376,'易洪艳','hongyan.yi@takeda.com',0,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01397','hs9205','RBU-SH','MR','','钱学廷','E02319','','否'),(1377,'唐静','Jing.Tang@takeda.com',206,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02804','eh7414','RBU-SH','MR','Ebrantil,Kestine','钱学廷','E02319','CNRDSM0018','否'),(1378,'吴爽','shuang.wu@takeda.com',206,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02964','hb1597','RBU-SH','MR','Ebrantil,Kestine','钱学廷','E02319','CNRDSM0018','否'),(1379,'朱正利','Zhengli.Zhu@takeda.com',206,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02978','vj3242','RBU-SH','MR','Ebrantil,Kestine','钱学廷','E02319','CNRDSM0018','否'),(1380,'公丕明','piming.gong@takeda.com',206,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02986','fv3946','RBU-SH','MR','Ebrantil,Kestine','钱学廷','E02319','CNRDSM0018','否'),(1381,'侯无敌','Wudi.Hou@takeda.com',206,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E03051','xv0206','RBU-SH','MR','Ebrantil','钱学廷','E02319','CNRDSM0018','否'),(1382,'吴凤华','Fenghua.Wu@takeda.com',206,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02803','el0440','RBU-SH','SMR','Ebrantil,Kestine','钱学廷','E02319','CNRDSM0018','否'),(1383,'郑玉凤','Yufeng.Zheng@takeda.com',206,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02919','es4722','RBU-SH','SMR','Ebrantil','钱学廷','E02319','CNRDSM0018','否'),(1384,'王小海','xiaohai.wang@takeda.com',214,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01814','pl9996','RBU-SH','MR','Kestine','徐海蓉','E02395','CNRDSM0027','否'),(1385,'肖艳','yan.xiao@takeda.com',214,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02094','el1491','RBU-SH','MR','Kestine','徐海蓉','E02395','CNRDSM0027','否'),(1386,'党同平','Tongping.Dang@takeda.com',214,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02283','pz0452','RBU-SH','MR','Kestine','徐海蓉','E02395','CNRDSM0027','否'),(1387,'李楠楠','Nannan.Li@takeda.com',214,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02323','yo2459','RBU-SH','MR','Kestine','徐海蓉','E02395','CNRDSM0027','否'),(1388,'袁君','Jun.Yuan@takeda.com',214,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02513','wp8202','RBU-SH','MR','Kestine','徐海蓉','E02395','CNRDSM0027','否'),(1389,'叶宁','Ning.Ye@takeda.com',214,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02581','tj1492','RBU-SH','MR','Kestine','徐海蓉','E02395','CNRDSM0027','否'),(1390,'颜亚方','Yafang.Yan@takeda.com',214,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02631','jz0548','RBU-SH','MR','Kestine','徐海蓉','E02395','CNRDSM0027','否'),(1391,'段琳','amy.duan@takeda.com',0,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01904','zn2463','RBU-SH','MR','','许敏','E01287','','否'),(1392,'杨雪敏','Xuemin.Yang@takeda.com',211,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02998','vc1226','RBU-SH','MR','Ebrantil,Kestine','许敏','E01287','CNRDSM0024','否'),(1393,'周迟翔','chixiang.zhou@takeda.com',211,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01815','kk1258','RBU-SH','SMR','Ebrantil,Kestine','许敏','E01287','CNRDSM0024','否'),(1394,'高彬','bin.gao@takeda.com',211,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01842','vi9659','RBU-SH','SMR','Ebrantil,Kestine','许敏','E01287','CNRDSM0024','否'),(1395,'徐文祺','Wenqi.Xu@takeda.com',211,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02668','ej3461','RBU-SH','SMR','Ebrantil,Kestine','许敏','E01287','CNRDSM0024','否'),(1396,'邹斌','Bin.Zou@takeda.com',209,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02429','pi9999','RBU-SH','Hospital Specialist','Ebrantil','严武睿','E02484','CNRDSM0022','否'),(1397,'沈阳','Yang.Shen@takeda.com',209,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E03052','uo7416','RBU-SH','Hospital Specialist','Ebrantil,Kestine','严武睿','E02484','CNRDSM0022','否'),(1398,'王永华','Yonghua.Wang@takeda.com',209,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02625','lz4943','RBU-SH','MR','Ebrantil,Kestine','严武睿','E02484','CNRDSM0022','否'),(1399,'张娟','juan1.zhang@takeda.com',209,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02766','ok2956','RBU-SH','MR','Ebrantil,Kestine','严武睿','E02484','CNRDSM0022','否'),(1400,'王雪宁','xuening.wang@takeda.com',209,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01536','ao6532','RBU-SH','SMR','Ebrantil,Kestine','严武睿','E02484','CNRDSM0022','否'),(1401,'叶晓晨','xiaochen.ye@takeda.com',209,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02866','pq0611','RBU-SH','SMR','Ebrantil','严武睿','E02484','CNRDSM0022','否'),(1402,'党晶','jing.dang@takeda.com',221,1,1,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01232','xq6780','RBU-SH','DSM','Ebrantil','张巍','E02314','CNRRSM0004','是'),(1403,'雷廷明','tingming.lei@takeda.com',221,1,1,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01286','jf4450','RBU-SH','DSM','Ebrantil','张巍','E02314','CNRRSM0004','是'),(1404,'李玲','ling.li@takeda.com',221,1,1,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01196','ho0585','RBU-SH','DSM','Ebrantil','张巍','E02314','CNRRSM0004','是'),(1405,'许敏','min.xu2@takeda.com',221,1,1,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01287','pk0924','RBU-SH','DSM','Kestine','张巍','E02314','CNRRSM0004','是'),(1406,'左治','zhi.zuo@takeda.com',221,1,1,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01170','eg6533','RBU-SH','DSM','Ebrantil','张巍','E02314','CNRRSM0004','是'),(1407,'钱学廷','xueting.qian@takeda.com',221,1,1,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02319','ww8304','RBU-SH','DSM','Ebrantil','张巍','E02314','CNRRSM0004','是'),(1408,'严武睿','wurui.yan@takeda.com',221,1,1,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02484','dg5346','RBU-SH','DSM','Ebrantil,Kestine','张巍','E02314','CNRRSM0004','是'),(1409,'罗俊','jun.luo@takeda.com',208,1,1,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01158','xj1707','RBU-SH','DSM(Acting)','Ebrantil','张巍','E02314','CNRDSM0021','是'),(1410,'桑红娇','hongjiao.sang@takeda.com',221,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02061','ub6664','RBU-SH','RPM','','张巍','E02314','CNRRSM0004','否'),(1411,'朱坚','jian.zhu@takeda.com',221,1,1,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01561','dn8544','RBU-SH','SDSM','Ebrantil,Kestine','张巍','E02314','CNRRSM0004','是'),(1412,'徐海蓉','Hairong.Xu@takeda.com',221,1,1,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02395','wz4746','RBU-SH','SDSM','Kestine','张巍','E02314','CNRRSM0004','是'),(1413,'方超','chao.fang@takeda.com',221,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01131','js6947','RBU-SH','SRPM','','张巍','E02314','CNRRSM0004','否'),(1414,'张巍','william.zhang@takeda.com',189,1,1,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02314','tu0941','RBU-SH','SRSM','','张伟','E01050','CNRBUD0001','是'),(1415,'姚瑶','yao.yao@takeda.com',203,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01267','eu7923','RBU-SH','Hospital Specialist','Ebrantil,Kestine','朱坚','E01561','CNRDSM0015','否'),(1416,'吴进升','jason.wu@takeda.com',203,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01228','jl2630','RBU-SH','Hospital Specialist','Ebrantil,Kestine','朱坚','E01561','CNRDSM0015','否'),(1417,'童飞','fei.tong@takeda.com',203,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01993','td5790','RBU-SH','MR','Ebrantil,Kestine','朱坚','E01561','CNRDSM0015','否'),(1418,'陈蓝心','Lanxin.Chen@takeda.com',203,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02628','ul6257','RBU-SH','MR','Ebrantil','朱坚','E01561','CNRDSM0015','否'),(1419,'成芸','Yun.Cheng@takeda.com',203,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02807','gh2496','RBU-SH','SMR','Ebrantil','朱坚','E01561','CNRDSM0015','否'),(1420,'李跃武','Yuewu.Li@takeda.com',203,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E03054','nr5268','RBU-SH','SMR','Ebrantil,Kestine','朱坚','E01561','CNRDSM0015','否'),(1421,'杨美玲','meiling.yang@takeda.com',0,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E01803','wt2200','RBU-SH','MR','','左治','E01170','','否'),(1422,'姚杰','jie.yao@takeda.com',213,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02007','hc6743','RBU-SH','MR','Ebrantil','左治','E01170','CNRDSM0026','否'),(1423,'裘摄雯','shewen.qiu@takeda.com',213,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02984','nh6343','RBU-SH','MR','Ebrantil','左治','E01170','CNRDSM0026','否'),(1424,'方文忠','wenzhong.fang@takeda.com',213,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02996','py2764','RBU-SH','MR','Ebrantil','左治','E01170','CNRDSM0026','否'),(1425,'原华敏','huamin.yuan@takeda.com',213,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E03013','ay4539','RBU-SH','MR','Ebrantil','左治','E01170','CNRDSM0026','否'),(1426,'袁一超','Yichao.Yuan@takeda.com',213,1,0,0,1,'2015-06-06 18:25:40',1,'2015-06-06 18:25:40','E02692','ac4369','RBU-SH','SMR','Ebrantil','左治','E01170','CNRDSM0026','否');
/*!40000 ALTER TABLE `users` ENABLE KEYS */;
UNLOCK TABLES;
/*!40103 SET TIME_ZONE=@OLD_TIME_ZONE */;

/*!40101 SET SQL_MODE=@OLD_SQL_MODE */;
/*!40014 SET FOREIGN_KEY_CHECKS=@OLD_FOREIGN_KEY_CHECKS */;
/*!40014 SET UNIQUE_CHECKS=@OLD_UNIQUE_CHECKS */;
/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
/*!40111 SET SQL_NOTES=@OLD_SQL_NOTES */;

-- Dump completed on 2015-06-21 11:57:50
